# LIBRO 2

# Que no te mueras de covid -19 por falta de tratamientos

31 diciembre 2020 Jexus Salud 0

Share with:

-

Se reglamenta el uso del Dióxido de cloro para toda persona que así lo requiera y bajo su consentimiento

La Corte Internacional de Derechos Humanos ha ORDENADO a los Países Miembros que Desapliquen las Normas que van en contra de los Derechos Humanos.
Ahora se entiende porque la Ministra de Salud de Perú, Pilar Mazzetti, haya declarado finalmente que:

Los Médicos podrán suministrar el Dióxido de Cloro bajo Tratamiento Informado.
«DERECHOS HUMANOS – TRATADOS INTERNACIONALES 8-8-2020 sobre el Dióxido de Cloro»

1:Derecho Humano a la Información

2 Derecho Humano a la Salud.
La Corte Interamericana de Derechos Humanos ha ordenado a todos los países que son miembros de la Comisión que si hay alguna Norma interna que vaya en contra de los Derechos Humanos o de

algún Tratado Internacional que proteja los Derechos Humanos, el país deberá DESAPLICAR esa norma.

LA DECLARACION DE HELSINKI (Tratado Internacional) DE LA ASOCIACIÓN MÉDICA MUNDIAL en su Artículo Cuarto dice: “Es deber del Médico promover y velar por la salud, bienestar y derechos de los pacientes, incluidos los que participan en investigación médica.

En el Séptimo dice: «La investigación médica está sujeta a normas éticas que sirven para promover y asegurar el respeto a todos los seres humanos y para proteger su salud y sus derechos individuales.
Artículo noveno habla del DERECHO A LA AUTODETERMINACIÓN

El Consejo Económico y Social de la ONU dice que las obligaciones de proteger influyen adoptar Leyes u otras medidas para velar la calidad de los servicios de atención de la salud y asegurar que los facultativos y otros profesionales de la salud reúnan experiencia. Por lo tanto Si un médico aplica el Dióxido de Cloro a pedido del Paciente y por esa razón lo despiden de su lugar de trabajo ES ILEGAL. Ya que
LA VOLUNTAD DEL PACIENTE ESTÁ POR ENCIMA DE TODO, DEBIDAMENTE INFORMADO

Si los médicos abandonan a un paciente por no utilizar el Dióxido de Cloro y éste fallece, éstos tendrán responsabilidad civil y penal, por mala praxis médica En caso de que sean familiares los que requieran ese tratamiento, deberán hacerlo por escrito y, ante la negativa, deben presentar su queja con el director o supervisor médico. Y si no hay respuesta afirmativa, acudir a las instancias gubernamentales.

Si un Ministro de Salud está debidamente informado de la existencia del Dióxido de Cloro y de su efecto curativo y aún sin tener evidencia científica hace caso omiso, y si prohíbe su uso en la ciudadanía, puede ser denunciado ante la justicia nacional, la Comisión interamericana de Derechos Humanos y la Corte interamericana de Derechos Humanos.

Si además un funcionario hace declaraciones falsas sobre el Dióxido de Cloro mintiendo a su población, está Violando el Derecho Humano Internacional a la información, que debe ser veraz y oportuna, por lo cual puede ser denunciado ante la justicia. Y si esto provoca la muerte de ciudadanos, puede convertirse en un

DELITO DE GENOCIDIO.
Fuente: GUILLERMO ROBERTSON, COMISIONADO FEDERAL DE LA COMISIÓN INTERNACIONAL DE DERECHOS HUMANOS” Para: Difusión Global, Posicionamiento Transcripción y Viralización a favor de los Derechos de todos los Humanos del Planeta.

https://radioacromatica.com/index.php/2020/12/31/que-no-te-mueras-de-covid-19-por-falta-de-tratamientos/

**Review Article**
Volume 15:S2, 2021

**Journal of Molecular and Genetic Medicine**

ISSN: 1747-0862
Open Access

# Determination of the Effectiveness of Chlorine Dioxide in the Treatment of COVID 19

**Insignares-Carrione Eduardo[1]*, Bolano Gómez Blanca[2], Andrade Yohanny[3], Callisperis Patricia[4], Suxo Ana Maria[5], Arturo Bernardo Ajata San Martín[6] and Camila Ostria Gonzales[7]**

*[1]LVWG Global Research Director, Liechtensteiner Verein für Wissenschaft und Gesundheit, Liechtenstein, Switzerland (https://orcid.org/0000-0001-9337-0884)*
*[2]Director of the Research Department, Genesis Foundation, Colombia*
*[3]Specialist in Medical Bioethics, Oncology Palliative Care Specialist, Spain*
*[4]Director, Orthopedic and Traumatology Specialist, South clinic, La Paz, Bolivia,Spain*
*[5]MSc, Training and Research Center - Bolivia Today Association, Epidemiologist, South Clinic, La Paz, Bolivia, Spain*
*[6]Internal Medicine specialist, C Sorata 1146 V Victory, La Paz, Bolivia, Spain*
*[7]La Paz, Bolivia, Spain (linkedin.com/in/camila-ostria-gonzales-96bb0514a)*

## Abstract

**Introduction:** The aim of this review is to determine the Effectiveness of Oral Chlorine Dioxide in the Treatmentof COVID 19.

**Methods:** Research on the mechanism of action of chlorine dioxide on viruses, on the oral consumption ofwater-solubilized Cl02 and on its toxicity was reviewed; a quasi-experimental investigation wasconducted on the use of oral water-soluble chlorine dioxide in the treatment of 20 patients withactive COVID19 infection, compared to a control group of 20 patients not treated with chlorinedioxide.

**Results:** To compare the effect in the experimental group versus the control group, a test of comparison of proportions and their confidence intervals was performed for the general symptoms, and for the VAS and Likert criteria, a paired test using the Wilcoxon-Mann-Whitney test (α: 95%) was performed . When comparing the experimental group with the control group on the seventh day after symptom manifestation, a significant difference was found in the experimental group with respect to the control group for the symptoms Fever (p: 0000), Cough (p: 0.0000), Chills (p: 0.0000) and Dyspnea (p: 0.0006). When performing the visual analogous comparison of pain in the control group and in the experimental group, it was found that in all the items that make up the scale decreased significantly in this group with respect to the control group (p: 0.0000; p:00017). On day 14 post-demonstration the difference was greater (p:0.000 ; p:0.0043). When evaluating both groups (Control and Experimental) in the laboratories, a difference was found for the values of the parameters PC Reactive on day 7 (p: 0.0001) and DH Lactate (0.0036), with higher scores for the experimental group; Dimero-D on day 7 (p: 0.0194) and on day 14 (p:0.0029) ; difference was found in all parameters. The results overall (p <0.05) demonstrate the hypothesis that chlorine dioxide is effective in the treatment of COVID19.

**Conclusion:** Chlorine dioxide is effective in the treatment of COVID19 and the mechanisms of action by which it acts to achieve it are proposed in this work. We recommend doing more research. We recommend conducting double-blind studies and delving into studies of toxicological safety and therapeutic efficacy of chlorine dioxide in pathologies of epidemiological impact in the near future.

**Keywords:** SARS-CoV-2 • COVID19 • Effectiveness • Chlorine Dioxide.

## Introduction

In December 2019, a new respiratory illness emerged in Wuhan, China. The source of this infection was identified as a new coronavirus, related to other coronaviruses that had previously caused outbreaks of Severe Acute Respiratory Syndrome (SARS) between 2002 and 2004 and Middle East Respiratory Syndrome (MERS) in 2012 (National Institutes of Health , 2020). This virus was called "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) and the disease resulting from infection by this virus was called "COVID-19". On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic.

Coronaviruses are a group of enveloped RNA viruses that can damage multiple organ systems. Like other coronaviruses, the SARS-CoV-2 virus is a spherical particle with glycoprotein spikes on its surface. Coronaviruses enter host cells when a region of the spike, known as the "receptor-binding domain," binds to angiotensin-converting enzyme 2 (hACE2) in human cells. The viral membrane then fuses with the host cell membrane, allowing the viral genome to enter the host cell.

Chlorine dioxide (ClO2) has been suggested as a potential agent in the fight against COVID-19 and has been proposed three clinical trials to examine the ability of ClO2 to treat COVID-19. However, this agent is not well known, is not understood and is even demonized in the medical community, we assume that by confusion conceptual with sodium hypochlorite. Therefore, we set out to verify the effectiveness of oral use of the dioxide of chlorine in COVID19 through this study, reviewing in depth the history of ClO2, its safety / toxicity profile and its possible applications in the fight against COVID-19. The objective of this research is to determine if chlorine dioxide is effective in managing covid19 [1-65].

## Literature Review

### Chlorine Dioxide (ClO$_2$) Physical and Chemical Properties of Chlorine Dioxide

---

***Address for Correspondence:** Dr. Eduardo Insignares-Carrione, LVWG Global Research Director, Liechtensteiner Verein für Wissenschaft und Gesundheit, Switzerland-Liechtenstein; E-mail: eduardoinsignarescarrione@gmail.com / eic@lvwg.org*

***Copyright:** © 2021 Insignares - Carrione, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.*

mass of 67.45 g/mol. Typically, $ClO_2$ gas can be synthesized from the reaction between $NaClO_2$ (sodium chlorite) and $C_{l2}$, $NaClO_2$ and HOCl, $NaClO_2$, and an acid such as HCl or H3$PO_4$. It is easily soluble in water with a solubility of 3 g / 100 mL https://www.vyphidroasesores.com/.

The reactivity of chlorine dioxide is related to its structure and bond. Chlorine dioxide is a bent symmetric triatomic molecule (C2v point group) with a Cl-O bond length of 147.3 picometers and a bond angle of 117.6 degrees (Figure 1A). ClO2 has an odd number of electrons with 19 valence electrons and therefore, is aparamagnetic radical.Its electronic structure puzzled chemists for a long time because none of the possible structures dandLewisit is very satisfactory for chlorine dioxide [1-10].

The molecular orbital theory reveals that a single electron occupies the highest unoccupied molecular orbital, the p* orbital, which makes the molecule a free radical and explains its reactive nature. The two resonance structures of $ClO_2$ are shown in figure 1B. The resonance structures of the $ClO_2$ radical indicate the forms of a double bond between the central Cl atom and an O atom, and a single bond in combination with a 3-electron bond in the other Cl-O bond. The unpaired electron it is shared between the three atoms within the two different resonance structures. Most of the density of a single electron is found in one or another O atom. This unique arrangement provides ClO2 with a single unpaired electron and two reaction centers (O and Cl) on which to react.

When chlorine dioxide dissolves in water, most of it does not hydrolyze: it remains as a dissolved gas in solution. Another part does, and forms both chlorite ion ($ClO_2^-$) and chlorate ion ($ClO_3^-$). The solubility of chlorine dioxide in water at sea level and at 25°C is close to 3 g / L (≈ 3000 ppm). Its solubility increases at lower temperatures. Therefore, when its concentration is greater than 3 grams per liter, it is common to store it at temperatures close to 5°C. Dissolved in pure water, in a hermetically closed container, in the absence of light, and at a low temperature, it is quite stable although it slowly decomposes into chlorine and oxygen. Chlorides catalyze its decomposition.

In biological systems, $ClO_2$ can be expected to play an important role as an antiviral / microbial agent through oxidative chemistry.

The therapeutic action of chlorine dioxide is given by its selectivity for pH. It means that this molecule dissociates and releases oxygen when it comes into contact with another acid. When it reacts, it becomes sodium chloride (common salt) and at the same time releases oxygen, which in turn oxidizes (burns) the pathogens (harmful germs) of acidic pH present, converting them into alkaline oxides ("ashes"). Therefore, when chlorine dioxide dissociates, it releases oxygen into the blood, as do erythrocytes (red blood cells) through the same principle (known as the Bohr effect), which is to be selective for acidity. Like blood, chlorine dioxide releases oxygen when it encounters acidity, either from lactic acid or from the acidity of the pathogen. ClO2 is a size-selective antimicrobial agent.

Multicellular tissue has the ability to dissipate this charge and is not affected in the same way. Chlorine dioxide, which is the second strongest disinfectant known after ozone, is much more suitable for use therapeutic since it is also capable of penetrating and eliminating biofilm, which ozone does not do. The great advantage of the therapeutic use of chlorine dioxide is the impossibility of a bacterial resistance to ClO2. Although ozone is stronger in terms antiseptics, its high oxidative potential of 2.07 and its short half-life of only 15 minutes at 25°C with a pH value of 7.0 make it less effective, for *in vivo* therapeutic applications [11-20].

## Chlorine Dioxide Antiviral Efficacy

### Mechanism of Antiviral Action of $ClO_2$

$ClO_2$ exhibits antiviral activity through its oxidative chemistry. A virus consists of an outer shell or shell and an inner nucleic acid core. The viral envelope can be composed of proteins, lipid bilayers, and polysaccharides, and the envelope protects the nucleic acid core, in addition to providing selective binding and receptor cell recognition. Altering or modifying the viral envelope or nucleic acid nucleus will disrupt the modes of viral infection.

In the case of SARS-CoV-2, the carbohydrate envelope encloses it and protects it even more, which makes it more difficult to attack than other viruses. Approximately 70% of the entire surface of the spike protein is coated with glycans; In the case of SARS-CoV-2, sugars are twice as essential. First of all, because they stabilize the spicule in a conformation that allows it to fit with ACE2 receptors on our cells, the process that initiates infection. By removing some glycans from the surface, the spike protein is destabilized and, furthermore, the binding with these receptors is weakened.

A line of research is being developed in post-covid syndrome by one of the authors (B.Bolano), focusing attention on the possibility that Cl02 acts at the level of inflammasomes or even NETosis as a possible explanation for the improvement in the post covid19 syndrome manifested by hundreds of doctors who have reported cases in the world. The relevance and evidence of these findings to the anti-inflammatory mechanism of action of $ClO_2$ remains unclear at this time.

In order to explore the mechanism of action more deeply, we selected published articles (pubmed, google scholar and other search engines) that describe the action of SARS-CoV-2 in cells, in its interaction with hACE2 and, in In particular, we investigated augmented reality videos or simulation videos based on Silicon, for the three-dimensional representation of the places of action, such as the videos in which the spicular protein and the hACE2 receptor are manipulated, among others, with ChimeraX (UCSF) augmented reality software.

Similarly, we reviewed the structure of the virus spike and drew on the research of Daniel Wrapp and Jason S. McLellan of the University of Texas.

The three-dimensional image of the spicular S glycoprotein of the SARS-CoV-2 betacoronavirus has been seen with electron cryomicroscopy in record time. Thanks to this image with a resolution of 3.5 Å, it is confirmed that this S protein binds to the hACE2 protein of human cells with a higher affinity than that of the SARS-CoV coronavirus. Protein S is the target of the antibodies that immunize us. Its 3D structure allows us to understand why the monoclonal antibodies published against SARS-CoV are not effective against SARS-CoV-2.



**Figure 1:** (A). Geometry of the ClO2 molecule with group of points (C2v). The bond angle a is 117.6 O and the length of bond d is 147.3 pm. (B). Two resonance structures of ClO2 are illustrated that reveal the unpaired electron, centered on the Oxygen atom, shared between the three atoms.

Based on this information, we did a study with a doctor in molecular biology from the University of Tsukuba in Japan, in which we sought to build the hypothesis of how chlorine dioxide acts on SARS-CoV-2 (Insignares - Carrione et al , 2020). As a result, we saw that there is an excellent correlation between its structure and its transmission mechanism, as well as the determination of the sites of action of promising substances or drugs in the treatment of covid19 and, however, we have not had the expected results for its rapid control with none of the drugs tested. Bioinformatics is a tool that uses biological data to study biological problems on a wide range of scales, such as evolution, structure, the function and regulation of nucleic acids and proteins with the help of computational methods. In our work in Japan, we carry out in silico analysis, which is a comprehensive quantitative approach that not only provides information on the dynamics of intracellular and intramolecular processes, but ultimately allows us to predict biological behavior from molecular interactions. This was done in our work by focusing on conserved domains, structure, function, and biochemical characteristics to understand the mechanism of action of chlorine dioxide on the spike and SARS-CoV-2 RNA. which is a complete quantitative approach that not only provides information on the dynamics of intracellular and intramolecular processes, but ultimately allows prediction of biological behavior from molecular interactions. This was done in our work by focusing on conserved domains, structure, function, and biochemical characteristics to understand the mechanism of action of chlorine dioxide on the spike and SARS-CoV-2 RNA. which is a complete quantitative approach that not only provides information on the dynamics of intracellular and intramolecular processes, but ultimately allows prediction of biological behavior from molecular interactions. This was done in our work by focusing on conserved domains, structure, function, and biochemical characteristics to understand the mechanism of action of chlorine dioxide on the spike and SARS-CoV-2 RNA (Figure 2).

This type of analysis not only provides information on RNA replication, but also simulates the dynamics of the interrelation between the spike and the hACE2 receptor. The investigation began with the nucleotide sequence of the viral RNA, the open reading frames (ORF's) were determined, which once analyzed, revealed the oxidation of guanine to 8-oxoguanine. The other bases were not modified. The amino acids oxidized by chlorine dioxide are found in the spike, located in the helices, S1, S2, RBD and hACE2, which could explain the almost immediate effect of clinical improvements achieved by dioxide (Insignares - Carrione et al, 2020).

Cysteine, belonging to the group of thiols, is an amino acid up to 50 times more reactive with all microbial systems than the other four amino acids and, therefore, it is impossible for it to create resistance against chlorine dioxide.

The hypothesis proposed by the authors (Insignares - Carrione, 2020) is that the cause of the antiviral effect of chlorine dioxide in SARS-CoV-2 can be explained by its actions on at least five amino acids (Cysteine, tryptophan, tyrosine, proline, hydroxyproline).

## Pharmacokinetics

The pharmacokinetics of $ClO_2$ varies with the route of exposure. Scatina et al. (1984) examined the dermal absorption of a ClO2 preparation applied to the shaved back of rats. The maximum absorption of Cl in plasma was observed after 72 hours and a plasma concentration of 69.4 mcg% Cl was reached. The absorption half-life was calculated as 22.1 hours, which corresponds to a rate constant of 0, 0314 h-1 (Figure 3).

Fridyland and Kagan (1971) measured the degree of ClO2 absorption in the oral cavity of human subjects by rinsing the mouth with water containing predetermined concentrations of ClO2, and then measuring the residual concentrations of ClO2 in the washings. They found that up to 30% of the ClO2 was absorbed.

## Safety / Toxicity

The safety / toxicity of ClO2 depends on several variables, including the route of administration (e.g., inhaled, topical, or oral), the state of the molecule (i.e., gaseous or aqueous), the concentration (usually measured in mg / L or ppm for aqueous and ppm or mg / m3 for gaseous), and the duration of exposure. ClO2 gas is toxic at much lower concentrations than aqueous ClO2. Toxicity also increases with the duration of exposure. The fact that ClO2 is less toxic in aqueous form allows the use of this molecule as a safe disinfectant in municipal drinking water, as a disinfectant for drinking water at points of use and as a food disinfectant, among other uses (Figure 4).

Below is a review of studies examining the safety and toxicity of $ClO_2$.

## $ClO_2$ Solubilized in Water

### *In vitro* studies

Noszticzius et al. (2013) examined the differential effects of $ClO_2$ on microbes versus humans or animals. They performed perfusion studies using protein membranes and found that the size of the organism exposed to $ClO_2$ influences the effects of the oxidant. They reported that a low concentration of $ClO_2$ quickly kills micron-sized organisms while causing little harm to larger organisms, such as humans. The authors suggested that the reasons for this differential effect are: (1) $ClO_2$ cannot penetrate deeply into the tissues of larger organisms and (2) the circulation of larger organisms provides a constant supply of antioxidants, offering protection against the effects. $ClO_2$ oxidants.

*In vitro* studies found that methemoglobin was not formed unless glutathione concentrations in red blood cells were almost completely depleted (Heffernan et al. 1979a).

### *In vivo* Animal Studies

Daniel et al. (1990) exposed rats to ClO2 concentrations of 0, 25, 50, 100 or 200 mg / liter for 90 days. This equates to doses of 11.5 mg / kg / day in males and 14.9 mg / kg / day in females. No exposure-related deaths were reported.

Abdel-Rahman et al (1982b) reported LD50 rates for female rats of 340 to 468 mg / kg and for male rats of 292 to 424 mg / kg after a single gavage dose. Additional reports of LD50 in rats include 94 mg / kg (WHO, 2002), 140 mg / kg (Musil et al., 1963), 292 ppm (National Institute for Occupational Safety and Health, 2014) and> 5,000 mg / kg (US Environmental Protection Agency, 2008). The LD50 in mice has been reported to be> 10,000 mg / kg (Shi et al. 1999).

In a study carried out at the University of Querétaro (Mexico) in 2020, researchers challenged the hypothesis that ClO2 decreases viral load and virus-induced mortality in a vertebrate model. To do this, they determined the



**Figure 2:** Positions of the amino acid (cysteine) in the structure of the spike, one of the possible sites of action of $ClO_2$.



**Figure 3:** Effectiveness of chlorine dioxide treatment based on concentration and contact time.



**Figure 4:** Review of experimental levels of chlorine dioxide / chlorite systemic toxicity. In blue, reference levels for disinfection of drinking water (US-EPA); in green, levels with evidence of therapeutic efficacy at zero toxicity (Refs A Kalcker and E. Insignares Carrione); red: minimum levels of toxicity detection reported in different in vivo studies in animals and humans.

viral load, virus-induced lesions, and mortality in 10-day-old chicken embryos inoculated with 104 EID50 / mL in media of attenuated avian coronavirus (IBV) strains from Massachusetts and Connecticut. ClO2 treatment had a marked impact on IBV infection. Specifically, viral titers were 2.4 times lower and mortality was reduced by half in infected embryos that were treated with ClO2. The infection caused developmental abnormalities, regardless of treatment. Lesions typical of IBV infections were observed in all inoculated embryos, but severity tended to be significantly less in ClO2-treated embryos. They found no gross or microscopic evidence of toxicity caused by ClO2 at the doses used in this case. The study concludes that ClO2 could be a safe and viable way to treat and mitigate the effects of avian coronavirus infections, and raises the possibility that similar effects may be observed in other organisms. (Xóchitl Zambrano-Estrada et al, 2020).

## Water Solubilized Chlorine Dioxide (CDS) in Human and Animal Studies

The studies by Lubbers et al. (1982, 1984a) at the Ohio State University School of Medicine evaluated the short-term toxicity of drinking ClO2. In the first study (Lubbers et al. 1982), a group of 10 healthy adult males drank 1,000 ml (divided into two 500 ml portions, 4 hours apart) of a gradually increasing dose of ClO2. The study included a series of six sequences of 3 days each in which subjects drank 0.1, 1.0, 5.0, 10.0, 18.0, and 24.0 mg / L of a ClO2 solution. (0.34 mg / kg, assuming a reference body weight of 70 kg). . In the second study (Lubbers et al., 1984a) groups of 10 adult males received 500 ml of distilled water containing 0 or 5 mg / L ClO2 (0.04 mg / kg-day assuming a reference body weight of 70 kg) for 12 weeks.

In a comparative study of hyperpure chlorine dioxide with two other irrigants regarding the viability of periodontal ligament stem cells (PLDSCs), cell viability experiments demonstrated that the application of ClO2 does not lead to a significant decrease in the viability of PLDSCs. in the concentrations used to kill microbes. In contrast, traditional irrigants, H2O2 and CHX are highly toxic to PDLSCs. The aging of PLDSC cultures (passages 3 vs. 7) has characteristic effects on their responsiveness to these agents, since the increased expression of the mesenchymal stem cell markers becomes decreased. They conclude that although the active ingredients of mouthwashes (H2O2,

## Oral ingestion of ClO$_2$ solubilized in water.

The only study conducted for the use of water-solubilized ClO2 (CDS) ingested by oral route is our present study carried out in a multicenter clinical trial in various countries from central and South America (https://clinicaltrials.gov/ct2/show/NCT0434374). Statistics of Bolivia where the use of water-solubilized ClO2 for the prevention and treatment of COVID-19 was approved by law in early August 2020, demonstrate a marked reduction in cases and deaths in that country. The highest peak recorded in Bolivia was epidemiological week 29 (10,939 cases), with cases falling to 670 in epidemiological week 45, (representing a 93% decrease). The case-fatality rate decreased from 8% to 4.5% in epidemiological week 36, coinciding with the massive use of dioxide in the population without it being possible to affirm with certainty that dioxide is responsible for this decrease. (https://snis.minsalud.gob.bo/). From a peak of 2,031 daily cases on August 20, 2020, cases dropped to 147 daily cases on October 21, 2020, representing a 93% decrease. Daily deaths decreased from a peak of 132 on September 3, 2020 to 24 deaths on October 21, 2020, with an 82% decrease in mortality. (https://www.covid19.onl/country/bolivia).

While there was a rebound in cases from epidemiological week 49 to 53, mortality remained relatively low. Some doctors linked to our research group (in Bolivia more than 220 doctors) provide feedback that the population reduced the consumption of dioxide and that could be a possible explanation for the peak, and the increase in the consumption of chlorine dioxide again reduced the peak to the previous levels, maintaining a reduced comparative mortality (personal communications) (Figure 5).

In summary, while in other countries the plateau was maintained, in Bolivia it fell, attributing this decrease (as a possible explanation) to preventive measures, the consumption of chlorine dioxide and the massive use of traditional medicine as a possible explanation.

## Dose

*In vitro* and *in vivo* studies demonstrate that low doses of water-solubilized ClO2 exhibit potent and rapid antiviral activity against a wide range of viruses. In a study on drinking water in the Netherlands, Jin et al. (2013) found that treatment with ClO2 at concentrations of 0.5 ppm for 25 minutes, or 1.5 ppm for 10 minutes, or 2 ppm for 5 minutes achieved at least a 4 log reduction of enterovirus. Schijven et al (2019) demonstrated that municipal drinking water treated with ClO2 (0.1 ppm in summer and 0.05 ppm in winter) significantly reduced adenovirus levels to levels that are considered safe for drinking water.

Alvarez and O'Brien (1982) found a ClO2 concentration of 40 ppm added to wastewater seeded with SARS-CoV that completely inactivated the SARS-CoV in 30 minutes.

The dose used in this research is 30 mg per day for 21 days, which is well below the NOAEL, or in the worst case the same as the NOAEL reported in previous studies in animals, as we discussed in previous lines. .

## Materials and Methods



* Data from January 8, 2021 At 11 a.m. CET.
Source: Johns Hopkins University

Figure 5: The death rate of the Coronavirus in Latin America.

To make the greatest search for scientific information on chlorine dioxide, sand they searched Google Scholar, PubMed (Medline), LILACS, Cochrane Library, Science, Scielo, MedScape, looking for articles in English and Spanish, which would contain search terms chlorine dioxide, virus, SARS-CoV-2, coronavirus, oxidant, water purification, "Chlorine dioxide" OR "Chlorine dioxide protocol" OR Chlorine dioxide AND virus; Chlorine dioxide AND SARS-COV-2; OR "COVID-19 drug treatment" OR "spike glycoprotein, COVID-19 virus" OR "severe acute respiratory syndrome coronavirus 2" OR "COVID-19" OR "2019-nCoV" OR "SARS-CoV-2" O "2019 new coronavirus "OR" 2019 coronavirus disease "OR (pneumonia).

Additionally, a Google search was conducted using these same search terms. The articles selected for inclusion consisted of publications related to the potential use of ClO2 as prevention or treatment of COVID-19, on the beneficial aspects and possible effects of maleficence or toxicity of the substance. All retrieved articles were screened and a subset of relevant abstracts was selected for further evaluation. The bibliographies of these articles were then searched for additional references. The final articles selected for inclusion in this review consisted of articles examining historical uses, chemistry, toxicity, antimicrobial and virucid ClO2, previous investigations in animals in vitro and in vivo, and research in humans. The registries of www.clinicaltrials.gov and those of the WHO International Clinical Registry Platform (ICTRP) were reviewed to identify ongoing or unpublished clinical trials.

From the search results, we selected those that referred to the virucidal action of chlorine dioxide on various microorganisms, in particular on viruses and, among them, SARS-CoV-2 or SARS-CoV.

On the other hand, we selected articles that describe the action of SARS-CoV-2 in cells, in its interaction with ACE2 and, in particular, we investigated augmented reality videos or simulation videos based on Silico, for three-dimensional representation. De sites of action such as videos in which the spicular protein and the ACE2 receptor (37) are manipulated, among others, with the ChimeraX (UCSF) augmented reality software.

Similarly, we reviewed the structure of the virus spike and relied on the research of Daniel Wrapp and Jason S. McLellan of the University of Texas, information with which, in a parallel study, we were able to hypothesize how chlorine dioxide acts on SAR-CoV-2.

With the information needed to conclude that chlorine dioxide was beneficent and that its use in the COVID19 pandemic is turned in an immense possibility to control it based on the scientific foundations revealed in previous investigations, and above all, that it was not maleficent for patients, we take the decision to carry out the investigation for determine if it was effective orally in the treatment of COVID19.

We decided to carry out a phase IIa design given the urgency to verify a option effective, fast and economical treatment that could be implemented quickly worldwide, which is why we opted for a quasi-experimental clinical trial.

The NCBI (National Center for Biotechnology Information) for Medline and Pubmed databases recently included the concept of ECE (Quasi Experimental Studies) under the MeSH term "Non-Randomized Controlled Trials as Topic" (NCBI, 2015).

Once the research protocol was done, it was decided to register it in clinicaltrials.gov which was accepted on April 7, 2020 under the number NCT 04343742. The design was made international multicenter in order to have a faster collection of the sample and in the future, to have a much larger and more representative sample. The same protocol was presented in eleven American countries and in Spain for approval. Unfortunately, drug control entities in all countries generated warnings and even bans on its use for human consumption that made it difficult for ethics committees to approve the protocol. In Bolivia the law was approved No. 1351 of 2020 that authorized the elaboration, commercialization, supply and consented use of the CDS chlorine dioxide solution as prevention and treatment in the face of the coronavirus pandemic (COVID 19); The ethics committee endorsed by the Bolivian Ministry of Health was legally constituted, which approved this multicenter research protocol of international scope, retro-prospective, made up of five (5) universities (Technical University of Oruro, Public University of El Alto, Universidad Mayor de San Simón, Gabriel René Moreno Autonomous University and Yacuiba Technical Institute "Gran Chaco" ) which in turn, through its scientific and ethical clinical research committees, are doing their own research on chlorine dioxide for use in different applications [20-35].

## Data collection and registration

Data collection and recording was carried out by recording demographic and symptomatic data and by means of observation scales based on visual analogue scale (VAS) and laboratory parameters organized by Likert scale for better evaluation and comparability. Thus, the instruments or formats were built, which were recorded in software specially designed for research with the following characteristics:

An electronic form in a WEB environment was specially designed for the registration of information required in the investigation through PCs, smartphones and tablets.

The application was developed by the company SCORPII SAS in 2020, with the following functionality:

- Registration of the contact information and basic profile of the investigating physician, who identifies the location of the medical center where the patient was treated for the first time and records their contact details and socio-cultural profile.
- File of the letter of informed consent for the use of an investigational substance, signed by each patient.
- Registration of the information on the patient's initial diagnostic clinical history.
- Record of the patient's follow-up clinical history in relation to his symptoms, pain scale (VAS) and assessment with the Likert scale of the laboratory reports made on day 0, 7, 14 and 21.
- In relation to the security conditions, the registered information does not have options to make changes or adjustments to the registered information by the investigating physicians, guaranteeing the authenticity, integrity and confidentiality of the information. Each researcher has access to the application through the authentication of their email and password, in such a way that they are solely responsible for the registration of information on each of their patients.
- Generation of information consolidation reports for statistical analysis,

a function of access exclusively by the research director, without options for modifying the database of records made by investigating physicians.

That is, the instruments made it possible to collect and record the results from the performance of semiological, clinical and laboratory examinations at the beginning of the study treatment of the experimental group and the control group, as well as after 7, 14 and 21 days.

In addition to demographic data, the following are measured:

Semiological: red eyes, fever, cough, expectoration, asthenia / adynamia, chills, vomiting, dyspnea, nasal congestion.

The VAS criteria ( The visual analog scale or VAS) for pain it is a straight line in which one end means no pain and the other end means the worst pain imaginable. The patient marks a point on the line that matches the amount of pain felt) and the variables investigated. They are: sore throat, head, chest, general myalgic type, affectation due to low back pain.

Likert criteria (The Likert scale is an *ordinal* scale using 5 levels) grouped paraclinical exams. The variables investigated are lymphocytes, leukocytes, platelets, C-reactive protein, Lactate dehydrogenase, AST, -D-dimer and lactate in oximetry.

The instruments made it possible to collect and record the results from the performance of semiological examinations, assessment of painful symptoms (VAS) and laboratory (LIKERT) at the beginning of the treatment under study (or baseline) as well as after 7, 14 and 21 days .

## Analysis and Interpretation of the Data

It is carried out according to the established variables, with the support of the IBM - SPSS Statistics software; the data of the experimental and control groups were analyzed, the general symptoms by means of a comparison of proportions test and their confidence intervals, and the VAS and Likert criteria by means of a paired test using the Wilcoxon - Mann - Whitney test $\alpha$: 95%).

## Population

The experimental population to which the multicenter study was directed consisted of a group of patients with active infection with COVID-19 , in various medical centers in Bolivia ( 14 patients ) , most of them in the southern clinic in La Paz, Bolivia , Peru ( two patients ) and Ecuador ( four patients ) for a total of twenty ( 20 ) patients. The control population consisted of eight (8) patients from Ecuador, seven (7) patients from Bolivia, three (3) from Mexico and two (2) from Peru, for a total of twenty (20) patients.

## Patients

The selection of the treatment or experimental group was made based on patients with active COVID19 infection, who were with positive RT-PCR, symptomatic in intervals from 3 to 7 days, which were not in the resolution phase, who were proposed to be voluntary research subjects. Control group patients chose not to be chlorine dioxide treatment subjects. Similarly, simultaneity was applied, which means that patients were obtained in the same period of time in which the cases arose. Viral load was not determined due to costs, technical and logistical difficulties of the reference laboratories in Mexico, Bolivia, Peru and Ecuador.

## Number of Patients

Twenty patients (n = 20) for the experimental group and 20 patients (n = 20) for the control group were included in the study. A one-to-one relationship per center was not maintained and they were presented randomly according to a probabilistic sample design.

## Acceptance Criteria in the Study

The following inclusion criteria were used: Covid 19 RT-PCR positive, characteristic symptoms of Covid-19: fever, odynophagia, respiratory distress, aged between 18 and 80 years.

## Exclusion Criteria

Covid 19 RT-PCR negative, IV / VI renal failure, congestive heart failure, patients who consume anticoagulants in particular warfarin sodium.

## Duration of Treatment per Patient

The observation period per patient in the experimental group was (21) twenty-one days. In the control group it was fourteen (14) days. A review was carried out at the beginning, at 7, 14 and 21 days in the experimental group; in the control group at the beginning, at 7 and 14 days. Post-protocol clinical follow-ups (day 22 onwards) were not included in the experimental group and neither in the control group. It is important to note that there was clinical follow-up by the research staff in most of the patients treated and not treated with chlorine dioxide, observing resolution completeness of symptoms in the treated group. As an empirical observation, the researchers' report that patients who consumed chlorine dioxide as a treatment for COVID19, substantially reduced post-COVID19 symptoms compared to patients with the disease, not treated with dioxide.

## Total duration of the study

The study began in July 2020 and concluded in December 2020.

## Assignment of study medication

Each patient received, in order of admission to the study, a consecutive patient number (odd numbers were selected) and the corresponding study medication. The allocation of this medication was made prior to the start of the study, by means of a computer generated list of vials produced for the purpose of the research. The patients received the chlorine dioxide base preparation at 3,000 ppm, produced by electrolysis with ultrapure chlorine dioxide generating equipment, brand medalab www.cl02.com with precise written instructions on how to prepare, drink and preserve dilutions. The chemists of the research team controlled the standardization of the water used for the base preparation of the dioxide at 3000 ppm, as well as the water used for diluting and drinking; the controlled variables were: conditions and characteristics of the preparation process, standardized characteristics of the container, use of standardized Merck 28% sodium chlorite, standardized sterile double-distilled water, buffered at pH 7 and chlorine dioxide concentration at 3,000 p.p.m.

The control group received anti-inflammatory treatment (ibuprofen at doses between 200 and 400 mg every 8 hours), antibiotics (azithromycin 500 mg daily for 5 days), antihistamines (hydroxyzine x 5 mg every 12 hours), corticosteroids (generally 40 mg of methylprednisolone every 12 hours for 3 days and then 20 mg every 12 hours for 3 days) and supportive measures. The experimental group did not receive this treatment.

## Dosage and Routes of Administration

The medication used is chlorine dioxide 3000 ppm in x 120 cc bottles marked with a planned label and administered according to the standard established in the research protocol.

**Chlorine Dioxide Administration Protocols** used:

**Initial protocol, loading or protocol (F)**: 10 ml of chlorine dioxide 3000 ppm is added to 1 liter of water, and the liter is taken in two hours, divided into eight (8) equal doses. Then it is administered.

**Maintenance protocol**: (C) 10 ml of chlorine dioxide 3000 ppm is added to 1 liter of water, and the liter is given to drink divided into ten (10) equal doses, during the day, every hour.

The medication is manages orally dissolved in the mouth, at least 60 minutes before or after a meal. There were no remnants or shortages in the medication delivered and the original protocol were strictly adhered to. There is no abandonment of treatment.

# Results

## Preliminary analysis of the parameters at study entry

The characteristics of the patients in the experimental group at the time

678-F

of admission, after verification of the positive RT-PCR, generated the following data: By sex: 13 male patients (65%) and 7 female (35%).

The ages range between 36 years the minimum and 72 years the maximum. The average age for men is 47.6 years and for women 58 years of age. The general average age is 53.2 years.

A parallel instrument was designed to record possible adverse effects of chlorine dioxide where the data of each patient and their adherence process are placed. In two patients, a slight sensation of gastritis was registered, 7 days after treatment, temporary, which resolved without intervention and did not require stopping the medication (Figure 6).

## Characteristics of the control group

The characteristics of the patients in the control group at the time of admission after verification of the positive RT-PCR generated the following data: By sex: 10 male patients (50%) and 10 female (50%).

The ages range between 44 years the minimum and 69 years the maximum. The average age for men is 55.6 years and for women 52 years of age. The general average age is 54.5 years (Figure 7).

## Result of the comparison of the Experimental versus Control Group by means of a comparison of proportions test and their confidence intervals and Wilcoxon – Mann – Whitney test (α: 95%)

To evaluate the effectiveness of the $ClO_2$, the results of each of the items were compared by means of a comparison of proportions test and their confidence intervals (general symptoms) and a Wilcoxon – Mann – Whitney test (α: 95%)(VAS and Likert) of the data obtained from the Experimental Group compared with the Control group in the Cohort points of Onset of Symptoms, 7 and 14 days after the first symptomatic manifestation.

Below we present the comparisons between the groups, for general symptoms, VAS and Likert (Table 1).

Regarding general symptoms, on the day of onset of general symptoms, both groups (Control and Experimental) were the same for most of the items (p > 0.05). However, for the Chills the Experimental group had a higher Average Range (25.5) than that of the Control Group (15.5) (p : 0,0001). These results confirm that in general for general symptoms, both groups had a similar behavior.

When making the comparison on the seventh day post symptom manifestation, a significant difference was found in the Experimental group with respect to the control group for Symptoms Fever (p: 0000), Cough (p: 0.000 ), Chills (p: 0.000) and Dyspnea (p: 0,0006). At day 14 in the symptoms that had not disappeared, the difference was very significant, decreasing its manifestations in the Experimental group (Table 2).

For the VAS Scale, at the time of symptom manifestation, both groups reported the same subjective assessment of pain. When performing the same visual analogue comparison of pain in the control group and in the experimental group, it was found that all the items that make up the scale decreased significantly in this group with respect to the Control group on day 7 ( p: 0,0000 ; p:0,0017). The only painful symptom that remained similar was low back pain (P: 0,9633). On day 14 post manifestation the difference was greater (p: 0.000 ; P: 0,0043 y P: 0,0067) (Table 3).

When evaluating both groups (Control and Experimental), a difference was found for the values for the PC Reactive parameters (p: 0.0398) and Lactate DH (0.0422), the scores being higher for the experimental group; no difference was found in the rest of the parameters. When comparing the groups at 7 days post-initial manifestation, only the Lymphocytes and Leukocytes showed no difference between groups (p> 0.05), the other parameters significantly decreased in the Experimental group with respect to the Control.( p:0,0001; p: 0,0036 ; p: 0,0403; p: 0,0194; p: 0,0003). At day 14, all the biochemical parameters had decreased significantly in the experimental group with respect to the Control group (p < 0,05).



Figure 6: Ages of Patients Experimental Group.



**Figure 7:** Ages of Patients. Control group.

The results overall (p < 0.05) demonstrate the hypothesis that chlorine dioxide is effective in the treatment of COVID19.

## Permanence of the intervention

As we noted in previous lines, the design of the protocol did not include post-intervention follow-up beyond day 21, which was the limit that we set ourselves from the beginning. As a non-parameterized observational annotation, we can share that the group of researchers did clinical follow-up of the patients until approximately two months after the onset of the disease, verifying a satisfactory evolution with very few post-covid symptoms. Some of the patients noted some mild spinal discomfort and some degree of chronic fatigue.

# Discussion and Recommendations

This research has focused on studying the effectiveness of the use of chlorine dioxide in patients with COVID19, by measuring before and after treatment, present clinical symptoms and laboratory variables based on standardized and accepted scales in research (VAS and Likert) of an experimental group compared to a control group.

Regarding the research question whether chlorine dioxide could effectively reduce morbidity and mortality in COVID19, the confirmatory significant statistical validation by the U test of Wilcoxon – Mann – Whitney test (α: 95%) in the experimental and control groups reveal this and confirm the hypothesis that chlorine dioxide is effective in the treatment of covid19.

This phase IIa clinical trial is the preliminary phase for the realization of an upcoming phase IIb, double-blind randomized study, where we can have a sample of 400 patients, a purpose in which we are already working.

The main advantage of the design we chose is that it is a simple and inexpensive study to carry out (the authors did not receive any external funding and the costs were paid directly and personally by them) than a clinical trial

**Table 1:** Result of the comparison of the Control Group versus the Experimental Group by means of a comparison of proportions test and their confidence intervals for General Symptoms.

| Syntom | Group | Day 0 |  | Day 7 |  | Day 14 |  |
|---|---|---|---|---|---|---|---|
|  |  | n (%) | *P*-value | n (%) | *P*-value | n (%) | *P*-value |
| Fever | Ctrl | 18 (90%) | 0,3160 | 14 (70%) | 0,0000 | 12 (60%) | 0,0000 |
|  | Exp | 17 (85%) |  | 0 (0%) |  | 0 (0%) |  |
| Cough | Ctrl | 20 (100%) | 0,0680 | 18 (90%) | 0,0000 | 18 (90%) | 0,0000 |
|  | Exp | 18 (90%) |  | 6 (30%) |  | 6 (30%) |  |
| Asthenia Adynamia | Ctrl | 18 (90%) | 0,1015 | 20 (100%) | 0,0000 | 20 (100%) | NA |
|  | Exp | 15 (75%) |  | 2 (10%) |  | 0 (0%) |  |
| Expectoration | Ctrl | 7 (35%) | 0,1405 | 3 (15%) | 0,0301 | 0 (0%) | NA |
|  | Exp | 4 (20%) |  | 0 (0%) |  | 0 (0%) |  |
| Chills | Ctrl | 17 (85%) | 0,0001 | 10 (50%) | 0,0000 | 4 (20%) | 0,0127 |
|  | Exp | 7 (35%) |  | 0 (0%) |  | 0 (0%) |  |
| Vomit | Ctrl | 1 (5%) | 0,1524 | 0 (0%) | NA | 0 (0%) | NA |
|  | Exp | 0 (0%) |  | 0 (0%) |  | 0 (0%) |  |
| Dysnea | Ctrl | 18 (90%) | 0,5000 | 16 (80%) | 0,0006 | 12 (60%) | 0,0005 |
|  | Exp | 18 (90%) |  | 7 (35%) |  | 3 (15%) |  |
| Nasal Congestion | Ctrl | 5 (25%) | 0,2438 | 2 (10%) | 0,0680 | 0 (0%) | NA |
|  | Exp | 7 (35%) |  | 0 (0%) |  | 0 (0%) |  |

**Table 2:** Result of the comparison of the Control Group versus the Experimental Group through a Wilcoxon – Mann – Whitney test (α: 95%) for the VAS Scale.

| VAS Scale | Group | Day 0 |  | Day 7 |  | Day 14 |  |
|---|---|---|---|---|---|---|---|
|  |  | median (IC) | *P*-value | median (IC) | *P*-value | median (IC) | *P*-value |
| Throat pain | Ctrl | 3,1 IC ± 0,6 | 0,9670 | 2,1 IC ± 0,4 | 0,0000 | 1,3 IC ± 0,3 | 0,0000 |
|  | Exp | 3,2 IC ± 0,9 |  | 0,0 IC ± 0,0 |  | 0,0 IC ± 0,0 |  |
| Headache | Ctrl | 2,9 IC ± 0,5 | 0,2665 | 2,9 IC ± 0,4 | 0,0000 | 2,5 IC ± 0,4 | 0,0000 |
|  | Exp | 2,6 IC ± 0,8 |  | 0,5 IC ± 0,2 |  | 0,4 IC ± 0,2 |  |
| Chest pain | Ctrl | 0,6 IC ± 0,3 | 0,9018 | 0,6 IC ± 0,3 | 0,0017 | 0,4 IC ± 0,2 | 0,0043 |
|  | Exp | 0,6 IC ± 0,2 |  | 0,1 IC ± 0,1 |  | 0,0 IC ± 0,0 |  |
| General pain | Ctrl | 2,1 IC ± 0,4 | 0,8660 | 2,4 IC ± 0,4 | 0,0000 | 2,6 IC ± 0,4 | 0,0000 |
|  | Exp | 2,1 IC ± 0,7 |  | 0,5 IC ± 0,2 |  | 0,0 IC±0,1 |  |
| Lumbar/affect | Ctrl | 1,5 IC ± 0,3 | 0,7827 | 1,6 IC ± 0,2 | 0,9633 | 1,6 IC±0,2 | 0,0067 |
|  | Exp | 1,6 IC ± 0,3 |  | 1,7 IC ± 0,3 |  | 2,0 IC±0,2 |  |

**Table 3:** Result of the comparison of the Control Group versus the Experimental Group through a Wilcoxon – Mann – Whitney test (α 95%) for Biochemical Parameters on the Likert Scale.

| Parameter | Group | Day 0 |  | Díay 7 |  | Day 14 |  |
|---|---|---|---|---|---|---|---|
|  |  | median (IC) | *P*-value | median(IC) | *P*-value | median (IC) | *P*-value |
| lymphocytes | Ctrl | 1,5 IC ± 0,3 | 0,7827 | 1,6 IC ± 0,2 | 0,9633 | 1,6 IC ± 0,2 | 0,0067 |
|  | Exp | 1,6 IC ± 0,3 |  | 1,7 IC ± 0,3 |  | 2,0 IC ± 0,2 |  |
| leukocytes | Ctrl | 2,6 IC ± 0,4 | 0,2582 | 3,1 IC ± 0,3 | 0,4842 | 3,3 IC ± 0,2 | 0,0002 |
|  | Exp | 2,8 IC ± 0,4 |  | 2,9 IC ± 0,3 |  | 2,5 IC ± 0,3 |  |
| Platelets | Ctrl | 2,4 IC ± 0,3 | 0,0816 | 2,7 IC ± 0,2 | 0,0202 | 3,0 IC ± 0,2 | 0,0212 |
|  | Exp | 2,7 IC ± 0,3 |  | 3,3 IC ± 0,4 |  | 2,6 IC ± 0,3 |  |
| PC Reactive | Ctrl | 3,2 IC ± 0,2 | 0,0398 | 3,4 IC ± 0,2 | 0,0001 | 3,5 IC ± 0,2 | 0,0000 |
|  | Exp | 3,0 IC ± 0,0 |  | 2,0 IC ± 0,5 |  | 1,4 IC ± 0,2 |  |
| Lactate DH | Ctrl | 2,6 IC ± 0,3 | 0,0422 | 2,7 IC ± 0,3 | 0,0036 | 2,7 IC ± 0,2 | 0,0000 |
|  | Exp | 3,2 IC ± 0,4 |  | 1,9 IC ± 0,4 |  | 1,5 IC ± 0,2 |  |
| AST | Ctrl | 3,2 IC ± 0,4 | 0,5319 | 3,2 IC ± 0,3 | 0,0403 | 3,5 IC ± 0,3 | 0,0000 |
|  | Exp | 3,2 IC ± 0,4 |  | 2,5 IC ± 0,6 |  | 1,9 IC ± 0,3 |  |
| Dimero D | Ctrl | 3,1 IC ± 0,4 | 0,3060 | 3,4 IC ± 0,4 | 0,0194 | 3,5 IC ± 0,3 | 0,0029 |
|  | Exp | 3,4 IC ± 0,5 |  | 2,6 IC ± 0,4 |  | 2,6 IC ± 0,4 |  |
| Lactate | Ctrl | 1,9 IC ± 0,3 | 0,0145 | 2,2 IC ± 0,2 | 0,0003 | 2,5 IC ± 0,2 | 0,0000 |
|  | Exp | 2,5 IC ± 0,4 |  | 1,5 IC ± 0,3 |  | 1,1 IC ± 0,1 |  |

with a larger sample number, in particular double blind that would increase the cost significantly. On the other hand, it is the only way to carry out a study when there are ethical and feasibility problems to carry out a random assignment of the sample (Manterola et al), or when it is necessary to carry it out under natural conditions and in this case, due to manifest urgency. given the pandemic.

The disadvantages are the high susceptibility to biases, especially those of selection and confusion, so to reduce it, we used random probability sampling, numbering the patients who were diagnosed and treated, selecting odd-numbered patients for inclusion in the research; the sample of control patients were selected in the same way.



8A. Blood sample with methemoglonemia

8B. Blood sample seconds after injecting chlorine dioxide at 50 ppm.
Note the change in red blood cells bathed by chlorine dioxide.
(Insignares-Carrione, Andreas Kalcher SCHWEIZER VEREIN FUR NATURWISSENS CHAFTLICHE BIOPHYSIK)

Figure 8: Blood samples with methahemoglobinemy and with $ClO_2$.



| | | | | | | | |
|---|---|---|---|---|---|---|---|
| k+ | 3,6 | mmoI/L | | k+ | 3,4 | mmoI/L | Haag |
| Ca++ | 1,20 | mmoI/L | | Ca++ | 1,13 | mmoI/L | Haag |
| Cl- | 102 | mmoI/L | | Cl- | 107 | mmoI/L | |
| cTCO2 | 31,6 | mmoI/L | Hoog | cTCO2 | 27,6 | mmoI/L | |
| Hct | 45 | % | | Hct | 38 | % | |
| Chgb | 9,5 | mmol/L | | Chgb | 8,0 | mmol/L | |
| BE(b) | 2,5 | mmol/L | | BE(b) | 1,3 | mmol/L | |
| Resultate: Meta+ | | | | Resultate: Meta+ | | | |
| Glu | 88 | mg/dL | | Glu | 79 | mg/dL | |
| Lac | 2,49 | mmoI/L | Hoog | Lac | 0,79 | mmoI/L | |
| Crea | 151 | umoI/L | Hoog | Crea | 122 | umoI/L | Hoog |

PRIOR TO INJECTION AFTER THE INJECTION

Figure 9: Variations in serum lactate before and 10 min after an IV clorine dioxide injection at 50 ppm. (A. Kalcker. SCHWEIZER VEREIN FUR NATURWISSENS CHAFTLICHE BIOPHYSIK).



| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Resultaten: Chiem+ | | | | Resultaten: Chiem+ | | | |
| Na+ | 141 | mmoI/L | | Na+ | 140 | mmoI/L | |
| k+ | 3,8 | mmoI/L | Haag | k+ | 3,9 | mmoI/L | |
| Ca++ | 1,14 | mmoI/L | Haag | Ca++ | 1,12 | mmoI/L | Haag |
| Cl- | 106 | mmoI/L | | Cl- | 104 | mmoI/L | |
| cTCO2 | 29,4 | % | | cTCO2 | 29,7 | % | Hoog |
| Hct | 42 | mmol/L | | Hct | 44 | mmol/L | |
| Chgb | 8,8 | mmol/L | | Chgb | 9,3 | mmol/L | |
| BE(b) | 2,4 | | | BE(b) | 2,5 | | |
| Resultate: Meta+ | | mg/dL | | Resultate: Meta+ | | mg/dL | |
| Glu | 85 | mmoI/L | | Glu | 91 | mmoI/L | |
| Lac | 0,82 | umoI/L | Hoog | Lac | 0,78 | umoI/L | Hoog |
| Crea | 127 | | | Crea | 126 | | |

Before injection with saline sol After injection with saline sol

Figure 10: Lactate variations before and one hour after injection with saline sol.

On the other hand, we chose not to use existing groups so as not to compromise the external validity and applicability of the results. Another inherent difficulty in our study is the risk of presenting a placebo effect and a Hawthorne effect, which we could not minimize given that, given the humanitarian crisis of the pandemic, we did not consider it ethical for the subjects to participate in the study without being informed of the intervention that would be applied to them (Molina and Ochoa, 2014). In fact, all participants signed an informed consent for the use of a drug or substance under investigation, in particular because chlorine dioxide has not yet complied with the corresponding process to be classified as a drug.

Regarding the results and the possible explanations for them, the most important thing in the experimental group is the negativization of the RT-PCR in one hundred percent of the cases at seven days, as well as the rapid way in which the results are reduced. general symptoms in patients, in particular fever, cough, dyspnea, asthenia and general pain, which is achieved in 70% of cases seven days after treatment, a very marked reduction in VAS values in percentage similar to 7 days, in particular reduction of sore throat by 100%, reduction of low back pain by almost 80%, results that reveal a significant improvement in morbidity in patients.

In the initial stage of administration of chlorine dioxide, patients show improvement in their febrile symptoms, this could be attributed to its direct virucidal effect due to its action on the spike and on the virus RNA, through the mechanism that we explained above. Oxidation of amino acids and guanine of viral RNA. Additionally, patients begin to improve their sore throat, dry cough and dyspnea. This effect could be attributable to a direct anti-inflammatory action, possibly through an action on inflammasomes and it is even postulated that it may be possible due to action on NETosis processes, through a mechanism that has not yet been clearly elucidated and that we are in the process of developing investigate in detail.

Although we did not include the oxygen saturation measurement variable by pulse oximetry in the parameters of this investigation, we did the measurement in all patients, observing a considerable improvement in some cases in oxygen saturation; being a consistent observation, this improvement could be explained by the action of the dioxide through the oxidative mechanism of amino acids of the virus "anchored" to the unitβ1 of hemoglobin, improving oxygenation. We verified this mechanism as a possibility, in the research that we did in molecular biology through in silico simulation, in Japan, and it will be the subject of a future paper. In the same way, Pichert (2019) in his research suggests that chlorite interacts with the forms of hemoglobin and oxidized hemoglobin. Chlorite inactivates iron hemoglobin and methemoglobin. By these mechanisms, chlorite effectively decreases the yield of cytotoxic hemoglobin species that may appear later of excessive hemolysis of red blood cells in pathological situations.

Likewise, in the laboratory of the Liechtensteiner Verein für Wissenschaft und Gesundheit in Switzerland we were able to verify the immediate oxygenation of erythrocytes, by injecting chlorine dioxide at a concentration of 50 ppm to a sample of red blood cells with methemoglobinemia, using contrast microscopies. Phase and direct (Figure 8).

An interesting characteristic when we observe the behavior of the reduction of thrombocytosis in the 21 days of treatment, is that there could be an action of dioxide on the rheological behavior of the blood, an idea that is reinforced with the evident decrease of D-dimer in treated patients with the dioxide.

The lymphopenia observed in most patients could be due to a process that begins with disorganization of the cytoskeleton, condensation of chromatin and cytoplasm, loss of mitochondrial function, DNA fragmentation and terminal formation of ruptured membranes or apoptotic bodies, finally eliminated by macrophages. This phenomenon is mediated by the synthesis of the caspase-8 complex, which we consider could be activated by non-canonical means. The complex is favored by protein kinase-R, also accelerated by interferon generated in the presence of the virus. The signaling pathways that are activated by these receptors initiate an inflammatory response, with antiviral effects,

The virus also activates the transforming growth factor-b through neuraminidase, thus generating another cascade that ends with c-Jun-N-kinase and triggers transcription followed by the expression of pro apoptosis genes. The virus could synthesize the virulence peptide PB1-F2, a small fragment responsible for destroying lymphocytes, a circumstance that could explain the lymphopenia observed in COVID19. The action could also be mediated by action on inflammasomes, where the signaling (redox) by ATP can induce the desubiquitination of NLRP3, possibly induced by chlorine dioxide.

Regarding the increase in lactate, it is clear that it can be caused by dysfunction of the enzyme pyruvate dehydrogenase (PDH), as has been demonstrated in patients with sepsis, by mitochondrial dysfunction, or by hyperlactacidemia. The observed improvement could be explained through a mechanism in which chlorine dioxide has a cellular oxygenating effect directly through the release of oxygen or by redox signaling mechanisms with enzyme activation / inhibition that activate the pyruvate pathway with efficient ATP production.

When we inject direct chlorine dioxide into the vein, the amount of lactate in the blood is reduced, as can be seen in the following graph which shows in a comparative way the level of lactate in the blood and after intravenous chlorine dioxide application at 50 ppm at ten minutes post injection (Figure 9).

In comparison, when administering normal saline solution via direct intravenous, and measuring the lactate levels, we observe that there is no variation in the lactate level (Figure 10).

The data obtained in this research validates the effectiveness of chlorine dioxide in COVID19. This is the first phase IIa clinical trial in the world. In this study there were no inconclusive results. The phase IIa study design is appropriate for the research phase of a new molecule - such as chlorine dioxide - in its development as a potential drug.

There is much to explore about chlorine dioxide and its therapeutic possibilities, about which there is enough reasonable information to continue to study further.

The findings of this research open a complete world of possibilities for medical therapists in the world, as these initial results will motivate more formal research, will support the search for new therapeutic options, particularly in COVID19, and will allow the generation of research spaces at the molecular level and genomics on the processes of cellular respiration, redox signaling and the implantation of oxidative therapies as a new possibility for the approach of multiple pathologies with altered common intracellular bioenergetic mechanisms.

The results can be extended to the control of infectious diseases in agronomy, the development of new nanotechnologies in pharmaceuticals and humans in general by alleviating and controlling COVID19 and other pandemics or epidemics that may occur in the short future.

The results found here, rather than expanding previous studies, as it is a pilot study and the first of its kind in the world, enable the initiation of many studies on dioxide and the related issues noted.

## Conclusion

In conclusion, we can affirm without a doubt, based on test of comparison of proportions and its confidence interval, as well as the paired tests where we used the Wilcoxon – Mann – Whitney test ($\alpha$: 95%), that the data in most of the variables ($P < 0.05$) obtained indicate that chlorine dioxide is effective in the treatment of COVID19, making RT-PCR negative in one hundred percent of cases at 7 days, significantly and rapidly modifying the symptoms of the disease, significantly reducing laboratory parameters to normality within 14 to 21 days. We recommend conducting randomized double-blind studies and delving into studies of toxicological safety and therapeutic efficacy of chlorine dioxide in pathologies of epidemiological impact in the near future.

### Recognition

We want to express our gratitude for your collaboration and contributions to the doctor

**Mitchell B. Liester, Doctor of Medicine,** University of Colorado School of Medicine, Colorado Springs Branch for their conceptual contributions and selfless support in the search for new options for patients.

***Our sincere thanks to*** **Engineer Victor Yela** for their permanent assistance with computer science topics, tabulation and research data; to the physicians of the eleven countries that are members of our research team, and to the thousands of physicians around the world who accompany us in this chlorine dioxide research process, to whom we thank for their support and testimonial, conceptual contributions, as well as their a voice of encouragement to remain in this investigation despite the immense difficulties of the way. **To Andreas Kalcker** for his lights, intelligence and injection of energy and motivation to advance being a beacon of wisdom born from the heart.

To all the patients who participated in the research, in particular for their trust in us, for accompanying us in seeking new possibilities for a world better.

To Nela who was our permanent support with patient data records.

To professors **Luis Prieto, Jorge Gaupp and Pablo Campra**, for his critical remarks to the work. With their observations they forced us to improve our effort.

**Money:** This work was supported with the researchers' own resources.

**Conflict of Interests:** The authors declare no conflict of interest or no competing economic interests. Authors have completed the ICMJE conflict of interest declaration form, translated into Spanish by Medwave, and declare that they have not received funding for the article / research; have no financial relationships with organizations that could have an interest in the published article in the last three years; and have no other relationships or activities that could influence the published article. Forms can be requested by contacting the responsible author. This does not alter the authors' adherence to all policies on the exchange of data and materials.

## References

1. https://www.naturalnews.com/2020-05-18-researchers-claim-100-percent-cure-rate-vs-covid-19-ecuador-intravenous-chlorine-dioxide.html
2. https://www.atsdr.cdc.gov/ToxProfiles/tp160-c1-b.pdf
3. Walls, Alexandra C, Young-Jun Park, M Alejandra Tortorici and Abigail Wall, et al. "Structure, Function, and Antigenicity of the SARS-Cov-2 Spike Glycoprotein." *Cell* 181(2020): 281-292.
4. Grifoni, Alba, John Sidney, Yun Zhang and Richard H Scheuermann, et al. "Candidate targets for Immune Responses to 2019-Novel Coronavirus (nCoV): Sequence Homology-and Bioinformatic-Based Predictions." *Cell-Host-Microbe-D-20-00119* (2020).
5. Alvarez, Maria E and RT O'Brien. "Mechanisms of Inactivation of Poliovirus by Chlorine Dioxide and Iodine." *Appl Environ Microbiol* 44(1982): 1064-1071.
6. Calabrese, Edward J, Gary S Moore and Robert W Tuthill. "The Health Effects of Chlorine Dioxide as a Disinfectant in Potable Water: A literature survey." *J Environ Health* 41(1978): 26-31.
7. Chen, Yu-Shiaw and James M Vaughn. "Inactivation of Human and Simian Rotaviruses by Chlorine Dioxide." *Appl Environ Microb* 56(1990): 1363-1366.
8. Sun, Chunyun, Long Chen, Ji Yang and Chunxia Luo, et al. "SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development." *Biorxiv* (2020).
9. https://clinicaltrials.gov/ct2/show/NCT04343742
10. https://clinicaltrials.gov/ct2/show/NCT04409873
11. https://clinicaltrials.gov/ct2/show/NCT04621149
12. Daniel, F Bernard, Lyman W Condie, Merrel Robinson and Judy A Stober, et al. "Comparative Subchronic Toxicity Studies of Three Disinfectants." *J Am Water Works Assoc* 82(1990): 61-69.
13. Department of Health and Human Services, DHSS, INH, United States.
14. DeZuane, John. *Handbook of drinking water quality*. John Wiley & Sons, 1997.
15. Food and Drug Administration. Food Additive Status, Specific Use Additives 173.300 Chlorine dioxide, 2020.
16. Guo, Yan-Rong, Qing-Dong Cao, Zhong-Si Hong and Yuan-Yang Tan, et al. "The Origin, Transmission and Clinical Therapies on Coronavirus Disease 2019 (COVID-19) Outbreak–An Update on the Status." *Military Med Res* 7(2020): 1-10.
17. Haag, HB. "The Effect on Rats of Chronic Administration of Sodium Chlorite and Chlorine Dioxide in the Drinking Water." *Report to the Mathieson Alkali Works from the Medical College of Virginia* (1949).
18. Heffernan, WP, C Guion and RJ Bull. "Oxidative Damage to the Erythrocyte Induced by Sodium Chlorite, *in vivo*." *J Environ Pathol Toxicol* 2(1979): 1487-1499.
19. https://www.vyphidroasesores.com/
20. Insignares- Carrione E, Bolano Gomez B and Kalcker Andreas. "Chlorine Dioxide in COVID-. 19: Hypothesis about the Possible Mechanism of Molecular Action in SARS-CoV-2." *J Mol Genet Med* 14 (2020): 468.

21. Jin, Min, Jinyang Shan, Zhaoli Chen and Xuan Guo, et al. "Chlorine Dioxide Inactivation of Enterovirus 71 in Water and its Impact on Genomic Targets." *Environ Sci Technol* 47(2013): 4590-4597.

22. Lan, Jun, Jiwan Ge, Jinfang Yu and Sisi Shan, et al. "Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor." *Nature* 581(2020): 215-220.

23. Junli, Huang, Wang Li, Ren Nenqi and Liu Xue Li, et al. "Disinfection Effect of Chlorine Dioxide on Viruses, Algae and Animal Planktons in Water." *Water Res* 31(1997): 455-460.

24. Kalcker, Andreas. Forbidden health. Voedia, 2016.

25. Kály-Kullai, K, M Wittmann, Z Noszticzius and László Rosivall. "Can Chlorine Dioxide Prevent the Spreading of Coronavirus or other Viral Infections? Medical Hypotheses." *Physiol Int* 107(2020): 1-11.

26. Letko, Michael, Andrea Marzi and Vincent Munster. "Functional Assessment of Cell Entry and Receptor Usage for SARS-CoV-2 and Other Lineage B Beta corona viruses." *Nature Microbiol* 5(2020): 562-569.

27. Li, Wenhui, Michael J Moore, Natalya Vasilieva and Jianhua Sui, et al. "Angiotensin-Converting Enzyme 2 is a Functional Receptor for the SARS Coronavirus." *Nature* 426(2003): 450-454.

28. Li, Jun Wen, Zhong Tao Xin, Xin Wei Wang and Jin Lai Zheng, et al. "Mechanisms of Inactivation of Hepatitis A Virus in Water by Chlorine Dioxide." *Water Res* 38(2004): 1514-1519.

29. Lin, Ja-Liang and Paik-Seong Lim. "Acute Sodium Chlorite Poisoning associated with Renal Failure." *Renal Failure* 15(1993): 645-648.

30. Zhang, Linlin, Daizong Lin, Xinyuanyuan Sun and Katharina Rox, et al. "X-ray Structure of Main Protease of the Novel Coronavirus SARS-Cov-2 Enables Design of αKetoamide Inhibitors." *BioRxiv* (2020).

31. Lubbers, Judith R, Sudha Chauan and Joseph R Bianchine. "Controlled Clinical Evaluations of Chlorine Dioxide, Chlorite and Chlorate in Man." *Environ Health Persp* 46(1982): 57-62.

32. Manterola, Carlos and Tamara Otzen. "Critical Analysis of Biomedical Literature." *Int J Morphol* 32(2014): 599-607.

33. Moore, Gary S, Edward J Calabrese, Salvatore R DiNardi and Robert W Tuthill. "Potential Health Effects of Chlorine Dioxide as a Disinfectant in Potable Water Supplies." *Med Hypotheses* 4(1978): 481-496.

34. Musil J, Kontek Z, Chalupa J and Schmidt P (1964) Toxicological Aspects Of $ClO_2$ Application for the Treatment of Water Containing Phenol. Chem-Technol Praze 8: 327-345.

35. https://www.cdc.gov/niosh/idlh/10049044.html

36. National Institutes of Health. Novel Coronavirus Structure Reveals Targets for Vaccines and Treatments, 2020.

37. Noszticzius, Zoltán, Maria Wittmann, Kristóf Kály-Kullai and Zoltán Beregvári, et al. "Chlorine dioxide is a Size-Selective Antimicrobial Agent." *PloS one* 8(2013): e79157.

38. Ogata, Norio. "Inactivation of influenza virus haemagglutinin by chlorine dioxide: Oxidation of the Conserved Tryptophan 153 Residue in the Receptor-Binding Site." *J Gen Virol* 93(2012): 2558-2563.

39. Láng, Orsolya, Krisztina S Nagy, Julia Láng and Katalin Perczel-Kovách, et al. "Comparative Study of Hyper pure Chlorine Dioxide with Two other Irrigants Regarding the Viability of Periodontal Ligament Stem Cells." *Clin Oral Invest* 2(2020): 1-12.

40. Pichert, Annelie and Jürgen Arnhold. "Interaction of the Chlorite-Based Drug WF10 and Chlorite with Hemoglobin, Methemoglobin and Ferryl Hemoglobin." *Arch Biochem Biophys* 585(2015): 82-89.

41. Couri, Daniel, Mohamed S Abdel-Rahman and Richard J Bull. "Toxicological Effects of Chlorine Dioxide, Chlorite and Chlorate." *Environ Health Persp* 46(1982): 13-17.

42. YanRH, ZhangYY. "Structural Basis for the Recognition of the SARS-CoV-2 by Full Length Human ACE2." *bioRxiv*.

43. Schijven, Jack, Peter Teunis, Trudy Suylen and Henk Ketelaars. "QMRA of Adenovirus in Drinking Water at a Drinking Water Treatment Plant using UV and Chlorine Dioxide Disinfection." *Water Res* 158(2019): 34-45.

44. Shi, L and C Xie. "Experimental Observation on Acute Toxicity and Irritative Effect of Stable Chlorine Dioxide." *Zhongguo Xiaoduxue Zashi* 16(1999): 39-40.

45. Simmons, Graham, Jacqueline D Reeves, Andrew J Rennekamp and Sean M Amberg, et al. "Characterization of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV) Spike Glycoprotein-Mediated Viral Entry." *Proc Nat Acad Sci* 101(2004): 4240-4245.

46. Song, Wenfei, Miao Gui, Xinquan Wang and Ye Xiang. "Cryo-EM Structure of the SARS Coronavirus Spike Glycoprotein in Complex with its Host Cell Receptor ACE2." *PLoS Pathog* 14(2018): e1007236.

47. https://www.atsdr.cdc.gov/toxprofiles/tp160.pdf

48. https://cfpub.epa.gov/ncea/iris/iris_documents/documents/toxreviews/0648tr.pdf

49. https://www3.epa.gov/pesticides/chem_search/ppls/074986-00001-20040414.pdf

50. https://www3.epa.gov/pesticides/chem_search/cleared_reviews/csr_PC-020503_26-Sep-08_a.pdf

51. https://iaspub.epa.gov/apex/pesticides/f?

52. https://www.epa.gov/pesticide-registration/list-n-disinfectants-coronavirus-covid-19

53. https://consumermedsafety.org/medication-safety-articles/item/179-miracle-treatment-turns-into-potent-bleach

54. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=173.300

55. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/coronavirus-disease-2019-covid-19-frequently-asked-questions.

56. Wang, Peigang, Jian Chen, Aihua Zheng and Yuchun Nie, et al. "Expression Cloning of Functional Receptor used by SARS Coronavirus." *Biochem Biophys Res Commun* 315(2004): 439-444.

57. Wang, Xin-Wei, Jin-Song Li, Min Jin and Bei Zhen, et al. "Study on the Resistance of Severe Acute Respiratory Syndrome-Associated Coronavirus." *J Virol Methods* 126(2005): 171-177.

58. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.

59. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen.

60. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200522-covid-19-sitrep

61. https://www.who.int/substance_abuse/facts/en/

62. Zambrano-Estrada, Xochitl, Carlos A Dominguez-Sanchez, Marina Banuet-Martinez and Fabiola Guerrero-de la Rosa, et al. "Evaluation of the Antiviral Effect of Chlorine Dioxide (ClO2) using a Vertebrate Model Inoculated with Avian Coronavirus." *bioRxiv*, 2020.

63. Xue, Bin, Min Jin, Dong Yang and Xuan Guo, et al. "Effects of Chlorine and Chlorine Dioxide on Human Rotavirus Infectivity and Genome Stability." *Water Res* 47(2013): 3329-3338.

64. Young, RO. "Chlorine dioxide ($ClO_2$) as a Non-Toxic Antimicrobial Agent for Virus, Bacteria and Yeast (*Candida albicans*)." *Int J Vaccines Vaccin* 2(2016): 00052.

65. Zhu, Zhenbang, Yang Guo, Piao Yu and Xiaoying Wang, et al. "Chlorine Dioxide Inhibits the Replication of Porcine Reproductive and Respiratory Syndrome Virus by Blocking Viral Attachment." *Infect Genet Evol* 67(2019): 78-87.

**How to cite this article:** Carrione E, Bolano Gomez B, Andrade Yohanny, Callisperis Patricia and Suxo Ana, et al. "Determination of the Effectiveness of Chlorine Dioxide in the Treatment of COVID 19." J Mol Genet Med 15(2021): S2

COMUSAV

COALICIÓN MUNDIAL SALUD Y VIDA

**NOVIEMBRE 2020**

# DIÓXIDO DE CLORO:
# Una solución segura y potencialmente efectiva para superar el COVID-19

# SUMARIO

LISTA DE SIGLAS Y ABREVIATURAS 2

1. INTRODUCCIÓN 3

    Antecedentes 3

    Un breve resumen sobre el dióxido de cloro 5

    ¿Qué es la Solución de Dióxido de Cloro (CDS) y cuáles son las diferencias con la Solución Mineral Milagrosa (MMS)? 7

    La controversia innecesaria y sus consecuencias 8

2. EFECTIVIDAD, SEGURIDAD Y TOXICIDAD DEL DIÓXIDO DE CLORO 10

    Acción frente a los virus 10

    Estudios preclínicos 10

    Estudios clínicos 11

    Toxicidad 13

3. HECHOS LEGALES Y DERECHOS HUMANOS 14

4. CONSIDERACIONES FINALES 19

5. REFERENCIAS 21

## LISTA DE SIGLAS Y ABREVIATURAS

| | |
|---|---|
| **AEMEMI** | Asociación Ecuatoriana de Médicos Expertos en Medicina Integrativa |
| **CDS** | Solución de dióxido de cloro |
| **Cl** | Cloro |
| $\mathbf{ClO_2}$ | Dióxido de Cloro |
| **COMUSAV** | Coalición Mundial Salud y Vida |
| **COVID-19** | Desde el inglés, *Coronavirus disease* -2019 |
| **ELA** | Esclerosis lateral amiotrófica |
| **FDA** | Del inglés: *Food and Drug Administration* |
| **H2O** | Agua |
| **HCl** | Ácido clorhídrico |
| **mL** | mililitro |
| **MMS** | Del inglés: *Miracle Mineral Supplement, Miracle Mineral Solution, Master Mineral Solution.* |
| **NaCl** | Cloruro de sodio (sal común) |
| **NaClO** | Hipoclorito de sodio (lejía - lavandina) |
| $\mathbf{NaClO_2}$ | Clorito de sodio |
| **NaClO3** | Clorato de sodio |
| **NaClO4** | Perclorato de sodio |
| **NaOH** | Hidróxido de sodio |
| $\mathbf{O_2}$ | Oxígeno |
| **OMC** | Organización Mundial de Comercio |
| **OPS/OMS/WHO** | Desde el español, *Organización **Mundial** da Salud.*<br>Desde el español, *Organización Panamericana de la Salud.*<br>Del inglés, *World Health Organization* |
| **pH** | Potencial de Hidrógeno |
| **ppm** | Parte por millón |
| **RNA** | Ácido ribonucleico |
| **SARS-CoV-2** | Síndrome respiratorio agudo del coronavirus tipo 2 |
| **TCLI** | Término de Consentimiento Libre e Informado |
| **VIH** | Virus de la inmunodeficiencia humana |

# 1. INTRODUCCIÓN

## Antecedentes

La reciente pandemia del Covid-19 conmocionó al mundo y ha cobrado miles de vidas, y como una de las consecuencias igualmente complicadas, la economía mundial se vio comprometida. Sin duda, este es un problema que requiere una solución urgente y el compromiso de todos, especialmente del personal de salud para la búsqueda de su pronta solución.

Con el objetivo de identificar una solución para este problema y además basándose en las evidencias científicas ya publicadas y experiencias clínicas de utilización del dióxido de cloro ($ClO_2$) por Médicos e Investigadores, hicimos una evaluación de las principales informaciones para apoyar nuestra propuesta de uso de la solución de dióxido de cloro (CDS), siguiendo el protocolo estandarizado por Andreas Ludwig Kalcker como una alternativa segura y eficaz para combatir la infección por SARS-COV2 (Kalcker 2017-2020; Kalcker & Valladares 2020).

De enero a julio de 2020 se llevó a cabo una investigación de revisión sobre el uso de dióxido de cloro en la literatura internacional indexada y como ejemplo, si analizamos solamente la página web PubMed (*National Library of Medicine 2020*), observamos que sólo utilizando la descripción "dióxido de cloro", tenemos disponible un total de 1.372 documentos que datan de 1933 hasta la fecha de la investigación en 2020 (Se muestra una captura de pantalla en la Figura 1).



Figura 1 – Número de documentos encontrados con la descripción "dióxido de cloro" en la base de datos científica de PubMed. La primera flecha roja indica la descripción utilizado para la búsqueda y la segunda el número de documentos publicados encontrados el 24 de julio de 2020.
Fuente: https://pubmed.ncbi.nlm.nih.gov/?term=chlorine+dioxide&sort=pubdate.

Otra fuente importante es la base de datos PubChem (Figura 2), en la cual es posible identificar informaciones bioquímicas y toxicológicas, entre otras y las patentes registradas (que también se pueden encontrar en Google Patents), entre las que destacan las siguientes:

1) La patente sobre la desinfección de bolsas de sangre (Kross & Scheer, 1991);
2) La patente sobre el VIH (Kuhne 1993);
3) La patente para el tratamiento de enfermedades neurodegenerativas como la Esclerosis Lateral Amiotrófica (ELA), la enfermedad de Alzheimer y la Esclerosis Múltiple (McGrath MS 2011);
4) La patente de Taiko Pharmaceutical (2014) para virus respiratórios, incluyendo el coronavirus humano;
5) La patente sobre un método y composición "*for treating cancerous tumors*" para tratar tumores cancerígenos (Howard 2018);
6) La patente de composición farmacéutica para el tratamiento de la inflamación interna. (Kalcker LA, 2017);
7) La patente sobre la composición farmacéutica para el tratamiento de la intoxicación aguda (Kalcker LA, 2017);
8) La patente de un compuesto farmacéutico para el tratamiento de enfermedades infecciosas (Kalcker LA, 2017) y
9) La patente sobre el uso de CDS para coronavirus tipo 2 (Kalcker LA, 2020 – aún pendiente de publicación: /11136-CH_Antrag_auf_Patenterteilung.pdf).



chlorine dioxide

CHLORINE DIOXIDE Chlorine Peroxide Chlorine Oxide (ClO2) 10049-04-4, Doxcide 50, Caswell No. 179A Chlorosyloxidanyl, HSDB 517

Figura 2 – Número de documentos encontrados con la descripción "*chlorine dioxide*" en la base de datos científica de *PubChem*. La primera flecha roja indica la descripción utilizado para la búsqueda y la segunda el número de documentos publicados encontrados el 24 de julio de 2020.
Fuente: https://pubchem.ncbi.nlm.nih.gov/#query=chlorine%20dioxide.

Por lo tanto, solamente con estos datos iniciales, constatamos que la investigación alrededor del $ClO_2$ no se trata de ninguna novedad, que se trata de una molécula química ya conocida desde hace más de 200 años y comercializada desde hace 70 años con diversas aplicaciones a saber: tratamiento del agua para el consumo humano, tratamiento del agua contaminada, para el control de *biofilm* en las torres de refrigeración y en el procesamiento de desinfección de alimentos y verduras.

Además, existen estudios preclínicos y clínicos realizados, así como estudios que nos permiten comprender sus características toxicológicas y de seguridad en especial para utilización por humanos (Lubbers et al 1984, Ma et al 2017). Por otro lado, verificamos que los ensaios clínicos y la aplicación de dióxido de cloro para la salud, aún necesita de más investigaciones.

## Un breve resumen sobre el dióxido de cloro

La fórmula química del dióxido de cloro es $ClO_2$ y según registro en *Chemical Abstracts Services* (CAS) *from Chemical American Society* su número CAS es 10049-04-4. En esta fórmula, está claro que hay un átomo de cloro (Cl) y dos átomos de oxígeno ($O_2$) en una molécula de dióxido de cloro. Estos 3 átomos se mantienen unidos por electrones para formar la molécula de $ClO_2$. Es posible utilizarlo como gas saturado en agua destilada y, por lo tanto, puede beberse o aplicarse directamente en la piel y mucosas, con las diluciones adecuadas. Andreas Ludwig Kalcker, Biofísico e Investigador, estandarizó una saturación del gas en agua destilada llamada solución de dióxido de cloro o CDS (por su sigla en inglés, CDS: ***C**hlorine **D**ioxide **S**olution*) (*National Library of Medicine 2020*).

El descubrimiento de la molécula $ClO_2$ en 1814, se atribuye al científico Sir Humphrey Davy. El $ClO_2$ es diferente del elemento cloro (Cl), tanto en su estructura química y molecular, como por su comportamiento. El $ClO_2$, como ya ha sido reportado ampliamente, puede tener efectos tóxicos si no se observan los cuidados necesarios para sus diversos usos y no se respetan las recomendaciones adecuadas para el consumo humano. Es más que conocido que el gas $ClO_2$ es tóxico para los seres humanos si se inhala puro y/o ingiere en cantidades superiores a las recomendadas (Lenntech 2020, IFA 2020).

El $ClO_2$ es uno de los biocidas más eficaces contra los patógenos, como las bacterias, los hongos, los virus, las biopelículas (*biofilm*) y otras especies de microorganismos que pueden causar enfermedades. Actúa interrumpiendo la síntesis de las proteínas de la pared celular del patógeno. Al tratarse de un oxidante selectivo, su modo de acción es muy similar a la fagocitosis, en la que se utiliza un proceso de oxidación suave para eliminar todo tipo de patógenos (Krogulec 2012, Noszticzius et al 2013, Lenntech 2020). Vale decir que el $ClO_2$, generado por el clorito de sodio ($NaClO_2$), es aprobado por la Agencia de Protección Ambiental en los Estados Unidos (EPA 2002) y por la Organización Mundial de la Salud para la utilización en agua apta para el consumo humano, ya que no deja residuos tóxicos (EPA 2000, WHO 2002).

Muchos siguen confundiendo el $ClO_2$ con el hipoclorito de sodio (NaClO - Lejía) y este último con el clorito de sodio ($NaClO_2$), además de otros compuestos químicos, lo que provoca frecuentes comentarios inapropiados tanto en los medios de comunicación como entre los profesionales por falta de conocimientos de química elemental. El NaClO (lejía), por ejemplo, es un potente agente corrosivo y el peligro a la exposición crónica y masiva es bien conocido. Se cree que los síntomas

684

de asma desarrollados por los profesionales que trabajan en contacto con esa sustancia pueden deberse a la exposición continua a la lejía y otros irritantes. En contacto con las grasas, el hidróxido de sodio (NaOH) degrada los ácidos grasos en glicerol y jabones (sales de ácidos grasos), lo que reduce la tensión superficial de la interfaz grasa-solución restante. El NaClO es responsable de la disolución del tejido orgánico. Así, se observa que la principal toxicidad de las sustancias generadas a partir de las reacciones químicas del hipoclorito de sodio es la aparición de un radical NAOH Hidroxilo, en las diversas reacciones con las secreciones y la estructura química de los tejidos humanos (Daniel et al 1990, Racioppi et al 1994; Estrela et al 2002, Medina-Ramon et al 2005, Fukuzaki 2006, Mohammadi 2008, Peck B et al 2011).

Mediante las patentes científicas, pruebas de las publicaciones científicas disponibles que demuestran la eficacia del $ClO_2$ para eliminar diferentes patógenos (Kullai-Kály et al 2020, Kalcker 2017-2020), incluido el SARS-CoV (Patente Taiko Pharmaceutical 2014), así como el trabajo que confirma la seguridad del uso del dióxido de cloro para la potabilización del agua y, más recientemente, el trabajo mencionado de la AEMEMI, evaluamos positivamente y con gran potencial biocida el uso de la solución acuosa de $ClO_2$ (CDS) para combatir los coronavirus (AEMEMI 2020, EPA 2000, OMS 2005, WHO 2002).

En este contexto, nos sorprende que las menciones de que órganos oficiales como los Ministerios de la Salud, la OPS/OMS (2020), FDA (2020) y las Agencias reguladoras y/o las entidades sanitarias no recomienden el uso de $ClO_2$ y todas, en lugar de recomendar, llaman la atención acerca de la toxicidad y el peligro de este, pero, en sus discursos, no indican claramente de qué forma y por cual vía de administración el $ClO_2$ es realmente tóxico. Sin embargo, todo nos lleva a entender que se refieren a la forma pura y concentrada de este gas y no a la fórmula estandarizada por Kalcker: la solución acuosa de dióxido de cloro (CDS), a 3.000 ppm.

De esta forma, para contribuir a aclarar los conceptos, invitamos a todos los organismos oficiales a que conozcan los trabajos de Andreas Kalcker con la solución acuosa que contiene dióxido de cloro gaseoso (CDS). Ciertamente, después de tener este conocimiento, creemos que definitivamente, estos organismos, que aprecian la salud, comprenderán naturalmente el potencial de esta solución para uso humano y a partir de entonces, podrán revisar sus documentos que pueden estar en desacuerdo con la realidad científica publicada y las experiencias médicas actuales y tal vez puedan ofrecer esta información de manera más clara y asertiva en sus artículos publicados en los sitios web oficiales o incluso en sus documentos.

Por lo tanto, para ayudar a aclarar los conceptos, invitamos a todos los organismos oficiales a conocer el trabajo y las patentes del Científico Andreas Ludwig Kalcker con la solución acuosa de dióxido de cloro (CDS). Ciertamente, después de tener este conocimiento, creemos que estos organismos, que aprecian la salud, comprenderán naturalmente el potencial de esta solución para el uso humano, y a partir de entonces podrán revisar sus documentos que pueden estar en desacuerdo con la realidad científica publicada y las experiencias médicas actuales y quizás puedan ofrecer esta

685

información de una manera más clara y asertiva en sus artículos publicados en los sitios oficiales o incluso en sus documentos.

Con base a la información disonante e incoherente cuando se compara con lo que realmente se conoce sobre el CDS y su potencialidad es que nosotros, profesionales de la salud en la intención de dar respetuosamente nuestra contribución para que las instituciones rectoras de la salud revisen su documentación y directrices publicadas oficialmente para promover la información más clara y veraz sobre el uso, la eficacia y la seguridad del $ClO_2$ para el consumo humano por vía oral (CDS), de acuerdo con lo normalizado por Kalcker (2020 - Sobre evaluación: /11136-CH_Antrag_auf_Patenterteilung.pdf), compartimos a continuación un resumen de los hechos científicos clave y la evidencia de que el CDS es eficaz contra varios patógenos, incluyendo el coronavirus humano tipo 2, agente etiológico de SARS-COV2. Desafortunadamente, la forma como se difunde la información sobre $ClO_2$ genera dudas y sobre todo nos revela, a quienes entienden el tema bajo los aspectos científicos, que la desinformación generada es algo sorprendente.

## ¿Qué es la Solución de Dióxido de Cloro (CDS) y cuáles son las diferencias con la Solución Mineral Milagrosa (MMS)?

Hace más de 13 años, Andreas Ludwig Kalcker inició una investigación científica para estudiar la aplicabilidad del $ClO_2$ y sus diluciones, de modo que pueda ser utilizado con seguridad para el consumo humano. En estos estudios, desarrolló 4 patentes, de las cuales 3 están publicadas y una está pendiente de aprobación (Kalcker 2017-2020). Esos estudios se basan en los niveles de toxicidad seguros establecidos por la base de datos de toxicología Aleman GESTIS (IFA 2020), y tienen en cuenta otros estudios científicos clásicos ya publicados y de referencia ya desarrollados, por ejemplo, por la OMS (2000, 2005) y la EPA (2000). Estos estudios confirman la no toxicidad de este gas diluido en el agua potable.

Mucho se ha dicho en los medios de comunicación sobre el riesgo de consumo de MMS y muy a menudo se confunde con el CDS. Es importante aclarar que el MMS es una solución preparada mezclando unas pocas gotas de cada uno de los dos reactivos: clorito de sodio, por un lado, y un ácido que puede ser cítrico o clorhídrico, por otro. Esta mezcla se añade a un litro de agua, se coloca en una botella, se sella y se consume por vía oral durante todo el día. El problema de esta mezcla es que ninguno de los reactivos es químicamente puro y al ingerir esta mezcla de estos dos reactivos, también se ingieren las impurezas de estos. Estas impurezas o subproductos químicos pueden generar molestias como diarrea, vómitos y otros efectos secundarios que, aunque no son graves, sí son irritantes, sobre todo cuando se bebe una dosis elevada de estos productos debido a la escasa información que existe en el público en general, lo que, debido a la emergencia sanitaria al tratar de prevenir o tratar el COVID-19, lleva a no buscar consejo o consulta médica y a consumir productos que no han sido preparados bajo la supervisión de profesionales capacitados para su fabricación.

Por otra parte, el otro compuesto conocido como solución acuosa de dióxido de cloro (CDS), sólo contiene dióxido de cloro disuelto en agua a una concentración de 3.000 ppm (mg/L) y no contiene

686

las impurezas contenidas en el preparado llamado MMS. En el caso del CDS, que es un compuesto extremadamente puro, durante su fabricación, las dos sustancias se colocan para que reaccionen en un recipiente que contiene otro pequeño contenedor en el que se produce la reacción química y a partir del cual se genera un gas de dióxido de cloro que saturará el agua del exterior de este recipiente. Es importante aclarar sin ninguna duda que el CDS no contiene absolutamente ningún clorito de sodio, ni ningún ácido. Otra forma de producir dióxido de cloro es por electrólisis, en la que no se utiliza ningún ácido.

Según el procedimiento de su preparación, la solución de CDS contiene un alto grado de pureza, ya que sólo contiene dióxido de cloro disuelto en el agua. En resumen, el MMS contiene impurezas que pueden causar molestias cuando se ingiere, pero el dióxido de cloro en solución acuosa (CDS) contiene sólo gas de dióxido de cloro a una concentración de sólo 0,3 g/L disuelto en agua y del cual se considera que sólo se ingieren de 5 a 10 ml a lo largo del día, disuelto en un litro de agua fría.

Esta gran diferencia permite que la solución de dióxido de cloro (CDS) sea segura y altamente tolerable de ingerir sin causar ninguna molestia o riesgo para la salud, cuando consumida adecuadamente.

Se ha establecido que la dosis letal sería de 292 mg/kg (IFA 2020). Por lo tanto, por ejemplo, el protocolo normalizado de Andreas Kalcker que consiste en el uso de 10 ml de CDS a 3.000 ppm, diluido en 1.000 ml de agua, está siendo utilizado con mucho éxito por los médicos en varios países como uno de los protocolos para combatir el SARS-COV2. En esta recomendación específica, se permite el consumo máximo de 30 mg/día, dividido en 10 dosis de 100 ml, al final, lo que constituye una dosis segura y no tóxica basada en referencias científicas reconocidas (Ma y otros 2017). En otras palabras, esta cantidad equivale a una dosis de 15 a 30 mg/día en pacientes adultos con un peso medio de 60 kg, un valor que varía de 0,25 a 0,50 mg/kg/día.

## La controversia innecesaria y sus consecuencias

Contextualizando el origen de la equivocada controversia que ha surgido sobre el tema del "dióxido de cloro", es importante aclarar:

Históricamente, un producto llamado "solución mineral milagrosa" (MMS) ha sido objeto de mucha controversia en los medios de comunicación de todo el mundo porque se vende como "medicina". A menudo vemos noticias en Internet que confunden la "solución mineral milagrosa" (MMS = ácido cítrico + clorito de sodio + agua) con la "solución de dióxido de cloro" (CDS = gas dióxido de cloro + agua) y esta última es confundida con hipoclorito de sodio (lejía). Las diferencias principales entre el MMS y el CDS pueden ser conferidas en la tabla 1:

687

**Tabla 1 – Características generales que diferencia la solución mineral milagrosa (MMS) de la solución de dióxido de cloro (CDS).**

| Características generales | MMS | CDS |
|---|---|---|
| Concentración de $ClO_2$ (parte por millón – ppm) | No se conoce | 3.000 ppm |
| PH | Ácido | Neutro (7) |
| Residuos | Cloratos, cloruro | Sin residuos |

Es muy preocupante ser testigo de las consecuencias y el impacto de la información publicada en disonancia con la realidad en un momento de emergencia de salud pública mundial, cuando la vida de muchas personas está en peligro. Por lo anterior, es urgente que todas las instituciones están alerta a través de la calificación previa de la información que se publica para que no haya fallas en la traducción del conocimiento científico, generando así espacio para dudas y malas interpretaciones a través de los medios de comunicación, con serias consecuencias e influyendo negativamente en la toma de decisiones de los gestores.

Si usáramos hipoclorito de sodio (NaClO) con ácido clorhídrico en el agua, la solución contendría $Cl_2 + NaCl + H_2O$. El $Cl_2$ es un gas tóxico que reacciona con sustancias orgánicas, principalmente en medios acuosos donde puede formar ácidos tóxicos. Aunque tengamos claras las diferencias bioquímicas muy bien establecidas, muchos siguen confundiendo algunas sustancias químicas con el $ClO_2$ (Tabla 2):

**Tabla 2: Resumen de las principales características bioquímicas del dióxido de cloro y compuestos derivados.**

| | COMPUESTOS QUÍMICOS | | | | | | |
|---|---|---|---|---|---|---|---|
| **CARACTERÍSTICAS BIOQUÍMICAS** | **Perclorato de sodio** | **Clorato de sodio** | **Clorito de sodio** | **Hipoclorito de sodio** | **Cloruro de sodio** | **Cloro** | **Dióxido de cloro** |
| **Estructura** |  |  |  |  | $Na^+ \cdots Cl^-$ | Cl — Cl |  |
| **Fórmula química** | $NaClO_4$ | $NaClO_3$ | $NaClO_2$ | NaClO | NaCl | $Cl_2$ | $ClO_2$ |
| **Peso molecular** | 122.44 g/mol | 106.44 g/mol | 90.44 g/mol | 74.44 g/mol | 58.44 g/mol | 70.9 g/mol | 67.45 g/mol |

Fuente: *PubChem*. Disponible en: https://pubchem.ncbi.nlm.nih.gov/#query=chlorine%20dioxide. Fecha de consulta: 24 de julio de 2020.

## 2. EFECTIVIDAD, SEGURIDAD Y TOXICIDAD DEL DIÓXIDO DE CLORO

### Acción frente a los virus

La mayoría de los virus se comportan de manera similar porque, una vez que infectan la célula, el ácido nucleico del virus se hace cargo de la síntesis de las proteínas de la célula. Ciertos segmentos del ácido nucleico del virus son responsables de la replicación del material genético de la cápside, una estructura cuya función es proteger el genoma viral durante su transferencia de una célula a otra y ayudar en su transferencia entre las células huéspedes. Cuando el $ClO_2$ se encuentra con una célula infectada, se produce un proceso de desnaturalización muy similar a la fagocitosis porque es un oxidante selectivo (Noszticzius et al 2013).

### Estudios preclínicos

Los estudios preclínicos que exploran la toxicidad del $ClO_2$ no suelen encontrar efectos adversos cuando los animales se exponen a diferentes concentraciones de este biocida. Aquí nos referiremos a algunos de los más importantes. Ogata (2007) expuso 15 ratas a 0,03 ppm de $ClO_2$ gaseoso durante 21 días. El examen microscópico de las muestras histopatológicas de los pulmones de estas ratas mostró que sus pulmones eran "completamente normales". En otro estudio preclínico, Ogata y colaboradores (2008) expusieron a ratas a 1 ppm de $ClO_2$ gaseoso durante 5 horas al día, 5 días a la semana por un período de 10 semanas. No se observaron efectos adversos. Concluyeron que el "nivel sin efectos adversos observados" (NOAEL) del dióxido de cloro gaseoso es de 1 ppm, un nivel que se cree que no es tóxico para los seres humanos y que supera la concentración reportada de 0,03 ppm para protegerse contra la infección del virus de la gripe.

En estudios sobre ratas, Haller y Northgraves (1955) encontraron que la exposición a largo plazo (2 años) a 10 ppm de dióxido de cloro no produce efectos adversos. Sin embargo, las ratas expuestas a 100 ppm mostraron un aumento de la tasa de mortalidad.

Fridliand & Kagan (1971) informó de que las ratas que consumieron por vía oral 10 ppm de solución de $ClO_2$ durante 6 meses no tuvieron efectos adversos para la salud. Cuando se aumentó la exposición a 100 ppm, la única diferencia entre el grupo de tratamiento y el grupo de control fue un aumento de peso más lento en el grupo de tratamiento. En un esfuerzo por simular el estilo de vida humano convencional, Akamatsu et al (2012) expusieron a las ratas al gas de dióxido de cloro en una concentración de 0,05 - 0,1 ppm, las 24 horas del día y los 7 días de la semana durante un período de 6 meses. Concluyeron que para las ratas la exposición de todo el cuerpo al dióxido de cloro gaseoso de hasta 0,1 ppm durante un período de 6 meses no es tóxica.

689

Dosis mayores de solución de $ClO_2$ (por ejemplo, 50-1.000 ppm) pueden producir cambios hematológicos en los animales, incluyendo la disminución del recuento de glóbulos rojos, metahemoglobinemia y anemia hemolítica. También se observaron niveles reducidos de tiroxina sérica en monos expuestos a 100 ppm en el agua potable y en crías de rata expuestas a concentraciones de hasta 100 ppm a través del gavage o indirectamente a través del agua potable de sus bebederos (*US Department of health and human service, 2004*).

Moore & Calabrese (1982) estudió los efectos toxicológicos del $ClO_2$ en las ratas y observó que al exponer a las ratas a un nivel máximo de 100 ppm mediante el agua potable y ni las ratas A/J ni C57L/J mostraron ningún cambio hematológico. También se encontró que las ratas expuestas a hasta 100 ppm de clorito de sodio ($NaClO_2$) en su agua potable durante un máximo de 120 días no podían demostrar ningún cambio histopatológico en la estructura de los riñones.

Shi e Xie (1999) indicó que un valor agudo de LD50 oral (que se espera resulte en la muerte del 50% de los animales dosificados) para el dióxido de cloro estable era >10.000 mg/kg en ratones. En las ratas, los valores orales agudos de LD50 para el clorito de sodio ($NaClO_2$) oscilaron entre 105 y 177 mg/kg (equivalente a 79-133 mg de clorito/kg) (Musil et al 1964, Seta et al 1991. No se observaron muertes relacionadas con la exposición en ratas que recibieron dióxido de cloro en el agua potable durante 90 días a concentraciones que dieron lugar a dosis de hasta aproximadamente 11,5 mg/kg/día en los hombres y 14,9 mg/kg/día en las mujeres (Daniel et al 1990).

## Estudios clínicos

Según la Agencia de Protección Ambiental de los Estados Unidos (EPA), la toxicidad a corto plazo del $ClO_2$ fue evaluada en estudios realizados en seres humanos por Lubbers et al (1981, 1982, 1984a y Lubbers & Bianchine 1984c). En el primer estudio (Lubbers et al 1981, publicado también como Lubbers y otros 1982), un grupo de 10 hombres adultos sanos bebió 1.000 ml (divididos en dos porciones de 500 ml, separadas por 4 horas) de una solución de 0 o 24 mg/L de dióxido de cloro (0,34 mg/kg, suponiendo un peso corporal de referencia de 70 kg). En el segundo estudio (Lubbers et al 1984a), grupos de 10 hombres adultos recibieron 500 ml de agua destilada que contenía 0 o 5 mg/L de $ClO_2$ (0,04 mg /kg día suponiendo un peso corporal de referencia de 70 kg) durante 12 semanas. En ningún estudio se encontraron cambios fisiológicamente pertinentes en la salud general (observaciones y examen físico), los signos vitales (presión arterial, frecuencia del pulso, frecuencia respiratoria y temperatura corporal), los parámetros químicos clínicos del suero (incluidos los niveles de glucosa, nitrógeno ureico y fósforo), la fosfatasa alcalina, la aspartato, la alanina aminotransferasa, la triyodotironina sérica (T3) y la tiroxina (T4), ni los parámetros hematológicos (EPA, 2004).

Michael et al (1981), Tuthill et al (1982) y Kanitz et al (1996) examinaron los efectos del agua potable desinfectada con $ClO_2$. Michael et al (1981) no encontró anomalías significativas en los parámetros hematológicos o en la química del suero. Tuthill y sus colaboradores (1982) compararon retrospectivamente los datos sobre la morbilidad y la mortalidad de los recién nacidos en dos comunidades: una que utiliza cloro y otra que utiliza $ClO_2$ para purificar el agua. Al revisar este estudio, la EPA no encontró diferencias entre estas comunidades (*US Department of Health and Human Service, 2004*).

Dos estudios realizados en la Escuela de Medicina de la Universidad Estatal de Ohio evaluaron la seguridad a corto plazo del $ClO_2$ en humanos. En el primer estudio, 10 varones adultos sanos bebieron 1.000 ml (divididos en dos porciones de 500 ml, separadas por 4 horas) de solución de $ClO_2$ 0 o 24 ppm. En el segundo estudio, grupos de 10 hombres adultos bebieron 500 ml de agua que contenía 0 o 5 ppm de $ClO_2$ durante 12 semanas. Ninguno de los estudios encontró ningún efecto adverso.

Haag (1949) expuso a grupos de ratas a $ClO_2$ en el agua potable durante dos años a concentraciones que resultaron en dosis estimadas de 0,07, 0,13, 0,7, 1,3, o 13 mg/kg/día. Los resultados no indicaron diferencias significativas en la mortalidad entre el grupo de control y el grupo tratado hasta el nivel más alto de exposición probado. La supervivencia no disminuyó significativamente en los grupos de ratas expuestas al clorito (como el clorito de sodio) en el agua potable durante dos años a concentraciones que dieron lugar a dosis estimadas de clorito de hasta 81 mg/kg/día. En otro estudio, Kurokawa y otros (1986) observaron que la supervivencia no se veía afectada negativamente en ratas que recibían clorito de sodio en el agua potable en concentraciones que daban lugar a dosis estimadas de clorito de hasta 32,1 mg/kg/día en los machos y 40,9 mg/kg/día en las hembras".

La exposición de las ratas al clorito de sodio durante un período de hasta 85 semanas a concentraciones que dan lugar a dosis estimadas de clorito de hasta 90 mg/kg/día no ha afectado a la supervivencia (Kurokawa et al. 1986).

Según Lubbers et al 1981, no hubo signos de efectos hepáticos adversos (evaluados en pruebas de química sérica) en varones adultos que consumieron $ClO_2$ en solución acuosa, lo que dio lugar a una dosis de aproximadamente 0,34 mg/kg o en otros varones adultos que consumieron aproximadamente 0,04 mg/kg/día durante 12 semanas. Los mismos investigadores administraron clorito a hombres adultos sanos y no encontraron pruebas de efectos hepáticos adversos después de que cada individuo consumiera un total de 1.000 ml de una solución que contenía 2,4 mg/L de clorito (aproximadamente 0,068 mg/kg) en dos dosis (separadas por 4 horas), o en otros hombres normales o con deficiencia de G6PD que consumieron aproximadamente 0,04 mg/kg/día durante 12 semanas (Lubbers et al 1984a, 1984b). No se observaron signos de deterioro de la función hepática inducida por el $ClO_2$ o el clorito entre los habitantes de las aldeas rurales que estuvieron expuestos durante 12 semanas a través del $ClO_2$ en el agua potable a concentraciones semanales medidas de 0,25 a 1,11 mg/L ($ClO_2$) o de 3,19 a 6,96 mg/L (clorito) (Michael et al 1981). En este estudio epidemiológico, los niveles de $ClO_2$ en el agua potable antes y después del período de tratamiento fueron <0,05 mg/L. El nivel de clorito en el agua potable era de 0,32 mg/L antes del tratamiento con $ClO_2$. A la semana y a las dos semanas de suspender el tratamiento, los niveles de clorito cayeron a 1,4 y 0,5 mg/L, respectivamente.

En su documento oficial titulado "Manual de bioseguridad en el laboratorio" (página 93), la OMS (2005) habla sobre el $ClO_2$:

*"El dióxido de cloro ($ClO_2$) es un poderoso germicida, desinfectante y oxidante de acción rápida que suele tener actividad en concentraciones inferiores a las necesarias en el caso del cloro blanqueador. La forma gaseosa es inestable y se descompone en gas cloro ($Cl_2$) y gas oxígeno ($O_2$), produciendo calor. Sin embargo, el $ClO_2$ es soluble en agua y estable en solución acuosa.*
*Se puede obtener de dos maneras:*
*1) Por generación in situ, mezclando dos componentes diferentes, el ácido clorhídrico (HCl) y el clorito de sodio ($NaClO_2$), o*
*(2) ordenando la forma estabilizada, que se activa en el laboratorio cuando es necesario.*
*El $ClO_2$ es el más selectivo de los biocidas oxidantes. El ozono y el cloro son mucho más reactivos que el $ClO_2$ y son consumidos por la mayoría de los compuestos orgánicos. Por el contrario, el $ClO_2$ sólo reacciona con compuestos de azufre reducidos, aminas secundarias y terciarias y otros compuestos orgánicos muy reducidos y reactivos. Por lo tanto, con el $ClO_2$ se puede obtener un residuo más estable en dosis mucho más bajas que cuando se utiliza cloro u ozono. Si se genera correctamente, el $ClO_2$, debido a su selectividad, puede ser utilizado más eficazmente que el ozono o el cloro en casos de mayor carga de materia orgánica".*

Sobre la base de la Estrategia de la OMS sobre la medicina tradicional 2014-2023 (OMS 2013), que reconoce las prácticas relacionadas con la medicina tradicional, complementaria e integradora o "no convencional" como una parte importante de los servicios de salud, a fin de integrarlas continuamente con los diversos países miembros signatarios de esta iniciativa, ponemos aquí el potencial de la solución acuosa de $ClO_2$ (Kalcker 2017) como potente biocida y, por lo tanto, como una alternativa complementaria segura para combatir el SARS-CoV2. El $ClO_2$ puede combatir los virus mediante el proceso de oxidación selectiva a través de la desnaturalización de las proteínas de la cápside y la posterior oxidación del material genético del virus, dejándolo inactivo. Como no hay una posible adaptación del virus al proceso de oxidación, es imposible que desarrolle resistencia al $ClO_2$, se convierte en un tratamiento prometedor para cualquier cepa de virus.

## Toxicidad

La toxicidad LD50 (índice de toxicidad aguda) establecida por la base de datos de toxicología alemana GESTIS para el $ClO_2$ es de 292 mg por kilogramo durante 14 días, cuando el equivalente en un adulto de 60 kg sería de 18.000 mg durante 14 días (IFA 2020). De acuerdo con el Departamento de Salud y Servicios Humanos de los Estados Unidos el $ClO_2$ actúa rápidamente cuando entra en el cuerpo humano y el $ClO_2$ se transforma rápidamente en iones de cloruro, que a su vez se descomponen en iones de cloruro. El cuerpo utiliza estos iones para su fisiología. Estos iones de cloruro salen del cuerpo en horas o días, principalmente a través de la orina (EPA 1999).

Ma et al (2017) evaluaron la eficacia y la seguridad de una solución acuosa de $ClO_2$ que contenía 2.000 ppm. La actividad antimicrobiana fue del 98,2% en concentraciones de entre 5 y 20 ppm para las bacterias fúngicas y los virus H1N1. En una prueba de toxicidad por inhalación, 20 ppm de $ClO_2$ durante 24h no mostró ninguna anomalía en los síntomas clínicos y/o en el funcionamiento de los pulmones y otros órganos. Una concentración de $CLO_2$ de hasta 40 ppm en el agua potable no mostró ninguna toxicidad oral subcrónica.

Taylor y Pfohl, 1985; Toth y otros, (1990), Orme y otros, 1985; Taylor y Pfohl, 1985; Mobley y otros, (1990) estudiaron la toxicidad del dióxido de cloro, en varios órganos del cuerpo, en diferentes etapas de desarrollo de los especímenes animales estudiados, y comunicaron un Nivel de Efectos Adversos Observados Mínimos (LOAEL) para estos efectos de 14 mg kg-1 día-1 de dióxido de cloro. Mientras que Orme, y otros (1985) identificaron un Nivel de Efectos Adversos No Observados (NOAEL) de 3 mg kg-1 día-1. La experiencia clínica de los médicos de América Latina, durante los últimos seis meses, sugiere que la ingestión de 30 mg al día de dióxido de cloro disuelto en un litro de agua, e ingerido distribuido en diez tomas a lo largo del día como un tratamiento exitoso para el COVID-19, que está 6 veces por debajo de la dosis considerada como NOAEL. Por lo tanto, la revisión de la literatura confirma que el uso de dióxido de cloro ingerido a una dosis de 0,50 mg por kg por día no representa un riesgo de toxicidad para la salud humana por ingestión, y sí representa un tratamiento muy plausible para COVID-19.

## 3. HECHOS LEGALES Y DERECHOS HUMANOS

Los avances y descubrimientos científicos son constantes, y en el ámbito de la salud, el pronto acceso a los mismos por el personal sanitario y los pacientes se vuelve primordial y apremiante, siendo lógico y obligado, por puro sentido humanitario y conforme al rigor científico, probar con sustancias como el Dióxido de Cloro ($ClO_2$) del que hay evidencia demostrada de su eficacia y utilidad. En la historia de la medicina ha sido constante la supremacía del criterio del “recurso compasivo” frente al criterio del “recurso perfectamente contrastado”.

El art.° 32 y 37 de la Declaración de Helsinki de 1964 así lo permiten en el caso de «Intervención No Comprobada» (INC), "*Cuando en la atención de un paciente las intervenciones probadas no existen u otras intervenciones conocidas han resultado ineficaces, el médico, después de pedir consejo de experto, con el consentimiento informado del paciente o de un representante legal autorizado, puede permitirse usar intervenciones no comprobadas, si, a su juicio, ello da alguna esperanza de salvar la vida, restituir la salud o aliviar el sufrimiento*".

Los médicos, conforme a la declaración de Ginebra de 1948, ante pacientes cuya salud y vida están en peligro , tienen la obligación de usar todos los medios y productos de que dispongan, que ofrezcan indicios de efectividad y en mayor medida ante una emergencia médica, ya que conforme al deber de fraternidad y ayuda humanitaria no puede limitarse ni negarse el uso del Dióxido de Cloro ($ClO_2$), cuya no toxicidad ha sido documentada y cuya eficacia y seguridad ha sido demostrada en los

693

estudios y prácticas llevadas a cabo en diferentes países. En la misma medida los Estados, Instituciones y Organizaciones no pueden restringir ni impedir su uso ante las evidencias clínicas existentes, pues de lo contrario incumplirían las obligaciones asumidas en los textos internacionales y nacionales, incurriendo en la vulneración de derechos fundamentales como el derecho a la vida y a la salud, así como del derecho de autodeterminación del paciente y autonomía profesional e independencia clínica.

Conforme a lo expuesto, el ejercicio de la profesión médica implica una vocación de servicio a la humanidad, siendo su mayor preocupación la salud y la vida del paciente, debiendo velar por el beneficio de los intereses de los ciudadanos, poniendo a su disposición los conocimientos médicos en el marco de la autonomía profesional e independencia clínica. En el marco legal actualmente existente, plenamente aplicable y exigible, la profesión médica debe disponer de libertad profesional sin interferencias en la atención y tratamiento de los pacientes, al ostentar el privilegio de usar su juicio y discreción profesional para tomar las decisiones clínicas y éticas necesarias.

A los médicos se les confiere legalmente un alto grado de autonomía profesional e independencia clínica, por lo que pueden hacer recomendaciones basadas en sus conocimientos y experiencia, evidencia clínica y comprensión holística de los pacientes, incluido lo mejor para ellos sin influencia externa indebida o inapropiada, y tomar medidas apropiadas para asegurar que sistemas eficaces estén implementados.

Todo paciente tiene derecho a ser atendido por un médico que él sepa que tiene libertad para dar una opinión clínica y ética, sin ninguna interferencia exterior. El paciente tiene derecho a la autodeterminación y a tomar decisiones libremente con relación a su persona. Los pacientes en el libre ejercicio de su derecho a la autonomía tienen derecho a disponer de su cuerpo debiendo respetarse sus decisiones, estando plenamente amparado para impedir que terceros intervengan en su cuerpo sin su consentimiento, debiendo ser informado adecuadamente sobre la finalidad de la intervención, la naturaleza, sus riesgos y consecuencias.

El derecho a la salud requiere que los gobiernos cumplan con las obligaciones que tienen asumidas en los referidos pactos, para que los bienes y servicios de salud estén disponibles en cantidad suficiente, con acceso público, y de buena calidad, conforme a lo dispuesto en la Observación General 14 del Comité del Pacto de Derechos Económicos, Sociales y Culturales.

Todo ello amparado en las disposiciones que se relacionan y cuyos contenidos esenciales se extractan a continuación;

- Declaración Universal de Derechos Humanos, de 10 de diciembre de 1948.
- Declaración americana de los derechos y deberes del hombre, Bogotá, 1948.
- Convención Americana sobre Derechos Humanos, San José (Costa Rica), del 7 al 22 de noviembre 1969.
- Pacto Internacional de derechos económicos, sociales y culturales de 16 de diciembre de 1966.

694

- El Convenio para la Protección de los Derechos Humanos y de las Libertades Fundamentales, Roma 4 de noviembre 1950.
- Pacto Internacional de derechos Civiles y Políticos de 16 de diciembre de 1966.
- Convenio para la protección de los derechos humanos y la dignidad del ser humano con respecto a las aplicaciones de la Biología y la Medicina del 4 de abril de 1997, convenio de Oviedo.
- Código de ética de Nuremberg del 19 de agosto de 1947.
- Declaración de Ginebra de 1948.
- Código internacional de ética médica de octubre de 1949.
- Declaración de Helsinki adoptada por la 18ª Asamblea Médica Mundial de 1964.
- Informe Belmont del 18 de abril de 1979.
- Declaración de Lisboa de la AMM sobre los Derechos del Paciente de 1981.
- Declaración de la AMM sobre la Independencia y Libertad Profesional del Médico de 1986.
- Declaración de Madrid de la AMM sobre la Autonomía y Autorregulación profesionales de 1987.
- Declaración de Seúl de la AMM sobre la Autonomía Profesional y la Independencia Clínica de 2008.
- Declaración de Madrid de la AMM sobre Regulación Profesional de 2009.
- Declaración de la AMM sobre la relación entre el derecho y la ética de 2003.
- Declaración Universal sobre Bioética y Derechos Humanos de la UNESCO de 2005.
- Reglamento Sanitario Internacional de 2005.

El Pacto Internacional de derechos económicos, sociales y culturales del 16 de diciembre de 1966, firmado por Ecuador el 24 de setiembre de 1968 y ratificado el 11 de junio de 2010, reconoce el derecho de toda persona al disfrute del más alto nivel posible de salud física y mental; artº12 "*1. Los Estados Parte en el presente Pacto reconocen el derecho de toda persona al disfrute del más alto nivel posible de salud física y mental.* "y el deber de proteger este derecho por el estado por un sistema global de atención sanitaria, que esté a disposición de todos, sin discriminación y económicamente accesible art.º 2:

> 1. "*Cada uno de los Estados Parte en el presente Pacto se compromete a adoptar medidas, tanto por separado como mediante la asistencia y la cooperación internacionales, especialmente económicas y técnicas, hasta el máximo de los recursos de que disponga, para lograr progresivamente, por todos los medios apropiados, inclusive en particular la adopción de medidas legislativas, la plena efectividad de los derechos aquí reconocidos.*"

El Código internacional de ética médica de octubre de 1949, para que se hagan efectivos entre otros el art.º 36 y 59 del referido texto;

- Artículo 36 del capítulo VII relativo a la atención médica al final de vida.

> "*1. El médico tiene el deber de intentar la curación o la mejoría del paciente, siempre que sea posible. Cuando ya no lo es, permanece la obligación de aplicar las medidas adecuadas para conseguir su bienestar, aun cuando de ello pueda derivarse un acortamiento de la vida.*

*2. El médico no debe emprender o continuar acciones diagnósticas o terapéuticas perjudiciales para el enfermo, sin esperanza de beneficios, inútiles u obstinadas. Debe retirar, ajustar o no instaurar un tratamiento cuando el pronóstico limitado así lo aconseja. Debe adecuar las pruebas diagnósticas y las medidas terapéuticas y de sostén a la situación clínica del paciente. Debe evitar la futilidad, tanto cuantitativa como cualitativa.*
*3. El médico, tras una adecuada información al paciente, debe tener en cuenta su voluntad de rechazar cualquier procedimiento, incluso los tratamientos dirigidos a prolongar la vida.*
*4. Cuando el estado del paciente no le permite tomar decisiones, el médico debe tener en consideración, por orden de preferencia, las indicaciones anteriormente hechas por el enfermo, las instrucciones previas y la opinión del paciente en voz de sus representantes. Es deber del médico colaborar con las personas que tengan la misión de garantizar el cumplimiento de las voluntades del paciente"*

- Artículo 59 del Capítulo XIV relativo a investigación médica;

*"1. La investigación médica es necesaria para el avance de la medicina, siendo un bien social que debe ser fomentado y alentado. La investigación con seres humanos debe realizarse cuando el avance científico no sea posible por otros medios alternativos de eficacia comparable o en aquellas fases de la investigación en las que sea imprescindible.*
*2.- El médico investigador debe adoptar todas las precauciones posibles para preservar la integridad física y psíquica de los sujetos de investigación. Debe tener especial cuidado en la protección de los individuos pertenecientes a colectivos vulnerables. El bien del ser humano que participe en una investigación biomédica debe prevalecer sobre los intereses de la sociedad y de la ciencia.*
3.- El respeto por el sujeto de investigación es el principio rector de la misma. Se deberá obtener siempre su consentimiento explícito. La información deberá contener, al menos: la naturaleza y finalidad de la investigación, los objetivos, los métodos, los beneficios previstos, así como los potenciales riesgos e incomodidades que le puede ocasionar su participación. También debe ser informado de su derecho a no participar o a retirarse libremente en cualquier momento de la investigación, sin resultar perjudicado por ello.
4.- El médico investigador tiene el deber de publicar los resultados de su investigación por los cauces normales de divulgación científica, tanto si son favorables como si no lo son. No es ética la manipulación o la ocultación de datos, ya sea para obtener beneficios personales o de grupo, o por motivos ideológicos."

La Declaración de Lisboa de la AMM sobre los Derechos del Paciente de 1981, *"Todo paciente tiene derecho a ser atendido por un médico que él sepa que tiene libertad para dar una opinión clínica y ética, sin ninguna interferencia exterior.*

*El paciente tiene derecho a la autodeterminación y a tomar decisiones libremente con relación a su persona. El médico informará al paciente las consecuencias de su decisión.*
*El paciente adulto mentalmente competente tiene derecho a dar o negar su consentimiento para cualquier examen, diagnóstico o terapia. El paciente tiene derecho a la información necesaria para tomar sus decisiones. El paciente debe entender claramente cuál es el*

696

> *propósito de todo examen o tratamiento y cuáles son las consecuencias de no dar su consentimiento"*
>
> La Declaración de la AMM sobre la Independencia y Libertad Profesional del Médico de 1986, conforme al cual; "*Los médicos deben gozar de una libertad profesional que les permita atender a sus pacientes sin interferencias. El privilegio del médico de usar su juicio y discreción profesional para tomar las decisiones clínicas y éticas necesarias para la atención y tratamiento de sus pacientes debe ser mantenido y defendido. Al garantizar la independencia y la libertad profesional para que el médico ejerza la medicina, la comunidad asegura la mejor atención médica para sus ciudadanos, lo cual, a su vez, contribuye a una sociedad fuerte y segura.*"

La Declaración de Madrid de la AMM sobre Regulación Profesional de 2009, reafirma la Declaración de Seúl sobre la autonomía profesional y la independencia clínica de los médicos al disponer *"A los médicos se les confiere un alto grado de autonomía profesional e independencia clínica, por lo que pueden hacer recomendaciones basadas en sus conocimientos y experiencia, evidencia clínica y comprensión holística de los pacientes, incluido lo mejor para ellos sin influencia externa indebida o inapropiada."*

Los principios universales que impregnan toda normativa deben cumplir con el respeto de las leyes humanitarias innatas en el inconsciente colectivo, como queda recogido en la máxima del juramento hipocrático "*MANTENER el mayor respeto por la vida humana desde sus comienzos, aun bajo amenazas, y no utilizar los conocimientos médicos en contra de las leyes de la humanidad.*" Los valores éticos tienen primacía sobre las disposiciones legales limitantes como bien reconoce la Declaración de la AMM sobre la relación entre el derecho y la ética de 2003, la cual dispone *"Cuando la legislación y la ética médica se encuentran en conflicto, los médicos deben tratar de hacer cambiar la legislación. Si se produce este conflicto, las responsabilidades éticas prevalecen sobre las obligaciones legales."*

Cuando un paciente ante una enfermedad busque alivio o salvar su vida y solicita probar una opción terapéutica de la cual hay indicios de utilidad, como ocurre con el Dióxido de Cloro ($ClO_2$), es deber del médico apoyar al paciente, adquirir conocimiento, hacer estudios, y divulgarlo de acuerdo con el art.º 27 de la Declaración Universal de Derechos humanos de 1948, para que todos se beneficien del progreso científico debe compartirse libremente la información para que se difundan en todos los países sin restricciones, "*Toda persona tiene derecho a tomar parte libremente en la vida cultural de la comunidad, a gozar de las artes y a participar en el progreso científico y en los beneficios que de él resulten.*"

## 4. CONSIDERACIONES FINALES

En vista del momento histórico que enfrenta toda la humanidad con la pandemia de Coronavirus y la urgente necesidad de salvar vidas, los recientes acontecimientos relacionados con el tratamiento de COVID-19 tanto en el ámbito médico como en el académico, y especialmente el objeto de este documento, que es proporcionar a las autoridades la información correcta sobre el dióxido de cloro para un uso humano correcto y seguro, vale la pena considerar algunas criterios fundamentales relacionadas con los derechos humanos y la práctica médica para la reflexión:

- ✓ La adhesión a cualquier tratamiento depende del acuerdo y la colaboración tácita entre las partes: el médico y el paciente (o su tutor cuando se encuentre en condiciones especiales que no permitan una elección consciente de la intervención médica, por ejemplo, situaciones de pérdida de memoria, inconsciencia inducida o por trauma, en niños/niñas). Este es un acuerdo libre y espontáneo;

- ✓ Basándose en su experiencia clínica, el médico tiene la libertad de prescribir lo que considere apropiado para el paciente, comunicando siempre la forma correcta de utilizar un medicamento, los posibles beneficios y riesgos de una intervención terapéutica. Por otra parte, el paciente, sobre la base de las explicaciones dadas, las creencias personales y la información complementaria, también tiene la libertad de aceptar o no cualquier forma de tratamiento indicado;

- ✓ La práctica médica siempre debe basarse, siempre que sea posible, en datos científicos que apoyen las conductas diagnósticas y terapéuticas que se empleen. Sin embargo, en situaciones en las que no se dispone de pruebas científicas, o éstas no son fiables, corresponde al Doctor utilizar sus conocimientos, su experiencia previa y su sentido común para conducir la situación clínica de la manera que le parezca más apropiada. En este caso, es importante que el médico le pida al paciente que firme un Término de Consentimiento Libre e Informado (TCLI). Para esta conducta, el Doctor se apoya en la Declaración de Helsinki (Art.º 37) que nos dice:

> *"En el tratamiento de un paciente individual, cuando se establece que no ha habido ninguna intervención u otras intervenciones conocidas que hayan sido ineficaces, el médico, tras solicitar el asesoramiento de expertos, con el consentimiento informado del paciente o de un representante autorizado, puede utilizar una intervención no probada si, a juicio del médico, ofrece la esperanza de salvar vidas, restablecer la salud o aliviar el sufrimiento. Esta intervención debería ser objeto de investigación para evaluar su seguridad y eficacia. En todos los casos, la nueva información debe registrarse y, cuando proceda, ponerse a disposición del público"*

698

- ✓ Respetando los aspectos mencionados, no podemos subestimar el hecho de que aún no hay suficiente evidencia en la literatura científica que indique el uso de los CDS para la profilaxis o para el tratamiento etiológico de los casos de COVID-19 de cualquier gravedad, pero sí disponemos, por ejemplo, del informe técnico de los médicos de AEMEMI constatando una eficacia del 97% en el tratamiento de pacientes con COVID-19 durante 4 días en Guayaquil/Ecuador (AEMEMI 2020). Cabe mencionar que hasta el momento aun seguimos con dificultades para aprobación de los ensayos clínicos y hasta el momento, aún no ha podido comenzar investigaciones en muchos países porque las instituciones reguladoras están trasladando el mensaje equivocado al considerar que el dióxido de cloro es tóxico;

- ✓ En el caso concreto del $ClO_2$, la información y las pruebas clínicas actualmente disponibles apuntan a la eficacia de esta sustancia luchando contra el coronavirus a ejemplo, el estudio observacional disponibilizado por el grupo de Médicos de AEMEMI (2020).

En resumen:

- En vista de lo anterior, sobre la base de las pruebas presentadas aquí con evidente experiencia por parte de Científicos y Profesionales de la Salud, así como ya queda bien demostrado en artículos científicos ya publicados, recomendamos el uso de la solución de dióxido de cloro (CDS) de acuerdo con lo estandarizado por Andreas Ludwig Kalcker (2017), debidamente diluido y por lo tanto, respetándose las dosis seguras de lo que ya se conoce como seguro según los estudios de toxicidad, que según relatos de médicos de varios países ha demostrado ser segura para el consumo humano y además eficaz contra el COVID-19 cuando se consume correctamente siguiendo los protocolos normalizados internacionalmente.

Como ejemplo del uso consciente y compasivo del dióxido de cloro (CDS), podemos citar el Estado Plurinacional de Bolivia, después de un proceso prolongado de debate y resolución en el marco del ejercicio de Derechos Humanos y en el marco de la Ley de Participación y Control Social, la población ha demandado a través de sus representantes asambleístas departamentales y nacionales la Ley que permita la autorización de la producción, distribución con control de calidad y uso compasivo de la solución acuosa del dióxido de cloro (CDS), según estandarizado por Andreas Ludwig Kalcker.

699

## 5. REFERENCIAS

1. AEMEMI - Asociación Ecuatoriana de Médicos Expertos en Medicina Integrativa. **Dióxido de cloro, una terapia efectiva para el tratamiento del SARS-COV2 (COVID-19)**. Mayo, 2020
2. Akamatsu et al. **Six-month low-level chlorine dioxide gas inhalation toxicity study with two-week recovery period in rats**. J Occup Med Toxicol. 2012; 7: 2.
3. Associación Médica Mundial. **Declaración de Helsinki**. 64ª Asamblea General, 2013.
4. Daniel et al. **Comparative sub chronic toxicity studies of three disinfectants**. J. Am. Water Works Assn. 1990; 82:61–69.
5. Estrela C et al. **Mechanism of action of sodium hypochlorite**. Brazilian dental journal, 13(2), 113-117, 2002.
6. Food and Drug Administration. **FDA release - Actualización del coronavirus (COVID-19): La FDA advierte a la empresa que comercializa productos peligrosos de dióxido de cloro que afirman tratar o prevenir el COVID-19**. Disponible en: https://www.fda.gov/news-events/press-announcements/actualizacion-del-coronavirus-covid-19-la-fda-advierte-empresa-que-comercializa-productos-peligrosos. Accedido en: 24.07.2020.
7. Fridliand AS & Kagan GZ. **Experimental Data for Substantiating Residual Concentrations of Chlorine Dioxide in Drinking Water**. Gig Sanit: Nov; 36 (11): 18-21, 1971.
8. Fukuzaki S. **Mechanisms of actions of sodium hypochlorite in cleaning and disinfection processes**. Biocontrol Science, 11(4), 147-157, 2006.
9. Haag HB. **The effect on rats of chronic administration of sodium chlorite and chlorine dioxide in the drinking water**. Report to the Mathieson Alkali Works from H.B. Haag of the Medical College of Virginia, 1949. Disponible en: http://www.epa.gov/iris/subst/0496.htm
10. Haller JF & Northgraves WW. **Chlorine dioxide and safety.** TAPPI 38:199-202, 1955.
11. Howard A. **Patente sobre un método de composiciones para tratamiento de tumores cancerosos.** Disponible en: https://patentimages.storage.googleapis.com/81/c6/fb/1bd9842e82e566/US10463690.pdf. Accedido en 20.05.2020.
12. Institute for occupational safety and health of Gernn Social Accident Insurance (IFA). **GESTIS Substance database : chlorine dioxide solution**. Disponible en: http://gestis.itrust.de/nxt/gateway.dll/gestis_en/000000.xml?f=templates&fn=default.htm&vid=gestiseng:sdbeng.
13. Kalcker AL & Valladares H. **Chlorine Dioxide for Coronavirus: a revolutionary, simple, and effective approach**. DOI: 10.13140/RG.2.2.23856.71680 License CC BY-NC-SA 4.0, Project: Toxicity study of chlorine dioxide in solution (CDS) ingested orally, 2020. Disponible en: http://mkilani.com/files/chlorine-dioxide-for-coronavirus-1.pdf.
14. Kalcker AL. **Pharmaceutical composition for treating acute intoxication**. 2018a ISBN: 9789088791567, nº: WO2018185348A1. Disponible en: https://patents.google.com/patent/WO2018185348A1/en?inventor=kalcker&oq=kalcker

15. Kalcker AL. **Pharmaceutical composition for treating infectious diseases**. 2018b ISBN: 9789088791567, nº: WO2018185346A1. Disponible en: https://patents.google.com/patent/WO2018185346A1/en?inventor=kalcker&oq=kalcker
16. Kalcker AL. **Pharmaceutical composition for treating internal inflammations**. 2018c ISBN: 9789088791567, nº: WO2018185347A1. Disponible en: https://patents.google.com/patent/WO2018185347A1/en?inventor=kalcker&oq=kalcker.
17. Kalcker AL. **Report of Series of experiments: applications of Chlorine Dioxide as an Active Pharmaceutical Ingredient**. Personal documents, 2018.
18. Kalcker AL. **Resultados de los ensayos con CDS.** Disponible en: https://lbry.tv/@Kalcker:7/100-Covid-19-Recuperados-Con-Cds--Aememi-1:1
19. Kalcker LA. **Salud Prohibida: incurable era ayer**. Editora Voedia, 8ª edición, 2020.
20. Kanitz S et al. **Association between drinking water disinfection and somatic parameters at birth**. Environ Health Perspectt 104(5): 516-520, 1996.
21. Krogulec T. **Patente sobre una solución estabilizada de dióxido cloro para uso como biocida universal: substancias químicas destinadas a destruir, neutralizar, prevenir la acción de cualquier organismo considerado perjudicial para el hombre**. Patente EUA 26 20120225135 A1 Fecha: 6/9/2012. Enlace directo a las Patentes de Google: http://goo.gl/RAUFWe.
22. Kross RD & Scheer DI. **Patente sobre el uso del dióxido de cloro para la desinfección o esterilización de componentes esencialmente sanguíneos (células sanguíneas, proteínas de sangre, etc.). La composición está formada por la adición de un compuesto que libera dióxido de cloro como un ácido orgánico débil**. Patente EUA 5019402 A, Data: 28/05/1991. Enlace directo a las Patentes de Google: http://goo.gl/LZpqdX
23. Kuhne FW. **Patente sobre el uso de dióxido de cloro para el tratamiento parenteral (intravenoso) de las infecciones del VIH.** El objetivo del presente tratamiento es proveer de un agente que inactive el virus del VIH en la sangre sin tener una influencia nociva en el cuerpo del paciente. Patente de los EUA 6086922 A Data: 19/03/1993. Enlace directo a las Patentes de Google: http://goo.gl/LJTbo8
24. Kullai-Kály K et al. **Can chlorine dioxide prevent the spreading of coronavirus or other viral infections? Medical hypotheses**. Physiology International, 2020, DOI: 10.1556/2060.2020.00015.
25. Kurokawa Y et al. **Long-term in vivo carcinogenicity tests of potassium bromate, sodium hypochlorite, and sodium chlorite conducted in Japan**. Environ Health Perspect 69:221, 1986.
26. Lenntech. Processes/Desinfection/Chemical desinfectants/Chlorine dioxide. Disponível em: https://www.lenntech.com.pt/processos/desinfeccao/chlorine-dioxide.htm. Acessado em: 04.06.2020.
27. Lubbers JR & Bianchine JR. **Effects of the acute rising dose administration of chlorine dioxide, chlorate and chlorite to normal healthy adult male volunteers**. J Environ Pathol Toxicol 5(4-5):215-228, 1984c.

28. Lubbers JR et al. **Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man.** Environmental Health Perspectives. Vol. 46, pp.57-62, 1982.
29. Lubbers JR et al. **The effects of chronic administration of chlorine dioxide, chlorite and chlorate to normal healthy adult male volunteers**. J Environ Pathol Toxicol Oncol 54(5):229-238, 1984a.
30. Lubbers JR et al. **The effects of chronic administration of chlorite to glucose-6-phosphate dehydrogenase deficient healthy adult male volunteers**. J Environ Pathol Toxicol Oncol 5-4(5):239-242, 1984b.
31. Ma JW & Huang BS. **Efficacy and safety evaluation of a chlorine dioxide solution**. Int J Environ Res Public Health 2017 Marc 22; 14 (3): 329. DOI: 10.3390/ijerph14030329.
32. McGrath MS. **Patente que trata del uso del clorito de sodio para el tratamiento de dolencias neurodegenerativas como la esclerosis lateral amiotrófica (ALS), enfermedad de Alzheimer (AD) o esclerosis múltiple (EM)**. Patente US UU. 8029826 B2 Data: 04/10/2011. Patente apoyada por el gobierno de los EEUU, donde el propio gobierno puede tener derechos sobre ella. Enlace directo a la Patente de Google: http://goo.gl/HCPxC7 27.
33. Medina-Ramon M et al. **Asthma, chronic bronchitis, and exposure to irritant agents in occupational domestic cleaning: a nested case-control study**. Occupational and environmental medicine, 62(9), 598-606, 2005.
34. Michael GE et al. **Chlorine dioxide water disinfection: a prospective epidemiology study**. Arch Environ Health 36:20-27, 1981
35. Mobley, SA; Taylor, DH; Laurie, RD; et al. (1990) Chlorine dioxide depresses T3 uptake and delays development of locomotor activity in young rats. In: Jolley, RL, et al., eds. Water chlorination: chemistry, environmental impact and health effects, vol. 6. Chelsea, MI: Lewis Publications, pp. 347-358.
36. Mohammadi Z. **Sodium hypochlorite in endodontics: an update review**. International Dental Journal, 58(6), 329-341, 2008.
37. Moore GS & Calabrese E. **Toxicological effects of chlorite in the mouse.** Environmental Health Perspectives. Vol. 46, pp. 31-37, 1982.
38. Musil J et al. Toxicologic aspects of chlorine dioxide application for the treatment of water containing phenols. Sb Vys Sk Chem Technol Praze Oddil Fak Technol Paliv Vody 8:327- 345, 1964.
39. National Institute of Health. **PubMed: chlorine dioxide.** Disponible en: x https://pubmed.ncbi.nlm.nih.gov/?term=chlorine+dioxide. Fecha de acceso: 24 de julio de 2020.
40. National Institute of Health. **PubChem: chlorine dioxide.** Disponible en: x pubmed.ncbi.nlm.nih.gov?term=chlorine+dioxide&sort=pubdate. Fecha de acceso: 24 de julio de 2020.
41. Noszticzius Z et al. **Chlorine Dioxide Is a Size-Selective Antimicrobial Agent**. PLoSONE 8(11): e79157. doi: 10.1371/journal.pone.0079157. 2013. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818415/pdf/pone.0079157.pdf
42. Ogata N & Shibata T. **Protective effect of low-concentration chlorine dioxide gas against influenza A virus infection**. Journal of General Virology: 89, 60–67, 2007.

702

43. Ogata N. & Taketa-Shi O, 2014. **Chlorine dioxide gas for use in treating respiratory virus infection**. Patente EP1955719B1. Este procedimiento patentado por la Taiko Pharmaceutical sirve para eliminar los coronavirus y otros virus, este proceso sirve también para curar infecciones por coronavirus de personas, además de eliminar virus de ambientes hospitalarios o de salas inundadas con dióxido de cloro, todo esto aplicable también de forma no tóxica. Enlace directo a la patente: https://patents.google.com/patent/EP1955719B1/en.
44. Organización Mundial de la Salud. **Manual de Bioseguridad en Laboratorio**. 3ª edición, 2005.
45. Organización Mundial de la Salud. **Estrategia de la OMS sobre medicina tradicional 2014-2023**, 2013. Disponible en: <https://apps.who.int/iris/handle/10665/95008.
46. Orme, J; Taylor, DH; Laurie, RD; et al. (1985) Effects of chlorine dioxide on thyroid function in neonatal rats. J Toxicol Environ Health 15:315-322.
47. Peck B et al. **Spectrum of sodium hypochlorite toxicity in man - also a concern for nephrologists**. NDT plus, 4(4), 231-235, 2011.
48. Racioppi F et al. **Household bleaches based on sodium hypochlorite: review of acute toxicology and poison control center experience**. Food and chemical toxicology, 32(9), 845-861, 1994.
49. Seta S, Miyake B, Sato H, et al. 1991. **Acute oral toxicity and acute irritation test to skin and eye of sodium chlorite**. Kagaku Keisatsu Kenkyusho Hokoku, Hokagaku Hen 44(1):7-22.
50. Shi L & Xie C. 1999. **Experimental observation on acute toxicity and irritative effect of stable chlorine dioxide**. Zhongguo Xiaoduxue Zazhi 16(1):39-40
51. Taylor, DH; Pfohl, RJ. (1985) **Effects of chlorine dioxide on the neurobehavioral development of rats**. In: Jolley, RL, et al., eds. Water chlorination: chemistry, environmental impact and health effects, vol. 6. Chelsea, MI: Lewis Publications, pp. 355-364.
52. Toth, GP; Long, RE; Mills, TS; et al. (1990) **Effects of chlorine dioxide on the developing rat brain**. J Toxicol Environ Health 31:29-44.
53. Tuthill RW et al. **Health effects among newborns after prenatal exposure to $ClO_2$-disinfected drinking water**. Environ Health Perspect 46:39-45, 1982.
54. United Department of Health and Human services. Public Health Service. Agency for toxic substances and disease registry. **Toxicological Profile for chlorine dioxide and chlorite.** 2004. Disponible en: https://www.atsdr.cdc.gov/toxprofiles/tp160.pdf.
55. United States Environmental Protection Agency (EPA). Guidance Manual Alternative disinfectants and Oxidants. **Chlorine dioxide.** EPA Registration. 1999.
56. World Health Organization. **Guidelines for Drinking-water quality**. Second edition, Addendum – microbiological agents in drinking water, 2002. Disponible en: https://books.google.com.br/books?hl=pt-BR&lr=&id=tDLdvJQAgmAC&oi=fnd&pg=PR5&dq=Guidelines+for+Drinking-water+Quality,+World+Health+Organization,+pg+140&ots=f_Q436_I3F&sig=HescVi5DXcwfNJTZMECPTVaUoWA#v=onepage&q&f=false

PUBLIC LAW 115–176—MAY 30, 2018

# TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017

704

# Public Law 115–176
115th Congress

## An Act

May 30, 2018
[S. 204]

To authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes.

*Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,*

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017. 21 USC 301 note.

### SECTION 1. SHORT TITLE.

This Act may be cited as the “Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017”.

### SEC. 2. USE OF UNAPPROVED INVESTIGATIONAL DRUGS BY PATIENTS DIAGNOSED WITH A TERMINAL ILLNESS.

(a) IN GENERAL.—Chapter V of the Federal Food, Drug, and Cosmetic Act is amended by inserting after section 561A (21 U.S.C. 360bbb–0) the following:

21 USC 360bbb–0a.

### “SEC. 561B. INVESTIGATIONAL DRUGS FOR USE BY ELIGIBLE PATIENTS.

“(a) DEFINITIONS.—For purposes of this section—

“(1) the term ‘eligible patient’ means a patient—

“(A) who has been diagnosed with a life-threatening disease or condition (as defined in section 312.81 of title 21, Code of Federal Regulations (or any successor regulations));

“(B) who has exhausted approved treatment options and is unable to participate in a clinical trial involving the eligible investigational drug, as certified by a physician, who—

“(i) is in good standing with the physician’s licensing organization or board; and

“(ii) will not be compensated directly by the manufacturer for so certifying; and

“(C) who has provided to the treating physician written informed consent regarding the eligible investigational drug, or, as applicable, on whose behalf a legally authorized representative of the patient has provided such consent;

“(2) the term ‘eligible investigational drug’ means an investigational drug (as such term is used in section 561)—

“(A) for which a Phase 1 clinical trial has been completed;

“(B) that has not been approved or licensed for any use under section 505 of this Act or section 351 of the Public Health Service Act;

705

“(C)(i) for which an application has been filed under section 505(b) of this Act or section 351(a) of the Public Health Service Act; or

“(ii) that is under investigation in a clinical trial that—

“(I) is intended to form the primary basis of a claim of effectiveness in support of approval or licensure under section 505 of this Act or section 351 of the Public Health Service Act; and

“(II) is the subject of an active investigational new drug application under section 505(i) of this Act or section 351(a)(3) of the Public Health Service Act, as applicable; and

“(D) the active development or production of which is ongoing and has not been discontinued by the manufacturer or placed on clinical hold under section 505(i); and

“(3) the term ‘phase 1 trial’ means a phase 1 clinical investigation of a drug as described in section 312.21 of title 21, Code of Federal Regulations (or any successor regulations).

“(b) Exemptions.—Eligible investigational drugs provided to eligible patients in compliance with this section are exempt from sections 502(f), 503(b)(4), 505(a), and 505(i) of this Act, section 351(a) of the Public Health Service Act, and parts 50, 56, and 312 of title 21, Code of Federal Regulations (or any successor regulations), provided that the sponsor of such eligible investigational drug or any person who manufactures, distributes, prescribes, dispenses, introduces or delivers for introduction into interstate commerce, or provides to an eligible patient an eligible investigational drug pursuant to this section is in compliance with the applicable requirements set forth in sections 312.6, 312.7, and 312.8(d)(1) of title 21, Code of Federal Regulations (or any successor regulations) that apply to investigational drugs.

“(c) Use of Clinical Outcomes.—

“(1) In general.—Notwithstanding any other provision of this Act, the Public Health Service Act, or any other provision of Federal law, the Secretary may not use a clinical outcome associated with the use of an eligible investigational drug pursuant to this section to delay or adversely affect the review or approval of such drug under section 505 of this Act or section 351 of the Public Health Service Act unless—

Determination.

“(A) the Secretary makes a determination, in accordance with paragraph (2), that use of such clinical outcome is critical to determining the safety of the eligible investigational drug; or

“(B) the sponsor requests use of such outcomes.

Notice.
Records.

“(2) Limitation.—If the Secretary makes a determination under paragraph (1)(A), the Secretary shall provide written notice of such determination to the sponsor, including a public health justification for such determination, and such notice shall be made part of the administrative record. Such determination shall not be delegated below the director of the agency center that is charged with the premarket review of the eligible investigational drug.

“(d) Reporting.—

“(1) In general.—The manufacturer or sponsor of an eligible investigational drug shall submit to the Secretary an annual summary of any use of such drug under this section. The summary shall include the number of doses supplied, the number of patients treated, the uses for which the drug was made available, and any known serious adverse events. The Secretary shall specify by regulation the deadline of submission of such annual summary and may amend section 312.33 of title 21, Code of Federal Regulations (or any successor regulations) to require the submission of such annual summary in conjunction with the annual report for an applicable investigational new drug application for such drug. Regulations.

"(2) POSTING OF INFORMATION.—The Secretary shall post an annual summary report of the use of this section on the internet website of the Food and Drug Administration, including the number of drugs for which clinical outcomes associated with the use of an eligible investigational drug pursuant to this section was—

"(A) used in accordance with subsection (c)(1)(A);

"(B) used in accordance with subsection (c)(1)(B); and

"(C) not used in the review of an application under section 505 of this Act or section 351 of the Public Health Service Act.".

21 USC 360bbb–0a note.

(b) NO LIABILITY.—

(1) ALLEGED ACTS OR OMISSIONS.—With respect to any alleged act or omission with respect to an eligible investigational drug provided to an eligible patient pursuant to section 561B of the Federal Food, Drug, and Cosmetic Act and in compliance with such section, no liability in a cause of action shall lie against—

(A) a sponsor or manufacturer; or

(B) a prescriber, dispenser, or other individual entity (other than a sponsor or manufacturer), unless the relevant conduct constitutes reckless or willful misconduct, gross negligence, or an intentional tort under any applicable State law.

(2) DETERMINATION NOT TO PROVIDE DRUG.—No liability shall lie against a sponsor manufacturer, prescriber, dispenser or other individual entity for its determination not to provide access to an eligible investigational drug under section 561B of the Federal Food, Drug, and Cosmetic Act.

(3) LIMITATION.—Except as set forth in paragraphs (1) and (2), nothing in this section shall be construed to modify or otherwise affect the right of any person to bring a private action under any State or Federal product liability, tort, consumer protection, or warranty law.

21 USC 360bbb–0a note.

## SEC. 3. SENSE OF THE SENATE.

It is the sense of the Senate that section 561B of the Federal Food, Drug, and Cosmetic Act, as added by section 2—

(1) does not establish a new entitlement or modify an existing entitlement, or otherwise establish a positive right to any party or individual;

(2) does not establish any new mandates, directives, or additional regulations;

(3) only expands the scope of individual liberty and agency among patients, in limited circumstances;

(4) is consistent with, and will act as an alternative pathway alongside, existing expanded access policies of the Food and Drug Administration;

(5) will not, and cannot, create a cure or effective therapy where none exists;

(6) recognizes that the eligible terminally ill patient population often consists of those patients with the highest risk of mortality, and use of experimental treatments under the criteria and procedure described in such section 561A involves an informed assumption of risk; and

(7) establishes national standards and rules by which investigational drugs may be provided to terminally ill patients.

Approved May 30, 2018.

---

LEGISLATIVE HISTORY—S. 204:

CONGRESSIONAL RECORD:
Vol. 163 (2017): Aug. 3, considered and passed Senate.
Vol. 164 (2018): May 22, considered and passed House.
DAILY COMPILATION OF PRESIDENTIAL DOCUMENTS (2018):
May 30, Presidential remarks.

○

# Right to Try

Print Fact Sheet (PDF - 660KB) (/media/133864/download)

The Right to Try Act, or the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act, was signed into law May 30, 2018. This law is another way for patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial (/patients/clinical-trials-what-patients-need-know) to access certain unapproved treatments.

Clinical trials provide information about whether a product is safe to use and can effectively treat or prevent a disease. People may have many reasons for participating in clinical trials. In addition to contributing to medical knowledge, some people participate in clinical trials because there is no treatment for their disease, treatments they tried have not worked, or they are not able to tolerate the current treatments.

For patients with serious or immediately life-threatening diseases or conditions, the FDA remains committed to enhancing access to promising investigational medicines for those unable to access investigational medical products through clinical trials. This is the mission of our expanded access program (/news-events/public-health-focus/expanded-access). The agency is dedicated to these purposes, and it has been for more than three decades.

Building on our long-standing efforts to help patients and families who are facing life-threatening diseases or conditions, the FDA is providing information for patients on the Right to Try Act. FDA's role in implementation of the Right to Try Act is largely focused on those obligations outlined in the law, which is limited to receipt and posting of certain information submitted regarding Right to Try use.

The Right to Try Act permits/allows eligible patients to have access to eligible investigational drugs.

An eligible patient is a patient who has:

- Been diagnosed with a life-threatening disease (https://www.ecfr.gov/cgi-bin/text-idx?SID=5c9f61d1c996ea8bef97684a25d67c97&mc=true&node=se21.5.312_181&rgn=div8) or condition
- Exhausted approved treatment options and is unable to participate in a clinical trial involving the eligible investigational drug (this must be certified by a physician who is in good standing with their licensing organization or board and who will not be compensated directly by the manufacturer for certifying)

709

- And has provided, or their legally authorized representative has provided, written informed consent regarding the eligible investigational drug to the treating physician

An eligible investigational drug is an investigational drug:

- For which a Phase 1 (https://www.ecfr.gov/cgi-bin/text-idx?SID=5c9f61d1c996ea8bef97684a25d67c97&mc=true&node=se21.5.312_121&rgn=div8)clinical trial has been completed
- That has not been approved or licensed by the FDA for any use
- For which an application has been filed with the FDA or is under investigation in a clinical trial that is intended to form the primary basis of a claim of effectiveness in support of FDA approval and is the subject of an active investigational new drug application submitted to the FDA
- Whose active development or production is ongoing, and that has not been discontinued by the manufacturer or placed on clinical hold (/drugs/investigational-new-drug-ind-application/ind-application-procedures-clinical-hold) by the FDA

If you are interested in Right to Try, you should discuss this pathway with your licensed physician. Companies who develop and make drugs and biologics, also known as sponsors, can provide information about whether their drug/biologic is considered an eligible investigational drug under Right to Try and if they are able to provide the drug/biologic under the Right to Try Act. Ultimately, sponsors developing drugs for life-threatening diseases or conditions are responsible for determining whether to make their products available to patients who qualify for access under the Right to Try Act.

The full text of the Right to Try Act, Public Law 115-176, can be found on US Congress's website: Public Law 115-176 (https://www.congress.gov/115/bills/s204/BILLS-115s204enr.pdf).

## Right to Try FAQs

### *1. If I'm a patient or a physician and I have a question about the Right to Try Act, who do I ask?*

A: FDA recommends that patients first consult with their physician and that physicians consult with the sponsor of the investigational drug or biological product. The sponsor is in the best position to provide information about whether the drug or biological product meets the criteria to be considered an eligible investigational drug for use under the Right to Try Act.

### *2. If I identify a drug that I would like to use under the Right to Try Act, how do I know if it is an "eligible investigational drug"?*

7/10

A: FDA recommends that you consult with the sponsor of the investigational drug or biological product. The sponsor is in the best position to provide information about whether the drug or biological product meets the criteria to be considered an eligible investigational drug for use under the Right to Try Act.

***3. Does FDA review or approve the Right to Try Act requests?***

A: FDA does not review or approve requests for Right to Try Act use. FDA's role is limited to receipt and posting of certain information submitted under the Right to Try Act.

***4. What does FDA do with the annual summaries submitted under the Right to Try Act?***

A: FDA will receive annual summaries from manufacturers or sponsors on use of an eligible investigational drug under the Right to Try Act. FDA will post a consolidated annual summary report of Right to Try Act use.

***5. Does an IRB review and/or approve Right to Try Act requests?***

A: Individual Right to Try Act requests do not require IRB review or approval; however, eligible investigational drugs under the Right to Try Act must meet certain criteria.

***6. Is written informed consent required for the Right to Try Act?***

A: Yes, a physician is responsible for getting written informed consent from the eligible patient or their legally authorized representative.

***7. Does the Right to Try Act obligate a sponsor to provide an eligible investigational drug to an eligible patient?***

A: No, the Right to Try Act does not require a sponsor provide an eligible investigational drug to an eligible patient.

***8. If the IND for a drug is on clinical hold, is the drug an eligible investigational drug for use under the Right to Try Act?***

A: No, a drug under IND clinical hold is not an eligible investigational drug and a sponsor cannot provide the drug for use under the Right to Try Act.

## Key FDA Contact Information

711

For specific questions on:

- **Investigational Drugs:** CDER's Division of Drug Information - 301-796-3400 or druginfo@fda.hhs.gov (mailto:druginfo@fda.hhs.gov)
- **Investigational Biologics:** CBER's Office of Communication, Outreach and Development - 240-402-8020 or 800-835-4709 or Industry.biologics@fda.hhs.gov (mailto:Industry.biologics@fda.hhs.gov)

For general questions, or if you are unsure of whom to contact, contact the Patient Affairs Staff - 301-796-8460 or patientaffairs@fda.hhs.gov. (mailto:patientaffairs@fda.hhs.gov)

FDA is available to answer questions regarding the Right to Try Act. Patients with specific Right To Try requests should consult their physician.

712

# SOLICITUD DEL PACIENTE PARA SER TRATADO CON DIOXIDO DE CLORO (CDS)

Ante el Hospital/Clinica/centro sanitario: ________________________________________

Dirección: ________________________________________

Yo, ________________________________________, mayor de edad, SS nº ,en plena posesión de sus capacidades intelectivas y volitivas, de forma libre y voluntaria, presta su consentimiento informado y manifiesta su voluntad de que sus familiares le entreguen el tratamiento con DIOXIDO DE CLORO (CDS) u otro remedio natural sin que el establecimiento limite o restringa el acceso a los mismos, y para el caso de que estuviere impedido para tomarlo por vía oral se le administre mediante el suero por un sanitario.

Con la presente solicitud se exonera de responsabilidades al médico y/o centro hospitalario/ Clínica, con la relación a las posibles consecuencias derivadas del tratamiento solicitado, para el caso de que se produjeren.

Los médicos que integran la asociación COMUSAV, más de tres mil, han preservado su vida tomando Dióxido de cloro en solución acuosa ( CDS ) sin haberse producido ninguna muerte entre sus integrantes, y en cumplimiento del juramento hipocrático conforme a la Declaración de Ginebra de 1948 han salvado a miles de pacientes haciendo uso del CDS, por lo que el 22 de octubre de 2020 se hizo el anuncio mundial ante la prensa de dichos avances titulado «El coronavirus ha sido derrotado», que pueden visionar en la página:
*https://www.facebook.com/Comusavmundial/videos/3825484484141829*.

Esta solicitud está amparada, por la obligación de «comportarse fraternalmente los unos con los otros» , artº 1 de la Declaración Universal de Derechos Humanos de 10 de diciembre de 1948, y por el deber de las instituciones públicas, privadas y la profesión médica;

.- de salvaguardar el derecho a la vida e integridad física y moral de la persona recogido en la Declaración Universal de Derechos Humanos de 10 de diciembre de 1948, Convenio para la Protección de los Derechos Humanos y de las Libertades Fundamentales Roma de 4 de noviembre 1950, Pacto Internacional de Derechos Civiles y Políticos de 16 de diciembre de 1966 .

.- del derecho de autodeterminación del paciente de Declaración de Lisboa de la AMM sobre los Derechos del Paciente de 1981.

.- del deber de reconocimiento de la autonomía profesional e independencia clínica de los médicos, conforme a la Declaración de la AMM sobre la Independencia y Libertad Profesional del Médico de 1986, Declaración de Madrid de la AMM sobre la Autonomía y Autorregulación profesionales de 1987, Declaración de Seúl de la AMM sobre la Autonomía Profesional y la Independencia Clínica de 2008, Declaración de Madrid de la AMM sobre Regulación Profesional de 2009.

.- del respeto del ser humano en las investigaciones científicas, Código de ética médica de Núremberg de 1947, Código internacional de deontología médica de 1949, Convenio de Oviedo de 1997, la Declaración de Helsinki de 1964, el Informe Belmont de 1978, las pautas éticas internacionales para la investigación biomédica en seres humanos de 2002 de la CIOMS, la Declaración universal sobre biomédica y derechos humanos de la UNESCO de 2005.

El CLORITO DE SODIO, fue declarado medicamento huérfano para el tratamiento de la esclerosis lateral amiotrófica por la Comisión Europea, conforme a la DECISIÓN DE EJECUCIÓN DE LA COMISIÓN del 19.6.2013.

Por dichos motivos se requiere al Centro asistencial y médicos del mismo se le aplique el tratamiento con DIOXIDO DE CLORO en cumplimiento del;

**.- art 37 de la Declaración de Helsinki** adoptada por la 18ª Asamblea Médica Mundial, de 1964:

«Cuando en la atención de un paciente las intervenciones probadas no existen u otras intervenciones conocidas han resultado ineficaces, **el médico,** después de pedir consejo de experto, con el consentimiento informado del paciente o de un representante legal autorizado, **puede permitirse usar intervenciones no comprobadas, si, a su juicio, ello da alguna esperanza de salvar la vida, restituir la salud o aliviar el sufrimiento»**

.- **art 36 del Código internacional de deontología médica** «1.El médico tiene el deber de intentar la curación o la mejoría del paciente, siempre que sea posible. Cuando ya no lo es, permanece la obligación de aplicar las medidas adecuadas para conseguir su bienestar , aun cuando de ello pueda derivarse un acortamiento de la vida..3.El médico, tras una adecuada información al paciente, debe tener en cuenta su voluntad de rechazar cualquier procedimiento, incluso los tratamientos dirigidos a prolongar la vida. 4.Cuando el estado del paciente no le permite tomar decisiones, el médico debe tener en consideración, por orden de preferencia, las indicaciones anteriormente hechas por el enfermo, las instrucciones previas y la opinión del paciente en voz de sus representantes. Es deber del médico colaborar con las personas que tengan la misión de garantizar el cumplimiento de las voluntades del paciente»

.- **art 59 del Código internacional de deontología médica** «La investigación con seres humanos debe realizarse cuando el avance científico no sea posible por otros medios alternativos de eficacia comparable o en aquellas fases de la investigación en las que sea imprescindible.»

El portador de esta solicitud y/o sus familiares, en caso de que el centro asistencial y/o médicos del mismo se negaren a proporcionar el tratamiento solicitado y usado en otros países en los que se ha demostrado su eficacia y efectividad en el tratamiento del COVID-19, se reservan el derecho de exigir responsabilidades penales y civiles por incumplimiento de las normas internacionales y nacionales en contra del derecho fundamental a la preservación de la vida, ante la comisión de posibles delitos de omisión del deber de socorro y delitos contra el derecho a la vida.

Firmado D.

, a de de 2020.

International Journal of
*Environmental Research
and Public Health*

MDPI

*Article*

# Efficacy and Safety Evaluation of a Chlorine Dioxide Solution

**Jui-Wen Ma [1,2], Bin-Syuan Huang [1], Chu-Wei Hsu [1], Chun-Wei Peng [1], Ming-Long Cheng [1], Jung-Yie Kao [2], Tzong-Der Way [2,3,4], Hao-Chang Yin [1,*] and Shan-Shue Wang [5,*]**

[1] Unique Biotech Co., Ltd., Rm. 1, 22 F, No. 56, Minsheng 1st Road, Xinxing District, Kaohsiung 800, Taiwan; a26154295@gmail.com (J.-W.M.); chiralrecognize@gmail.com (B.-S.H.); wei751001@gmail.com (C.-W.H.); f08220927@gmail.com (C.-W.P.); great.tree00@msa.hinet.net (M.-L.C.)

[2] Institute of Biochemistry, College of Life Science, National Chung Hsing University, No. 145 Xingda Road, South District, Taichung 402, Taiwan; biosjyk@gmail.com (J.-Y.K.); tdway@mail.cmu.edu.tw (T.-D.W.)

[3] Department of Health and Nutrition Biotechnology, College of Health Science, Asia University, No. 500, Lioufeng Road, Wufeng District, Taichung 41354, Taiwan

[4] Department of Biological Science and Technology, College of Biopharmaceutical and Food Sciences, China Medical University, No. 91, Hsueh-Shih Road, Taichung 40402, Taiwan

[5] Department of Applied Cosmetology/Degree Program of Cosmetology and Health Care, Kao Yuan University, No. 1821, Zhongshan Road, Lujhu District, Kaohsiung 82151, Taiwan

[*] Correspondence: lique.unique@gmail.com (H.-C.Y.); sswang168@gmail.com (S.-S.W.);
Tel.: +886-7-222-5711 (H.-C.Y.); +886-7-607-7663 (S.-S.W.);
Fax: +886-7-222-5719 (H.-C.Y.); +886-7-607-7050 (S.-S.W.)

Academic Editor: Miklas Scholz
Received: 24 February 2017; Accepted: 17 March 2017; Published: 22 March 2017

**Abstract:** In this study, a chlorine dioxide solution (UC-1) composed of chlorine dioxide was produced using an electrolytic method and subsequently purified using a membrane. UC-1 was determined to contain 2000 ppm of gaseous chlorine dioxide in water. The efficacy and safety of UC-1 were evaluated. The antimicrobial activity was more than 98.2% reduction when UC-1 concentrations were 5 and 20 ppm for bacteria and fungi, respectively. The half maximal inhibitory concentrations ($IC_{50}$) of H1N1, influenza virus B/TW/71718/04, and EV71 were $84.65 \pm 0.64$, $95.91 \pm 11.61$, and $46.39 \pm 1.97$ ppm, respectively. A 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test revealed that the cell viability of mouse lung fibroblast L929 cells was 93.7% at a 200 ppm UC-1 concentration that is over that anticipated in routine use. Moreover, 50 ppm UC-1 showed no significant symptoms in a rabbit ocular irritation test. In an inhalation toxicity test, treatment with 20 ppm UC-1 for 24 h showed no abnormality and no mortality in clinical symptoms and normal functioning of the lung and other organs. A $ClO_2$ concentration of up to 40 ppm in drinking water did not show any toxicity in a subchronic oral toxicity test. Herein, UC-1 showed favorable disinfection activity and a higher safety profile tendency than in previous reports.

**Keywords:** chlorine dioxide (PubChem CID: 24870); antimicrobial efficacy; antiviral assay; inhalation toxicity; subchronic oral toxicity

---

## 1. Introduction

Chlorine dioxide, a strong oxidant, can inhibit or destroy microbes [1–5]. Studies have investigated the application of chlorine dioxide in numerous fields such as water or wastewater treatment, environment and food disinfection, and medicine [6–13]. Typically, chlorine dioxide is produced using either an acid-based or an electrolytic method [7,8,10,12]. In the acid-based method, chlorine dioxide is produced by mixing starting materials, such as sodium chlorite and hydrochloric acid, sodium chlorite and ferric trichloride, or sodium chlorite and chlorine gas. In the electrolytic method, the reactants are aqueous sodium chloride or saturated saline and sodium hypochlorite.

According to the disinfectants and disinfection byproducts rule (DBPR) of the United States Environmental Protection Agency Microbial and Disinfection Byproduct Rules Simultaneous Compliance Guidance Manual [14], the maximum residual disinfectant level goals (MRDLG) and maximum residual disinfectant levels (MRDL) of chlorine dioxide are 0.8 mg/L [14]. The permissible exposure limits (PELs) for chlorine dioxide defined by the Occupational Safety and Health Administration are as follows: (a) General industry: 0.1 ppm and 0.3 mg/m$^3$; (b) Construction industry: 0.1 ppm and 0.3 mg/m$^3$ time weighted average (TWA); (c) American Conference of Governmental Industrial Hygienists threshold limit value: 0.1 ppm and 0.28 mg/m$^3$ TWA; 0.3 ppm and 0.83 mg/m$^3$ short term exposure limit (STEL); (d) National Institute for Occupational Safety and Health recommended exposure limit: 0.1 ppm TWA; 0.3 ppm STEL.

The application of chlorine dioxide products or their contact with food or the human body is a serious issue if the products contain high levels of impurities. Impurities are mainly caused by impure reactants such as 10% $H_2SO_4$ and 15% $NaClO_2$ or reaction byproducts such as $Cl_2$ and chloroxy anion. For example, 10% $H_2SO_4$ and 15% $NaClO_2$ contain 90% and 85% unknown impurities, respectively. The chlorine dioxide product obtained from a mixture of 10% $H_2SO_4$ and 15% $NaClO_2$ is highly impure. The $Cl_2$ product can react with organic matter to form trihalomethane, which is a carcinogen. Chloroxy anions, such as $ClO_2^-$ or $ClO_3^-$, can be harmful to human health [15].

The domestic and industrial use of chlorine dioxide should be assessed according to product purity, for which the preparation method is an essential step. Low purity starting materials (e.g., 5% HCl and 10% $NaClO_2$) have a high impurity content. If the product of these reactions is not further purified, then the chlorine dioxide products produced, which also contain high levels of impurities, are useful only for wastewater treatment and are unsuitable for contact with humans or food because of the harmful impurities. Therefore, a higher percentage of chlorine dioxide gas molecules must be obtained through further chlorine dioxide gas molecule purification.

To increase the safety of chlorine dioxide solution, eliminating or reducing the impurities and increasing the gas chlorine dioxide concentration in a solution is a reasonable approach. Herein, a clean and concentrated process for chlorine dioxide gas production was designed and implemented. We produced a chlorine dioxide solution (UC-1) containing 2000 ppm chlorine dioxide gas in water through the electrolytic method. The solution was further purified with a film membrane, and subsequently dissolved in reverse osmosis (RO) water. UC-1 was investigated to determine its efficacy, and safety issues such as the antimicrobial activity, in vitro cytotoxicity, in vivo rabbit ocular irritation, in vivo inhalation toxicity, and in vivo subchronic oral toxicity were assessed.

## 2. Materials and Methods

### 2.1. Electrolytic Method for Gas Chlorine Dioxide Production

The UC-1 solution is produced in an apparatus, the technical details of which will be published later in the form of a patent application (PCT applied PCT/CN2016/080198; PCT applied PCT/CN2016/080199; PCT applied PCT/CN2015/099515; DE202016103175) by an electrochemical method. Briefly, sodium chloride solution was made from 99% (food grade) sodium chloride and RO water and pumped into the electrobath equipment. The electrolysis was operated by 6–12 V and 40–80 A current. After electrolysis, the $ClO_2$ gas was mixed with water using a water-$ClO_2$ mixer which was designed based on the Venturi effect. Mixing of water with $ClO_2$ gas was continued by the cycle till the concentration of $ClO_2$ in water was over 2000 ppm (Figure 1) and pH value was 2.2. The chlorine dioxide solution produced by this process is named as UC-1.

The chemical composition of the UC1 solution was determined according to a standard method [16]. The following data were obtained: $ClO_2$: 2120 ppm, free chlorine ($Cl_2$): 882 ppm, and total chlorine ($Cl_2$ + HOCl + $OCl^-$): 900 ppm. The total chlorine concentration is somewhat higher

716

than in the case of other $ClO_2$ generators because the electrolyte applied by us does not contain any $NaClO_2$. The UC-1 solution was produced by using only 25% NaCl solution, with no other additive, which is an obvious advantage. At the same time, despite the higher total chlorine content (which is present in the diluted UC-1 solutions mostly as HOCl), no detectable adverse effects were observed on the test animals or animal tissues.



**Figure 1.** Flowchart of chlorine dioxide solution production.

### 2.2. *Antimicrobial Efficacy Test*

The test was performed following U.S. Pharmacopeia 34 NF29 Microbiological Tests/<51> [17]. Antimicrobial Effectiveness Testing. The test organisms were as follows: *Escherichia coli* (BCRC 11634/ATCC 8739), *Staphylococcus aureus* (BCRC 10451/ATCC 6538P), *Pseudomonas aeruginosa* (BCRC 11633/ATCC 9027), *S. aureus subsp. aureus* (BCRC 15211/ATCC 33591), *Bacillus subtilis subspecies.* (BCRC 10447/ATCC 6633), *Listeria monocytogenes* (BCRC 14848/ATCC 19114), *Acinetobacter baumannii* (BCRC 10591/ATCC 19606), *Salmonella enterica subspecies.* (BCRC 12947/ATCC 13311), *Klebsiella pneumoniae* (BCRC 16082/ATCC 4352), *Penicillium funiculosum* (BCRC 30438/ATCC 11797), and *Candida albicans* (BCRC 21538/ATCC10231).

### 2.3. *Antiviral Assay*

Viruses were amplified in MDCK/RD cells. MDCK/RD cells were cultured in 10% fetal bovine serum Dulbecco's modified Eagle's medium (FBS DMEM). When the cells reached 90% confluence, they were washed with phosphate-buffered saline (PBS) and infected at a multiplicity of infection of 0.01. Following the infection, 0% FBS DMEM was added, and the cells were incubated at 35 °C in a 5% $CO_2$ incubator for 48 h.

A 1-mL cell suspension ($6 \times 10^5$ cells) was loaded into each well of a 6-well plate, which was incubated at 37 °C for 18–24 h. PBS was used to dilute UC-1 to final concentrations of 0, 25, 50, 100, and 200 ppm in wells reacted with cells and viruses for 2 min at 37 °C. Following the reaction, the total reaction mixture was diluted to $10^{-8}$. Subsequently, the $10^{-8}$ dilution mixture was incubated at 37 °C for 48–64 h. The cells were fixed with 10% formalin for 1 h and stained with 0.1% crystal violet for 5 min. The virus-formed plaque number was counted and compared between the test and control groups. The antiviral activity is shown as the percentage of virus control = plaques in the test group/plaques in the control group × 100. The virus control is defined as infected virus with cells without the testing agent and is considered as 100%.

7/7

### 2.4. In Vitro Cytotoxicity Test (MTT Assay)

Mouse lung fibroblast L929 cells were cultured in complete Eagle minimum essential medium (MEM) and incubated at 37 °C ± 1 °C in 5% ± 1% $CO_2$. Furthermore, 100 μL of L929 cell suspension ($1 \times 10^5$ cells/mL) was transferred into each well of a 96-well cell culture plate. The cells were subsequently incubated at 37 °C ± 1 °C for 24 h ± 2 h. The culture medium was replaced with 100 μL of the test solution or blank, positive, or negative control. The test solutions contained 0 (control), 200, 400, 600, and 800 ppm UC-1 in MEM. The blank control medium contained 10% horse serum. The cells were incubated for another 24 h. The cells were treated with the solutions in triplicate. After the MTT solution was added to each well, the plate was incubated for 2 h ± 10 min at 37 °C ± 1 °C. The MTT solution was replaced with 100 μL of dimethyl sulfoxide and subsequently subjected to a microplate reader equipped with a 570-nm filter for colorimetric measurement (reference, 650 nm). The triplicate results of the MTT assay are presented as mean ± standard deviation (SD). Cell viability (%) = optical density of the test group/optical density of the control group × 100.

### 2.5. White Rabbit Ocular Irritation Test

Six 2–3-kg female New Zealand white rabbits were purchased from the Taiwan Livestock Research Institute (Xinhua, Tainan, Taiwan); the rabbits were quarantined and acclimatized before treatment. The animals were fed ad libitum and maintained at 20–26 °C under 30%–70% humidity. Furthermore, 0.1 mL of 50 ppm UC-1 (test solution) was administered to the left eye of the rabbits, and 0.1 mL of 0.9% normal saline (control solution) was administered to the right eye. Subsequently, the eyelids were held together for 1 s for instillation. Each treatment was repeated three times. Ocular irritations were observed for at the 1st, 24th, 48th, and 72nd hour using an ophthalmoscope (Welch Allyn, Skaneateles Falls, NY, USA). Extended observation was necessary in case of persistent lesions to determine the progression or reversal of the lesions. Ocular irritation scores were based on the system for grading ocular lesions (ISO 10993-10). When more than one animal in the test group showed a positive result at any stage of the observations, the test component was considered an eye irritant and further testing was not required or performed. When only one of the test groups showed a mild or moderate reaction that was equivocal, the procedure was conducted on three additional animals. When more than half of the eyes showed a positive result at any stage of the observation, the test component was considered an eye irritant. A severe reaction in only one animal was considered sufficient to label the test component as an eye irritant.

### 2.6. Inhalation Toxicity Test

Fifteen 4-week-old BALB/c male mice were purchased from the National Laboratory Animal Center (Taipei, Taiwan); they were quarantined and acclimatized before treatment in an animal room at China Medical University, Taiwan. The animals were fed ad libitum and maintained at 20–25 °C and 65%–80% humidity. Five mice were housed in one cage and fed with 0 (PBS) and 10 or 20 ppm UC-1 (test solution), which was administered as mist by using a humidifier in an airtight box for 24 h. The clinical symptoms and body weight of the animals were observed; they were subsequently sacrificed to examine their lung sections and organ weight. The experimental animals were observed, and their clinical symptoms were recorded as abnormality (%), defined as the animals behaving abnormally compared with normal animals, and mortality (%), defined as animal death.

#### 2.6.1. Evaluation of the Organ Weight

During the experiment, the animals were immediately dissected on death, and a record was made. All surviving animals were sacrificed and autopsied to observe their appearance and all organs in the mouth, chest, and cranial and abdominal cavities. Subsequently, the organs, including the liver, adrenal glands, kidneys, and gonads, were removed, weighed, and recorded.

#### 2.6.2. Hematoxylin and Eosin Staining of Mouse Lung Sections

Tissue sections frozen in the optimal cutting temperature compound were fixed in acetone and chloroform; the sections were immersed in filtered Harris hematoxylin (Leica Biosystems Richmond, Inc., Richmond, IL, USA) for 1 min. The slides were rewashed with Tris-buffered saline and Tween 20 (Biokit Biotechnology Inc., Miaoli, Taiwan), and the sections were counterstained with eosin (Leica Biosystems Richmond, Inc., Richmond, IL, USA) for 1–2 min. The sections were dehydrated in ascending alcohol solutions and cleared with xylene. The prepared slides were examined through light microscopy.

### *2.7. Subchronic Oral Toxicity Test*

Twenty-five 4-week-old BALB/c male mice were purchased from the National Laboratory Animal Center; they were quarantined and acclimatized before treatment in an animal room at China Medical University. The animals were fed ad libitum and maintained at 20–25 °C under 65%–80% humidity. Five mice were housed in one cage and fed 0 (PBS; control), 5, 10, 20, and 40 ppm UC-1 (test solutions) continuously for 90 days. PBS or test solutions fed as drinking water were freshly prepared daily before treatments.

#### 2.7.1. Evaluation of the Clinical Symptoms

The experimental animals were observed, and their clinical symptoms were recorded as abnormality (%), defined as the animals behaving abnormally compared with normal animals, and mortality (%), defined as animal death.

#### 2.7.2. Body Weight

The body weight of the experimental animals was recorded at treatment initiation and once per week during the experimental period using an electronic balance (AND, FX-2000i, Tokyo, Japan).

#### 2.7.3. Necropsy, Gross Examination, and Organ Weighing

During the experiment, the animals were dissected immediately on death, and a record was made. All surviving animals were sacrificed and autopsied to observe their appearance, and all organs in the mouth, chest, and cranial and abdominal cavities were analyzed. Subsequently, the organs, including the liver, adrenal glands, kidneys, and gonads, were removed, weighed, and recorded.

### *2.8. Statistical Analysis*

The results were analyzed using SPSS Version 20.0 (IBM Corp., Armonk, NY, USA) with one-way analysis of variance, *F*-test, and Duncan's new multiple range test for comparing more than two mean values; results with $p < 0.05$ indicated significant differences. The results represent at least 3 independent experiments and are shown as the mean ± SD.

### *2.9. Ethical Statement*

This research was approved by the China Medical University Laboratory Animal Service Center. Program Number: 10442699 (for the white rabbit ocular irritation test) and 10442686 (for the inhalation toxicity and subchronic oral toxicity tests).

## 3. Results

In this study, a UC-1 containing 2000 ppm chlorine dioxide in water was produced through the electrolytic method with food-grade salt (99% NaCl) and RO water as the starting reactants. Subsequently, the chlorine dioxide was purified through a film and dissolved in RO water. Because a chlorine dioxide solution can be directly applied to food or human hygiene or preventative health measures, its safety and efficacy were investigated.

### 3.1. Antimicrobial Efficacy Test

The in vitro antimicrobial activity of UC-1 was examined. The in vitro antimicrobial activity was more than 98.2% reduction for bacteria and fungi (Table 1); excellent antimicrobial activity was observed at low concentrations of 5 and 20 ppm UC-1 for bacteria and fungi, respectively.

**Table 1.** Antimicrobial efficacy of UC-1.

| Organisms | Original Inoculum (CFU/mL) | Counts of UC-1 at Contact Time $^{a}$ (CFU/mL) | Percent Reductions (R) $^{b}$ |
|---|---|---|---|
| *Escherichia coli* $^{c,*}$ | $2.55 \times 10^5$ | <1 | >99.9 |
| *Staphylococcus aureus* $^{c,*}$ | $3.15 \times 10^5$ | <1 | >99.9 |
| *Pseudomonas aeruginosa* $^{c,*}$ | $2.55 \times 10^5$ | <1 | >99.9 |
| *Staphylococcus aureus subsp. Aureus* $^{c,*}$ | $2.60 \times 10^5$ | <1 | >99.9 |
| *Bacillus subtilis subspecies* $^{c,*}$ | $3.75 \times 10^5$ | $1.35 \times 10^3$ | 99.6 |
| *Listeria monocytogenes* $^{c,*}$ | $8.20 \times 10^5$ | <1 | >99.9 |
| *Acinetobacter baumannii* $^{c,*}$ | $5.40 \times 10^5$ | <1 | >99.9 |
| *Salmonella enterica subspecies* $^{c,*}$ | $4.80 \times 10^5$ | <1 | >99.9 |
| *Klebsiella pneumoniae* $^{c,*}$ | $9.30 \times 10^5$ | <1 | >99.9 |
| *Penicillium funiculosum* $^{,c\Delta}$ | $3.70 \times 10^5$ | $6.70 \times 10^3$ | 98.2 |
| *Candida albicans* $^{c,\Delta}$ | $3.20 \times 10^5$ | <1 | >99.9 |

[a] The contact time was 10 min. [b] Percent reductions of <1% represent no significant bacteriostasis or fungistasis. [c] UC-1 concentrations were 5 and 20 ppm for bacteria and fungi, respectively. * presented as bacteria; $^{\Delta}$ presented as fungi. CFU: colony-forming unit.

### 3.2. Antiviral Assay

The antiviral activity of 0, 25, 50, 100, and 200 ppm UC-1 after 2 min of reaction is shown in Figure 2. For H1N1 and influenza virus B/TW/71718/04, 200 ppm UC-1 had the most significant effect in inhibiting viral plaque formation. The half maximal inhibitory concentration ($IC_{50}$) of H1N1 was 84.65 ± 0.64 ppm and that of influenza virus B/TW/71718/04 was 95.91 ± 11.61 ppm. For EV71, 50 ppm UC-1 showed significant inhibition activity, with an $IC_{50}$ of 46.39 ± 1.97 ppm at 2 min. The results showing statistical significance ($p < 0.05$) are presented. Bars are plotted as means ± SD.



**Figure 2.** Antiviral efficacy against influenza virus A/WSN/33, influenza virus B/TW/71718/04, and enterovirus 71. Bars are plotted as means ± standard deviation (SD). Means with the same letter did not differ significantly at $p < 0.05$ according to the ANOVA (Analysis of Variance) F-test and Duncan's new multiple range test.

### 3.3. *In Vitro Cytotoxicity Test (MTT Assay)*

The cytotoxic effect of 0, 200, 400, 600, and 800 ppm UC-1 against L929 lung fibroblast cells was analyzed. The cell viability was 74.0%–100.0% at UC-1 concentrations below 600 ppm. L929 cell viability was reduced to 40.3% at 800 ppm UC-1 (Figure 3).



**Figure 3.** Cytotoxic effects of various UC-1 concentrations on L929 cells.

### 3.4. *Ocular Irritation Test*

The cornea, iris, and conjunctivae were evaluated in a rabbit ocular irritation test. The 50 ppm UC-1 solution induced neither significant clinical signs nor ocular gross changes in the rabbits at each time point (Table 2). Therefore, single ocular applications with 0.1 mL of 50 ppm UC-1 did not cause ocular irritation in rabbits.

**Table 2.** Grades in the clinical observation of individual rabbits for the ocular irritation test.

| Applied Regions | Test Component | Animal No. | Items for Grading | Clinical Observation (Time point/h) | | | |
|---|---|---|---|---|---|---|---|
| | | | | 1 | 24 | 48 | 72 |
| Left Eye | Test<br>(50 ppm UC-1) | RB-160114-01 | Cornea | 0 | 0 | 0 | 0 |
| | | | Iris | 0 | 0 | 0 | 0 |
| | | | Conjunctivae | 0 | 1 | 0 | 0 |
| | | RB-160114-03 | Cornea | 0 | 0 | 0 | 0 |
| | | | Iris | 0 | 0 | 0 | 0 |
| | | | Conjunctivae | 0 | 0 | 0 | 0 |
| | | RB-160114-06 | Cornea | 0 | 0 | 0 | 0 |
| | | | Iris | 0 | 0 | 0 | 0 |
| | | | Conjunctivae | 0 | 0 | 0 | 0 |
| Right Eye | Control<br>(0.9% Saline) | RB-160114-01 | Cornea | 0 | 0 | 0 | 0 |
| | | | Iris | 0 | 0 | 0 | 0 |
| | | | Conjunctivae | 0 | 0 | 0 | 0 |
| | | RB-160114-03 | Cornea | 0 | 0 | 0 | 0 |
| | | | Iris | 0 | 0 | 0 | 0 |
| | | | Conjunctivae | 0 | 0 | 0 | 0 |
| | | RB-160114-06 | Cornea | 0 | 0 | 0 | 0 |
| | | | Iris | 0 | 0 | 0 | 0 |
| | | | Conjunctivae | 0 | 0 | 0 | 0 |

### 3.5. *Inhalation Toxicity Test*

In an inhalation toxicity test, we used 0, 10, and 20 ppm UC-1, which was administered as mist by using a humidifier in an airtight box containing five mice. The test showed no abnormality and no mortality for the control and test components within 24 h (Table 3). The weights of the heart, liver, spleen, and kidney of the test group did not differ significantly from those in the control group (Table 4). Hematoxylin and eosin staining of the mice lung sections (Figure 4) showed that 10 and 20 ppm UC-1 did not induce significant clinical signs of changes in the mouse lung cells at 24 h. Therefore, inhalation of 10 and 20 ppm UC-1 did not cause irritation in the mice.

**Table 3.** Evaluation of clinical symptoms in the inhalation toxicity test.

| Test Component | Animal No. | Abnormality Rate (%) | Mortality (%) |
|---|---|---|---|
| Control: PBS | 5 | 0 | 0 |
| 10 ppm UC-1 | 5 | 0 | 0 |
| 20 ppm UC-1 | 5 | 0 | 0 |

PBS: phosphate-buffered saline.

**Table 4.** Evaluation of organ weight for the inhalation toxicity test.

| Test Component | Heart (g) | Liver (g) | Spleen (g) | Kidney (g) |
|---|---|---|---|---|
| Control: PBS | 0.3 ± 0.1 | 0.7 ± 0.2 | 0.5 ± 0.1 | 0.6 ± 0.1 |
| 10 ppm UC-1 | 0.4 ± 0.1 | 0.7 ± 0.2 | 0.5 ± 0.2 | 0.6 ± 0.2 |
| 20 ppm UC-1 | 0.3 ± 0.2 | 0.8 ± 0.1 | 0.6 ± 0.1 | 0.6 ± 0.2 |

Statistical analyses of the presented data were performed at the 95% significance level ($p < 0.05$).



**Figure 4.** Hematoxylin and eosin staining of mouse lung sections in the inhalation toxicity test. The Scale bar labeled in this figure was 100 μm.

722

### *3.6. Subchronic Oral Toxicity Test*

In the subchronic oral toxicity test, 0, 5, 10, 20, and 40 ppm UC-1 was prepared to feed the mice. Clinical observations of the mice showed no abnormality and no mortality after 90 days for the control and test groups (Table 5). The mouse weight was not influenced (Figure 5). Moreover, necropsy and gross examination did not show any pathological symptoms (Figure 6). The weights of the heart, liver, spleen, and kidney of the test groups did not differ significantly compared with those in the control group (Table 6). Therefore, administration of up to 40 ppm UC-1 to mice for 90 days is nontoxic.



**Figure 5.** Mouse weight trend chart in the subchronic oral toxicity test. CTL: control.



**Figure 6.** Observation of mouse lungs and organs in the subchronic oral toxicity test.

**Table 5.** Evaluation of clinical symptoms in the subchronic oral toxicity test.

| Test Component | Animal No. | Abnormality Rate (%) | Mortality (%) |
|---|---|---|---|
| Control: PBS | 5 | 0 | 0 |
| 5 ppm UC-1 | 5 | 0 | 0 |
| 10 ppm UC-1 | 5 | 0 | 0 |
| 20 ppm UC-1 | 5 | 0 | 0 |
| 40 ppm UC-1 | 5 | 0 | 0 |

**Table 6.** Evaluation of organ weight in the subchronic oral toxicity test.

| Test Component | Heart (g) | Liver (g) | Spleen (g) | Kidney (g) |
|---|---|---|---|---|
| Control: PBS | 0.4 ± 0.1 | 0.8 ± 0.2 | 0.5 ± 0.1 | 0.7 ± 0.1 |
| 5 ppm UC-1 | 0.5 ± 0.2 | 0.8 ± 0.3 | 0.6 ± 0.1 | 0.6 ± 0.2 |
| 10 ppm UC-1 | 0.4 ± 0.2 | 0.9 ± 0.1 | 0.5 ± 0.3 | 0.7 ± 0.2 |
| 20 ppm UC-1 | 0.4 ± 0.1 | 0.8 ± 0.2 | 0.5 ± 0.1 | 0.7 ± 0.1 |
| 40 ppm UC-1 | 0.5 ± 0.1 | 0.8 ± 0.3 | 0.5 ± 0.1 | 0.6 ± 0.1 |

Statistical analyses of the presented data were performed at the 95% significance level ($p < 0.05$).

723

## 4. Discussion

UC-1 with gas chlorine dioxide and fewer impurities was prepared using a patented green process design, and the efficacy and safety of UC-1 were evaluated. Many studies have reported the potent oxidant and antimicrobial activity of chlorine dioxide in vitro. Recent reports have addressed concerns related to microbial decontamination of food by chlorine dioxide [6,9,18–21]. In these studies, chlorine dioxide was produced using various methods (e.g., 2% $NaClO_2$ with $H_3PO_4$, 4% $Cl_2$ with 80% $NaClO_2$, and by using an electrogenerator); the antimicrobial activity was more than 2% for 5–75 mg/L $ClO_2$ within 5–30 min. Here, the antimicrobial activity was more than 98.2% reduction at UC-1 concentrations of 5 and 20 ppm for bacteria and fungi, respectively. In the MTT test, the viability of L929 cells was 93.7% at 200 ppm UC-1 that a concentration is over routine use.

No significant symptoms were observed with 50 ppm UC-1 in the ocular irritation test. No abnormality or mortality was observed in clinical symptoms, lungs, and other organs at 10 ppm or 20 ppm UC-1 in the inhalation toxicity test. Paulet and Desbrousses [22] administered 2.5, 5, and 10 ppm chlorine dioxide to rats and rabbits in 1970; they reported that 2.5 ppm chlorine dioxide had the lowest-observed-adverse-effect level (LOAEL), causing thoracic effects in rats at 7 h/day for 30 days and pulmonary effects in rabbits at 4 h/day for 45 days. Paulet and Desbrousses [23] increased the test concentration to 5, 10, and 15 ppm chlorine dioxide and reduced the dose time to 15 min per dose, 2–4 times per day, for 4 weeks in rats. The results showed a no-observed-averse-effect level (NOAEL) of 5 ppm and an LOAEL of 10 ppm for lung damage.

The mice were fed drinking water containing up to 40 ppm UC-1 for 90 days; the concentration showed no toxicity in the sub-chronic orally toxicity test. Daniel et al. [24] reported the oral exposed toxicity of chlorine dioxide in drinking water administered to Sprague–Dawley rats for 90 days; they used different concentrations of chlorine dioxide (0, 25, 50, 100, and 200 mg/L corresponding to doses of 0, 2, 5, 8, and 15 mg/kg·day). The spleen and liver weight decreased significantly at 25 and 50 mg/L, respectively. They showed nasal lesions caused by 25 mg/L chlorine dioxide vapors in drinking water. In that study, the LOAEL was 25 mg/L. Bercz et al. [25] conducted a similar test in African green monkeys (*Cercopithecus aethiops*) by using 0, 30, 100, and 200 mg/L chlorine dioxide for 4–6 weeks. Furthermore, 200 mg/L chlorine dioxide caused erythema and ulceration of the oral mucosa after 1 week, and 100 mg/L chlorine dioxide reduced the serum thyroxine (T4) levels after 6 weeks; in that study, the NOAEL was 30 mg/L and LOAEL was 100 mg/L for the oral exposure of the monkeys.

## 5. Conclusions

UC-1 was produced through a green process with clean starting materials and procedures. UC-1 solution demonstrated satisfactory antibacterial, antifungal, and antiviral activity. Low toxicity was demonstrated through an in vitro cytotoxicity test (high $IC_{50}$ 765 ± 18 ppm), 50 ppm $ClO_2$ did not cause eye irradiation in an ocular irritation test, mice did not exhibit abnormality and mortality in a 20 ppm $ClO_2$ inhalation toxicity test, and concentrations of UC-1 up to 40 ppm were nontoxic to mice for 90 days in subchronic oral toxicity test. Therefore, a higher safety profile for UC-1 than those yielded in previous studies was demonstrated.

**Acknowledgments:** We thank Unique Biotech Co. Ltd. for providing UC-1 solution support. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Author Contributions:** Hao-Chang Yin and Shan-Shue Wang were involved in research design, discussion, analysis, decision, revision, and funds. Jui-Wen Ma and Bin-Syuan Huang processed the data, implemented most experiments, and wrote the manuscript. Chu-Wei Hsu, Chun-Wei Peng, and Ming-Long Cheng helped execute detailed experiments as well as collect and manage data. Jung-Yie Kao and Tzong-Der Way were technical advisors and study coordinators and provided helpful suggestions for experimental design, novel opinions for the study, and collaboration with other laboratories.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Sanekata, T.; Fukuda, T.; Miura, T.; Morino, H.; Lee, C.; Maeda, K.; Araki, K.; Otake, T.; Kawahata, T.; Shibata, T. Evaluation of the antiviral activity of chlorine dioxide and sodium hypochlorite against feline calicivirus, human influenza virus, measles virus, canine distemper virus, human herpesvirus, human adenovirus, canine adenovirus and canine parvovirus. *Biocontrol Sci.* **2010**, *15*, 45–49. [CrossRef] [PubMed]
2. Ogata, N.; Shibata, T. Protective effect of low-concentration chlorine dioxide gas against influenza a virus infection. *J. Gen. Virol.* **2008**, *89*, 60–67. [CrossRef] [PubMed]
3. Morino, H.; Fukuda, T.; Miura, T.; Lee, C.; Shibata, T.; Sanekata, T. Inactivation of feline calicivirus, a norovirus surrogate, by chlorine dioxide gas. *Biocontrol Sci.* **2009**, *14*, 147–153. [CrossRef] [PubMed]
4. Tanner, R.S. Comparative testing and evaluation of hard-surface disinfectants. *J. Ind. Microbiol.* **1989**, *4*, 145–154. [CrossRef]
5. Junli, H.; Li, W.; Nenqi, R.; Li, L.X.; Fun, S.R.; Guanle, Y. Disinfection effect of chlorine dioxide on viruses, algae and animal planktons in water. *Water Res.* **1997**, *31*, 455–460. [CrossRef]
6. Kim, J.; Marshall, M.R.; Du, W.X.; Otwell, W.S.; Wei, C.I. Determination of chlorate and chlorite and mutagenicity of seafood treated with aqueous chlorine dioxide. *J. Agric. Food Chem.* **1999**, *47*, 3586–3591. [CrossRef] [PubMed]
7. Hubbard, H.; Poppendieck, D.; Corsi, R.L. Chlorine dioxide reactions with indoor materials during building disinfection: Surface uptake. *Environ. Sci. Technol.* **2009**, *43*, 1329–1335. [CrossRef] [PubMed]
8. Yu, C.H.; Huang, T.C.; Chung, C.C.; Huang, H.H.; Chen, H.H. Application of highly purified electrolyzed chlorine dioxide for Tilapia fillet disinfection. *Sci. World J.* **2014**. [CrossRef] [PubMed]
9. Choi, S.; Park, S.; Kim, Y.; Kim, B.S.; Beuchat, L.R.; Hoikyung, K.; Ryu, J.H. Reduction of *Salmonella enterica* on the surface of eggshells by sequential treatment with aqueous chlorine dioxide and drying. *Int. J. Food Microbiol.* **2015**, *210*, 84–87. [CrossRef] [PubMed]
10. Smith, D.J.; Ernst, W.; Herges, G.R. Chloroxyanion residues in cantaloupe and tomatoes after chlorine dioxide gas sanitation. *J. Agric. Food Chem.* **2015**, *63*, 9640–9649. [CrossRef] [PubMed]
11. Hsu, C.S.; Chen, I.M.; Liang, C.K.; Shih, C.H. Evaluation of disinfection efficiency in pet's hospital by using chlorine dioxide. *Sustain. Environ. Res.* **2016**, *26*, 191–195. [CrossRef]
12. Hsu, M.S.; Wu, M.Y.; Huang, Y.T.; Liao, C.H. Efficacy of chlorine dioxide disinfection to non-fermentative Gram-negative bacilli and non-tuberculous mycobacteria in a hospital water system. *J. Hosp. Infect.* **2016**, *93*, 22–28. [CrossRef] [PubMed]
13. Yeturu, S.K.; Acharya, S.; Urala, A.S.; Pentapati, K.C. Effect of Aloe vera, chlorine dioxide, and chlorhexidine mouth rinses on plaque and gingivitis: A randomized controlled trial. *J. Oral Biol. Craniofac. Res.* **2016**, *6*, 54–58. [CrossRef] [PubMed]
14. U.S. Environmental Protection Agency. *Microbial and Disinfection Byproduct Rules Simultaneous Compliance Guidance Manual*; U.S. Environmental Protection: Washington, DC, USA, 1999.
15. Couri, D.; Abdel-Rahman, M.S.; Bull, R.J. Toxicological effects of chlorine dioxide, chlorite and chlorate. *Environ. Health Perspect.* **1982**, *46*, 13–17. [CrossRef] [PubMed]
16. *Standard Methods for the Examination of Water and Wastewater*, 19th ed.; American Public Health Association: Washington, DC, USA; American Water Works Association: Washington, DC, USA; Water Environment Federation: Alexandria, VA, USA, 1995.
17. U.S. Pharmacopeia. *34 NF29 Microbiological Tests/<51> Antimicrobial Effectiveness Testing*; U.S. Pharmacopeial Convention: Rockville, MD, USA.
18. Trinetta, V.; Morgan, M.; Linton, R.; Dermirci, A.; Ngadi, M.O. Chlorine dioxide for microbial decontamination of food. In *Microbial Decontamination in the Food Industry*; Demirci, A., Ngadi, M.O., Eds.; Woodhead Publishing: Cambridge, UK, 2012; pp. 533–562.
19. Sorlini, S.; Gialdini, F.; Biasibetti, M.; Collivignarelli, C. Influence of drinking water treatments on chlorine dioxide consumption and chlorite/chlorate formation. *Water Res.* **2014**, *54*, 44–52. [CrossRef] [PubMed]
20. Park, S.H.; Kang, D.H. Antimicrobial effect of chlorine dioxide gas against foodborne pathogens under differing conditions of relative humidity. *LWT- Food Sci. Technol.* **2015**, *60*, 186–191. [CrossRef]
21. Arango, J.; Rubino, M.; Auras, R.; Gillett, J.; Schilder, A.; Grzesiak, A.L. Evaluation of chlorine dioxide as an antimicrobial against *Botrytis cinerea* in California strawberries. *Food Packag. Shelf Life* **2016**, *9*, 45–54. [CrossRef]

725

22. Paulet, G.D.; Desbrousses, S. On the action of $ClO_2$ at low concentrations on laboratory animals. *Arch. Mal. Prof.* **1970**, *31*, 97–106. [PubMed]
23. Paulet, G.D.; Desbrousses, S. Actions of discontinuous exposure to chlorine dioxide ($ClO_2$) on the rat. *Arch. Mal. Prof.* **1974**, *35*, 797–804.
24. Daniel, F.B.; Condie, L.W.; Robinson, M.; Stober, J.A.; York, R.G.; Olson, G.R.; Wang, S.R. Comparative subchronic toxicity studies of three disinfectants. *J. Am. Water Works Assn.* **1990**, *82*, 61–69.
25. Bercz, J.P.; Jones, L.; Garner, L.; Murray, D.; Ludwig, D.A.; Boston, J. Subchronic toxicity of chlorine dioxide and related compounds in drinking water in the nonhuman primate. *Environ. Health Perspect.* **1982**, *46*, 47–55. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

726

**ClorDiSys**

*Solutions For All Your Gaseous Chlorine Dioxide Needs* *The Chlorine Dioxide People*

# Biological Efficacy of Chlorine Dioxide

***Spaulding Classification:***

Bacterial Endospores
(*Clostridium, Bacillus*)
↓
Mycobacteria
(*Mycobacterium*)
↓
Non-enveloped, non-lipid viruses
(Parvoviruses)
↓
Fungi
(*Aspergillus, Stachybotrys*)
↓
Gram negative vegetative bacteria
(*Escherichia, Pseudomonas*)
↓
Gram positive bacteria
(*Enterococcus, Staphylococcus*)
↓
Enveloped, lipid viruses
(Influenza)

Chlorine dioxide gas is highly effective against fungi, viruses, bacteria, and spores both in the laboratory and in real-world settings. Extensive testing has been done using chlorine dioxide on a multitude of specific organisms, and that information can be found in each of the listed tables below. It is not a complete list of organisms in which chlorine dioxide gas is effective against, only a sample of organisms in which chlorine dioxide has been successfully tested against. To date, no organism tested against chlorine dioxide gas has proved resistant. The Spaulding classification listed on the left lists organisms in order of decreasing resistance to sterilizing agents.

As testing is continually being performed on other organisms, updated data will be added to this list as the results come in. If an organism is not listed here, it does not necessarily mean that chlorine dioxide gas is ineffective against it. Please contact us to see if there is any data or information regarding your specific organism, or to arrange for specific organism testing.

| Bacteria | Ref |
|---|---|
| *Blakeslea trispora* | 28 |
| *Bordetella bronchiseptica* | 8 |
| *Brucella suis* | 30 |
| *Burkholderia mallei* | 36 |
| *Burkholderia pseudomallei* | 36 |
| *Campylobacter jejuni* | 39 |
| *Clostridium botulinum* | 32 |
| *Corynebacterium bovis* | 8 |
| *Coxiella burneti (Q-fever)* | 35 |
| *E. coli ATCC 11229* | 3 |
| *E. coli ATCC 51739* | 1 |
| *E. coli K12* | 1 |
| *E. coli O157:H7 13B88* | 1 |
| *E. coli O157:H7 204P* | 1 |
| *E. coli O157:H7 ATCC 43895* | 1 |
| *E. coli O157:H7 EDL933* | 13 |

| Bacteria | Ref |
|---|---|
| *E. coli O157:H7 G5303* | 1 |
| *E. coli O157:H7 C7927* | 1 |
| *Erwinia carotovora (soft rot)* | 21 |
| *Franscicella tularensis* | 30 |
| *Fusarium sambucinum (dry rot)* | 21 |
| *Fusarium solani var. coeruleum (dry rot)* | 21 |
| *Helicobacter pylori* | 8 |
| *Helminthosporium solani (silver scurf)* | 21 |
| *Klebsiella pneumonia* | 3 |
| *Lactobacillus acidophilus NRRL B1910* | 1 |
| *Lactobacillus brevis* | 1 |
| *Lactobacillus buchneri* | 1 |
| *Lactobacillus plantarum* | 5 |
| *Legionella* | 38 |
| *Legionella pneumophila* | 42 |
| *Leuconostoc citreum TPB85* | 1 |

| Bacteria | Ref. |
|---|---|
| *Leuconostoc mesenteroides* | 5 |
| *Listeria innocua ATCC 33090* | 1 |
| *Listeria monocytogenes F4248* | 1 |
| *Listeria monocytogenes F5069* | 19 |
| *Listeria monocytogenes LCDC-81-861* | 1 |
| *Listeria monocytogenes LCDC-81-886* | 19 |
| *Listeria monocytogenes Scott A* | 1 |
| *Methicillin-resistant Staphylococcus aureus (MRSA)* | 3 |
| *Multiple Drug Resistant Salmonella typhimurium (MDRS)* | 3 |
| *Mycobacterium bovis* | 8 |
| *Mycobacterium fortuitum* | 42 |
| *Pediococcus acidilactici PH3* | 1 |
| *Pseudomonas aeruginosa* | 3 |
| *Pseudomonas aeruginosa* | 8 |
| *Salmonella* | 1 |
| *Salmonella spp.* | 2 |
| *Salmonella Agona* | 1 |
| *Salmonella Anatum Group E* | 1 |
| *Salmonella Choleraesins ATCC 13076* | 1 |
| *Salmonella choleraesuis* | 8 |
| *Salmonella Enterica (PT30) BAA-1045* | 1 |
| *Salmonella Enterica S. Enteritidis* | 13 |
| *Salmonella Enterica S. Javiana* | 13 |
| *Salmonella Enterica S. Montevideo* | 13 |
| *Salmonella Enteritidis E190-88* | 1 |
| *Salmonella Javiana* | 1 |
| *Salmonella newport* | 4 |
| *Salmonella Typhimurium C133117* | 1 |
| *Salmonella Anatum Group E* | 1 |
| *Shigella* | 38 |
| *Staphylococcus aureus* | 23 |
| *Staphylococcus aureus ATCC 25923* | 1 |
| *Staphylococcus faecalis ATCC 344* | 1 |
| *Tuberculosis* | 3 |
| *Vancomycin-resistant Enterococcus faecalis (VRE)* | 3 |
| *Vibrio strain Da-2* | 37 |
| *Vibrio strain Sr-3* | 37 |
| *Yersinia enterocolitica* | 40 |
| *Yersinia pestis* | 30 |
| *Yersinia ruckerii ATCC 29473* | 31 |

| Viruses | Ref. |
|---|---|
| *Adenovirus Type 40* | 6 |
| *Calicivirus* | 42 |
| *Canine Parvovirus* | 8 |
| *Coronavirus* | 3 |
| *Feline Calici Virus* | 3 |
| *Foot and Mouth disease* | 8 |
| *Hantavirus* | 8 |
| *Hepatitis A Virus* | 3 |
| *Hepatitis B Virus* | 8 |
| *Hepatitis C Virus* | 8 |
| *Human coronavirus* | 8 |
| *Human Immunodeficiency Virus* | 3 |
| *Human Rotavirus type 2 (HRV)* | 15 |
| *Influenza A* | 22 |
| *Minute Virus of Mouse (Parovirus)(MVM-i)* | 8 |
| *Minute Virus of Mouse (Parovirus)(MVM-p)* | 8 |
| Mouse Hepatitis Virus (MHV-A59) | 8 |
| Mouse Hepatitis Virus (MHV-JHM) | 8 |
| Mouse Parvovirus type 1 (MPV-1) | 8 |
| Murine Parainfluenza Virus Type 1 (Sendai) | 8 |
| Newcastle Disease Virus | 8 |
| Norwalk Virus | 8 |
| Poliovirus | 20 |
| Rotavirus | 3 |
| Severe Acute Respiratory Syndrome (SARS) Coronavirus | 43 |
| Sialodscryoadenitis Virus (Coronavirus)(SDAV) | 8 |
| Simian rotavirus SA-11 | 15 |
| Theiler's Mouse Encephalomyelitis Virus (TMEV) | 8 |
| Vaccinia Virus | 10 |

| Algae/Fungi/Mold/Yeast | Ref. |
|---|---|
| *Alternaria alternata* | 26 |
| *Aspergillus aeneus* | 28 |
| *Aspergillus aurolatus* | 28 |
| *Aspergillus brunneo-uniseriatus* | 28 |
| *Aspergillus caespitosus* | 28 |
| *Aspergillus cervinus* | 28 |
| *Aspergillus clavatonanicus* | 28 |
| *Aspergillus clavatus* | 28 |

| Algae/Fungi/Mold/Yeast | Ref |
|---|---|
| *Aspergillus egyptiacus* | 28 |
| *Aspergillus elongatus* | 28 |
| *Aspergillus fischeri* | 28 |
| *Aspergillus fumigatus* | 28 |
| *Aspergillus giganteus* | 28 |
| *Aspergillus longivesica* | 28 |
| *Aspergillus niger* | 12 |
| *Aspergillus ochraceus* | 28 |
| *Aspergillus parvathecius* | 28 |
| *Aspergillus sydowii* | 28 |
| *Aspergillus unguis* | 28 |
| *Aspergillus ustus* | 28 |
| *Aspergillus versicolor* | 28 |
| *Botrytis species* | 3 |
| *Candida spp.* | 5 |
| *Candida albicans* | 28 |
| *Candida dubliniensis* | 28 |
| *Candida maltosa* | 28 |
| *Candida parapsilosis* | 28 |
| *Candida sake* | 28 |
| *Candida sojae* | 28 |
| *Candida spp.* | 5 |
| *Candida tropicalis* | 28 |
| *Candida viswanathil* | 28 |
| *Chaetomium globosum* | 7 |
| *Cladosporium cladosporioides* | 7 |
| *Debaryomyces etchellsii* | 28 |
| *Eurotium spp.* | 5 |
| *Fusarium solani* | 3 |
| *Lodderomyces elongisporus* | 28 |
| *Mucor circinelloides* | 28 |
| *Mucor flavus* | 28 |
| *Mucor indicus* | 28 |
| *Mucor mucedo* | 28 |
| *Mucor rademosus* | 28 |
| *Mucor ramosissimus* | 28 |
| *Mucor saturnus* | 28 |
| *Penicillium chrysogenum* | 7 |
| *Penicillium digitatum* | 3 |
| *Penicillium herquei* | 28 |
| *Penicillium spp.* | 5 |
| *Phormidium boneri* | 3 |
| *Pichia pastoris* | 3 |
| *Poitrasia circinans* | 28 |
| *Rhizopus oryzae* | 28 |
| *Roridin A* | 33 |
| *Saccharomyces cerevisiae* | 3 |
| *Stachybotrys chartarum* | 7 |
| *T-mentag (athlete's foot fungus)* | 3 |
| *Verrucarin A* | 33 |

| Bacterial Spores | Ref |
|---|---|
| *Alicyclobacillus acidoterrestris* | 17 |
| *Bacillus coagulans* | 12 |
| *Bacillus anthracis* | 10 |
| *Bacillus anthracis Ames* | 30 |
| *Bacillus atrophaeus* | 14 |
| *Bacillus atrophaeus ATCC 49337* | 31 |
| *Bacillus megaterium* | 12 |
| *Bacillus polymyxa* | 12 |
| *Bacillus pumilus ATCC 27142* | 12 |
| *Bacillus pumilus ATCC 27147* | 11 |
| *Bacillus subtillis (globigii) ATCC 9372* | 11 |
| *Bacillus subtillis ATCC 19659* | 31 |
| *Bacillus subtillis 5230* | 12 |
| *Clostridium. sporogenes ATCC 19404* | 12 |
| *Geobacillus stearothermophilus ATCC 12980* | 11 |
| *Geobacillus stearothermophilus ATCC 7953* | 31 |
| *Geobacillus stearothermophilus VHP* | 11 |
| *Bacillus thuringiensis* | 18 |

| Chemical Decontamination | Ref |
|---|---|
| Mustard Gas | |
| Ricin Toxin | 10 |
| dihydronicotinamide adenine dinucleotide | 24 |
| microcystin-LR (MC-LR) | 25 |
| cylindrospermopsin (CYN) | 25 |

| Beta Lactams | Ref |
|---|---|
| Amoxicillin | 29 |
| Amplicillin | 29 |
| Cefadroxil | 29 |
| Cefazolin | 29 |

| Beta Lactams | Ref. |
|---|---|
| Cephalexin | 29 |
| Imipenem | 29 |
| Penicillin G | 29 |
| Penicillin V | 29 |

| Protozoa | Ref. |
|---|---|
| *Chironomid larvae* | 27 |
| *Cryptosporidium* | 34 |

| Protozoa | Ref. |
|---|---|
| *Cryptosporidium parvum Oocysts* | 9 |
| *Cyclospora cayetanensis oocysts* | 41 |
| *Giardia* | 34 |

| Microsporidia | Ref. |
|---|---|
| *Encephalitozoon intestinalis* | 27 |

ClorDiSys' gaseous chlorine dioxide is registered with the EPA as a sterilant

**Product:** CSI CD CARTRIDGE
**EPA Reg#:** 80802-1
**Registrant:** CLORDISYS SOLUTIONS, INC
**Approval Date:** 02/25//2005
**Active Ingredients:** Sodium chlorite 72.8%

**Contact us for more information on the power of a TRUE GAS and to discuss your project**

**908.236.4100**

730

**CD ClorDiSys**

*Solutions For All Your Gaseous Chlorine Dioxide Needs* *The Chlorine Dioxide People*

ClorDiSys Solutions, Inc. of Lebanon, New Jersey (est. 2001) is a company providing years of experience in all aspects of chlorine dioxide technology with a strong background in the Medical Device and pharmaceutical industry operating under GxP. We are a flexible, responsive organization with a network of resources to handle any size project. Each project is approached by utilizing our strong sterilization and engineering skills while drawing on our background in Operations, Service, Validation, and Quality to provide solutions for all of your Chlorine Dioxide (CD) needs. We provide personal attention to ensure customer satisfaction in all services and equipment we supply.

**References**:

1. Selecting Surrogate Microorganism for Evaluation of Pathogens on Chlorine Dioxide Gas Treatment, Jeongmok Kim, Somi Koh, Arpan Bhagat, Arun K Bhunia and Richard H. Linton. Purdue University Center for Food Safety 2007 Annual Meeting October 30 - 31, 2007 at Forestry Center, West Lafayette, IN.
2. Decontamination of produce using chlorine dioxide gas treatment, Richard Linton, Philip Nelson, Bruce Applegate, David Gerrard, Yingchang Han and Travis Selby.
3. Chlorine Dioxide, Part 1 A Versatile, High-Value Sterilant for the Biopharmaceutical Industry, Barry Wintner, Anthony Contino, Gary O'Neill. BioProcess International DECEMBER 2005.
4. Chlorine Dioxide Gas Decontamination of Large Animal Hospital Intensive and Neonatal Care Units, Henry S. Luftman, Michael A. Regits, Paul Lorcheim, Mark A. Czarneski, Thomas Boyle, Helen Aceto, Barbara Dallap, Donald Munro, and Kym Faylor. Applied Biosafety, 11(3) pp. 144-154 © ABSA 2006
5. Efficacy of chlorine dioxide gas as a sanitizer for tanks used for aseptic juice storage, Y. Han, A. M. Guentert*, R. S. Smith, R. H. Linton and P. E. Nelson. Food Microbiology, 1999, 16, 53]61
6. Inactivation of Enteric Adenovirus and Feline Calicivirus by Chlorine Dioxide, Jeanette A. Thurston-Enriquez, Charles N. Haas, Joseph Jacangelo, and Charles P. Gerba. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, June 2005, p. 3100–3105.
7. Effect of Chlorine Dioxide Gas on Fungi and Mycotoxins Associated with Sick Building Syndrome, S. C. Wilson,* C. Wu, L. A. Andriychuk, J. M. Martin, T. L. Brasel, C. A. Jumper, and D. C. Straus. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Sept. 2005, p. 5399–5403.
8. BASF Aseptrol Label
9. Effects of Ozone, Chlorine Dioxide, Chlorine, and Monochloramine on Cryptosporidium parvum Oocyst Viability, D. G. KORICH, J. R. MEAD, M. S. MADORE, N. A. SINCLAIR, AND C. R. STERLING. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, May 1990, p. 1423-1428.
10. NHSRC's Systematic Decontamination Studies, Shawn P. Ryan, Joe Wood, G. Blair Martin, Vipin K. Rastogi (ECBC), Harry Stone (Battelle). 2007 Workshop on Decontamination, Cleanup, and Associated Issues for Sites Contaminated with Chemical, Biological, or Radiological Materials Sheraton Imperial Hotel, Research Triangle Park, North Carolina June 21, 2007.
11. Validation of Pharmaceutical Processes 3rd edition, edited by Aalloco James, Carleton Frederick J. Informa Healthcare USA, Inc., 2008, p267
12. Chlorine dioxide gas sterilization under square-wave conditions. Appl. Environ. Microbiol. 56: 514-519 1990. Jeng, D. K. and Woodworth, A. G.
13. Inactivation kinetics of inoculated Escherichia coli O157:H7 and Salmonella enterica on lettuce by chlorine dioxide gas. Food Microbiology Volume 25, Issue 2, February 2008, Pages 244-252, Barakat S. M. Mahmoud and R. H. Linton.
14. Determination of the Efficacy of Two Building Decontamination Strategies by Surface Sampling with Culture and Quantitative PCR Analysis. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Aug. 2004, p. 4740–4747. Mark P. Buttner, Patricia Cruz, Linda D. Stetzenbach, Amy K. Klima-Comba, Vanessa L. Stevens, and Tracy D. Cronin
15. Inactivation of Human and Simian Rotaviruses by Chlorine Dioxide. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, May 1990, p. 1363-1366. YU-SHIAW CHEN AND JAMES M. VAUGHN

```
ERROR: syntaxerror
OFFENDING COMMAND: true        cvt              fpgm       /    eglyf           >head

STACK:

-mark-
/sfnts
```

732

*Environmental Health Perspectives*
*Vol. 46, pp. 57-62, 1982*

# Controlled Clinical Evaluations of Chlorine Dioxide, Chlorite and Chlorate in Man

by Judith R. Lubbers,* Sudha Chauan,* and Joseph R. Bianchine*

**To assess the relative safety of chronically administered chlorine water disinfectants in man, a controlled study was undertaken. The clinical evaluation was conducted in the three phases common to investigational drug studies. Phase I, a rising does tolerance investigation, examined the acute effects of progressively increasing single doses of chlorine disinfectants to normal healthy adult male volunteers. Phase II considered the impact on normal subjects of daily ingestion of the disinfectants at a concentration of 5 mg/l. for twelve consecutive weeks. Persons with a low level of glucose-6-phosphate dehydrogenase may be expected to be especially susceptible to oxidative stress; therefore, in Phase III, chlorite at a concentration of 5 mg/l. was administered daily for twelve consecutive weeks to a small group of potentially at-risk glucose-6-phosphate dehydrogenase-deficient subjects. Physiological impact was assessed by evaluation of a battery of qualitative and quantitative tests. The three phases of this controlled double-blind clinical evaluation of chlorine dioxide and its potential metabolites in human male volunteer subjects were completed uneventfully. There were no obvious undesirable clinical sequellae noted by any of the participating subjects or by the observing medical team. In several cases, statistically significant trends in certain biochemical or physiological parameters were associated with treatment; however, none of these trends was judged to have physiological consequence. One cannot rule out the possibility that, over a longer treatment period, these trends might indeed achieve proportions of clinical importance. However, by the absence of detrimental physiological responses within the limits of the study, the relative safety of oral ingestion of chlorine dioxide and its metabolites, chlorite and chlorate, was demonstrated.**

## Introduction

Chlorine dioxide is currently under serious consideration in the United States as an alternative to chlorine water treatment. Before chlorine dioxide may be used routinely as a water disinfectant, the safety of oral human ingestion of chlorine dioxide and its by-products must be assessed. For this purpose, a controlled clinical evaluation of chlorine dioxide, chlorite and chlorate was undertaken under the auspices of USEPA HERL #CR805643.

The study was conducted in three parts. Phase I was designed to evaluate the acute physiological effects of progressively increasing doses of disinfectants administered to normal healthy adult males. Chronic ingestion by normal male volunteers was studied in Phase II. Phase III assessed the physiological response of a small group of potentially susceptible individuals, those deficient in glucose-6-phosphate dehydrogenase, to chronic ingestion of chlorite.

## Methods

### Subject Selection

For Phase I and for Phase II, normal healthy adult male volunteers were selected. No prospective study participant who exhibited a significant abnormality in the routine clinical serum analysis, blood count, urinalysis, or electrocardiogram was selected. Subjects manifested no physical abnormalities at the pretreatment examination, were 21 to 35 years of age, and weighed within ± 10% of normal body weight for their frame and stature. A history of disease or any medical or surgical condition which might interfere with the absorption, excretion, or metabolism of substances by the body precluded inclusion. Regular drug intake prior to the start of the investigation, either therapeutic or recreational, resulted in exclusion from the study. Normal methemoglobin levels, thyroid function, and glutathione levels were mandatory. Written informed consent was obtained from each subject prior to initiation of treatment.

---

* The Department of Pharmacology, The Ohio State University, College of Medicine, 333 W. 10th Avenue, Columbus, OH 43210

733

For Phase III, volunteers were defined as glucose-6-phosphate dehydrogenase (G-6-PD)-deficient on the basis of a hemoglobin G-6-PD level of less than 5.0 IU/GM hemoglobin in the pre-study screening. Phase III subjects were normal in all other respects.

### Water Disinfectant Preparation

A detailed description of the water disinfectant preparation techniques has been presented by Lubbers and Bianchine (*1*). In general, freshly prepared stock solutions of chlorine dioxide, sodium chlorite, sodium chlorate, chlorine and chloramine were assayed by the colorimetric techniques of Palin (*2*) then diluted with organic-free demineralized deionized water to appropriate concentrations. Individual bottles were capped and stored in the dark under refrigeration until use. All bottles were coded by an independent observer and the identity of each bottle remained "double-blind" to both the investigative staff and the volunteer subjects.

### Study Design: Phase I

The 60 volunteers in Phase I were divided at random into six treatment groups (*1*). Ten persons were assigned to receive each of the disinfectants; the ten members of the control group received untreated water. The study involved a series of six sequences of three days each. Treatment concentrations were increased for each treatment. The specific concentrations or disinfectant administered to the study participants are listed in Table 1. A clinical evaluation of the collection of blood and urine samples for determination of pretreatment baseline laboratory values preceded the first treatment. On the first day of each three day treatment sequence, each volunteer ingested 1000 ml of the water in two portions. The second 500 ml portion aliquot was administered 4 hr after the first. Each 500 ml portion was consumed within 15 min. Only two doses of disinfectant were administered on the first day of each treatment sequence. No disinfectant was administered on the second and third day of each sequence, since these two days were to serve as followup observation days. The second day of the treatment sequence consisted of a physical examination and collection of blood and urine samples for determination of posttreatment laboratory values. On the third day, each volunteer was given a physical examination to determine residual effects of treatment with the water disinfectants and byproducts.

Taste evaluations were obtained at each dose level. Study participants were asked to rate the treated water as very unpleasant, slightly unpleasant, not pleasant, pleasant, or tasteless.

### Study Design: Phase II

The sixty volunteers of Phase II were divided at random into six treatment groups of ten subjects each (*3*). In order to assure efficient management of the 60 subjects, they were randomly assigned to three subsets. These subsets were sequentially entered into the study on three successive days and exited from this study in a similar fashion. For all of the treatment groups, the concentration of disinfectants ingested was 5 mg/l. The control group received untreated water. Each subject received 500 ml daily for 12 weeks. Physicals, collection of blood and urine samples for laboratory assays, and taste evaluations were conducted on a weekly basis during the treatment period and for 8 weeks following cessation of treatment.

### Study Design: Phase III

The three glucose-6-phosphate dehydrogenase-deficient subjects of Phase III were given sodium chlorite at a concentration of 5 mg/l. chlorite (4). The treatment protocol was identical to that of Phase II, with daily administration of 500 ml of solution to each volunteer.

## Evaluation Procedures

An extensive battery of parameters was monitored to assess the biochemical and physiological response to the oral ingestion of the water disinfectants and water treatment by-products (Table 2). All laboratory determinations of biochemical parameters were conducted by a licensed medical laboratory, Consolidated Biomedical Laboratories, Inc. (CBL), Columbus, Ohio, HEW license number 34-1030. For each volunteer, pretreatment baseline values and six sets of posttreatment values were compiled. Laboratory tests were carefully chosen.

**Table 1. Concentration of disinfectants in phase I: acute rising dose tolerance.[a]**

| Water disinfectant | Disinfectant concentration, mg/l. | | | | | |
|---|---|---|---|---|---|---|
| | Day 1 | Day 4 | Day 7 | Day 10 | Day 13 | Day 16 |
| Chlorate | 0.01 | 0.1 | 0.5 | 1.0 | 1.8 | 2.4 |
| Water control | 0 | 0 | 0 | 0 | 0 | 0 |
| Chlorine dioxide | 0.1 | 1.0 | 5.0 | 10.0 | 18.0 | 24.0 |
| Chlorite | 0.01 | 0.1 | 0.5 | 1.0 | 1.8 | 2.4 |
| Chlorine | 0.1 | 1.0 | 5.0 | 10.0 | 18.0 | 24.0 |
| Chloramine | 0.01 | 1.0 | 8.0 | 18.0 | 24.0 | |

[a] For each dose, two portions of 500 ml each were administered at 4-hr intervals.

**Table 2. Biochemical parameters assayed in the controlled clinical evaluation of chlorine dioxide, chlorite and chlorate in man.**

| | |
|---|---|
| Serum chemistry | Plasma glucose, sodium, potassium, chloride, urea nitrogen, creatinine, BUN/creatinine ratio, uric acid, calcium, phosphorus, alkaline phosphatase, gamma glutamyl transferase, total bilirubin, serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase, lactic dehydrogenase, cholesterol, triglycerides, total protein albumin, globulin, albumin/globulin ratio, iron |
| Blood count | Platelet count, white blood cell count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, high peroxidase activity, neutrophils, lymphocytes, monocytes, eosinophils, basophils, large unstained cells |
| Urinalysis | Color,[a] appearance,[a] specific gravity, pH, protein, sugar,[a] acetone, blood,[a] white blood count, red blood count, casts,[a] crystals,[a] bacteria,[a] mucus*, amorphous cells,[a] epithelial cells |
| Special tests | Serum haptoglobin, sickle cell,[a] methemoglobin, glucose-6-phosphate dehydrogenase, Coombs test,[a] hemoglobin electrophoresis,[a] T-3 (uptake), T-4 (RIA), free thyroxine index, electrocardiogram[a] |
| Physical exam | Systolic blood pressure, diastolic blood pressure, respiration rate, pulse rate, oral temperature |

[a] These parameters yielded qualitative data only; no statistical analysis was performed.

On the basis of the literature (*5–8*), areas of suspected biochemical response to ingestion of chlorine oxidants were defined; a portion of the test battery was specifically devoted to monitoring this response. Red blood cell surface antibody formation was clinically monitored by the qualitative Coombs test; thyroid function by T-3 (uptake), T-4 (RIA), and free thyroxine; and response to oxidative stress by glucose-6-phosphate dehydrogenase, methemoglobin and glutathione levels. Hemoglobin electrophoresis was used to detect possible hemoglobin abnormalities. A battery of peripheral parameters was assayed to provide supplementary information and to assist in evaluation of overall physiological well-being. The specific serum, blood and urine parameters assayed have been discussed by Lubbers and Bianchine (*1*).

The numerical values obtained were collected and analyzed by utilizing the facilities of The Ohio State University Division of Computing Services for Medical Education and Research. Specially designed programs facilitated rapid clinical feedback. Any value for an individual subject which differed from the group mean by more than two standard deviations was noted. In addition, every individual value which fell outside normal laboratory ranges for that parameter was designated as abnormal. Chemical parameters for volunteers who exhibited abnormal values were subjected to careful scrutiny; the safety and the possibility of hypersensitivity to the disinfectant agents were evaluated for each of these individuals on a continuing basis throughout the study.

Statistical analyses utilized commercially available computer packages, specifically, the Biomedical Computer Programs (BMDP) and the Statistical Package for the Social Sciences (SPSS). Two-way analyses of variance with repeated measures utilized BMDP2V. BMDP1R was used to perform multiple linear regression analyses. For pairwise *t*-tests and simple *t*-tests, SPSS-*T*-test was employed.

## Results

### Qualitative

An important aspect of this study was the careful and continued medical observation of all subjects. The general clinical histories and physical examinations alone with subjective observations and qualitative laboratory tests throughout this study were accumulated in each subject's medical file. A careful inspection of each of these medical files presented a review of the general clinical health of each subject.

The careful clinical evaluation of every subject in Phases I, II and III failed to reveal any clinically important impact upon the medical well-being of any subject as a result of disinfectant ingestion. Further, there was no apparent grouping of the minor subjective symptoms and objective signs noted throughout the study; the "colds," "lymphadenopathy," "sore throats" and "flu" problems noted episodically appear to be randomly dispersed among the treatment groups. All subjects remained negative with respect to the Coombs tests and the sickle cell tests during the investigation. Hemoglobin electrophoresis results indicated that, in Phase II, a small number of subjects yielded abnormal hemoglobin distributions but these individuals were found to be randomly distributed in both the treatment groups and in the control group. Examination of electrocardiograms revealed no abnormalities.

Vital signs (blood pressure, pulse rate, respiration rate and body temperature) were measured on a regular basis to provide immediate feedback to the monitoring physician on the acute physiological response of study participants to treatment. The statistical analysis of the vital signs was limited to the calculation of arithmetic group means and standard deviations from the mean. The compiled vital signs were examined for evidence of consistent response to treatment. No such evidence was found.

The subjective evaluations of palatability indicated that few subjects found the test substances to have an objectionable taste at levels up to 24 mg/l.

## Quantitative

For the Phase I acute rising-dose tolerance study, a two-way analysis of variance with repeated measures was used to compare the treatment group values of each biochemical parameter to the corresponding values of the control group. The analysis of variance allowed distinctions to be made among the possible sources of variation. Differences between two groups that existed prior to treatment, parallel variations in quantitative chemical values due to laboratory drift and authentic treatment-related changes in physiological parameters could be distinguished. Three probabilities were calculated for each case: the group main effect (G), the time main effect (R), and group-time interaction (RG). The treatment groups and the corresponding biochemical parameters for which a strong probability of treatment-related change was computed (that is, $RG \leq 0.05$) are listed in the first column of Table 3.

To assist in determining the clinical importance of the statistically significant group time interactions, the group, mean and standard deviations from the mean were examined for the pretreatment baseline assay and each posttreatment assay for each of the treatment groups. In all instances, the group mean values remain well within the established normal ranges.

On the basis of the small magnitude of change within the normal range and the duration of the study, it was concluded that the trends identified by the analysis of variance are unlikely to be of clinical importance. The possibility that the trends might become clinically important with increased exposure cannot be excluded.

Alternative statistical techniques were employed for Phase II. An omnibus testing technique was used initially. To test the hypothesis that the response of one or more of the groups was different to that of the rest of the groups, an analysis of variance with repeated measures was performed in which values for all six treatment groups were included. For the parameters urea nitrogen and mean corpuscular hemoglobin, RG-values $< 0.05$ were obtained. Supplementary tests were performed. Analyses of variance with repeated measures in which the values of each treatment group were compared to the corresponding values of the control group were chosen. The use of the analysis of variance in this manner is flawed by the common control group. However, the results of the analyses may be used with caution. The analysis of variance yielded statistically significant RG-values in the comparison of the group mean corpuscul ar hemoglobin values for the chlorite and the chlorate groups and of the group mean urea nitrogen values of chlorate and chlorine dioxide treatment groups to the corresponding control group values, as shown in Table 3.

No linear trends were detected by linear regression analysis of the chlorite group's mean corpuscular hemoglobin values, the chlorate group's urea nitrogen levels or the chlorite group's urea nitrogen values.

Mean corpuscular hemoglobin levels in the chlorate group yielded a probability of 0.01 upon linear regression analysis. The relative slope associated with the change during the 12-week treatment period was approximately 1% of the normal physiological range per week. We believe that no physiological importance may be attributed with confidence to the variation. However, it is impossible on the basis of this study to rule out the potential physiological significance of the trend. Further study is warranted.

The small number of subjects (three) in Phase III negated the value of many statistical procedures. Linear regression analyses were chosen. The third column of Table 3 lists the biochemical parameters for which a high probability of change with respect to time was calculated. The *p*-values computed by

736

**Table 3. Biochemical parameters and treatment groups in which statistical analyses indicated a high probability of change which could be attributed to ingestion of disinfectant.**

| Test | Phase I[a] | Phase II[b] | Phase III[c] |
|---|---|---|---|
| Urea nitrogen (BUN) | Chlorite | Chlorate<br>Chlorine dioxide | |
| Creatinine | Chlorite<br>Chlorine | | |
| BUN/creatinine Ratio | Chlorite | | |
| Uric acid | Chlorine dioxide | | |
| Calcium | Chlorine | | |
| Gamma glutamyl transferase | Chlorine | | |
| Total bilirubin | Chlorate | | |
| Albumin/globulin ratio | | | Chlorite |
| Iron | Chlorate | | |
| Methemoglobin | Chlorate | | Chlorite |
| T-4 (RIA) | | | Chlorite |
| Free thyroxine index | | | Chlorite |
| Mean corpuscular hemoglobin | | Chlorite<br>Chlorate | |
| Mean corpuscular hemoglobin concentration | | | Chlorite |
| Lymphocytes | Chlorine | | |

[a] Two-way analysis of variance yielded group-time interactions (RG values) $\leq 0.05$ in comparisons of treatment group values to those of the control group.

[b] Two-way analysis of variance yielded group-time interactions (RG-values) $\leq 0.05$ in both the omnibus and treatment group-control group comparisons.

[c] Linear regression analysis indicated a strong probability of change with respect to time; $p$-values $\leq 0.05$.

the linear regression analysis were less than 0.05 for four biochemical parameters. To gauge the relative magnitude of change, the percent change of the normal range per week was computed. These statistical analyses indicate a good probability that, for A/G ratio, T-4 (RIA), free thyroxine, mean corpuscular hemoglobin concentration, and methemoglobin values, a change with respect to time occurs during the 12-week treatment period. However, in the absence of a concurrent control group and taking into consideration the small group size and the possibility of laboratory drift, one must exercise caution in dealing with the results. We can say with confidence only that trends were indicated. We cannot say that these trends were of physiological origin nor can we attribute physiological consequence to them.

## Discussion

Several researchers have addressed the physiological effects of oral ingestion of the oxidizing agents, chlorine dioxide, chlorite and chlorate. Musil et al. (*9*) associated oral chlorite ingestion with methemoglobin formation. In studies by Heffernan et al. (*7,8*), Abdel-Rahman et al. (*5*) and Couri et al. (*6*), hemolytic anemia and suppressed glutathione levels were observed in animals treated with chlorite. The oral administration of chlorate to laboratory animals has been shown to induce oxidative destruction of hemoglobin and methemoglobin formation (*10, 11*). The possibility of renal toxicity at high levels of chlorite ingestion was suggested by the increased kidney/body weight ratio reported by Heffernan et al. (*7*). Haller and Northgraves (*12*) and Fridlyand and Kagan (*13*) examined the chronic toxicity of orally consumed chlorine dioxide in rats; a slightly increased two-year mortality rate and a decreased rate of weight gain were observed. Oral administration of chlorite (*14–16*) to mice was shown to increase mean corpuscular volume, osmotic fragility, and glucose-6-phosphate dehydrogenase activity of erythrocytes; morphologic changes were reported. In the African Green monkey, chlorine dioxide adversely affected thyroid function; chlorite ingestion yielded transient changes in hemoglobin levels and red cell count (*17*). The maternal toxicity, embryonic toxicity and the teratogenic potential of concentrations of sodium chlorite was evaluated in rats (*18*).

Unfortunately, the information available on the impact of chlorine dioxide, chlorite, and chlorate ingestion in man is severely limited. Epidemiological studies (*19,20*) have failed to conclusively identify any significant exposure related effects. The clinical evaluation described in this report was an attempt to elucidate the effects of the chlorite, chlorine dioxide and chlorate in man under controlled clinical conditions.

During the course of the three-phase study, a massive volume of raw data was acquired. Routine urinalyses were performed and a meticulous examination of this body of information was made. No definitive finding of detrimental physiological impact was made in any of the three phases of this human investigation of the relative safety and tolerance of oral chlorine disinfectant ingestion. In several cases, statistically significant trends were associated with treatment; however, none of these trends were judged to have immediate physiological consequence. One cannot rule out the possibility that, over a longer treatment period, these trends might indeed achieve proportions of clinical importance. However, within the limits of the study, the relative safety of oral ingestion of chlorine dioxide and its metabolites, chlorite and chlorate, was demonstrated by the absence of detrimental physiological response.

## REFERENCES

1. Lubbers, J. R., and Bianchine, J. R. The effects of the acute rising dose administration of chlorine dioxide, chlorate and chlorite to normal healthy adult male volunteers. J. Environ. Pathol. Toxicol. 5 (2, 3): 865-878 (1982).
2. Palin, A. T. Methods for the determination, in water of free and combined available chlorine, chlorine dioxide and chlorite, bromine, iodine and ozone, using diethyl-*p*-phenylene diamine (DPD). J. Inst. Water Engr. 21: 537–549 (1976).
3. Lubbers, J. R., Chauhan, S., Miller, J. K., and Bianchine, J. R. The effects of chronic administration of chlorine dioxide, chlorite and chlorate to normal healthy adult male volunteers. J. Environ. Pathol. Toxicol. 5 (2, 3): 879-888 (1982).
4. Lubbers, J. R., Chauhan, S., Miller, J. K. and Bianchine, J. R. The effects of chronic administration of chlorite to glucose-6-phosphate dehydrogenase deficient healthy adult male volunteers. J. Environ. Pathol. Toxicol. 5 (2, 3): 889-892 (1982).
5. Abdel-Rhaman, M. S., Couri, D., and Bull, R.J. Kinetics of $ClO_2$ and effects of $ClO_2$, and $ClO_2$ , and $ClO_3$ in drinking water on blood glutathione and hemolysis in rat and chicken. J. Environ. Path. Toxicol. 3(1,2): 431–449 (1979).
6. Couri, D., and Abdel-Rahman, M.S. Effect of chlorine dioxide and metabolites on glutathione dependent system in rat, mouse and chicken blood. J. Environ. Pathol. Toxicol. 3(1,2): 451–460 (1979).
7. Heffernan, W. P., Guion, C., and Bull, R. J. Oxidative damage to the erythrocyte induced by sodium chlorite *in vitro*. J. Environ. Pathol. Toxicol. 2(6): 1487–1499 (1979).
8. Heffernan, W. P., Guion, C., and Bull, R. J. Oxidative damage to the erythrocyte induced by sodium chlorite *in vitro*. J. Environ. Pathol. Toxicol. 2(6): 1501–1510 (1979).
9. Musil, J., Kontek, Z., Chalupa, J., and Schmidt, P. Toxicological aspects of chlorine dioxide application for the treatment of water containing phenol. Chem. Technol. Praze. 8: 327–345 (1964).
10. Richardson, A. P. Toxic potentialities of continued administration of chlorate for blood and tissues. J. Pharmacol. Exptl. Therap. 59: 101-103, (1937).
11. Jung, F., and Kuon, R. Zum inaktiven hemoglobin das Bluter. Naunyn-Schmiedebergs Arch. Exptl. Pathol. Pharmakol. 216: 103–111 (1951).
12. Haller, S. F., and Northgraves, W.W. Chlorine dioxide and safety. TAPPI 33: 199–202 (1955).
13. Fridyland, S. A., and Kagan, G. Z. Experimental validation of standards for residual chlorine dioxide in drinking water. Hygiene Sanitation 36: 18–21 (1971).
14. Moore, G. S., and Calabrese, E. J. The effects of chlorine dioxide and sodium chlorite on erythrocytes of A-J and C-57L-J mice. J. Environ. Pathol. Toxicol. 4(2, 3): 513–524 (1980).
15. Moore, G. S. and Calabrese, E. J. G-6-PD-deficiency—a potential high-risk group to copper and chlorite ingestion. J. Environ. Pathol. Toxicol. 4(2, 3): 271–279 (1980).
16. Moore, G. S., Calabrese, E. J. and Ho, S. C. Groups at potentially high-risk from chlorine dioxide treated water. J. Environ. Pathol. Toxicol. 4(2, 3): 465–470 (1980).
17. Bercz, J. P., DiBiasi, D. L., Jones, L., Murray, D., and Boston, J. Subchronic toxicity of alternate disinfectants and related compounds in the non-human primate. Environ. Health Perspect. 46: 47–55 (1982).
18. Couri, D., Miller, C. H., Bull, R. J., Delphia, J. M., and Ammar, E. M. Assessment of maternal toxicity, embryotoxicity and teratogenic potential of sodium chlorite in Sprague-Dawley rats. Environ. Health Perspect. 46: 25–29 (1982).
19. Haring, B. J., and Zoetman, B. C. Corrosiveness of drinking water and cardiovascular diesase mortality. Bull. Environ. Contam. Toxicol. 25: 658–662 (1981).
20. Michael, G. E., Miday, R. K., Bercz, J. P., Miller, R. G., Greathouse, D. G., Kraemer, D. F., and Lucas, J. B. Chlorine dioxide water disinfection: a prospective epidemiology. Arch. Environ. Health 36(1): 20–27 (1981).

# Chlorine Dioxide Is a Size-Selective Antimicrobial Agent

**Zoltán Noszticzius[1], Maria Wittmann[1*], Kristóf Kály-Kullai[1], Zoltán Beregvári[2], István Kiss[3], László Rosivall[4], János Szegedi[2]**

**1** Department of Physics, Budapest University of Technology and Economics, Budapest, Hungary, **2** Jósa András Hospital, Nyíregyháza, Hungary, **3** St. Imre Hospital, Budapest, Hungary, **4** Semmelweis University, Budapest, Hungary

## Abstract

***Background / Aims:*** $ClO_2$, the so-called "ideal biocide", could also be applied as an antiseptic if it was understood why the solution killing microbes rapidly does not cause any harm to humans or to animals. Our aim was to find the source of that selectivity by studying its reaction-diffusion mechanism both theoretically and experimentally.

***Methods:*** $ClO_2$ permeation measurements through protein membranes were performed and the time delay of $ClO_2$ transport due to reaction and diffusion was determined. To calculate $ClO_2$ penetration depths and estimate bacterial killing times, approximate solutions of the reaction-diffusion equation were derived. In these calculations evaporation rates of $ClO_2$ were also measured and taken into account.

***Results:*** The rate law of the reaction-diffusion model predicts that the killing time is proportional to the square of the characteristic size (e.g. diameter) of a body, thus, small ones will be killed extremely fast. For example, the killing time for a bacterium is on the order of milliseconds in a 300 ppm $ClO_2$ solution. Thus, a few minutes of contact time (limited by the volatility of $ClO_2$) is quite enough to kill all bacteria, but short enough to keep $ClO_2$ penetration into the living tissues of a greater organism safely below 0.1 mm, minimizing cytotoxic effects when applying it as an antiseptic. Additional properties of $ClO_2$, advantageous for an antiseptic, are also discussed. Most importantly, that bacteria are not able to develop resistance against $ClO_2$ as it reacts with biological thiols which play a vital role in all living organisms.

***Conclusion:*** Selectivity of $ClO_2$ between humans and bacteria is based not on their different biochemistry, but on their different size. We hope initiating clinical applications of this promising local antiseptic.

**Citation:** Noszticzius Z, Wittmann M, Kály-Kullai K, Beregvári Z, Kiss I, et al. (2013) Chlorine Dioxide Is a Size-Selective Antimicrobial Agent . PLoS ONE 8(11): e79157. doi:10.1371/journal.pone.0079157

**Editor:** Patrick M Schlievert, University of Iowa Carver College of Medicine, United States of America

**Received** June 17, 2013; **Accepted** September 25, 2013; **Published** November 5, 2013

**Copyright:** © 2013 Noszticzius et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by OTKA Grant 77908. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** ZN, MW and KKK declare competing financial interest as they are co-inventors of the European patent 2069232 "Permeation method and apparatus for preparing fluids containing high purity chlorine dioxide", see also reference 13. In addition ZN is also a founder of the Solumium Ltd. The other four authors have no competing financial interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: wittmann@eik.bme.hu

## Introduction

The emergence and dissemination of new antibiotic-resistant bacterial strains caused by an overuse of antibiotics [1] is a global public-health concern. Methicillin Resistant Staphylococcus aureus (MRSA) [1,2] and Carbapenem- or Extreme Drug-Resistant *Acinetobacter baumannii* [3,4] are only two well known examples for such bacteria attracting world wide attention. Moreover, while the number of antibiotic resistant infections is on the rise, the number of new antibiotics is declining [1,2]. As a result of such a dangerous situation, searches for new antimicrobial agents, as well as strategies including a switch from antibiotic to antiseptic therapies, whenever that is feasible, have been initiated.

When treating local infections of wounds, ulcers or an infected mucous membrane, the application of antiseptics instead of antibiotics is a reasonable alternative especially because bacteria are less able to develop resistance against them [5]. Presently the majority of the antiseptics used for wounds [6] are organic compounds. The most frequently applied ones [6] are chlorhexidine (chlorhexidine digluconate), octenidine (octanidine dihydrochloride), polyhexanide (polyhexametylene biguanide) and triclosan (5-chlorine-2-(2,4-dichlorphenoxy)-phenol). Notable exceptions are PVP-iodine (poly(vinylpirrolidone)-iodine complex) [6] where the active ingredient is iodine, and silver [7], both being inorganic compounds.

There are some other, less used, inorganic antiseptics such as aqueous sodium hypochlorite (NaOCl), or hydrogen peroxide ($H_2O_2$) solutions, or ozone ($O_3$) gas which have some applications in dentistry [8]. These compounds, however, are mainly used as disinfectants because they can be toxic even in low concentrations, a property seriously limiting their antiseptic applications. NaOCl, for example, one of the most commonly used components of irrigating solutions in endodontic practice, can cause poisoning and extensive tissue destruction if it is injected (inadvertently) into periapical tissues in the course of endodontic therapy [9]. $H_2O_2$ is also a double edged sword against bacteria as it also hurts living tissue [10]. Moreover, many bacteria are able to resist $H_2O_2$ as their catalase enzyme is able to decompose $H_2O_2$ rapidly [11]. Thus, beside toxicity, resistance can be also a problem even with the use of inorganic disinfectants [5]. It would be therefore reasonable to choose an antiseptic which would be free of such problems. We believe that in this respect chlorine dioxide ($ClO_2$) may be the right choice, moreover $ClO_2$ has other characteristic features favourable for antiseptic applications.

In the last twenty or more years chlorine dioxide emerged as a new and popular inorganic disinfectant. It is often referred to as „the ideal biocide" [12] because of its advantageous properties. In spite of that, as far as we know, $ClO_2$ solutions are not frequently used as antiseptic. This is because the available $ClO_2$ solutions were more or less contaminated with other chemicals applied in its synthesis and that contamination formed a major obstacle in medical applications like treating infected wounds, for example. Since 2006, however, with the help of an invention [13], it is relatively easy to produce high purity aqueous $ClO_2$ solutions. These solutions are already commercially available [14] and have been successfully used in dentistry [15] since 2008. Thus, it seems reasonable to ask the question whether the "ideal biocide" in its pure form can also be an "ideal local antiseptic" at the same time.

Such an ideal local antiseptic should satisfy many criteria. First of all, it should be safe: it should act only locally to avoid the danger of systemic poisoning and should not inflict cytotoxic effects even in the disinfected area. In this respect, it is one of the main aims of the present work to find a reasonable answer for the following intriguing question: how is it possible that contacting or even drinking $ClO_2$ solution is practically harmless for animals [16] and human beings [17], while the same aqueous solution can be a very effective and a rapid killer for bacteria, fungi, and viruses? What is the basis of this unexpected selectivity?

The answer suggested in the Results section is the following: the selectivity between humans or animals and microbes is based not on their different biochemistry, but on their different size. Denominating $ClO_2$ in the title as a „size selective" antimicrobial agent aims to emphasize this new type of selectivity. To reach that conclusion, $ClO_2$ transport was studied experimentally via protein membranes. The results of these experiments were evaluated applying a reaction-diffusion model for the $ClO_2$ transport in a reactive medium to obtain the diffusion coefficient of $ClO_2$, and the concentration of reactive groups in a protein medium. Based on these parameters the killing time, the time needed to flood a bacterium completely with $ClO_2$, can be calculated. (Details of the reaction-diffusion model and the derivation of formulae estimating the killing time are given in the Information S1.) It was found that the characteristic time necessary to kill a microbe is only a few milliseconds. As $ClO_2$ is a rather volatile compound its contact time (its staying on the treated surface) is limited to a few minutes. While this stay is safely long enough (being at least 3 orders of magnitude longer than the killing time) to inactivate all bacteria on the surface of the organism, it is too short for $ClO_2$ to penetrate deeper than few tenths of a millimetre; thus, it cannot cause any real harm to an organism which is much larger than a bacterium.

In the Discussion part, it is shown that $ClO_2$ can meet the safety and effectiveness requirements for a local antiseptic. Next, the chemical mechanism of the antiseptic action of $ClO_2$ is discussed and compared with that of hypochlorous and hypoiodous acids (HOCl and HOI) which are „natural" antiseptics. These hypohalous acids are used by neutrophil granulocytes, the most abundant type of white blood cells in mammals, to kill bacteria after phagocytosis. Both hypohalous acids and also $ClO_2$ attack sulfhydryl groups [18,19] which play an essential role in the life processes of all living systems, e.g. in ATP synthesis. That explains why bacteria were not able to develop resistance against HOCl during eons of evolution and why the emergence of $ClO_2$ resistant bacterial strains cannot be expected either. Besides this similarity, however, there are also important dissimilarities among these reagents, e.g. $ClO_2$ is more selective than HOCl. Last of all, circulation in multicellular organisms can provide some additional protection to these organisms against $ClO_2$.

## Methods

### Materials

Reagent grade chemicals were purchased from Sigma-Aldrich and pork skin gelatine from Fluka (48719). High purity chlorine dioxide solutions were produced according to our invention [13]. Dried pig bladders were purchased in the Great Market Hall of Budapest at the shop "Solvent" (www.solvent.hu). These bladders are usually applied for kulen sausage production.

### Physico-chemical methods

**Measurement of $ClO_2$ permeation through protein membranes.** The rate of $ClO_2$ transport was measured with the apparatus shown in Figure 1 through two kinds of protein membranes: gelatin and pig bladder membranes, respectively. Choosing a membrane geometry for the experiments is advantageous because then the problem is „one dimensional", the concentration is a function of only one spatial coordinate $x$, which is perpendicular to the membrane, and the concentration distribution can be given as $c=c(x,t)$.

As Figure 1 shows, the membrane is in a horizontal position and the transport of $ClO_2$ takes place across the membrane bounded by two horizontal planes we denote by $x=0$ and $x=d$ in our calculations, where $d$ is the thickness of the membrane.

Constant $ClO_2$ concentrations are maintained at both boundaries of the membrane, i.e. we have constant boundary


stirrer motor
PVC holder
PTFE tubing stirrer
upper part of the glass apparatus
lower part of the glass apparatus
stirrer bar
syringe with 0.01 M $Na_2S_2O_3$ solution
PTFE tubing
acidic KI solution with starch indicator
silicone rubber membrane (permeable for $ClO_2$ only)
gelatin or pig bladder membrane
$ClO_2$ gas phase
aqueous $ClO_2$ solution

**Figure 1. Apparatus to measure $ClO_2$ transport through gelatine or pig bladder membranes.** The two glass parts of the apparatus are held together by a pair of extension clamps (not shown in the Figure) which are fixed to a support stand by clamp holders. The active cross-section of the membranes is 28 cm$^2$. See text for the working principle.
doi: 10.1371/journal.pone.0079157.g001

conditions: $c(0,t)=c_0$ and $c(d,t)=0$, respectively. There is no $ClO_2$ in the membrane at the start of the experiment, so the initial condition: $c(0<x\le d,0)=0$ (see Figure S1 in Information S1).

While the lower face of the protein membrane is not in direct contact with the liquid phase, such direct contact would not make any difference regarding the $ClO_2$ transport. This is because the chemical potential of $ClO_2$ in the liquid and the vapour phase is the same due to the equilibrium between the liquid and the vapour phase established by continuous stirring.

Above the protein membrane there is a silicone rubber membrane in order to block the transport of any other chemicals except $ClO_2$. Silicone rubber is highly permeable for chlorine dioxide, but it is practically impermeable for other reagents [13]. This way the $ClO_2$ transport across the test membrane can be measured selectively.

Both protein membranes had a thickness of 0.5 mm and a diameter of 10 cm. The diameter of the active area in the apparatus was 6 cm resulting in an active area of 28 cm$^2$. The volume of the aqueous $ClO_2$ solution was 40 ml and its $ClO_2$ concentration was around 1000 ppm. (The exact value is given at each experiment.)

After crossing the membranes, $ClO_2$ enters the upper aqueous solution which is made by mixing 10 ml of water, 2 ml of 1 M sulphuric acid, 1 ml of 1 M KI, and 0.5 ml of 0.01 M $Na_2S_2O_3$ and as an indicator, two drops of 5 % starch solution is also added. When $ClO_2$ enters the upper solution, it oxidizes iodide to iodine, which, in turn, is reduced back to iodide again by $Na_2S_2O_3$ as long as thiosulphate is in excess. However, when all thiosulphate is consumed, the intense blue-black colour of the starch-triiodide complex appears suddenly. The time *t* when the whole solution becomes homogeneously black (the time of the „black burst") was recorded and another 0.5 ml of $Na_2S_2O_3$ solution was added with the help of the syringe shown in the Figure. Addition of the thiosulphate eliminated the blue-black colour immediately but, after a certain period, when enough new $ClO_2$ was transported across the membrane, it reappeared again. Then the cycle was repeated starting with the injection of a new 0.5 ml portion of the $Na_2S_2O_3$ solution. The results of the measurements were depicted in a $V=V(t)$ diagram where *t* is the time of the n-th dark burst and $V = n\times0.5$ ml that is the total volume of the thiosulphate solution added before the *n*-th breakthrough.

The experiments were performed at laboratory temperature 24 ± 2 °C.

### Preparation of the gelatin membrane

To prepare a mechanically strong membrane, it was reinforced by filter paper and the gelatin was cross-linked with glutaraldehyde. As the cellulose in the filter paper does not react with $ClO_2$ from the point of our experiments, it is an inert material.

10 ml of 10 % aqueous gelatin solution was mixed rapidly with 0.5 ml of 25 % glutaraldehyde solution at room temperature, and a filter paper disk (diameter: 10 cm) was soaked with the mixture. Then the disk was placed between two glass plates covered with polyethylene foils. Spacers were applied to produce a 0.5 mm thick membrane. After a 2 hour setting time the filter paper reinforced gelatin membrane was removed from the form and it was placed into distilled water overnight before the measurements.

### Preparation of the pig bladder membrane

For the experiments, membrane disks with 10 cm diameters were cut from commercially available pig bladders and they were kept in distilled water for one day at +4 °C to stabilize their water content. The pig bladder membranes are slightly asymmetric: the surface of one side is smoother than the other. To obtain reproducible results, the membrane was always fixed in the apparatus with its smoother side facing downwards.

## Results

Our results cover the following themes: First, we present and evaluate membrane transport experiments aiming to determine

i) the diffusion coefficient of ClO2 D in a reactive protein medium, and

ii) the concentration of reactive groups s0 in that medium.

To evaluate the membrane transport experiments we applied a reaction-diffusion model for the transport of $ClO_2$ in a medium containing reactive proteins. The details of that theory and the



**Figure 2. Permeation of $ClO_2$ through a gelatin membrane as a function of time *t*.** Each point in the diagram represents a „black burst" (see Methods). *V* is the cumulative volume of the 0.01 M $Na_2S_2O_3$ titrant added before the burst and *N* is the amount of $ClO_2$ permeated until time *t*. $T_{L1}$ = 627 s and $T_{L2}$ = 175 s are time lags of the first and the second experiments, respectively. The concentration of $ClO_2$ source in the magnetically stirred aqueous solution was 1360 ppm (mg/kg) or 20.1 mM.

doi: 10.1371/journal.pone.0079157.g002

mathematical derivation of formulas applied in this section are given in the Information S1. Then, based on the experimentally determined *D* and $s_0$ we calculate $T_{KILL}$, the time needed to kill bacteria by $ClO_2$, and *p*, the penetration depth of $ClO_2$ into human tissue during a wound healing treatment.

$ClO_2$ permeation was measured via gelatin and pig bladder membranes. The apparatus is shown in Figure 1 of the Methods section.

## Permeation of $ClO_2$ through an artificial gelatin membrane

Gelatin was our first choice for a model material because we wanted to study the $ClO_2$ transport in a protein medium with a known amino acid composition. Pork skin gelatin (Fluka 48719) contains only two amino acids that can react with $ClO_2$: methionine (0.88 %) and tyrosine (0.6 %) [20].

Figure 2 shows the results of two consecutive experiments performed with the same gelatin membrane (see the two curves denoted as 1st exp. and 2nd exp.). After the first experiment, the membrane was removed from the apparatus and was kept in distilled water for 1 hour before the second experiment.

## Calculating the $ClO_2$ diffusion coefficient *D* and the effective concentration of $ClO_2$ consuming substrates $s_0$ in gelatin

Figure 2 shows N, the cumulated amount of ClO2 permeated through the membrane as a function of time.

(N was calculated from the titrant volumes V that are given in Table S1 in Information S1. together with the times t of addition.) It is a common feature of both curves shown in Figure 2 that two characteristically different dynamical regimes can be observed. In the first regime, the amount of the permeated ClO2 is very small, then, after a rapid transition period the cumulated amount of ClO2 increases linearly with time. Real dynamics can be approximated with the following simplified model: zero permeation is assumed at the beginning during a waiting period but right after that a constant diffusion current appears, thus, the permeated amount increases linearly with time. To characterize such a dynamic behaviour the concept of „time lag" can be introduced: it is the time where the asymptote of the linear regime crosses the time axis [21].

Regarding the asymptotes of the corresponding curves, the time lag in the first and in the second experiment is $T_{L1}$ = 627 s and $T_{L2}$ = 175 s, respectively. A logical explanation for this difference is that some $ClO_2$ is consumed inside the gelatin in the rapid reaction with methionine and tyrosine. So $ClO_2$ can break through only after it eliminates all these highly reactive amino acid residues. In the case of the second experiment, the breakthrough occurs earlier as most of these residues already reacted with $ClO_2$ during the first experiment.

If we assume that in the second experiment the reaction plays a minor role only, then in that case, the time lag is entirely due to diffusion. Roughly speaking the diffusional time lag is the time necessary to establish a steady state concentration profile inside the membrane that is to "fill up" the membrane with $ClO_2$. Based on dimensional analysis considerations (the dimension of the diffusion coefficient is $(\text{length})^2/(\text{time})$ ) we can expect that the time lag should be proportional with the square of the thickness and inversely proportional with the diffusional coefficient. Really, the exact result [21] is that the diffusional time lag $T_{DM}$ for a membrane of thickness *d* can be calculated as:

$$T_{DM}=\frac{1}{6}\cdot\frac{d^2}{D} \qquad (1)$$

Thus, with the assumption $T_{L2} = T_{DM}$ = 175 s, *D*, the diffusion coefficient of $ClO_2$ in the gelatin membrane can be calculated knowing that d = 0.5 mm. The result: $D = 2.4\times10^{-6}\ cm^2s^{-1}$.

*D* can be determined in another way as well, from the steady state regime. The steady state $ClO_2$ current is the slope of the curve in the linear regime. For the 2nd experiment $J_2$ = 30 nmol/s. Then Fick's law of diffusion

$$J=A\cdot D\cdot\frac{\Delta c}{d} \qquad (2)$$

can be applied to calculate D. Here $A$= 28.3 $cm^2$ is the active cross-section of the membrane and $\Delta c$ is the concentration difference between the two sides of the membrane. Regarding our boundary conditions $\Delta c=c_0 = 20.1\times10^{-3}$ M. This way $D = 2.6\times10^{-6}\ cm^2s^{-1}$ is obtained.

The two *D* values, the one calculated from the time lag and the other calculated from the steady state, agree reasonably well indicating that indeed the 175 s time lag is caused mostly by diffusion and any delay due to chemical reactions is negligible in the second experiment.

On the other hand, in the first experiment, the time lag $T_{RM}$ is caused mostly by the reaction between $ClO_2$ and the reactive amino acid residues (in short "substrates") in the membrane. It is important to realize that $T_{RM}$ is not due to a slowness of the



**Figure 3. Permeation of $ClO_2$ through a pig bladder membrane as a function of time *t*.** *V* and *N* have the same meaning like in Figure 2. $T_{L1}$ = 2770 s, $T_{L2}$ = 586 s and $T_{L3}$ = 226 s are time lags of the experiments performed on the 1st, 2nd, and 3rd day, respectively. The concentration of the $ClO_2$ source was 946 ppm (14.0 mM) in these experiments.

doi: 10.1371/journal.pone.0079157.g003

reaction kinetics (as the rate constants of the relevant $ClO_2$ – amino acid reactions are relatively high [22–24]), but it is due to the actual $ClO_2$ consumption by the reactions within the membrane delaying the breakthrough. If we assume that the rate of the chemical reaction is limited by the diffusional transport of $ClO_2$ across a zone already without reactive amino acids toward a zone of unreacted ones, then a sharp reaction front will develop on the boundary of the two zones (see Figure S1 in Information S1). The front starting from one side of the membrane and driven by diffusion, propagates slowly through the membrane and $T_{RM}$ is the time when it arrives to the other side of the membrane. According to a detailed derivation in the Information S1, $T_{RM}$ can be given by the so-called parabolic rate law (see equation (S12) in Information S1):

$$T_{RM}=\frac{1}{2}\cdot\frac{s_0}{c_0}\cdot\frac{d^2}{D} \tag{3}$$

where $s_0$ is the initial effective substrate concentration, i.e. the $ClO_2$ consuming capacity of the membrane in unit volume, and $c_0$ is $ClO_2$ concentration at the boundary of the membrane.

Substituting the more reliable diffusion coefficient measured in the steady-state of the second experiment $D$ = 2.6×$10^{-6}$ $cm^2s^{-1}$ and applying the assumption that $T_{RM} = T_{L1}$ = 627 s, the effective substrate concentration of the gelatin membrane $s_0$ can be calculated. The result: $s_0$ = 26.2 mM.

## Permeation of $ClO_2$ through a pig bladder membrane

In this experiment, we studied the $ClO_2$ permeability of a pig bladder membrane which is a relatively thin (in our case it was 0.5 mm thick) but sturdy animal tissue. The same apparatus was applied as in the case of the gelatin membrane and the experimental points were depicted in Figure 3 also with the same method. (Titrant volumes and the time of addition are given in Table S2 in Information S1.)

All the three measurements (indicated as 1st day, 2nd day and 3rd day) were performed with the same pig bladder membrane but on three successive days. The membrane was kept in distilled water at +4 °C overnight between the experiments which were always started with fresh solutions.

To check the reproducibility of our measurements, we repeated the measurements with another pig bladder membrane (not shown in the Figure). While the new membrane was from a different pig bladder and its blood vessel pattern was also different, the relative deviation between the results of the two series of experiments was surprisingly small: only about 10 %. (The blood vessel structure of the membrane becomes visible as a dark network before a „black burst" because the permeability of the membrane is somewhat higher through those vessels.)

Another interesting observation was that the pig bladder membrane maintained its integrity and its mechanical strength even after the third experiment. This is because $ClO_2$ reacts selectively with certain amino acid residues of the proteins but does not destroy the peptide bonds thus the primary protein structure can survive.

## Calculating the $ClO_2$ diffusion coefficient and the effective concentration of $ClO_2$ consuming substrates in pig bladder

Evaluation of the results was made in a similar way as in the case of the gelatin membrane. It was assumed that the time lag measured in the third experiment $T_{L3}$ =226 s is a purely diffusional time lag that is $T_{L3} \approx T_{DM}$. The diffusion coefficient of $ClO_2$ in a pig bladder membrane calculated from the above assumption is $D$ = 1.84×$10^{-6}$ $cm^2s^{-1}$. That value is in good agreement with the $D$ = 1.80×$10^{-6}$ $cm^2s^{-1}$ value calculated from the steady state current $J_3$ = 14.1 nmol/s of the 3rd experiment.

As we can see, the diffusion coefficient of $ClO_2$ in a pig bladder tissue is only 30 % smaller than in the unstructured gelatin. This supports our assumption that the cellular structure of the pig bladder tissue does not matter too much from the point of the diffusional transport of $ClO_2$ as it can penetrate through the external and internal lipid membranes of the individual cells of the tissue.

However, there is a more significant deviation between the pig bladder and the gelatin regarding $s_0$, the effective substrate concentration. Assuming that the time lag in the first experiment $T_{L1}$ = 2770 s is due to the chemical reaction, $T_{L1} \approx T_{RM}$, then from (3) we get $s_0$ = 56 mM, indicating that the concentration of the reactive components in the pig bladder tissue is about two times higher than that is in the gelatin. This is a reasonable result as the animal tissue is denser, and it contains not only methionine and tyrosine like gelatin, but also cysteine and tryptophan residues.

We would like to add that in a series of measurements performed with the same membrane the steady state $ClO_2$ current in the first experiment is always smaller than in the subsequent ones, although the $ClO_2$ source is not changed. This effect is more pronounced in the case of an animal membrane (compare the slope of the 1st day experiment with that of the other days). The phenomenon can be understood if we assume that some components, which are able to react with $ClO_2$ but only slowly, can remain in the pig bladder even after the first $ClO_2$ breakthrough. As it is shown in equation (S40) in the Information S1, the slow $ClO_2$ consumption of these components can explain a smaller quasi-steady state current. The fact that these components disappear from the membrane after keeping it in water overnight suggests that they are reaction products which can be leached out from the membrane or are unstable intermediates which decompose.

## Estimating the killing time for bacteria with cylindrical and spherical geometries

We assume that a bacterium is killed when its whole volume is flooded by $ClO_2$. To calculate the killing time, if we know the shape and the size of the bacterium, we would need two more parameters, the diffusion coefficient of $ClO_2$ $D$ and the effective concentration of $ClO_2$ consuming substrates $s_0$ in the bacterial medium. In the absence of bacterial data it will be assumed that the parameters $D$ and $s_0$ in the single cell of a bacterium are close to that what we have measured above in the animal cell aggregates of the pig bladder. A further simplifying assumption is that only spherical and cylindrical bacteria are considered. Numerical results are calculated for a diameter of 1 μm, which is a characteristic length-scale for bacteria. Mathematical formulas for the killing time and the penetration depth are derived in the Information S1. In this section only the results of those derivations will be given together with some qualitative explanations on their meaning.

It will be assumed that the rate of the "$ClO_2$ – bacterium reaction" is also limited by the diffusion of $ClO_2$ to the fast reacting amino acid residues fixed in protein molecules like in the case of the much larger membranes and this way a sharp reaction front propagates from the cell wall toward the centre of the bacterium.

Intuitively, the killing time $T_{KILL}$ should be analogous to the time lag $T_{RM}$ in a membrane caused by a chemical reaction, because these are the times needed to flood the whole volume. We can expect, however, that the geometric factor should be different depending on the shape of the bacterium. For a cylindrical bacterium with a diameter of $d$ the killing time is

$$T_{KILL,C}=\frac{1}{16}\cdot\frac{s_0}{c_0}\cdot\frac{d^2}{D} \tag{4}$$

see equation (S18) in the Information S1, and for a spherical bacterium also with a diameter of $d$ it is

$$T_{KILL,S}=\frac{1}{24}\cdot\frac{s_0}{c_0}\cdot\frac{d^2}{D} \tag{5}$$

according to equation (S24) in Information S1. We can see that (4) and (5) are analogous to (3) but the geometric factors for a cylinder and for a sphere are much smaller than for the planar membrane indicating that in these geometries the surface from where diffusion current is starting is relatively larger compared to the volume that has to be flooded.

Substituting the pig bladder parameters $D$ = $1.8\times10^{-6}$ $cm^2s^{-1}$ and $s_0$ = 56 mM into formulas (4,5) together with the $ClO_2$ concentration applied in the wound healing experiments (see later) $c_0$ = 4.45 mM (Solumium Oral®, 300 ppm) and using d = 1 μm we obtain that the killing time for a cylindrical bacterium with a diameter of 1 μm is

$$T_{KILL,C}=4.4\text{ ms},$$

while the killing time for a spherical bacterium with a diameter of 1 μm is

$$T_{KILL,S}=2.9\text{ ms}.$$

As we can see, the killing time for a bacterium is only a few ms due to its small size. Even if $s_0$, the effective substrate concentration of a bacterium would be an order of magnitude higher than we assumed, the killing time would be still less than 0.1 s. Other approximations applied in our calculations can only overestimate the real killing time. For example, the diffusion coefficient of $ClO_2$ in the pig bladder was measured at 24 ± 2 °C. If $ClO_2$ is used to disinfect a living human tissue, the temperature is higher, which means a larger diffusion coefficient and an even shorter killing time. Another approximation is the concept of fixed substrates. Inside a bacterium mobile substrates like glutathione [25], free amino acids and various antioxidants also occur. These small molecules can diffuse by and large freely within the bacterium. Nevertheless $T_{KILL}$ would still work as a good upper estimate because the mobility of the substrate can only shorten the time needed for $ClO_2$ to reach these substrates and react with them. Furthermore, when the killing time $T_{KILL}$ is regarded as the time when the sharp front reaches the center of the sphere or the symmetry axis of the cylindrical bacterium, it will surely be overestimated, as it is not necessary to oxidize all the available substrate content of a bacterium to kill it. For example, it is enough to oxidize less than 40 % of the methionine content of *E. coli* to achieve a 100 % kill [26].

## Contact time and penetration depth of $ClO_2$ into human skin or wound

When an organism is not submerged in the aqueous $ClO_2$ solution but the solution is applied on its surface only, as in the case of disinfecting wounds, the volatility of $ClO_2$ also has to be taken into account. The effective contact time is much shorter using a $ClO_2$ solution than with less or non-volatile disinfectants. According to our measurements, when a wound is covered with 3 wet and 3 dry layers of gauze more than 80 % of $ClO_2$ evaporates from the bandage within one minute due to the high volatility of $ClO_2$ and to the high specific surface of the gauze. Thus, to give an upper limit for the penetration depth into the human tissue, we will assume that the initial $ClO_2$ concentration ($c_0$ = 4.45 mM, Solumium Oral®) is maintained for 60 s, that is $T_{CON}$ = 60 s, where $T_{CON}$ denotes the contact time. As a zero-th estimate, we assume again that the human tissue has the same $D$ and $s_0$ values like that of the pig bladder tissue.

Applying the parabolic rate law (see equation (S13) in Information S1 where $t$ = $T_{CON}$) the penetration depth $p$ can be estimated:

$$p=\sqrt{\frac{2c_0D\cdot T_{CON}}{s_0}} \tag{6}$$

$p(T_{CON} = 60\text{ s}) = 41.5\ \mu m$. We remark that (6) can be derived from (3) directly if we realize that for the present problem $d = p$ and $T_{RM} = T_{CON}$.

Nevertheless, the actual penetration depth into a living tissue - either its surface is a wound or an intact human skin – should be even much smaller than the above estimate. This is due to the capillary circulation which is present in living tissue but is absent from dead tissue like the pig bladder membrane used for the measurements. The serum in the blood vessels and also the extracellular fluid contain many components capable of reacting rapidly with $ClO_2$. The fluid transport of these reactive components in the blood capillaries of the dermis [27] can maintain a finite reactant concentration in that region. Then the diffusive transport of these reactants outward from the dermis into the epidermis [27] can halt an inward propagating reaction front establishing a steady state.

Moreover, in the case of intact human skin, $ClO_2$ should permeate through the stratum corneum [28] first, which is the 10–40 μm thick outermost layer of epidermis consisting of several layers of dead cells. This keratinous layer forms a barrier to protect the underlying tissue from infection, dehydration and chemicals. The diffusion coefficient of $ClO_2$ in that layer should be much lower compared to the underlying tissue.

As we can see, the penetration depth into human skin is only few tens of a micrometer even if we neglect circulation. Such shallow penetration cannot really harm human tissues. On the other hand, this short contact time is still several orders of magnitude larger than the killing time, $T_{CON} >> T_{KILL}$, which is the necessary criterion of a successful disinfection.

### Therapeutic window

The above formulas and calculations indicate that disinfection of living tissues with aqueous $ClO_2$ solutions has a very wide therapeutic window: while surprisingly low concentrations and short contact times are able to kill bacteria, much higher concentrations and residence times are still safe to use.

There is one notable exception: inhaling high concentration $ClO_2$ gases for an extended time can be dangerous for human health because the alveolar membrane is extremely thin (a mere 1-2 microns and in some places even below 1 micron). The effect of $ClO_2$ in these membranes is somewhat counterbalanced, however, by the intense blood circulation there.

## Discussion

In this section first we discuss whether $ClO_2$ should be regarded as an "exotic" antiseptic only or it has the promise to become a commonly used antiseptic to treat local infections. To this end safety and effectiveness requirements for a local antiseptic are collected to check how $ClO_2$ can meet these requirements compared to other antiseptics.

Next a biochemical action mechanism, explaining the antiseptic effect of $ClO_2$ is discussed, which is partly analogous to that of hypochlorous and hypoiodous acids. These "natural" antiseptics also react, among others, with sulfhydryl groups like $ClO_2$ but their reaction products can be different. The importance of that difference and the protective role of SH groups and of the circulatory system, existing in a multicellular organism only, is also discussed.

### Safety and effectiveness requirements for a local antiseptic

A local antiseptic should meet the following requirements to be considered as safe:

i) it should act only locally to avoid systemic poisoning, and

ii) it should not prevent or delay the process of healing, i.e. it should not be cytotoxic.

and as effective:

iii) it should be effectual in relatively low concentrations, and even in biofilms (biofilms are medically important, accounting for over 80 percent of microbial infections in the body [29]) as well, and

iv) microbes should not be able to develop resistance against it (a problem related to the biochemical mechanism of action).

As it was shown in the Results section $ClO_2$ as a size selective antiseptic, meets requirements i) and ii). Thus only criteria iii) and iv) are discussed here.

### Comparing the biocidal activity of $ClO_2$ to that of other antiseptics (criterion iii)

In free aqueous solutions, the strongest chemical disinfectant is ozone. In biofilms, however, the performance of ozone is rather poor. In addition, ozone is toxic and decomposes in aqueous solutions rapidly. (Its half life is only 15 min at 25 °C at pH 7.) All of these disadvantageous properties of ozone prevent its use as an antiseptic in most applications.

The second strongest disinfectant after ozone is chlorine dioxide. Tanner [30] made a comparative testing of eleven disinfectants on three test organisms (including two bacteria: Staphylococcus aureus and Pseudomonas aeruginosa and one yeast: Saccharomyces cerevisiae). He found that the disinfectant containing $ClO_2$ had the highest biocidal activity on a mg/l basis against the test organisms. Beside antibacterial and antifungal properties, $ClO_2$ also shows strong antiviral activity, about ten times higher than that of sodium hypochlorite [31]. And it inactivates practically all microbes including algae and animal planktons [32] and protozoans [33].

Moreover $ClO_2$ can remove biofilms swiftly [12] because it is highly soluble in water and unlike ozone it does not react with the extracellular polysaccharides of the biofilm. This way $ClO_2$ can penetrate into biofilms rapidly to reach and kill the microbes living within the film.

### Impossibility of bacterial resistance against $ClO_2$ (criterion iv)

$ClO_2$ is a strong, but a rather selective oxidizer. Unlike other oxidants it does not react (or reacts extremely slowly) with most organic compounds of a living tissue. $ClO_2$ reacts rather fast, however, with cysteine [22] and methionine [34] (two sulphur containing amino acids), with tyrosine [23] and tryptophan [24]

745

(two aromatic amino acids) and with two inorganic ions: $Fe^{2+}$ and $Mn^{2+}$. It is generally assumed that the antimicrobial effect of $ClO_2$ is due mostly to its reactions with the previously mentioned four amino acids and their residues in proteins and peptides. In the peptide group it is important to mention glutathione – a small tripeptide containing cysteine – which is a major antioxidant in cells, with an intracellular concentration of 0.1-10 mM [35].

Margerum's group [22–24] reported the following second order rate constants at pH 7 and 25 °C: cysteine $1\times10^7$ $M^{-1}s^{-1}$ >> tyrosine $1.8\times10^5$ $M^{-1}s^{-1}$ > tryptophan $3.4\times10^4$ $M^{-1}s^{-1}$. As can be seen, cysteine is the far most reactive amino acid because of its thiol group. As the above mentioned four amino acids and especially cysteine and biological thiols play a crucial role in all living systems, including microbes, it is impossible for any microbe to develop a resistance against chlorine dioxide.

As an important analogy we can mention that bacteria have never been able to become resistant against hypochlorous acid (HOCl) either, which is an important natural antiseptic used by neutrophils for millions of years. Neutrophils, a type of white blood cells, are phagocytes which kill the engulfed microbes by applying various hydrolytic enzymes and hypohalogeneous acids, chiefly HOCl [36,37]. On that basis Robson and co-workers applied HOCl as a kind of „natural" wound care agent [38,39]. Thus, it is reasonable to compare the action mechanisms and other properties of $ClO_2$ and HOCl as antiseptic agents.

## Comparison of $ClO_2$ and HOCl as possible antiseptic agents

HOCl, like $ClO_2$, reacts rapidly with the sulphur containing amino acid residues of methionine and cysteine, the second order rate constant (at pH 7.4 and 22 °C) being $3.8\times10^7$ $M^{-1}s^{-1}$ and $3.0\times10^7$ $M^{-1}s^{-1}$, respectively, and also reacts with tryptophan ($1.1\times10^4$ $M^{-1}s^{-1}$) and tyrosine (44 $M^{-1}s^{-1}$) [40]. However, unlike $ClO_2$, HOCl reacts rapidly with many other amino acid residues and even with peptide bonds [40], and many other compounds such as carbohydrates, lipids, nucleobases, and amines [41].

As we can see the important similarity is the fast reaction of both HOCl and $ClO_2$ with the SH group of cysteine. This is important because it is assumed that abolition of ATP synthesis and killing bacteria by HOCl is due to its reaction with sulfhydryl groups [18]. It is a logical assumption that $ClO_2$ can also stop the ATP synthesis as it reacts with the very same SH groups like HOCl.

At the same time, however, there are important dissimilarities between HOCl and $ClO_2$:

i) HOCl is much less specific and reacts rapidly with numerous other substrates. Thus killing bacteria with HOCl requires more reagent than with $ClO_2$.

ii) While $ClO_2$ evaporates rapidly from its aqueous solution and can reach and kill bacteria even through a gas phase, e.g. through an air bubble blocking a dental root canal [42], evaporation of HOCl is not significant. Thus HOCl stays at the disinfected area for a long time even after killing all bacteria which can cause inflammation there [43].

iii) HOCl is a more drastic reagent and causes irreversible damage. For example $ClO_2$ oxidizes glutathione (GSH) mainly to glutathione disulfide (GSSG) [22] which can be reduced back to GSH easily in a natural way in the body. On the other hand, HOCl can attack disulfide bonds and oxidizes GSH mostly to glutathione sulfonamide (GSA) [44] causing an irreversible loss of the cellular GSH.

## Sulfhydryl groups and circulation can protect multicellular organisms from $ClO_2$ inflicted irreversible damage

As it was mentioned, the $ClO_2$ –SH group reaction has the highest rate constant among the $ClO_2$ – amino acid reactions. (Cysteine or GSH [22] reacts about 50 times faster than the runner up tyrosine.) Consequently, as long as some SH groups are present (mostly in the form of GSH), these groups react with $ClO_2$ rapidly protecting other amino acid residues from oxidative damage. Moreover the oxidation of SH groups to disulfide bonds can be reversed. An interesting example was presented by Müller and Kramer [45,46]. They found that the cytotoxic effect of povidone-iodine after a 30 min contact with murine fibroblast was only temporal: after a 24 hour culture without the antiseptic an unexpected revitalization of the fibroblasts was observed [45]. According to Winterbourn and co-workers [47], HOI (the reactive hydrolysis product of iodine) also oxidises GSH to GSSG but not to GSA. That parallelism between the reversible HOI-GSH and the $ClO_2$-GSH reactions raises the question whether an analogous revitalization might be also possible in the case of $ClO_2$. This question is all the more justified since in some animal experiments [16] rats were drinking water containing 200 ppm $ClO_2$ for 90 days but without developing any gastrointestinal problems. In those experiments all $ClO_2$ must have reacted with the animal tissues as it cannot evaporate from the stomach of the rats. To interpret that result it is reasonable to assume that SH groups transported by the circulation system of the rodent protected the epithelial cells in its gastrointestinal tract from an irreversible oxidation by $ClO_2$.

Above a certain limit, however, when a too high percentage of the protective SH groups is already oxidized, $ClO_2$ would inflict irreversible changes to the higher order protein structures by oxidizing the tyrosine and tryptophan residues [48]. That would certainly happen with the bacteria on the surface of an infected tissue as their GSH supply [26] can be rapidly exhausted by $ClO_2$. Mammalian cells below the surface, however, might survive being supported by the circulation which transports protective sulfhydryl and other reductive compounds to the cells, continuously repairing or even revitalizing them.

Thus beside their size there is another important difference between single cell and more complex multicellular organisms: it is the circulation which can help the cells of a multicellular organism to survive while that type of help is not available for a bacterium.

## Conclusion

Chlorine dioxide is a size selective antimicrobial agent which can kill micron sized organisms rapidly but cannot make real harm to much larger organisms like animals or humans as it is not able to penetrate deeply into their living tissues. Moreover the circulation of multicellular organisms can provide an additional protection to these organisms against $ClO_2$.

It is an aim of the present work to initiate clinical studies hoping that $ClO_2$ could be applied to treat various local infections, especially where bacterial resistance is a problem. We have already obtained an official permission [49] to start such studies.

## Supporting Information

**Information S1. This file contains the description of a reaction-diffusion (RD) model for the transport of $ClO_2$ in a medium containing reactive proteins, and its quasi steady state solution when the $ClO_2$ – substrate reaction is fast and when it is slow.** Figure S1. Schematic $ClO_2$ and substrate concentration profiles in a hydrogel slab. Table S1. Data depicted in Figure 2 (the cumulative volume V of the 0.01 M $Na_2S_2O_3$ titrant added until time *t*). Table S2. Data depicted in Figure 3 (the cumulative volume V of the 0.01 M $Na_2S_2O_3$ titrant added until time *t*). (PDF)

## Acknowledgements

The authors thank Ms. Marianna Megyesi for performing the physico-chemical experiments and Dr. György Berencsi, Dr. Mihály Kádár, Dr. Márta Milassin, Prof. Ferenc Rozgonyi and Dr. Gusztáv Várnai for helpful discussions. We also thank Ms. Mary-Beth Sinamon for proofreading our MS as a native English speaker.

## Author Contributions

Conceived and designed the experiments: ZN MW KKK ZB IK LR JSz. Performed the experiments: ZN MW KKK. Analyzed the data: ZN MW KKK ZB IK LR JSz. Contributed reagents/materials/analysis tools: ZN MW KKK. Wrote the manuscript: ZN MW KKK. Evaluated the physico-chemical experiments from the point of medical relevance and future research protocols: ZB IK LR JSz.

## References

1. Amyes SGB (2010) Antibacterial Chemotherapy. Theory, Problems and Practice. Oxford: Oxford University Press.
2. Spellberg B (2009) Rising Plague. The Global Threat from Deadly Bacteria and Our Dwindling Arsenal to Fight Them. Amherst, NY: Prometheus Books.
3. Evans BA, Hamouda A, Amyes SGB (2013) The rise of carbapenem-resistant Acinetobacter baumannii. Curr Pharm Des 19(2): 223-238. doi:10.2174/138161213804070285. PubMed: 22894617.
4. Luo G, Lin L, Ibrahim AS, Baquir B, Pantapalangkoor P et al. (2012) Active and Passive Immunization Protects against Lethal, Extreme Drug Resistant-*Acinetobacter baumannii* Infection. PLOS ONE 7(1): e29446. doi:10.1371/journal.pone.0029446. PubMed: 22253723.
5. McDonnell G, Russell AD (1999) Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 12: 147–179. PubMed: 9880479.
6. Koburger T, Hübner NO, Braun M, Siebert J, Kramer A (2010) Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. J Antimicrob Chemother 65: 1712–1719. doi:10.1093/jac/dkq212. PubMed: 20551215.
7. Lansdown ABG (2010) Silver in Healthcare: Its Antimicrobial Efficacy and Safety in Use. Issues in Toxicology. Cambridge: RSC Publications.
8. Das S (2011) Application of ozone therapy in dentistry. Rev Ind J Dent Adv 3: 538–542.
9. Mehra P, Clancy C, Wu J (2000) Formation of facial hematoma during endodontic therapy. J Am Dent Assoc 131: 67–71. PubMed: 10649874.
10. Cadenas E (1989) Biochemistry of oxygen toxicity. Annu Rev Biochem 58: 79–110. doi:10.1146/annurev.bi.58.070189.000455. PubMed: 2673022.
11. Harris AG, Hinds FE, Beckhouse AG, Kolesnikow T, Hazell SL (2002) Resistance to hydrogen peroxide in Helicobacter pylori: role of catalase. Microbiology 148: 3813–3825. PubMed: 12480885.
12. Simpson GD, Miller RF, Laxton GD, Clements WR (1993) A focus on chlorine dioxide: the "ideal" biocide. Corrosion 93. New Orleans, La, March 8-12. paper No. 472.. Available: http://www.clo2.gr/en/pdf/secure/chlorinedioxideidealbiocide.pdf. Accessed 2013 April 15.
13. Noszticzius Z, Balogh S, Gyökérné Wittmann M, Kály-Kullai K, Megyesi M et al. (2006) Permeation method and apparatus for preparing fluids containing high purity chlorine dioxide. Available: http://patentscope.wipo.int/search/en/WO2008035130 Accessed 2013 April 15.
14. Solumium website. Available: www.solumium.com. Accessed 2013 April 15.
15. Csikány Cs, Várnai G, Noszticzius Z (2009) SOLUMIUM DENTAL: a hipertiszta klórdioxid oldat és alkalmazása a fogorvosi gyakorlatban II. (SOLUMIUM DENTAL: Application of high purity chlorine dioxide solution in the dental practice II., in Hungarian). Dental Hírek 2009/5: 36-38
16. Daniel FB, Condie LW, Robinson M, Stober JA, York RG et al. (1990) Comparative 90-day subchronic toxicity studies on three drinking water disinfectants, chlorine, monochloramine and chlorine dioxide in the Sprague-Dawley rats. J Am Water Works Assoc 82: 61–69.
17. Lubbers JR, Chauan SR, Bianchine JR (1982) Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. Environ Health Perspect 46: 57–62. doi:10.1289/ehp.824657. PubMed: 6961033.
18. Barrette WC Jr, Hannum DM, Wheeler WD, Hurst JK (1989) General mechanism for the bacterial toxicity of hypochlorous acid: abolition of ATP production. Biochemistry 28: 9172–9178. doi:10.1021/bi00449a032. PubMed: 2557918.
19. Smit MJ, Anderson R (1992) Biochemical mechanisms of hydrogen peroxide- and hypochlorous acid-mediated inhibition of human mononuclear leukocyte functions in vitro: protection and reversal by anti-oxidants. Agents Actions 36: 58-65. doi:10.1007/BF01991229. PubMed: 1329447.
20. Eastoe JE (1955) The amino acid composition of mammalian collagen and gelatin. Biochem J 61: 589–600. PubMed: 13276342.
21. Crank J (1975) Mathematics of Diffusion. Oxford: Clarendon. 51 pp.
22. Ison A, Odeh IN, Margerum DW (2006) Kinetics and mechanisms of chlorine dioxide and chlorite oxidations of cysteine and glutathione. Inorg Chem 45: 8768–8775. doi:10.1021/ic0609554. PubMed: 17029389.
23. Napolitano MJ, Green BJ, Nicoson JS, Margerum DW (2005) Chlorine dioxide oxidations of tyrosine, N-acetyltyrosine, and Dopa. Chem Res Toxicol 18: 501–508. doi:10.1021/tx049697i. PubMed: 15777090.
24. Stewart DJ, Napolitano MJ, Bakhmutova-Albert EV, Margerum DW (2008) Kinetics and mechanisms of chlorine dioxide oxidation of tryptophan. Inorg Chem 47: 1639–1647. doi:10.1021/ic701761p. PubMed: 18254588.
25. Chesney JA, Eaton JW, Mahoney JR (1996) Bacterial glutathione: a sacrificial defense against chlorine compounds. J Bacteriol 178: 2131–2135. PubMed: 8606194.
26. Rosen H, Klebanoff SJ, Wang Y, Brot N, Heinecke JW et al. (2009) Methionine oxidation contributes to bacterial killing by the myeloperoxidase system of neutrophils. Proc Natl Acad Sci U S A 106: 18686–18691. 18688 p. Fig. 3B doi:10.1073/pnas.0909464106. PubMed: 19833874.
27. Wikipedia: Skin. Available: http://en.wikipedia.org/wiki/Skin. Accessed 2013 April 15.

28. Wikipedia: Stratum corneum. Available: http://en.wikipedia.org/wiki/Stratum_corneum. Accessed 2013 April 15.
29. NIH Guide: Research on microbial biofilms. Available: http://grants.nih.gov/grants/guide/pa-files/PA-03-047.html. Accessed 2013 April 15
30. Tanner R (1989) Comparative testing and evaluation of hard-surface disinfectants. J Ind Microbiol 4: 145–154. doi:10.1007/BF01569799.
31. Sanekata T, Fukuda T, Miura T, Morino H, Lee C et al. (2010) Evaluation of the antiviral activity of chlorine dioxide and sodium hypochlorite against feline calicivirus, human influenza virus, measles virus, canine distemper virus, human herpesvirus, human adenovirus, canine adenovirus and canine parvovirus. Biocontrol Sci 15/2: 45–49. doi:10.4265/bio.15.45. PubMed: 20616431.
32. Junli H, Li W, Nenqi R, Li LX, Fun SR et al. (1997) Disinfection effect of chlorine dioxide on viruses, algae and animal planktons in water. Water Res 31: 455–460. doi:10.1016/S0043-1354(96)00276-X.
33. EPA Guidance Manual, Alternative Disinfectants and Oxidants, 4.4.3.2 Protozoa Inactivation.. Available: http://www.epa.gov/ogwdw/mdbp/pdf/alter/chapt_4.pdf. Accessed 2013 April 15
34. Loginova IV, Rubtsova SA, Kuchin AV (2008) Oxidation by chlorine dioxide of methionine and cysteine derivatives to sulfoxide. Chem Nat Compd 44: 752–754. doi:10.1007/s10600-009-9182-8.
35. Meister A (1988) Glutathione metabolism and its selective modification. J Biol Chem 263: 17205–17208. PubMed: 3053703.
36. Nauseef WM (2007) How human neutrophils kill and degrade microbes. An integrated view. Immunol Rev 219: 88–102. doi:10.1111/j.1600-065X.2007.00550.x. PubMed: 17850484.
37. Rosen H, Klebanoff SJ, Wang Y, Brot N, Heinecke JW et al. (2009) Methionine oxidation contributes to bacterial killing by the myeloperoxidase system of neutrophils. Proc Natl Acad Sci U S A 106: 18686-18691. doi:10.1073/pnas.0909464106. PubMed: 19833874.
38. Wang L, Bassiri M, Najafi R, Najafi K, Yang J et al. (2007) Hypochlorous acid as a potential wound care agent, Part I. J Burns Wounds 6: 65–79.
39. Robson MC, Payne WG, Ko F, Mentis M, Donati G et al. (2007) Hypochlorous acid as a potential wound care agent, Part II. J Burns Wounds 6: 80–90.
40. Pattison DI, Davies MJ (2001) Absolute rate constants for the reaction of hypochlorous acid with protein side chains and peptide bonds. Chem Res Toxicol 14: 1453–1464. doi:10.1021/tx0155451. PubMed: 11599938.
41. Pattison DI, Davies MJ (2006) Reaction of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Curr Med Chem 13: 3271–3190. doi:10.2174/092986706778773095. PubMed: 17168851.
42. Hercegh A, Ghidan Á, Friedreich D, Gyurkovics M, Bedő Zs et al. (2013) Effectiveness of a high purity chlorine dioxide solution in eliminating intercanal Enterococcus faecialis biofim. Acta microbiol Immunol Hung 60(1): 63–75.
43. Pullar JM, Vissers MCM, Winterbourn CC (2000) Living with a killer: the effects of hypochlorous acid on mammalian cells. IUBMB Life 50: 259–266. doi:10.1080/15216540051080958. PubMed: 11327319.
44. Pullar JM, Vissers MCM, Winterbourn CC (2001) Glutathione oxidation by hypochlorous acid in endothelial cells produces glutathione sulfonamide as a major product but not glutathione disulfide. J Biol Chem 276: 22120–22125. doi:10.1074/jbc.M102088200. PubMed: 11283008.
45. Müller G, Kramer A (2006) Comparative study of in vitro cytotoxicity of povidone-iodine in solution, in ointment or in a liposomal formulation (Repithel) and selected antiseptics.Dermatology 212 Suppl 1: 91-93. doi:10.1159/000090102. PubMed: 16490982.
46. Müller G, Kramer A (2007) Revitalisierung von Säugerzellen nach Einwirkung von Antiseptika. (Revitalisation of mammalian cells exposed to antiseptics, in German). GMS Krankenhaushyg Interdiszip 2007 2(2):Doc35. Available: http://www.egms.de/static/en/journals/dgkh/2007-2/dgkh000068.shtml. Accessed 2013 April 15.
47. Harwood DT, Kettle AJ, Winterbourn CC (2006) Production of glutathione sulfonamide and dehydroglutathione from GSH by myeloperoxidase-derived oxidants and detection using a novel LC–MS/MS method. Biochem J 399: 161–168. doi:10.1042/BJ20060978. PubMed: 16846394.
48. Ogata N (2007) Denaturation of Protein by Chlorine Dioxide: Oxidative Modification of Tryptophane and Tyrosine Residues. Biochemistry 46: 4898-4911. doi:10.1021/bi061827u. PubMed: 17397139.
49. KLO2-UCD-HU_2010ssued by the Hungarian National Health and Medical Officer Service (ANTSZ) following the suggestion of the Scientific Committee named ETT TUKEB. Available: http://www.ett.hu/tukeb.htm Accessed 2013 April 15.

# Coalición Mundial Salud y Vida
# -COMUSAV-

**Resumen de la identificación de riesgos por la ingesta del dióxido de cloro en humanos y otros mamíferos, basado en el reporte de la U.S. Enviromental Protection Agency (EPA): CHLORINE DIOXIDE AND CHLORITE. (CAS Nos. 10049-04-4 and 7758-19-2). Publicado en el año 2,000.**

*En letras cursivas van los comentarios y la comparación de los resultados publicados en los reportes de investigación con las dosis de ingesta que se están proponiendo por los médicos de COMUSAV, para prevenir o para tratar pacientes de COVID 19.*

**Antecedentes:**

*La FDA reporta en su sitio Web (https://www.fda.gov/news-events/press-announcements/actualizacion-del-coronavirus-covid-19-la-fda-advierte-empresa-que-comercializa-productos-peligrosos, de fecha 8 de abril del 2020), los efectos adversos del dióxido de cloro a la salud humana, y lo ha difundido masivamente en los medios, tanto escritos como en las redes sociales. Por otro lado, las instituciones de salud de cada país han copiado este aviso y lo transcriben tal cual, en sus medios de comunicación, sin verificar la certeza de estas aseveraciones. Entre los síntomas adversos que reporta la FDA incluye los siguientes:*

1. *Insuficiencia respiratoria causada por una condición grave en donde la cantidad de oxígeno que se transporta a través del torrente sanguíneo se reduce considerablemente (metahemoglobinemia).*
2. *Cambios en la actividad eléctrica del corazón (prolongación del QT), lo que puede llevar a ritmos cardíacos anormales y posiblemente mortales.*
3. *Baja presión arterial mortal causada por deshidratación.*
4. *Insuficiencia hepática aguda.*
5. *Conteo bajo de células sanguíneas, debido a la rápida destrucción de los glóbulos rojos (anemia hemolítica), lo que requiere una transfusión de sangre.*
6. *Vómitos severos.*

*Sin embargo, dicho aviso no indica si estos síntomas son por la ingesta o por la inhalación del gas dióxido de cloro, condiciones totalmente distintas en cuanto a los efectos que esta molécula causa al organismo. Además, no deja claro si dichos síntomas son por el uso del producto conocido en internet como MMS (Magistral Mineral Solution) o por la solución de dióxido de cloro (CDS) a una concentración de solo 0.3 g/litro (3,000 ppm). Solo hace mención a: "es un producto líquido que se vende con 28% clorito sódico en agua destilada y con instrucciones de uso para que los consumidores mezclen la solución de clorito sódico con ácido cítrico, jugo de limón o lima, u otro ácido como el ácido clorhídrico, antes de tomarlo. Además de referir que el clorito sódico se vende como parte de un kit con un ácido cítrico que sirve como activador y al mezclarse produce dióxido de cloro, un potente agente blanqueador que causa serios efectos colaterales que comprometen la vida". Por lo que se asume que se refiere al MMS y no al Dióxido de cloro en solución (el cual se encuentra ya preparado). Tampoco se indican las dosis a las que se podrían causar los síntomas arriba descritos.*

*Por otro lado, la Coalición Mundial Salud y Vida (COMUSAV) que agrupa a 3,000 médicos de 19 países del mundo reporta, por el contrario, que el dióxido de cloro, utilizado a la dosis correcta*

749

*es una molécula capaz de prevenir y ser tratamiento ante el COVID19. (afirmaciones basadas en prácticas de campo y estudios científicos observacionales retrospectivos en humanos amparados en la declaración de Helsinski de la Asociación Médica Mundial que en su artículo 37 dice a la letra:*

***Intervenciones no probadas en la práctica clínica***

*Artículo 37: Cuando en la atención de un paciente las intervenciones probadas no existen u otras intervenciones conocidas han resultado ineficaces, el médico, después de pedir consejo de expertos, con el consentimiento informado del paciente o de un representante legal autorizado, puede permitirse usar intervenciones no comprobadas, si, a su juicio, ello da alguna esperanza de salvar la vida, restituir la salud o aliviar el sufrimiento. Tales intervenciones deben ser investigadas posteriormente a fin de evaluar su seguridad y eficacia. En todos los casos, esa información nueva debe ser registrada y, cuando sea oportuno, y puesta a disposición del público.*

### *Revisión de literatura científica relacionada con la toxicidad del dióxido de cloro (CDS)*

*Para ello se recurrió a uno de los reportes más completos al respecto, el cual fue generado por otra agencia de los Estados Unidos de América: la U. S. Environmental Protection Agency (U.S. EPA " CHLORINE DIOXIDE AND CHLORITE (CAS Nos. 10049-04-4 and 7758-19-2) In Support of Summary Information on the Integrated Risk Information System (IRIS) September 2000"), la cual emitió un reporte donde analiza la posible toxicidad tanto del dióxido de cloro, como del clorito de sodio, y las dosis a las que dicha toxicidad podría ocurrir en caso de ser ingerido. En este reporte que realiza COMUSAV el análisis se reduce específicamente al dióxido de cloro ingerido por vía oral, el producto que ha mostrado cualidades preventivas y de tratamiento ante el COVID 19, según manifiestan los médicos de los diversos países de esta organización.*

### Diferencias entre el CDS y MMS.

*Mucho se ha vertido en los medios sobre el riesgo de consumir MMS y con mucha frecuencia suele confundirse con CDS (Solución de dióxido de cloro). Es importante clarificar que el MMS es una solución que se prepara a partir de la mezcla de algunas gotas de cada uno de los dos reactivos: Clorito de sodio, por un lado, y un ácido que puede ser cítrico o clorhídrico. A esta mezcla se agrega en un litro de agua, se deposita en una botella, se cierra herméticamente y se ingiere a lo largo del día. El problema de esta mezcla es que ninguno de los dos reactivos es químicamente puro y al tomar la mezcla de estos se ingieren las impurezas que traen ambos reactivos. Estas impurezas o subproductos químicos pueden generar malestares como diarreas, vómitos y otros efectos colaterales que, aunque no son de gravedad, no dejan de ser molestias, en especial cuando se bebe una dosis elevada de estos productos debidos a la mala información que existe en el público en general, quienes por la urgencia sanitaria que se vive al intentar prevenir o tratar el COVID 19, lleva a no acudir a una asesoría o consulta médica y a consumir productos que no han sido preparados bajo la supervisión de químicos capacitados en la elaboración.*

*Por otro lado, el otro compuesto que solo contiene dióxido de cloro disuelto en agua (CDS) a una concentración de 3,000 ppm (mg/L) no contiene las impurezas que contiene el denominado MMS proveniente de la mezcla de los dos reactivos descritos arriba. En el caso del CDS se trata de un compuesto sumamente puro, pues las dos sustancias se ponen a reaccionar en un recipiente que contiene adentro otro pequeño contenedor donde se lleva a cabo la reacción química y de donde se genera el gas dióxido de cloro que saturará el agua que esta por fuera de este recipiente. Es importante aclarar sin lugar a duda que el dióxido de cloro en solución no contiene absolutamente*

750

*nada de clorito de sodio, ni de algún ácido, como se he pretendido confundir en varios spots publicitarios que pretenden denostrar la solución del dióxido de cloro. Otra forma de producir el dióxido de cloro es por electrolisis.*

*En base al procedimiento de su preparación, la solución CDS contiene un elevado grado de pureza, pues solo contiene el dióxido de cloro disuelto en agua. En resumen, el MMS contiene impurezas que pueden causar malestar al ser ingerido, pero el dióxido de cloro en solución, conocido también como CDS, solo contiene el gas dióxido de cloro a una concentración de solo 0.3 g/L disuelto en agua y del cual se toman solo 5 a 10 ml para ser ingeridos a lo largo del día, disueltos en un litro de agua fría. Esta gran diferencia permite que la solución de dióxido de cloro sea inocua y sumamente tolerable para ser ingerida en diversas dosis sin causar ningún malestar o riesgo para la salud. Los problemas que pudieran existir con relación a la variación de la calidad del producto se eliminarían si existiera una estrecha colaboración entre las Agencias, Comités o Entidades reguladoras en cada país con la COMUSAV para llevar a cabo la supervisión en la elaboración del Dióxido de cloro en solución y asegurar su adecuada calidad, tal como ya se ha establecido por ley en el país de Bolivia.*

### *Introducción*

*Este documento se centra solo en la toxicidad por ingesta del compuesto dióxido de cloro, y no trata los aspectos de toxicidad por inhalación, pues esa parte no es del interés de esta revisión de literatura, además, es bien sabido que aspirar este gas resulta perjudicial para la salud. Por otro lado, las dosis reportadas en cada uno de los citados estudios sobre toxicidad se comparan con las dosis que se utilizan en la prevención y tratamiento de COVID 19, por los médicos de COMUSAV, que van de 5 a 10 ml/día de una solución de dióxido de cloro a una concentración de 3,000 ppm (5 ml para gente poco expuesta y 10 ml para gente más expuesta, como por ejemplo el personal de salud que está atendiendo pacientes COVID 19 u otro personal que por su actividad de servidor público se encuentre expuesto a una carga viral elevada. Dicha cantidad de solución madre de 3,000 ppm se disuelve en un litro de agua fría y se bebe durante el día. Es decir, esto equivale a una dosis de 15 a 30 mg/día en pacientes adultos con un peso promedio de 60 kg, un valor que oscila entre 0.25 y 0.50 mg/kg-día. Contra esta dosis estaremos comparando todos los reportes que se presentarán a lo largo de esta revisión bibliográfica, tomada de fuentes científicas debidamente acreditadas.*

### *Propiedades físicas del compuesto*

El dióxido de cloro ($ClO_2$) es un gas con un peso molecular de 67.46, un punto de ebullición de 11 °C, una solubilidad en agua de 3,000 mg/L a 25°C y presenta una gravedad específica de 1.642 a 0°C (Budavari et al., 1989).

### *Absorción gastrointestinal*

Después de la ingestión, el dióxido de cloro se absorbe rápidamente por el tracto digestivo. Los niveles plasmáticos máximos se observan 2 horas después de su ingestión y se estima que al menos el 30% de la dosis de prueba ingerida fue absorbida (Abdel-Rahman et al., 1979a).

### *Distribución en el organismo después de su ingesta*

Una vez ingerido el compuesto se distribuye por todo el cuerpo, pero las concentraciones más altas se encontraron en la sangre, el estómago y el intestino delgado (Abdel-Rahman et al., 1982).

751

Setenta y dos horas después de la ingesta de una dosis única de 100 mg/L, la mayor parte del cloro se detectó en la forma de ion cloruro ($Cl^-$), y la proporción de cloruro a clorito ($ClO_2$) fue de 4 a 1 (Abdel-Rahman et al., 1979b).

***Metabolismo***

El ion cloruro es el metabolito final del dióxido de cloro en el organismo, acumulándose en orina y plasma en 87 y 80% respectivamente. A partir de una solución ingerida de 100 mg/litro y utilizando cloro marcado radiactivamente para seguir su curso en el organismo, el clorito fue un metabolito importante, representando aproximadamente el 11% en la orina y el 21% en plasma del total del cloro del dióxido de cloro marcado (Abdel-Rahman et al., 1979b). Un estudio de recuperación *in vivo* en ratas, realizado por Bercz et al. (1982) sugiere que el dióxido de cloro ingerido se reduce rápidamente en el estómago a especies no oxidantes (presumiblemente cloruro).

**Eliminación**

La forma química en la que se elimina el dióxido de cloro es a través de orina y heces. Setenta y dos horas después de la ingesta de dióxido de cloro marcado en ratas, el 31 y el 10% de éste fue excretado en la orina y las heces, respectivamente y la relación de $Cl^-$ a $ClO_2$, fue de 5 a 1 durante las primeras 24 horas y de 4 a 1 durante las primeras 72 horas (Abdel-Rahman et al., 1979b).

***Identificación de riesgos en humanos***

La toxicidad a corto plazo del dióxido de cloro se evaluó en dos estudios en humanos. En el primer estudio Lubbers et al. (1982) evaluaron a un grupo de 10 adultos varones sanos de 70 kg de peso, que ingirieron una dosis única de 0.34 mg/kg de peso vivo. En el segundo estudio (Lubbers et al., 1984a) evaluaron la ingesta 0.04 mg/kg-día, durante 12 semanas. después de realizar observaciones y exámenes físicos. Dentro de éstos incluyeron, los signos vitales como presión arterial, frecuencia del pulso, tasa de respiración y temperatura corporal, también parámetros de química clínica sérica (incluyendo glucosa, nitrógeno de urea, fósforo, fosfatasa alcalina y aminoácidos de aspartato y alanina), así como niveles de triyodotironina sérica (T3) y tiroxina (T4) al igual que parámetros hematológicos. *Ninguno de los dos estudios reportó alteraciones fisiológicamente relevantes en la salud general.*

***Consumo de agua potable desinfectada con dióxido de cloro.***

Michael et al. (1981), Tuthill et al. (1982) y Kanitz et al. (1996) compararon comunidades que consumían agua potable desinfectada con dióxido de cloro versus comunidades que no usaban este reactivo químico y compararon su efecto por medio de análisis de sangre. El estudio duró 10 semanas y se realizó con 118 individuos. La ingesta media de dióxido de cloro en las comunidades que lo consumían fue de 0.15 mg/kg al día. Estos investigadores reportan que no se detectaron alteraciones hematológicas o en química sérica en este estudio. *Este valor de 0.15 mg/kg-día es moderadamente cercano a los valores que utiliza COMUSAV para prevenir y de tratamiento ante COVID 19, que van de 0.25 a 0.50 mg/kg-día.*

Tuthill et al. (1982) compararon retrospectivamente los datos de morbilidad y mortalidad infantil para una comunidad que había utilizado niveles "altos" de dióxido de cloro como desinfectante de agua potable en la década de 1940 con datos de una comunidad vecina que utilizaba prácticas convencionales de cloración de agua potable, desafortunadamente no informaron de las concentraciones de dióxido de cloro en el agua tratada. La exposición al agua

752

tratada con dióxido de cloro no afectó negativamente a la mortalidad fetal, neonatal, post neonatal o infantil, ni afectó el peso al nacer, la proporción sexual o la condición de nacimiento.

Por su parte, en Italia Kanitz et al. (1996) dieron seguimiento a 548 nacimientos en el Hospital Galliera de Génova y 128 nacimientos en el Hospital Chiavari, en Chiavari, durante 1988-1989. Las mujeres en Génova fueron expuestas a agua filtrada desinfectada con dióxido de cloro, hipoclorito de sodio, o ambos; los niveles de trihalometano variaron de 8 a 16 ppb en agua tratada con hipoclorito sódico y de 1 a 3 ppb en agua desinfectada con dióxido de cloro. Los autores del estudio concluyeron que los bebés de mujeres que consumían agua potable tratada con compuestos de cloro durante el embarazo tenían un mayor riesgo de adquirir ictericia neonatal, circunferencia craneal menor de 35 cm y longitud corporal menor de 49.5 cm. Sin embargo, los datos de referencia atípicos plantean preocupaciones sobre la población testigo seleccionada para este estudio y dificultan la interpretación de cualquier comparación con el grupo expuesto, excluyendo así la capacidad de sacar conclusiones de este estudio (Selevan, 1997), *por lo que dicho trabajo no puede ser considerado confiable para dilucidar las conclusiones reportadas por los autores que lo generaron.*

***Efectos de largo plazo del dióxido de cloro.***

Daniel et al., (1990) trabajaron con ratas de la línea Sprague-Dawley y expusieron grupos de 10 machos y 10 hembras al dióxido de cloro en el agua potable durante 90 días, a dosis administradas de 0, 2, 4, 6 ó 12 mg/kg-día de dióxido de cloro para machos; y 0, 2, 5, 8 ó 15 mg/kg-día de dióxido de cloro para las hembras. La exposición a 12 mg/kg-día, dio lugar a reducciones significativas en el peso corporal final. También se observaron disminuciones en el consumo de alimentos en la dosis más alta. Los pesos hepáticos absolutos disminuyeron en los machos a partir de la dosis de 6 mg/kg-día y los pesos absolutos del bazo disminuyeron en las hembras a partir de la dosis de 2 mg/kg-día. No se observaron alteraciones consistentes en los parámetros hematológicos (recuentos totales y de leucocitos totales y diferenciales, niveles de hemoglobina, hematocrito y volumen corpuscular medio, medido). Los niveles séricos de lactato deshidrogenasa y aspartato aminotransferasa disminuyeron y los niveles séricos de creatinina aumentaron en los machos expuestos a 6 y 12 mg/kg-día. No se encontraron otras alteraciones en los parámetros de química sérica. Por lo tanto, 2 mg/kg-día se podría considerar como un nivel en el cual no se aprecia un efecto adverso (NOAEL). *Esta dosis es 4 a 8 veces más alta que la dosis que han usado los médicos de COMUSAV para prevenir y de tratamiento ante el COVID 19.*

En un estudio de toxicidad crónica realizado por Haag (1949), grupos de siete ratas macho y siete ratas hembra fueron expuestos a dosis de dióxido de cloro de: 0, 0.07, 0.13, 0.7, 1.3 y 13.0 mg/kg-día según lo calculado por la EPA de los Estados Unidos, durante 2 años. La supervivencia en el grupo de 13 mg/kg al día disminuyó significativamente. No se observaron alteraciones relacionadas con el dióxido de cloro en el examen histopatológico de animales representativos (2-6/sexo) de cada grupo. Para este estudio identificaron un nivel en el cual no se observa ningún efecto adverso (NOAEL), de 1.3 mg/kg-día y un nivel de efectos francos (FEL), basado en una disminución de la supervivencia, de 13 mg/kg-día. *En este estudio el valor NOAEL fue menor que en el estudio de Daniel et al. (1990), pero, aun así, es 3 a 5 veces más alto que las dosis usadas para prevenir o de tratamiento ante el COVID 19, propuesto por la COMUSAV.*

Bercz et al. (1982) utilizaron un diseño de dosis ascendente en el que cada animal servía como su propio control. Cinco monos verdes africanos adultos y siete hembras (*Cercopithecus*

753

*aethiops*) fueron expuestos a 0, 3.5 y 9.5 mg/kg-día de dióxido de cloro. En este estudio no se presentaron alteraciones significativas en la química clínica hematológica (eritrocitos, leucocitos totales y diferenciales, recuentos de reticulocitos, niveles de hemoglobina, hematocrito, fragilidad osmótica y niveles de metahemoglobina) o en química clínica sérica (creatinina, nitrógeno de urea en sangre [BUN], fosfatasa alcalina, deshidrogenasa de lactato y alanina y aspartato aminotransferasa) o aumento de peso corporal. Los niveles séricos de T4 disminuyeron significativamente en los monos expuestos a dióxido de cloro de 9.5 mg/kg-día. Así, este estudio identifica un NOAEL de 3.5 mg/kg-día y un LOAEL de 9.5 mg/kg-día, para alteraciones en los niveles de hormona tiroidea en monos expuestos al dióxido de cloro en el agua potable durante 4-6 semanas. *Para este estudio, la NOAEL, es decir el nivel más bajo en el que no se observan efectos adversos es de 3.5 mg/kg-día, es decir 7 a 14 veces más alto que el usado para prevenir o de tratamiento ante el COVID 19 propuesto por la COMUSAV.*

Abdel-Rahman y col. (1984b) expusieron grupos de cuatro ratas macho Sprague-Dawley a dosis logarítmicamente consecutivas de 0, 0.1, 1, 10 y 100 mg/kg-día. Estos investigadores evaluaron el peso corporal de las ratas y algunas variables hematológicas como: fragilidad osmótica, hematocrito, y hemoglobina. Sin embargo, la falta de una relación consistente entre la dosis y las alteraciones hematológicas y el pequeño número de animales (solo cuatro machos/grupo) confunden la interpretación del estudio, lo que dificulta obtener conclusiones definitivas de este trabajo. De igual forma, Couri y Abdel-Rahman (1980) realizaron una investigación en ratas Sprague-Dawley (cuatro machos/grupo) con 4 niveles de dióxido de cloro además del testigo (0, 0.1, 1, 10 ó 100 mg/kg-día) y estudiaron los niveles de glutatión reductasa en sangre, glutatión peroxidasa y niveles de catalasa en eritrocitos. Sin embargo, al igual que con Abdel-Rahman et al. (1984b), la relación inconsistente entre la dosis y la magnitud de las alteraciones en el sistema dependiente del glutatión dificulta la interpretación de sus resultados. Además, no está claro si estos efectos son biológicamente significativos, lo que excluyó la determinación de una NOAEL y una LOAEL para estos estudios. Por otro lado, Moore y Calabrese (1982) expusieron grupos de 10 ratones A/J o C57L/J (sexo no especificado) a 0 ó 19 mg/kg-día durante 30 días y no observaron alteraciones significativas en los parámetros hematológicos (hemograma completo, recuento de reticulocitos, actividad de glucosa-6-fosfato y fragilidad osmótica) en ninguna de las cepas de ratón.

**Efecto del dióxido de cloro sobre el desarrollo reproductivo.**

Carlton y col. (1991) administraron dosis diarias por sonda de 0, 2.5, 5, ó 10 mg/kg-día, de dióxido de cloro en agua desionizada a grupos de 12 ratas Long-Evans macho, durante 56 días antes del apareamiento y durante un período de apareamiento de 10 días. Grupos de 24 ratas hembra recibieron las mismas dosis por sonda durante 14 días antes del apareamiento, durante el período de apareamiento y durante la gestación y la lactancia. No se observaron alteraciones significativas en la mortalidad, los signos clínicos, las tasas de fertilidad, los parámetros de los espermatozoides, la duración de la gestación, las muertes prenatales, el tamaño medio de la camada o el peso medio de las crías. Tampoco se observaron alteraciones significativas en el peso de los órganos del tracto reproductivo en las ratas macho F1. En las ratas hembra F1, hubo disminuciones estadísticamente significativas en los pesos absolutos y relativos de la vagina en el grupo de 10 mg/kg-día, pero no hubo diferencias en los pesos corporales terminales o los pesos uterinos y ováricos. No se midieron alteraciones consistentes relacionadas con el dióxido de cloro en los niveles de T3 ó T4 en las ratas macho y hembra F0 y en las ratas macho F1 (niveles hormonales medidos en los días 17, 28 y 40 postnatales). *Este estudio identifica un NOAEL de 10 mg/kg-día*

754

*para efectos reproductivos en ratas que reciben dosis de dióxido de cloro por sonda. Esta NOAEL es 20 a 40 veces más elevada que la usada para fines de prevenir o de tratamiento ante el COVID 19.*

En un estudio de toxicidad para el desarrollo realizado por Suh et al. (1983), a grupos de seis a ocho ratas hembra Sprague-Dawley se les administró 0, 0.1, 1 y 10 mg / kg-día, durante 2.5 meses antes del apareamiento con machos no expuestos y durante los días de gestación 0-20; las madres se sacrificaron al día 20 de gestación. Este estudio identifica un NOAEL de 1 mg/kg-día y LOAEL de 10 mg / kg-día, para efectos de desarrollo en la descendencia de ratas expuestas al dióxido de cloro en el agua potable. *En este caso la NOAEL es 2 a 4 veces más elevada a la recomendada y usada para prevenir o de tratamiento ante el COVID 19.*

Toth et al. (1990) examinaron la toxicidad del dióxido de cloro en el desarrollo neurológico en las ratas encapuchadas Long-Evans expuestas postnatalmente. Este estudio identifica una LOAEL de 14 mg/kg-día para el parámetro desarrollo del cerebro en ratas expuestas postnatalmente.

Mobley y col. (1990) expusieron grupos de 12 ratas hembra Sprague-Dawley a 0 ó 14 mg/kg-día. En el día 42 posterior a la concepción, no hubo alteraciones significativas en la captación total de T3 o T4, T4 libre o T3. El día en que abrieron los ojos no se vio afectado significativamente por la exposición al dióxido de cloro. Por lo tanto 14 mg/kg-día es el LOAEL para la disminución del peso de la camada y la actividad exploratoria.

En un estudio realizado por Orme et al., (1985) diseñado para evaluar la toxicidad del dióxido de cloro en la tiroides, grupos de ratas hembra Sprague-Dawley fueron expuestos dosis de 0, 1, 3 y 14 mg/kg-día durante 2 semanas antes del apareamiento y durante la gestación y la lactancia. Este estudio identifica un NOAEL de 3 mg/kg-día, y un LOAEL de 14 mg/kg-día para efectos neuroconductuales. *El estudio de Orme et al. (1985) muestra una NOAEL de 6 a 12 veces más elevada que la dosis usada para prevenir o de tratamiento ante el COVID 19.*

Taylor y Pfohl (1985) expusieron grupos de 13-16 ratas hembra Sprague-Dawley a 0 y 14 mg/kg-día de dióxido de cloro y reportan una LOAEL para efectos neuroconductuales, disminución del peso cerebral y número de células en la descendencia de ratas expuestas al dióxido de cloro en el agua potable y en ratas expuestas postnatalmente al dióxido de cloro por sonda nasogástrica, de 14 mg/kg-día. *Un nivel 28 a 56 veces más elevado que la dosis usada para prevenir o de tratamiento ante el COVID 19.*

### Estudios de carcinogenicidad con la ingestión de dióxido de cloro.

Miller et al. (1986) probaron el potencial carcinogénico del agua potable desinfectada con dióxido de cloro utilizando tres ensayos a corto plazo. Después de la desinfección con dióxido de cloro, las muestras de agua (que contenían 0.5 mg/L de residuos de dióxido de cloro) se concentraron 2,000 y 4,000 veces usando un proceso de resina macrorreticular. Se administraron por vía oral a grupos de 14 a 34 ratones SENCAR (no se especifica el sexo) 0.5 ml del concentrado 4000 × en emulforado al 2% por tres veces a la semana durante 2 semanas, seguido de exposición tópica a 1.0 g de 12 tetradecanilforbal-13-acetato (TPA) en acetona aplicado a la piel dorsal 3 veces / semana durante 20 semanas y luego sacrificado. No se observaron aumentos significativos,

755

en comparación con los controles de vehículo, en el número de tumores de piel o en el número de tumores por animal.

En un ensayo de adenoma de pulmón realizado por Miller et al. en 1986, evaluaron en grupos de 20 ratones macho y 20 hembras de la cepa A, los cuales recibieron dosis de 0.25 ml por sonda de concentrados de 2000 y 4000 veces concentrado al 2%, 3 veces por semana durante 8 semanas seguidas en un período de observación de 16 semanas. En este ensayo el número de animales con adenomas pulmonares y el número de adenomas por animal no se alteraron significativamente en comparación con los testigos de vehículo. Miller et al. (1986) también examinaron el desarrollo de focos hepáticos en ratas en un ensayo a corto plazo. En este estudio, grupos de ratas parcialmente hepatectomizadas recibieron una dosis única de agua concentrada (no se informa la concentración de dióxido de cloro) en emulfora al 2%, seguida una semana después de la administración de 500 ppm de fenobarbital sódico en agua potable durante 56 días; los animales se sacrificaron el día 70. Un grupo testigo recibió agua no desinfectada. No se observaron aumentos significativos en la incidencia de focos de β-glutamiltranspeptidasa, la cual es un indicador de trastornos hepáticos. *Los estudios revisados hasta la fecha no reportan ninguna evidencia de que el dióxido de cloro pueda causar efectos cancerígenos.*

## Estudios de Genotoxicidad

Se han encontrado resultados tanto positivos como negativos en estudios de genotoxicidad in vitro. Por un lado, el dióxido de cloro no aumentó las aberraciones cromosómicas en las células de fibroblastos de hámster chino, pero sí aumentó la mutación inversa en Salmonella typhimurium (con activación) (Ishidate et al., 1984). Sin embargo, las muestras de agua desinfectadas con dióxido de cloro no indujeron mutaciones inversas en S. *typhimurium* con o sin activación (Miller et al., 1986). Los ensayos de aberración cromosómica de micronúcleo y médula ósea in vivo en ratones Swiss CD-1 a los que se les administró de 0.1 a 0.4 mg de dióxido de cloro por sonda durante 5 días consecutivos fueron negativos, al igual que un ensayo de anomalías en la cabeza del esperma en ratones B6C3F1 a los que se les administraron 0.1 a 0.4 mg por sonda por 5 días consecutivos (0, 3.2, 8 y 16 mg/kg-día) (Meier et al., 1985). Hayashi y col. (1988) informaron resultados positivos en el ensayo de micronúcleos en ratones ddY después de una única inyección intraperitoneal de 3.2 a 25 mg/kg de dióxido de cloro.

## Mecanismos de acción del dióxido de cloro en dosis elevadas.

*Es muy probable que el daño oxidativo a los eritrocitos y la producción de metahemoglobina en dosis elevadas de dióxido de cloro, por encima de las dosis que se usan para prevenir y de tratamiento ante el COVID 19, estén relacionados con sus propiedades oxidantes (U.S. EPA, 1994d).* Se cree que el clorito es la especie intermedia responsable de muchos de los efectos hematológicos del dióxido de cloro, debido a su producción más eficiente de metahemoglobina, el agotamiento del glutatión de los glóbulos rojos (RBC) y la alteración de la fragilidad de los eritrocitos.

En una serie de experimentos, Bercz, et al. (1982, 1986); y Harrington et al. (1986) sugirieron que el dióxido de cloro aumenta la unión del yoduro de la dieta al tejido y contenido gastrointestinal, produciendo una deficiencia funcional de yoduro. Bercz y col. (1982) encontraron niveles reducidos de tiroxina circulante en monos que bebían más de 9.5 mg/kg de dióxido de cloro al día. En un estudio de seguimiento, Harrington et al. (1986) demostraron aumentos en la absorción de yoduro de tiroides y un rebote en los niveles de tiroxina en monos que un año después de una exposición por 8 semanas a aproximadamente 5 mg/kg-día de dióxido de cloro en el agua potable. A diferencia de los monos, las ratas mostraron disminuciones relacionadas con la dosis en los niveles de tiroxina y ninguna alteración en la absorción de yoduro de tiroides después de una exposición de 8 semanas a 10 mg/kg de dióxido de cloro al día en el agua potable. *Estas dosis son excesivamente altas (20 a 40 veces más elevadas) con relación a las que se usan en el tratamiento preventivo o de tratamiento de dióxido de cloro en solución contra el COVID 19.*

## Síntesis general de los estudios de toxicidad

*A la fecha no se ha podido demostrar que el dióxido de cloro cause efectos tóxicos al ser humano a los niveles utilizados para prevenir o de tratamiento ante el COVID-19, cuyas dosis van de 0.25 a 0.50 mg/kg-día y están muy por debajo de las concentraciones reportadas como NOAEL en la mayoría de los reportes de investigación.*

El estudio crónico de agua potable de Haag (1949) informó disminuciones en la supervivencia de ratas expuestas a 13 mg/kg-día de dióxido de cloro, durante 2 años, pero no se informó la causa de la muerte y no se observaron efectos a concentraciones más bajas. Otros estudios subcrónicos/crónicos examinaron principalmente los parámetros hematológicos. Bercz, et al., (1982) encontraron disminuciones significativas en los niveles séricos de T4 en monos expuestos a 9.5 mg/kg de dióxido de cloro al día en el agua potable durante 4 a 6 semanas. Los efectos hematológicos adversos no pudieron discernirse en Abdel-Rahman et al. (1984b) porque no hubo una relación dosis-efecto consistente. Además, Daniel et al. (1990), Bercz et al. (1982) y Moore y Calabrese (1982) no encontraron alteraciones hematológicas en ratas, monos o ratones, respectivamente. Abdel-Rahman y col. (1984b) y Couri y Abdel-Rahman (1980) informaron de alteraciones en el sistema dependiente del glutatión, en particular, disminuciones en los niveles de glutatión en los eritrocitos, aumentos en la actividad del glutatión peroxidasa y aumentos en los niveles de catalasa en los eritrocitos. Sin embargo, al igual que con los efectos hematológicos que encontró este grupo, faltaron relaciones consistentes entre la dosis y la magnitud de las alteraciones. *Solo en dosis elevadas de dióxido de cloro con niveles 30 veces mayores a los usados para prevenir o de tratamiento ante el COVID-19, se han observado efectos dañinos en ratas o monos.*

## Estudio de efectos cancerígenos del dióxido de cloro

Según las pautas actuales (U.S. EPA, 1986a), el dióxido de cloro está clasificado como Grupo D, (no clasificable en cuanto a carcinogenicidad en humanos) debido a que no hay datos que hayan probado su efecto cancerígeno. Según el borrador de las Directrices de Evaluación de Carcinógenos (U.S. EPA, 1996a), la carcinogenicidad humana del dióxido de cloro no se puede determinar porque no se encontraron estudios satisfactorios en humanos o animales que evalúen el potencial carcinogénico crónico del dióxido de cloro. El potencial carcinogénico de los concentrados preparados a partir de agua potable tratada con dióxido de cloro fue estudiado por Miller et al. (1986) y los concentrados de dióxido de cloro no aumentaron la incidencia de adenomas pulmonares en ratones de la cepa A.

## Conclusiones generales del efecto de la dosis sobre la toxicidad del dióxido de cloro.

En general, los estudios en humanos no han reportado efectos adversos en individuos que consumen bajas concentraciones (0.04-0.15 mg/kg-día) de dióxido de cloro en estudios experimentales (Lubbers et al., 1981, 1982, 1984a) o que consumen agua potable desinfectada con dióxido de cloro (Michael et al., 1981; Tuthill et al., 1982).

El estudio epidemiológico de Kanitz et al. (1996) donde reportan aumentos en el riesgo de varios efectos en el desarrollo (ictericia neonatal, circunferencia craneal pequeña y longitud corporal más corta) en una comunidad con agua potable desinfectada con dióxido de cloro, tiene numerosas limitaciones (incluidas múltiples exposiciones químicas; falta de datos de exposición; falta de control del tabaquismo, la edad y los hábitos nutricionales; y datos de control atípicos), por lo que queda descartado como un estudio serio para obtener conclusiones válidas.

Taylor y Pfohl, 1985; Toth et al., 1990), Orme et al., 1985; Taylor y Pfohl, 1985; Mobley et al., 1990) estudiaron la toxicidad del dióxido de cloro, sobre diversos órganos del cuerpo, en diferentes etapas de desarrollo del animal estudiado, y reportan una LOAEL para estos efectos de 14 mg/kg-día de dióxido de cloro. Por su parte Orme, et al., (1985) identificaron un NOAEL de 3 mg / kg-día. *Esta última, por cierto, se ubica 6 a 12 veces por encima de las dosis utilizadas en seres humanos para prevenir o de tratamiento para el coronavirus COVID 19, propuesto por la COMUSAV.*

**Conclusiones generales**

*Los valores más frecuentes a partir de la literatura revisada y citada en este reporte indican que la FEL (Nivel de efectos francos) es de 27 mg/kg-día, la LOAEL (Nivel más bajo que muestra efectos adversos) de 13 mg/kg-día y la NOAEL (Nivel sin efectos adversos observables) resultó ser del orden de 3.0 mg/kg-día. El protocolo sugerido por Kalcker (2020) propone la ingesta de 10 mililitros de una solución de dióxido de cloro a una concentración de 3,000 mg/litro, disueltos en un litro de agua y bebidos durante el día, como estrategia para prevenir y de tratamiento ante el COVID 19, es decir que la ingesta real es de 30 mg/día para adultos con pesos de 50 a 80 kg. Si consideramos un peso promedio de 60 kg, la dosis que se ingiere es de 0.5 mg/kg-día, es decir 6 veces por debajo de la dosis considerada como NOEAL. En otras ocasiones la dosis preventiva para personas no expuestas o muy poco expuestas se ha reducido a solo 5 ml de la solución de 3,000 ppm por día, lo que representa una ingesta de solo 0.25 mg/kg-día. Por lo anterior la revisión de literatura confirma que el uso de dióxido de cloro ingerido a una dosis de 0.25 a 0.50 mg/kg-día no representa un riesgo demostrado de toxicidad para la salud humana por ingestión.*

**Adendum**

*Es importante hacer notar que las Agencias, Comités o entidades encargadas de la supervisión de la salud pública, una vez que se siga demostrando mediante diversos reportes científicos la inocuidad del dióxido de cloro a las dosis adecuadas, deben de destinar recursos para la investigación, en los cuales se incluyan al sector gubernamental, iniciativa privada en su rama de la industria farmacéutica y a la COMUSAV. Dichos recursos son de vital importancia para continuar el estudio de esta molécula del dióxido de cloro la cual no obstante que ha demostrado bajo la experimentación observacional retrospectiva ser un recurso para el manejo del COVID-19, y teniendo en cuenta que al ser una emergencia médica la actual pandemia por COVID-19 y que pocos o ningún medicamento han podido concluir las fases tradicionales de investigación como actualmente se requiere. También se tiene que hacer notar que el dióxido de cloro tiene otras aplicaciones ya patentadas en la rama de la medicina y muchas otras que pueden ser estudiadas para la generación de nuevas patentes.*

**Abreviaturas utilizadas en el texto.**

**FEL.** El Nivel de efecto franco, por sus siglas en inglés: *Frank effect level*

758

**LOAEL.** El Nivel más bajo que muestra efectos adversos, por sus siglas en inglés: *Lowest Observed Adverse Effect Level.*
**NOAEL.** Nivel sin efectos adversos observables, por sus siglas en inglés: *Non Observed Adverse Effect Level.*
**CDS.** Solución de dióxido de cloro, por sus siglas en ingles *Chlorine Dioxide Solution.*
**MMS.** Por sus siglas en ingles Magistral Mineral Solution; o Solución que contiene la mezcla de una dosis en gotas de clorito de sodio y otra cantidad igual en gotas de ácido cítrico o ácido clorhídrico (1 a 10 gotas de cada una), se esperan 40 segundos a que se lleve a cabo la reacción, se le agrega agua y se ingiere la solución.
**PPB.** Partes por billón, o micro gramos de una sustancia contenidos en un litro de agua.
**PPM.** Partes por millón o mg de una sustancia disueltos en un litro de agua.

**Bibliografía citada**

Abdel-Rahman, MS; Couri, D; Bull, RJ. (1979a) Kinetics of $ClO_2$ and effects of $ClO_2$, $ClO_2^-$, and $ClO_3$ in drinking water on blood glutathione and hemolysis in rat and chicken. J Environ Pathol Toxicol 3:431-449.

Abdel-Rahman, MS; Couri, D; Jones, JD. (1979b) Chlorine dioxide metabolism in rat. J Environ Pathol Toxicol 3:421-430.

Abdel-Rahman, MS; Couri, D; Bull, RJ. (1982) Metabolism and pharmacokinetics of alternate drinking water disinfectants. Environ Health Perspect 46:19-23.

Abdel-Rahman, MS; Couri, D; Bull, RJ. (1984b) Toxicity of chlorine dioxide in drinking water. J Am Coll Toxicol 3:277-284.

Budavari, S; O'Neil, MJ; Smith, A; et al. (eds). (1989) The Merck index: an encyclopedia of chemicals, drugs, and biologicals, 11th ed. Whitehouse Station, NJ: Merck and Co, Inc.

Bercz, JP; Jones, LL; Garner, L; et al. (1982) Subchronic toxicity of chlorine dioxide and related compounds in drinking water in the nonhuman primate. Environ Health Perspect 46:47-55.

Bercz, JP; Jones, LL; Harrington, RM; et al. (1986) Mechanistic aspects of ingested chlorine dioxide on thyroid function: impact of oxidants on iodide metabolism. Environ Health Perspect 69:249-255.

Carlton, BD; Basaran, AH; Mezza, LE; et al. (1991) Reproductive effects in Long-Evans rats exposed to chlorine dioxide. Environ Res 56:170-177.

Couri, D; Abdel-Rahman, MS. (1980) Effect of chlorine dioxide and metabolites on glutathione dependent system in rat, mouse and chicken blood. J Environ Pathol Toxicol 3:451-460.

Daniel, FB; Condie, LW; Robinson, M; et al. (1990) Comparative subchronic toxicity studies of three disinfectants. J Am Water Works Assoc 82:61-69.

759

Haag, HB. (1949) The effect on rats of chronic administration of sodium chlorite and chlorine dioxide in the drinking water. Report to the Mathieson Alkali Works from H.B. Haag of the Medical College of Virginia. February 7, 1949.

Harrington, RM; Shertzer, HG; Bercz, JP. (1986) Effects of chlorine dioxide on thyroid function in the African green monkey and the rat. J Toxicol Environ Health 19:235-242.

Hayashi, M; Kishi, M; Sofuni, T; et al. (1988) Micronucleus test in mice on 39 food additives and eight miscellaneous chemicals. Food Chem Toxicol 26:487-500.

Ishidate, M; Sofuni, T; Yoshikawa, K; et al. (1984) Primary mutagenicity screening of food additives currently used in Japan. Food Chem Toxicol 22:623-636.

Kalcker, A. L. 2020. Salud prohibida, incurable era ayer. 8ª Edicoin. Edit. Voedia 451 p.

Kanitz, S; Franco, Y; Patrone, V; et al. (1996) Associations between drinking water disinfection and somatic parameters at birth. Environ Health Perspect 104:516-520.

Lubbers, JR; Chauhan, S; Bianchine, JR. (1981) Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. Fundam Appl Toxicol 1:334-338.

Lubbers, JR; Chauhan, S; Bianchine, JR. (1982) Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. Environ Health Perspect 46:57-62.

Lubbers, JR; Chauhan, S; Miller, JK; et al. (1984a) The effects of chronic administration of chlorine dioxide, chlorite and chlorate to normal healthy adult male volunteers. J Environ Pathol Toxicol Oncol 5:229-238.

Meier, JR; Bull, RJ; Stober, JA; et al. (1985) Evaluation of chemicals used for drinking water disinfection for production of chromosomal damage and sperm-head abnormalities in mice. Environ Mutagen 7:201-211.

Michael, GE; Miday, RK; Bercz, JP; et al. (1981) Chlorine dioxide water disinfection: a prospective epidemiology study. Arch Environ Health 36:20-27.

Miller, RG; Kopler, FC; Condie, LW; et al. (1986) Results of toxicological testing of Jefferson Parish pilot plant samples. Environ Health Perspect 69:129-139.

Mobley, SA; Taylor, DH; Laurie, RD; et al. (1990) Chlorine dioxide depresses T3 uptake and delays development of locomotor activity in young rats. In: Jolley, RL, et al., eds. Water chlorination: chemistry, environmental impact and health effects, vol. 6. Chelsea, MI: Lewis Publications, pp. 347-358.

Moore, GS; Calabrese, EJ. (1982) Toxicological effects of chlorite in the mouse. Environ Health Perspect 46:31-37.

760

Orme, J; Taylor, DH; Laurie, RD; et al. (1985) Effects of chlorine dioxide on thyroid function in neonatal rats. J Toxicol Environ Health 15:315-322.

Selevan, S. (1997) Comments on Italian study: association between drinking water disinfection and somatic parameters by Kanitz et al., Environ Health Perspect 104(5):516-520, 1996. Memorandum to J. Wiltse, U.S. EPA, Washington, DC, May 7.

Suh, DH; Abdel-Rahman, MS; Bull, RJ. (1983) Effect of chlorine dioxide and its metabolites in drinking water on fetal development in rats. J Appl Toxicol 3:75-79.

Taylor, DH; Pfohl, RJ. (1985) Effects of chlorine dioxide on the neurobehavioral development of rats. In: Jolley, RL, et al., eds. Water chlorination: chemistry, environmental impact and health effects, vol. 6. Chelsea, MI: Lewis Publications, pp. 355-364.

Toth, GP; Long, RE; Mills, TS; et al. (1990) Effects of chlorine dioxide on the developing rat brain. J Toxicol Environ Health 31:29-44.

Tuthill, RW; Giusti, RA; Moore, GS; et al. (1982) Health effects among newborns after prenatal exposure to $ClO_2$-disinfected drinking water. Environ Health Perspect 46:39-45.

U.S. Environmental Protection Agency. (1986a) Guidelines for carcinogen risk assessment. Federal Register 51(185):33992-34003.

U.S. Environmental Protection Agency. (1994d) Final draft of the drinking water criteria document on chlorine dioxide, chlorite, and chlorate. Office of Science and Technology, Office of Water, Washington, DC. Office of Research and Development, Washington, DC.

U.S. Environmental Protection Agency. (1996a) Proposed guidelines for carcinogen risk assessment. Federal Register 61(79):17960-18011. http://www.epa.gov/nceawww1/cancer.htm

# Dosis de DIOXIDO DE CLORO/CLORITO empleadas en estudios de toxicidad subaguda (<28d), o crónica (>90d) para US-EPA



@Pablo Campra

# Anexo 1.

SALUD
SECRETARIA DE SALUD
Oficina del C. Secretario
Control de Gestion
RECIBIDO
NOMBRE Ely
HORA 10.52

a carpeta

COMUSAV
COALICIÓN MUNDIAL SALUD Y VIDA
**COMUSAV MEXICO A.C.**

Ciudad de México a 13 de octubre del 2020.

Dr. Jorge Alcocer Varela
Titular de la Secretaría de Salud
Presente

Muy estimado doctor Alcocer Varela,

Sirva la presente para enviar un cordial saludo, así como para presentar a la Secretaría de Salud dignamente representada por usted, documentos muy importantes sobre la Seguridad, Eficacia y los aspectos generales del Dióxido de Cloro (CDS por sus siglas en inglés):

1. Resumen de la identificación de riesgos por la ingesta del dióxido de cloro en humanos y otros mamíferos, con comentarios de la COMUSAV, basado en el reporte de la U.S. Environmental Protection Agency (EPA): CHLORINE DIOXIDE AND CHLORITE. (CAS Nos. 10049-04-4 and 7758-19-2). Publicado en el año 2,000. (Anexo 1)
2. El reporte científico en extenso, del cual se obtuvo el resumen mencionado anteriormente: TOXICOLOGICAL REVIEW OF CHLORINE DIOXIDE AND CHLORITE (CAS Nos. 10049-04-4 and 7758-19-2) In Support of Summary Information on the Integrated Risk Information System (IRIS) *September 2000 2) (Anexo 2)*
3. -Dióxido de Cloro, una terapéutica efectiva para el tratamiento de SARS-COV2 COVID-19). Asociación Ecuatoriana de Médicos Expertos en Medicina Integrativa.
   -Efficacy and Safety Evaluation of a Chlorine Dioxide Solution. Jui-Wen Ma, et al. International Journal of Environmental Research and public Health. 2017.
   -Es tiempo de salvar vidas. Recopilado por la Asociación #ClO2Hope4ThePlanet (Anexo 3)
4. Dióxido de Cloro como componente de productos patentados para uso médico (Anexo 4)
5. Ley Departamental de 22 de Julio de 2020 de Cochabamba, Bolivia para la "Producción y Distribución Gratuita y Supervisada de Dióxido de Cloro"
   Ley Departamental No. 193 de 9 de septiembre de 2020. Departamento de La Paz, Bolivia. "Ley que autoriza la producción, distribución y uso del Dióxido de Cloro (CDS) para la prevención, atención y tratamiento del Covid-19 en el Departamento de La Paz" (Anexo 5)

El primer documento consta de 11 hojas (Folios 004 al 014), y se trata del resumen de una gran cantidad de estudios científicos realizados a nivel internacional sobre la toxicidad del dióxido de cloro, con comentarios de la COMUSAV en *letra itálica*, donde claramente se demuestra que a las dosis convenientes el dióxido de cloro en solución, conocido como CDS resulta inocuo para la salud humana en todas sus manifestaciones (Anexo 1).

El segundo documento es el artículo original que consta de 56 páginas (Folios 015 al 070), y del cual se elaboró el resumen anterior para que pueda ser consultado en su totalidad y cotejado con el documento presentado (Anexo 2).

El tercer documento que consta de 69 hojas (Folios 071 al 139), presenta el trabajo de investigación clínica que se realizó en la Cd. de Guayaquil, Ecuador, del 26 de marzo al 10 de abril de 2020, y el cual fue dirigido por el Dr. Roberto Edmundo Garcia Espinosa, un profesional de la salud con 35 años de experiencia en la práctica médica y 5 médicos más, todos ellos acreditados en su especialidad, y con amplia experiencia médica profesional.

Este estudio clínico se realizó con 104 pacientes que dieron COVID-19 positivo, y cuyas edades variaron de 18 a 80 años, de ambos sexos. Estos pacientes fueron intervenidos tempranamente en fases 1, 2 y 3 de la enfermedad. El tratamiento aplicado varió según la gravedad de los pacientes. En el caso de los pacientes graves se les indico ingerir 60 mg de dióxido de cloro diariamente por 2 o 3 días y luego reducir la dosis a 30 mg/día durante 14 días. Los pacientes sin sintomatología grave ingirieron desde el principio una dosis de 30 mg/día durante 14 días.

Los resultados más destacados, tal como se constata en el reporte de investigación clínica, certificado por el notario público Dr. Renato Vazquez Leyva, titular de la Notaria 9ª del Cantón de Guayaquil, Ecuador, fueron los siguientes: 1) En el 82% de los pacientes los síntomas remitieron al 4° día, 2) La mortalidad en los 104 pacientes fue de cero pacientes fallecidos y 3) Los 104 pacientes una vez aliviados no presentaron secuela alguna de la enfermedad.

En forma adicional al reporte comentado en los párrafos anteriores me permito presentar el artículo "Efficacy and Safety Evaluation of a Chlorine Dioxide Solution". Jui-Wen Ma, et al. International Journal of Environmental Research and public Health. 2017,en el cual se demuestra mediante la prueba subcrónica de toxicidad oral la NO Toxicidad del CDS. (Folios 140 al 151).

En el documento "Es tiempo de salvar vidas" se integra la información disponible sobre los aspectos generales del Dióxido de Cloro con referencias de publicaciones por parte de Organismos Internacionales (Anexo 3). Constituído por 21 páginas (Folios 152 al 172)

La finalidad es informar a la Secretaría de Salud sobre los usos de la molécula de Dióxido de cloro a dosis no tóxicas y sí eficaces y seguras, en beneficio del Pueblo de México, así como solicitar sean autorizados los diversos protocolos de investigación que se presenten ante esa comisión para corroborar científicamente su utilidad y estimular la investigación por parte de otras entidades científicas nacionales y extranjeras, privadas o gubernamentales con la finalidad de que sea investigada la molécula de dióxido de cloro, y se tome en cuenta que esta molécula cuenta con varias patentes de uso médico (Anexo 4), abriendo el camino para la investigación en otras indicaciones médicas y el desarrollo de nuevas presentaciones que podrían ser propuestas e incluso patentadas por parte de la industria farmacéutica nacional o internacional. (Folios 173 al 206)

Es importante mencionar también, que a nivel internacional como es el caso de Bolivia, ya se cuenta con legislaciones actualizadas sobre la producción y distribución gratuita y supervisada de Dióxido de Cloro (Anexo 5). (Folios 207 al 212)

Con la honrosa representación y en calidad de Presidente de la Coalición Mundial Salud y Vida México, A.C., quedo a sus órdenes para cualquier duda o aclaración, en el domicilio que señalamos para oír y recibir toda clase de notificaciones ubicado en Avenida Jesús del Monte No. 37 Piso 2 Despacho No. 9 Col. Jesús del Monte, Huixquilucan, Estado de México C.P. 52763, teléfono 5547 470605 y correo electrónico drubus8@gmail.com.

En espera de sus amables comentarios queda de usted

Atentamente

Dr. Pedro Chávez Zavala
Presidente
COMUSAV MEXICO A.C

c.c.p Dr. José Alonso Novelo Baeza. Titular de la Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS)

766

C MUSAV
COALICIÓN MUNDIAL SALUD Y VIDA

**COMUSAV MEXICO A.C.**

Ciudad de México a 13 de octubre del 2020.

Dr. José Alonso Novelo Baeza
Titular de la Comisión Federal para la
Protección contra Riesgos Sanitarios (COFEPRIS)
Presente

13 OCT 2020
11:22

Muy estimado doctor Novelo Baeza,

Sirva la presente para enviar un cordial saludo, así como para presentar a la Comisión Federal para la Protección contra Riesgos Sanitarios dignamente representada por usted, documentos muy importantes sobre la Seguridad, Eficacia y los aspectos generales del Dióxido de Cloro (CDS por sus siglas en inglés):

1. Resumen de la identificación de riesgos por la ingesta del dióxido de cloro en humanos y otros mamíferos, con comentarios de la COMUSAV, basado en el reporte de la U.S. Environmental Protection Agency (EPA): CHLORINE DIOXIDE AND CHLORITE. (CAS Nos. 10049-04-4 and 7758-19-2). Publicado en el año 2,000. (Anexo 1)
2. El reporte científico en extenso, del cual se obtuvo el resumen mencionado anteriormente: TOXICOLOGICAL REVIEW OF CHLORINE DIOXIDE AND CHLORITE (CAS Nos. 10049-04-4 and 7758-19-2) In Support of Summary Information on the Integrated Risk Information System (IRIS) *September 2000 2) (Anexo 2)*
3. -Dióxido de Cloro, una terapéutica efectiva para el tratamiento de SARS-COV2 COVID-19). Asociación Ecuatoriana de Médicos Expertos en Medicina Integrativa.
   -Efficacy and Safety Evaluation of a Chlorine Dioxide Solution. Jui-Wen Ma, et al. International Journal of Environmental Research and public Health. 2017.
   -Es tiempo de salvar vidas. Recopilado por la Asociación #ClO2Hope4ThePlanet (Anexo 3)
4. Dióxido de Cloro como componente de productos patentados para uso médico (Anexo 4)
5. -Ley Departamental de 22 de Julio de 2020 de Cochabamba, Bolivia para la "Producción y Distribución Gratuita y Supervisada de Dióxido de Cloro"
   -Ley Departamental No. 193 de 9 de septiembre de 2020. Departamento de La Paz, Bolivia. "Ley que autoriza la producción, distribución y uso del Dióxido de Cloro (CDS) para la prevención, atención y tratamiento del Covid-19 en el Departamento de La Paz" (Anexo 5)

767

El primer documento consta de 11 hojas (Folios 004 al 014), y se trata del resumen de una gran cantidad de estudios científicos realizados a nivel internacional sobre la toxicidad del dióxido de cloro, con comentarios de la COMUSAV en *letra itálica*, donde claramente se demuestra que a las dosis convenientes el dióxido de cloro en solución, conocido como CDS resulta inocuo para la salud humana en todas sus manifestaciones (Anexo 1).

El segundo documento es el artículo original que consta de 56 páginas (Folios 015 al 070), y del cual se elaboró el resumen anterior para que pueda ser consultado en su totalidad y cotejado con el documento presentado (Anexo 2).

El tercer documento que consta de 69 hojas (Folios 071 al 139), presenta el trabajo de investigación clínica que se realizó en la Cd. de Guayaquil, Ecuador, del 26 de marzo al 10 de abril de 2020, y el cual fue dirigido por el Dr. Roberto Edmundo Garcia Espinosa, un profesional de la salud con 35 años de experiencia en la práctica médica y 5 médicos más, todos ellos acreditados en su especialidad, y con amplia experiencia médica profesional.

Este estudio clínico se realizó con 104 pacientes que dieron COVID-19 positivo, y cuyas edades variaron de 18 a 80 años, de ambos sexos. Estos pacientes fueron intervenidos tempranamente en fases 1, 2 y 3 de la enfermedad. El tratamiento aplicado varió según la gravedad de los pacientes. En el caso de los pacientes graves se les indico ingerir 60 mg de dióxido de cloro diariamente por 2 o 3 días y luego reducir la dosis a 30 mg/día durante 14 días. Los pacientes sin sintomatología grave ingirieron desde el principio una dosis de 30 mg/día durante 14 días.

Los resultados más destacados, tal como se constata en el reporte de investigación clínica, certificado por el notario público Dr. Renato Vazquez Leyva, titular de la Notaria 9ª del Cantón de Guayaquil, Ecuador, fueron los siguientes: 1) En el 82% de los pacientes los síntomas remitieron al 4º día, 2) La mortalidad en los 104 pacientes fue de cero pacientes fallecidos y 3) Los 104 pacientes una vez aliviados no presentaron secuela alguna de la enfermedad.

En forma adicional al reporte comentado en los párrafos anteriores me permito presentar el artículo "Efficacy and Safety Evaluation of a Chlorine Dioxide Solution". Jui-Wen Ma, et al. International Journal of Environmental Research and public Health. 2017,en el cual se demuestra mediante la prueba subcrónica de toxicidad oral la NO Toxicidad del CDS. (Folios 140 al 151)

En el documento"Es tiempo de salvar vidas" se integra la información disponible sobre los aspectos generales del Dióxido de Cloro con referencias de publicaciones por parte de Organismos Internacionales (Anexo 3). Constituído por 21 páginas (Folios 152 al 172)

La finalidad es informar a esta Comisión sobre los usos de la molécula de Dióxido de cloro a dosis no tóxicas y sí eficaces y seguras, en beneficio del Pueblo de México, así como solicitar sean autorizados los diversos protocolos de investigación que se presenten ante esa comisión para corroborar científicamente su utilidad y estimular la investigación por parte

000.: 768

de otras entidades científicas nacionales y extranjeras, privadas o gubernamentales con el objeto de que sea investigada la molécula de dióxido de cloro, y se tome en cuenta que esta molécula cuenta con varias patentes de uso médico (Anexo 4), abriendo el camino para la investigación en otras indicaciones médicas y el desarrollo de nuevas presentaciones que podrían ser propuestas e incluso patentadas por parte de la industria farmacéutica nacional o internacional. (Folios 173 al 206)

Es importante mencionar también, que a nivel internacional como es el caso de Bolivia, ya se cuenta con legislaciones actualizadas sobre la producción y distribución gratuita y supervisada de Dióxido de Cloro (Anexo 5). (Folios 207 al 212.)

Con la honrosa representación y en calidad de Presidente de la Coalición Mundial Salud y Vida México A.C., quedo a sus órdenes para cualquier duda o aclaración, en el domicilio que señalamos para oír y recibir toda clase de notificaciones ubicado en Avenida Jesús del Monte No. 37 Piso 2 Despacho No. 9 Col. Jesús del Monte, Huixquilucan, Estado de México C.P. 52763, teléfono 5547 47 0605 y correo electrónico drubus8@gmail.com.

En espera de sus amables comentarios queda de usted

Atentamente

Dr. Pedro Chávez Zavala
Presidente
COMUSAV MEXICO A.C

c.c.p. Dr. Jorge Alcocer Varela. Secretario de Salud

COMUSAV
COALICIÓN MUNDIAL SALUD Y VIDA

**COMUSAV MEXICO A.C.**

Ciudad de México a 21 de octubre del 2020.

SENADO DE LA REPÚBLICA
12:41hrs.
21 OCT 2020
Recibí escrito con 1carpeta
DOCUMENTOS

Senador Miguel Ángel Navarro Quintero
Presidente de la Comisión de Salud
Honorable Cámara de Senadores LXIV Legislatura
Presente

Muy estimado Senador Navarro Quintero,

Sirva la presente para enviar un cordial saludo, así como para presentar a la Comisión de Salud de la Honorable Cámara de Senadores dignamente representada por usted, documentos muy importantes sobre la Seguridad, Eficacia y los aspectos generales del Dióxido de Cloro (CDS por sus siglas en inglés):

1. Resumen de la identificación de riesgos por la ingesta del dióxido de cloro en humanos y otros mamíferos, con comentarios de la COMUSAV, basado en el reporte de la U.S. Environmental Protection Agency (EPA): CHLORINE DIOXIDE AND CHLORITE. (CAS Nos. 10049-04-4 and 7758-19-2). Publicado en el año 2,000. (Anexo 1).

2. El reporte científico en extenso, del cual se obtuvo el resumen mencionado anteriormente: TOXICOLOGICAL REVIEW OF CHLORINE DIOXIDE AND CHLORITE (CAS Nos. 10049-04-4 and 7758-19-2) In Support of Summary Information on the Integrated Risk Information System (IRIS) *September 2000 (Anexo 2).*

3. -Dióxido de Cloro, una terapéutica efectiva para el tratamiento de SARS-COV2 COVID-19). Asociación Ecuatoriana de Médicos Expertos en Medicina Integrativa.
   -Efficacy and Safety Evaluation of a Chlorine Dioxide Solution. Jui-Wen Ma, et al. International Journal of Environmental Research and public Health. 2017.
   -Es tiempo de salvar vidas. Recopilado por la Asociación #ClO2Hope4The Planet
   - *In vivo* evaluation of the antiviral effect of $ClO_2$ in chicken embryos inoculated with avian infectious bronchitis coronavirus. Xochitl Zambrano-Estrada, et al. doi: https://doi.org/10.1101/2020.10.13.336768. BioRxIV. The Reprint Server for Biology. (Anexo 3)

4. Dióxido de Cloro como componente de productos patentados para uso médico (Anexo 4)

5. -Ley Departamental de 22 de Julio de 2020 de Cochabamba, Bolivia
-Ley Departamental No. 193 de 9 de septiembre de 2020, Departamento de La Paz Departamento de La Paz Bolivia. "
-Decreto de la Asamblea Legislativa Plurinacional: Ley que regula la elaboración, comercialización, suministro y uso consentido de la solución de Dióxido de cloro (SDC) como prevención y tratamiento ante la pandemia del coronavirus COVID-19 (Anexo 5).

El primer documento consta de 11 páginas (Folios 004 al 014), y se trata del resumen de una gran cantidad de estudios científicos realizados a nivel internacional sobre la toxicidad del dióxido de cloro, con comentarios de la COMUSAV en *letra itálica*, donde claramente se demuestra que a las dosis convenientes el dióxido de cloro en solución, conocido como CDS resulta inocuo para la salud humana en todas sus manifestaciones (Anexo 1).

El segundo documento es el artículo original que consta de 56 páginas (Folios 015 al 070), y del cual se elaboró el resumen anterior para que pueda ser consultado en su totalidad y cotejado con el documento presentado (Anexo 2).

El tercer documento que consta de 69 páginas (Folios 071 al 139), presenta el trabajo de investigación clínica que se realizó en la Cd. de Guayaquil, Ecuador, del 26 de marzo al 10 de abril de 2020, y el cual fue dirigido por el Dr. Roberto Edmundo Garcia Espinosa, un profesional de la salud con 35 años de experiencia en la práctica médica y 5 médicos más, todos ellos acreditados en su especialidad, y con amplia experiencia médica profesional.

Este estudio clínico se realizó con 104 pacientes que dieron COVID-19 positivo, y cuyas edades variaron de 18 a 80 años, de ambos sexos. Estos pacientes fueron intervenidos tempranamente en fases 1, 2 y 3 de la enfermedad. El tratamiento aplicado varió según la gravedad de los pacientes. En el caso de los pacientes graves se les indico ingerir 60 mg de dióxido de cloro diariamente por 2 o 3 días y luego reducir la dosis a 30 mg/día durante 14 días. Los pacientes sin sintomatología grave ingirieron desde el principio una dosis de 30 mg/día durante 14 días.

Los resultados más destacados, tal como se constata en el reporte de investigación clínica, certificado por el notario público Dr. Renato Vazquez Leyva, titular de la Notaria 9ª del Cantón de Guayaquil, Ecuador, fueron los siguientes: 1) En el 82% de los pacientes los síntomas remitieron al 4° día, 2) La mortalidad en los 104 pacientes fue de cero pacientes fallecidos y 3) Los 104 pacientes una vez aliviados no presentaron secuela alguna de la enfermedad.

En forma adicional al reporte comentado en los párrafos anteriores me permito presentar el artículo "Efficacy and Safety Evaluation of a Chlorine Dioxide Solution". Jui-Wen Ma, et al. International Journal of Environmental Research and public Health. 2017,en el cual se demuestra mediante la prueba subcrónica de toxicidad oral la NO Toxicidad del CDS. (Folios 140 al 151)

771

En el documento “Es tiempo de salvar vidas” se integra la información disponible sobre los aspectos generales del Dióxido de Cloro con referencias de publicaciones por parte de Organismos Internacionales. Constituído por 21 páginas (Folios 152 al 172).

La evaluación del efecto antiviral del ClO2 en embriones de pollo inoculados con coronavirus aviar productor de bronquitis infecciosa, realizado por Xóchitl Zambrano-Estrada y colaboradores permite concluir que el Dióxido de cloro representa una opción segura y viable en el control del coronavirus aviar y abre la posibilidad de que los mismos efectos sean observados en otros organismos. (Folio 173-174 Anexo 3).

La finalidad es informar a la Comisión de Salud de la H Cámara de Senadores sobre los usos de la molécula de Dióxido de cloro a dosis no tóxicas y sí eficaces y seguras, en beneficio del Pueblo de México, así como solicitar su intervención ante las instancias correspondientes (COFEPRIS) para que sean autorizados los diversos protocolos de investigación que se presenten para corroborar científicamente su utilidad y estimular la investigación por parte de otras entidades científicas incluidas la Industria Farmacéutica Nacional y Multinacional en cualquier indicación médica, considerándose el hecho de que ya cuenta con varias patentes de uso médico (Anexo 4 Folios 175 al 208).

Es importante mencionar también, que a nivel internacional como es el caso de Bolivia, ya se cuenta con la Ley a nivel Nacional que regula la elaboración, comercialización, suministro y uso consentido de la solución de Dióxido de cloro (SDC) como prevención y tratamiento ante la pandemia del coronavirus, COVID-19. (Anexo 5 Folios 209 al 217).

Con la honrosa representación y en calidad de Presidente de la Coalición Mundial Salud y Vida México A.C., quedo a sus órdenes para cualquier duda o aclaración, en el domicilio que señalamos para oír y recibir toda clase de notificaciones ubicado en Avenida Jesús del Monte No. 37 Piso 2 Despacho No. 9 Col. Jesús del Monte, Huixquilucan, Estado de México C.P. 52763, teléfono 5547 47 0605 y correo electrónico drubus8@gmail.com.

En espera de sus amables comentarios queda de usted

Atentamente

Dr. Pedro Chávez Zavala
Presidente
COMUSAV MEXICO A.C

c.c.p. Diputada Miroslava Sánchez Galván. Presidenta de la Comisión de Salud de la Honorable Cámara de Diputados.

772

COMUSAV
COALICIÓN MUNDIAL SALUD Y VIDA

T 21 [illegible] 11:56

**COMUSAV MEXICO A.C.**

Ciudad de México a 21 de octubre del 2020.

Diputada Miroslava Sánchez Galván
Presidenta de la Comisión de Salud de la
Honorable Cámara de Diputados LXIV Legislatura
Presente

Muy estimada Diputada Sánchez Galván,

Sirva la presente para enviar un cordial saludo, así como para presentar a la Comisión de Salud de la Honorable Cámara de Diputados dignamente representada por usted, documentos muy importantes sobre la Seguridad, Eficacia y los aspectos generales del Dióxido de Cloro (CDS por sus siglas en inglés):

1. Resumen de la identificación de riesgos por la ingesta del dióxido de cloro en humanos y otros mamíferos, con comentarios de la COMUSAV, basado en el reporte de la U.S. Environmental Protection Agency (EPA): CHLORINE DIOXIDE AND CHLORITE. (CAS Nos. 10049-04-4 and 7758-19-2). Publicado en el año 2,000. (Anexo 1).

2. El reporte científico en extenso, del cual se obtuvo el resumen mencionado anteriormente: TOXICOLOGICAL REVIEW OF CHLORINE DIOXIDE AND CHLORITE (CAS Nos. 10049-04-4 and 7758-19-2) In Support of Summary Information on the Integrated Risk Information System (IRIS) *September 2000 (Anexo 2).*

3. -Dióxido de Cloro, una terapéutica efectiva para el tratamiento de SARS-COV2 COVID-19). Asociación Ecuatoriana de Médicos Expertos en Medicina Integrativa.
   -Efficacy and Safety Evaluation of a Chlorine Dioxide Solution. Jui-Wen Ma, et al. International Journal of Environmental Research and public Health. 2017.
   -Es tiempo de salvar vidas. Recopilado por la Asociación #ClO2Hope4The Planet
   - *In vivo* evaluation of the antiviral effect of $ClO_2$ in chicken embryos inoculated with avian infectious bronchitis coronavirus. Xochitl Zambrano-Estrada, et al. doi: https://doi.org/10.1101/2020.10.13.336768. BioRxIV. The Reprint Server for Biology. (Anexo 3)

4. Dióxido de Cloro como componente de productos patentados para uso médico (Anexo 4)

5. -Ley Departamental de 22 de Julio de 2020 de Cochabamba, Bolivia
   -Ley Departamental No. 193 de 9 de septiembre de 2020, Departamento de La Paz Departamento de La Paz Bolivia. "
   -Decreto de la Asamblea Legislativa Plurinacional: Ley que regula la elaboración, comercialización, suministro y uso consentido de la solución de Dióxido de cloro (SDC) como prevención y tratamiento ante la pandemia del coronavirus COVID-19 (Anexo 5).

El primer documento consta de 11 páginas (Folios 004 al 014), y se trata del resumen de una gran cantidad de estudios científicos realizados a nivel internacional sobre la toxicidad del dióxido de cloro, con comentarios de la COMUSAV en *letra itálica*, donde claramente se demuestra que a las dosis convenientes el dióxido de cloro en solución, conocido como CDS resulta inocuo para la salud humana en todas sus manifestaciones (Anexo 1).

El segundo documento es el artículo original que consta de 56 páginas (Folios 015 al 070), y del cual se elaboró el resumen anterior para que pueda ser consultado en su totalidad y cotejado con el documento presentado (Anexo 2).

El tercer documento que consta de 69 páginas (Folios 071 al 139), presenta el trabajo de investigación clínica que se realizó en la Cd. de Guayaquil, Ecuador, del 26 de marzo al 10 de abril de 2020, y el cual fue dirigido por el Dr. Roberto Edmundo Garcia Espinosa, un profesional de la salud con 35 años de experiencia en la práctica médica y 5 médicos más, todos ellos acreditados en su especialidad, y con amplia experiencia médica profesional.

Este estudio clínico se realizó con 104 pacientes que dieron COVID-19 positivo, y cuyas edades variaron de 18 a 80 años, de ambos sexos. Estos pacientes fueron intervenidos tempranamente en fases 1, 2 y 3 de la enfermedad. El tratamiento aplicado varió según la gravedad de los pacientes. En el caso de los pacientes graves se les indico ingerir 60 mg de dióxido de cloro diariamente por 2 o 3 días y luego reducir la dosis a 30 mg/día durante 14 días. Los pacientes sin sintomatología grave ingirieron desde el principio una dosis de 30 mg/día durante 14 días.

Los resultados más destacados, tal como se constata en el reporte de investigación clínica, certificado por el notario público Dr. Renato Vazquez Leyva, titular de la Notaria 9ª del Cantón de Guayaquil, Ecuador, fueron los siguientes: 1) En el 82% de los pacientes los síntomas remitieron al 4° día, 2) La mortalidad en los 104 pacientes fue de cero pacientes fallecidos y 3) Los 104 pacientes una vez aliviados no presentaron secuela alguna de la enfermedad.

En forma adicional al reporte comentado en los párrafos anteriores me permito presentar el artículo "Efficacy and Safety Evaluation of a Chlorine Dioxide Solution". Jui-Wen Ma, et al. International Journal of Environmental Research and public Health. 2017,en el cual se demuestra mediante la prueba subcrónica de toxicidad oral la NO Toxicidad del CDS. (Folios 140 al 151)

774

En el documento “Es tiempo de salvar vidas” se integra la información disponible sobre los aspectos generales del Dióxido de Cloro con referencias de publicaciones por parte de Organismos Internacionales. Constituído por 21 páginas (Folios 152 al 172).

La evaluación del efecto antiviral del ClO2 en embriones de pollo inoculados con coronavirus aviar productor de bronquitis infecciosa, realizado por Xóchitl Zambrano-Estrada y colaboradores permite concluir que el Dióxido de cloro representa una opción segura y viable en el control del coronavirus aviar y abre la posibilidad de que los mismos efectos sean observados en otros organismos. (Folio 173-174 Anexo 3).

La finalidad es informar a la Comisión de Salud de la H Cámara de Diputados sobre los usos de la molécula de Dióxido de cloro a dosis no tóxicas y sí eficaces y seguras, en beneficio del Pueblo de México, así como solicitar su intervención ante las instancias correspondientes (COFEPRIS) para que sean autorizados los diversos protocolos de investigación que se presenten para corroborar científicamente su utilidad y estimular la investigación por parte de otras entidades científicas incluidas la Industria Farmacéutica Nacional y Multinacional en cualquier indicación médica, considerándose el hecho de que ya cuenta con varias patentes de uso médico (Anexo 4 Folios 175 al 208).

Es importante mencionar también, que a nivel internacional como es el caso de Bolivia, ya se cuenta con la Ley a nivel Nacional que regula la elaboración, comercialización, suministro y uso consentido de la solución de Dióxido de cloro (SDC) como prevención y tratamiento ante la pandemia del coronavirus, COVID-19. (Anexo 5 Folios 209 al 217.)

Con la honrosa representación y en calidad de Presidente de la Coalición Mundial Salud y Vida México A.C., quedo a sus órdenes para cualquier duda o aclaración, en el domicilio que señalamos para oír y recibir toda clase de notificaciones ubicado en Avenida Jesús del Monte No. 37 Piso 2 Despacho No. 9 Col. Jesús del Monte, Huixquilucan, Estado de México C.P. 52763, teléfono 5547 47 0605 y correo electrónico drubus8@gmail.com.

En espera de sus amables comentarios queda de usted

Atentamente

Dr. Pedro Chávez Zavala
Presidente
COMUSAV MEXICO A.C

c.c.p. Senador Miguel Ángel Navarro Quintero. Presidente de la Comisión de Salud
Honorable Cámara de Senadores LXIV Legislatura

COMUSAV
COALICIÓN MUNDIAL SALUD Y VIDA

**COMUSAV MEXICO A.C.**

Ciudad de México a 21 de octubre del 2020.

Maestra Rosario Piedra Ibarra
Presidenta de la Comisión Nacional de los Derechos Humanos
Presente

COMISIÓN NACIONAL DE LOS DERECHOS HUMANOS
21 OCT 2020
1045
OFICIALIA DE PARTES
79679/2020

Muy estimada Maestra Piedra Ibarra,

Sirva la presente para enviar un cordial saludo, así como para presentar a la Comisión Nacional de los Derechos Humanos dignamente representada por usted, documentos muy importantes sobre la Seguridad, Eficacia y los aspectos generales del Dióxido de Cloro (CDS por sus siglas en inglés):

1. Resumen de la identificación de riesgos por la ingesta del dióxido de cloro en humanos y otros mamíferos, con comentarios de la COMUSAV, basado en el reporte de la U.S. Environmental Protection Agency (EPA): CHLORINE DIOXIDE AND CHLORITE. (CAS Nos. 10049-04-4 and 7758-19-2). Publicado en el año 2,000. (Anexo 1).

2. El reporte científico en extenso, del cual se obtuvo el resumen mencionado anteriormente: TOXICOLOGICAL REVIEW OF CHLORINE DIOXIDE AND CHLORITE (CAS Nos. 10049-04-4 and 7758-19-2) In Support of Summary Information on the Integrated Risk Information System (IRIS) *September 2000 (Anexo 2).*

3. -Dióxido de Cloro, una terapéutica efectiva para el tratamiento de SARS-COV2 COVID-19). Asociación Ecuatoriana de Médicos Expertos en Medicina Integrativa.
   -Efficacy and Safety Evaluation of a Chlorine Dioxide Solution. Jui-Wen Ma, et al. International Journal of Environmental Research and public Health. 2017.
   -Es tiempo de salvar vidas. Recopilado por la Asociación #ClO2Hope4The Planet
   - *In vivo* evaluation of the antiviral effect of $ClO_2$ in chicken embryos inoculated with avian infectious bronchitis coronavirus. Xochitl Zambrano-Estrada, et al. doi: https://doi.org/10.1101/2020.10.13.336768. BioRxIV. The Reprint Server for Biology. (Anexo 3)

4. Dióxido de Cloro como componente de productos patentados para uso médico (Anexo 4)

776

5. -Ley Departamental de 22 de Julio de 2020 de Cochabamba, Bolivia
-Ley Departamental No. 193 de 9 de septiembre de 2020, Departamento de La Paz Departamento de La Paz Bolivia. "
-Decreto de la Asamblea Legislativa Plurinacional: Ley que regula la elaboración, comercialización, suministro y uso consentido de la solución de Dióxido de cloro (SDC) como prevención y tratamiento ante la pandemia del coronavirus COVID-19 (Anexo 5).

El primer documento consta de 11 páginas (Folios 004 al 014), y se trata del resumen de una gran cantidad de estudios científicos realizados a nivel internacional sobre la toxicidad del dióxido de cloro, con comentarios de la COMUSAV en *letra itálica*, donde claramente se demuestra que a las dosis convenientes el dióxido de cloro en solución, conocido como CDS resulta inocuo para la salud humana en todas sus manifestaciones (Anexo 1).

El segundo documento es el artículo original que consta de 56 páginas (Folios 015 al 070), y del cual se elaboró el resumen anterior para que pueda ser consultado en su totalidad y cotejado con el documento presentado (Anexo 2).

El tercer documento que consta de 69 páginas (Folios 071 al 139), presenta el trabajo de investigación clínica que se realizó en la Cd. de Guayaquil, Ecuador, del 26 de marzo al 10 de abril de 2020, y el cual fue dirigido por el Dr. Roberto Edmundo Garcia Espinosa, un profesional de la salud con 35 años de experiencia en la práctica médica y 5 médicos más, todos ellos acreditados en su especialidad, y con amplia experiencia médica profesional.

Este estudio clínico se realizó con 104 pacientes que dieron COVID-19 positivo, y cuyas edades variaron de 18 a 80 años, de ambos sexos. Estos pacientes fueron intervenidos tempranamente en fases 1, 2 y 3 de la enfermedad. El tratamiento aplicado varió según la gravedad de los pacientes. En el caso de los pacientes graves se les indico ingerir 60 mg de dióxido de cloro diariamente por 2 o 3 días y luego reducir la dosis a 30 mg/día durante 14 días. Los pacientes sin sintomatología grave ingirieron desde el principio una dosis de 30 mg/día durante 14 días.

Los resultados más destacados, tal como se constata en el reporte de investigación clínica, certificado por el notario público Dr. Renato Vazquez Leyva, titular de la Notaria 9ª del Cantón de Guayaquil, Ecuador, fueron los siguientes: 1) En el 82% de los pacientes los síntomas remitieron al 4° día, 2) La mortalidad en los 104 pacientes fue de cero pacientes fallecidos y 3) Los 104 pacientes una vez aliviados no presentaron secuela alguna de la enfermedad.

En forma adicional al reporte comentado en los párrafos anteriores me permito presentar el artículo "Efficacy and Safety Evaluation of a Chlorine Dioxide Solution". Jui-Wen Ma, et al. International Journal of Environmental Research and public Health. 2017,en el cual se demuestra mediante la prueba subcrónica de toxicidad oral la NO Toxicidad del CDS. (Folios 140 al 151)

777

En el documento "Es tiempo de salvar vidas" se integra la información disponible sobre los aspectos generales del Dióxido de Cloro con referencias de publicaciones por parte de Organismos Internacionales. Constituído por 21 páginas (Folios 152 al 172).

La evaluación del efecto antiviral del ClO2 en embriones de pollo inoculados con coronavirus aviar productor de bronquitis infecciosa, realizado por Xóchitl Zambrano-Estrada y colaboradores permite concluir que el Dióxido de cloro representa una opción segura y viable en el control del coronavirus aviar y abre la posibilidad de que los mismos efectos sean observados en otros organismos. (Folio 173-174 Anexo 3).

La finalidad es informar a la Comisión Nacional de los Derechos Humanos sobre los usos de la molécula de Dióxido de cloro a dosis no tóxicas y sí eficaces y seguras, en beneficio del Pueblo de México, así como solicitar su intervención ante las instancias correspondientes (SECRETARIA DE SALUD, COFEPRIS) para que sean autorizados los diversos protocolos de investigación que se presenten para corroborar científicamente su utilidad considerándose el hecho de que ya cuenta con varias patentes de uso médico (Anexo 4 Folios 175 al 208).

Es importante mencionar también, que a nivel internacional como es el caso de Bolivia, ya se cuenta con la Ley a nivel Nacional que regula la elaboración, comercialización, suministro y uso consentido de la solución de Dióxido de cloro (SDC) como prevención y tratamiento ante la pandemia del coronavirus, COVID-19. (Anexo 5 Folios 209 al 217.)

Con la honrosa representación y en calidad de Presidente de la Coalición Mundial Salud y Vida México A.C., quedo a sus órdenes para cualquier duda o aclaración, en el domicilio que señalamos para oír y recibir toda clase de notificaciones ubicado en Avenida Jesús del Monte No. 37 Piso 2 Despacho No. 9 Col. Jesús del Monte, Huixquilucan, Estado de México C.P. 52763, teléfono 5547 47 0605 y correo electrónico drubus8@gmail.com.

En espera de sus amables comentarios queda de usted

Atentamente

Chávez

Dr. Pedro Chávez Zavala
Presidente
COMUSAV MEXICO A.C

c.c.p. Diputada Miroslava Sánchez Galván. Presidenta de la Comisión de Salud de la Honorable Cámara de Diputados.
c.c.p. Senador Miguel Ángel Navarro Quintero. Presidente de la Comisión de Salud Honorable Cámara de Senadores LXIV Legislatura

# Anexo 2.

779

# Coalición Mundial Salud y Vida
# -COMUSAV-

**Resumen de la identificación de riesgos por la ingesta del dióxido de cloro en humanos y otros mamíferos, basado en el reporte de la U.S. Environmental Protection Agency (EPA): CHLORINE DIOXIDE AND CHLORITE. (CAS Nos. 10049-04-4 and 7758-19-2). Publicado en el año 2,000.**

*En letras cursivas van los comentarios y la comparación de los resultados publicados en este reporte de investigación, con las dosis de ingesta que se están proponiendo por los médicos de COMUSAV para prevenir o para tratar pacientes de COVID 19.*

**Antecedentes:**

*La FDA reporta en su sitio Web (https://www.fda.gov/news-events/press-announcements/actualizacion-del-coronavirus-covid-19-la-fda-advierte-empresa-que-comercializa-productos-peligrosos, con fecha 8 de abril del 2020), que el dióxido de cloro tiene efectos adversos a la salud humana, y lo ha difundido masivamente en los medios, tanto escritos como en las redes sociales. Por otro lado, las instituciones de salud de cada país han copiado este aviso y lo transcriben íntegramente en sus medios de comunicación, sin verificar la veracidad y certeza de estas aseveraciones. Entre los síntomas adversos que reporta la FDA incluye los siguientes:*

1. *Insuficiencia respiratoria causada por una condición grave en donde la cantidad de oxígeno que se transporta a través del torrente sanguíneo se reduce considerablemente (metahemoglobinemia).*
2. *Cambios en la actividad eléctrica del corazón (prolongación del QT), lo que puede llevar a ritmos cardíacos anormales y posiblemente mortales.*
3. *Baja presión arterial mortal causada por deshidratación.*
4. *Insuficiencia hepática aguda.*
5. *Conteo bajo de células sanguíneas, debido a la rápida destrucción de los glóbulos rojos (anemia hemolítica), lo que requiere una transfusión de sangre.*
6. *Vómitos severos.*

*Sin embargo, dicho aviso no indica si estos síntomas son por la ingesta o por la inhalación del gas dióxido de cloro, condiciones totalmente distintas en cuanto a los efectos que esta molécula causa al organismo. Además, no deja claro si dichos síntomas son por el uso del producto conocido en internet como MMS (Magistral Mineral Solution) o por la solución de dióxido de cloro (CDS) a una concentración de solo 0.3 g/litro (3,000 ppm). Solo hace menciónа:* **"es un producto líquido que se vende con 28% clorito sódico en agua destilada y con instrucciones de uso para que los consumidores mezclen la solución de clorito sódico con ácido cítrico, jugo de limón o lima, u otro ácido como el ácido clorhídrico, antes de tomarlo. Además de referir que el clorito sódico se vende como parte de un kit con un ácido cítrico que sirve como activador y al mezclarse produce dióxido de cloro, un potente agente blanqueador que causa serios efectos colaterales que comprometen la vida".** *Por lo que se asume que este comunicado de la FDA se refiere al MMS y no al Dióxido de cloro en solución (el cual se encuentra ya preparado). Tampoco se indican las dosis a las que se podría causar los síntomas arriba descritos.*

780

*Por otro lado, la Coalición Mundial Salud y Vida (COMUSAV) que agrupa a 3,000 médicos de 19 países del mundo reporta, por el contrario, que el dióxido de cloro, utilizado a la dosis correcta es una molécula capaz de prevenir y ser tratamiento ante el COVID19. (afirmaciones basadas en prácticas de campo y estudios científicos observacionales retrospectivos en humanos, amparados en la declaración de Helsinki de la Asociación Médica Mundial que en su artículo 37 dice a la letra:*

**Intervenciones no probadas en la práctica clínica**

Artículo 37: Cuando en la atención de un paciente las intervenciones probadas no existen u otras intervenciones conocidas han resultado ineficaces, el médico, después de pedir consejo de expertos, con el consentimiento informado del paciente o de un representante legal autorizado, puede permitirse usar intervenciones no comprobadas, si, a su juicio, ello da alguna esperanza de salvar la vida, restituir la salud o aliviar el sufrimiento. Tales intervenciones deben ser investigadas posteriormente a fin de evaluar su seguridad y eficacia. En todos los casos, esa información nueva debe ser registrada y, cuando sea oportuno, y puesta a disposición del público.

***Revisión de literatura científica relacionada con la toxicidad del dióxido de cloro (CDS)***

*Para ello se recurrió a uno de los reportes más completos al respecto, el cual fue generado por otra agencia de los Estados Unidos de América:* la U. S. Environmental Protection Agency (U.S. EPA" CHLORINE DIOXIDE AND CHLORITE (CAS Nos. 10049-04-4 and 7758-19-2) In Support of Summary Information on the Integrated Risk Information System (IRIS) September 2000"), *la cual emitió un reporte donde analiza la posible toxicidad tanto del dióxido de cloro, como del clorito de sodio, y las dosis a las que dicha toxicidad podría ocurrir en caso de ser ingerido. En este reporte que realiza COMUSAV, el análisis se reduce específicamente al dióxido de cloro ingerido por vía oral, el producto que ha mostrado cualidades preventivas y de tratamiento ante el COVID 19, según manifiestan los médicos de los diversos países de esta organización.*

**Diferencias entre el CDS y MMS.**

*Mucho se ha vertido en los medios sobre el riesgo de consumir MMS y con mucha frecuencia suele confundirse con CDS (Solución de dióxido de cloro). Es importante clarificar que el MMS es una solución que se prepara a partir de la mezcla de algunas gotas de cada uno de los dos reactivos: Clorito de sodio, por un lado, y un ácido que puede ser cítrico o clorhídrico, por el otro. A esta mezcla se agrega en un litro de agua, se deposita en una botella, se cierra herméticamente y se ingiere a lo largo del día. El problema de esta mezcla es que ninguno de los dos reactivos es químicamente puro y al tomar la mezcla de estos se ingieren las impurezas que traen ambos reactivos. Estas impurezas o subproductos químicos pueden generar malestares como diarreas, vómitos y otros efectos colaterales que, aunque no son de gravedad, no dejan de ser molestias, en especial cuando se bebe una dosis alta de estos productos. También puede ser debido a la mala información que existe en el público en general sobre el producto, quienes por la urgencia sanitaria que se vive, al intentar prevenir o tratar el COVID 19, lleva a no acudir a una asesoría o consulta médica y a consumir productos que no han sido preparados bajo la supervisión de químicos capacitados en la elaboración.*

*Por otro lado, el otro compuesto que solo contiene dióxido de cloro disuelto en agua (CDS) a una concentración de 3,000 ppm (mg/L) no contiene las impurezas que contiene el denominado MMS proveniente de la mezcla de los dos reactivos descritos arriba. En el caso del CDS se trata de un*

781

*compuesto sumamente puro, pues las dos sustancias se ponen a reaccionar en un recipiente que contiene adentro otro pequeño contenedor donde se lleva a cabo la reacción química y de donde se genera el gas dióxido de cloro que saturará el agua que esta por fuera de este recipiente. Es importante aclarar sin lugar a duda que el dióxido de cloro en solución no contiene absolutamente nada de clorito de sodio, ni de algún ácido, como se he pretendido confundir en varios spots publicitarios que pretenden denostrar la solución del dióxido de cloro. Otra forma de producir el dióxido de cloro es por electrolisis.*

*En base al procedimiento de su preparación, la solución CDS contiene un elevado grado de pureza, pues solo contiene el dióxido de cloro disuelto en agua. En resumen, el MMS contiene impurezas que pueden causar malestar al ser ingerido, pero el dióxido de cloro en solución, conocido también como CDS, solo contiene el gas dióxido de cloro a una concentración de solo 0.3 g/L disuelto en agua y del cual se toman solo 5 a 10 ml para ser ingeridos a lo largo del día, disueltos en un litro de agua fría. Esta gran diferencia permite que la solución de dióxido de cloro sea inocua y sumamente tolerable para ser ingerida en diversas dosis sin causar ningún malestar o riesgo para la salud. Los problemas que pudieran existir con relación a la variación de la calidad del producto se eliminarían si existiera una estrecha colaboración entre las Agencias, Comités o Entidades reguladoras en cada país con la COMUSAV para llevar a cabo la supervisión en la elaboración del Dióxido de cloro en solución y asegurar su adecuada calidad, tal como ya se ha establecido por ley en el país de Bolivia.*

### *Introducción*

*Este documento se centra solo en la toxicidad por ingesta del compuesto dióxido de cloro, y no trata los aspectos de toxicidad por inhalación, pues esa parte no es del interés de esta revisión de literatura, además, es bien sabido que aspirar este gas resulta perjudicial para la salud. Por otro lado, las dosis reportadas en cada uno de los citados estudios sobre toxicidad se comparan con las dosis que se utilizan en la prevención y tratamiento de COVID 19, por los médicos de COMUSAV, que van de 5 a 10 ml/día de una solución de dióxido de cloro a una concentración de 3,000 ppm (5 ml para gente poco expuesta y 10 ml para gente más expuesta, como por ejemplo el personal de salud que está atendiendo pacientes COVID 19 u otro personal que por su actividad de servidor público se encuentre expuesto a una carga viral elevada. Dicha cantidad de solución madre de 3,000 ppm se disuelve en un litro de agua fría y se bebe durante el día. Es decir, esto equivale a una dosis de 15 a 30 mg/día en pacientes adultos con un peso promedio de 60 kg, un valor que oscila entre 0.25 y 0.50 mg/kg-día. Contra esta dosis estaremos comparando todos los reportes que se presentarán a lo largo de esta revisión bibliográfica, tomada de fuentes científicas debidamente acreditadas.*

### *Propiedades físicas del compuesto*

El dióxido de cloro ($ClO_2$) es un gas con un peso molecular de 67.46, un punto de ebullición de 11 °C, una solubilidad en agua de 3,000 mg/L a 25°C y presenta una gravedad específica de 1.642 a 0°C (Budavari et al., 1989).

### *Absorción gastrointestinal*

782

Después de la ingestión, el dióxido de cloro se absorbe rápidamente por el tracto digestivo. Los niveles plasmáticos máximos se observan 2 horas después de su ingestión y se estima que al menos el 30% de la dosis de prueba ingerida fue absorbida (Abdel-Rahman et al., 1979a).

### *Distribución en el organismo después de su ingesta*

Una vez ingerido el compuesto se distribuye por todo el cuerpo, pero las concentraciones más altas se encontraron en la sangre, el estómago y el intestino delgado (Abdel-Rahman et al., 1982). Setenta y dos horas después de la ingesta de una dosis única de 100 mg/L, la mayor parte del cloro se detectó en la forma de ion cloruro ($Cl^-$), y la proporción de cloruro a clorito ($ClO_2$) fue de 4 a 1 (Abdel-Rahman et al., 1979b).

### *Metabolismo*

El ion cloruro es el metabolito final del dióxido de cloro en el organismo, acumulándose en orina y plasma en 87 y 80% respectivamente. A partir de una solución ingerida de 100 mg/litro y utilizando cloro marcado radiactivamente para seguir su curso en el organismo, el clorito fue un metabolito importante, representando aproximadamente el 11% en la orina y el 21% en plasma del total del cloro del dióxido de cloro marcado (Abdel-Rahman et al., 1979b). Un estudio de recuperación *in vivo* en ratas, realizado por Bercz et al. (1982) sugiere que el dióxido de cloro ingerido se reduce rápidamente en el estómago a especies no oxidantes (presumiblemente cloruro).

### **Eliminación**

La forma química en la que se elimina el dióxido de cloro es a través de orina y heces. Setenta y dos horas después de la ingesta de dióxido de cloro marcado en ratas, el 31 y el 10% de éste fue excretado en la orina y las heces, respectivamente y la relación de $Cl^-$ a $ClO_2$, fue de 5 a 1 durante las primeras 24 horas y de 4 a 1 durante las primeras 72 horas (Abdel-Rahman et al., 1979b).

### *Identificación de riesgos en humanos*

La toxicidad a corto plazo del dióxido de cloro se evaluó en dos estudios en humanos. En el primer estudio Lubbers et al. (1982) evaluaron a un grupo de 10 adultos varones sanos de 70 kg de peso, que ingirieron una dosis única de 0.34 mg/kg de peso vivo. En el segundo estudio (Lubbers et al., 1984a) evaluaron la ingesta 0.04 mg/kg-día, durante 12 semanas. después de realizar observaciones y exámenes físicos. Dentro de éstos incluyeron, los signos vitales como presión arterial, frecuencia del pulso, tasa de respiración y temperatura corporal, también parámetros de química clínica sérica (incluyendo glucosa, nitrógeno de urea, fósforo, fosfatasa alcalina y aminoácidos de aspartato y alanina), así como niveles de triyodotironina sérica (T3) y tiroxina (T4) al igual que parámetros hematológicos. *Ninguno de los dos estudios reportó alteraciones fisiológicamente relevantes en la salud general.*

### *Consumo de agua potable desinfectada con dióxido de cloro.*

Michael et al. (1981), Tuthill et al. (1982) y Kanitz et al. (1996) compararon comunidades que consumían agua potable desinfectada con dióxido de cloro versus comunidades que no usaban este reactivo químico y compararon su efecto por medio de análisis de sangre. El estudio duró 10 semanas y se realizó con 118 individuos. La ingesta media de dióxido de cloro en las comunidades que lo consumían fue de 0.15 mg/kg al día. Estos investigadores reportan que no se detectaron alteraciones hematológicas o en química sérica en este estudio. *Este valor de 0.15 mg/kg-día es*

783

*moderadamente cercano a los valores que utiliza COMUSAV para prevenir y de tratamiento ante COVID 19, que van de 0.25 a 0.50 mg/kg-día.*

Tuthill et al. (1982) compararon retrospectivamente los datos de morbilidad y mortalidad infantil para una comunidad que había utilizado niveles "altos" de dióxido de cloro como desinfectante de agua potable en la década de 1940 con datos de una comunidad vecina que utilizaba prácticas convencionales de cloración de agua potable, desafortunadamente no informaron de las concentraciones de dióxido de cloro en el agua tratada. La exposición al agua tratada con dióxido de cloro no afectó negativamente a la mortalidad fetal, neonatal, post neonatal o infantil, ni afectó el peso al nacer, la proporción sexual o la condición de nacimiento.

Por su parte, en Italia Kanitz et al. (1996) dieron seguimiento a 548 nacimientos en el Hospital Galliera de Génova y 128 nacimientos en el Hospital Chiavari, en Chiavari, durante 1988-1989. Las mujeres en Génova fueron expuestas a agua filtrada desinfectada con dióxido de cloro, hipoclorito de sodio, o ambos; los niveles de trihalometano variaron de 8 a 16 ppb en agua tratada con hipoclorito sódico y de 1 a 3 ppb en agua desinfectada con dióxido de cloro. Los autores del estudio concluyeron que los bebés de mujeres que consumían agua potable tratada con compuestos de cloro durante el embarazo tenían un mayor riesgo de adquirir ictericia neonatal, circunferencia craneal menor de 35 cm y longitud corporal menor de 49.5 cm. Sin embargo, los datos de referencia atípicos plantean preocupaciones sobre la población testigo seleccionada para este estudio y dificultan la interpretación de cualquier comparación con el grupo expuesto, excluyendo así la capacidad de sacar conclusiones de este estudio, según lo refiere Selevan, (1997), *por lo que dicho trabajo no puede ser considerado confiable para dilucidar las conclusiones reportadas por los autores que lo generaron.*

### *Efectos de largo plazo del dióxido de cloro.*

Daniel et al., (1990) trabajaron con ratas de la línea Sprague-Dawley y expusieron grupos de 10 machos y 10 hembras al dióxido de cloro en el agua potable durante 90 días, a dosis administradas equivalentes a 0, 2, 4, 6 ó 12 mg/kg-día de dióxido de cloro para machos; y 0, 2, 5, 8 ó 15 mg/kg-día de dióxido de cloro para las hembras. La exposición a 12 mg/kg-día, dio lugar a reducciones significativas en el peso corporal final. También se observaron disminuciones en el consumo de alimentos en la dosis más alta. Los pesos hepáticos absolutos disminuyeron en los machos a partir de la dosis de 6 mg/kg-día y los pesos absolutos del bazo disminuyeron en las hembras a partir de la dosis de 2 mg/kg-día. No se observaron alteraciones consistentes en los parámetros hematológicos (recuentos totales y de leucocitos totales y diferenciales, niveles de hemoglobina, hematocrito y volumen corpuscular medio, medido). Los niveles séricos de lactato deshidrogenasa y aspartato aminotransferasa disminuyeron y los niveles séricos de creatinina aumentaron en los machos expuestos a 6 y 12 mg/kg-día. No se encontraron otras alteraciones en los parámetros de química sérica. Por lo tanto, a partir de 2 mg/kg-día se podría considerar como un nivel en el cual no se aprecia un efecto adverso (NOAEL). *Esta dosis es 4 a 8 veces más alta que la dosis que han usado los médicos de COMUSAV para prevenir y de tratamiento ante el COVID 19.*

En un estudio de toxicidad crónica realizado por Haag (1949), grupos de siete ratas macho y siete ratas hembra fueron expuestos a dosis de dióxido de cloro equivalentes a: 0, 0.07, 0.13, 0.7, 1.3 y 13.0 mg/kg-día según lo calculado por la EPA de los Estados Unidos, durante 2 años. La

784

supervivencia en el grupo de 13 mg/kg-día disminuyó significativamente. No se observaron alteraciones relacionadas con el dióxido de cloro en el examen histopatológico de animales representativos (2-6/sexo) de cada grupo. Para este estudio identificaron un nivel en el cual no se observa ningún efecto adverso (NOAEL), de 1.3 mg/kg-día y un nivel de efectos francos (FEL), basado en una disminución de la supervivencia, de 13 mg/kg-día. *En este estudio el valor NOAEL fue menor que en el estudio de Daniel et al. (1990), pero, aun así, es 3 a 5 veces más alto que las dosis usadas para prevenir o de tratamiento ante el COVID 19, propuesto por la COMUSAV.*

Bercz et al. (1982) utilizaron un diseño de dosis ascendente en el que cada animal servía como su propio control. Cinco monos verdes africanos adultos y siete hembras (*Cercopithecus aethiops*) fueron expuestos a dosis equivalentes a 0, 3.5 y 9.5 mg/kg-día de dióxido de cloro. En este estudio no se presentaron alteraciones significativas en la química clínica hematológica (eritrocitos, leucocitos totales y diferenciales, recuentos de reticulocitos, niveles de hemoglobina, hematocrito, fragilidad osmótica y niveles de metahemoglobina) o en química clínica sérica (creatinina, nitrógeno de urea en sangre [BUN], fosfatasa alcalina, deshidrogenasa de lactato y alanina y aspartato aminotransferasa) o aumento de peso corporal. Los niveles séricos de T4 disminuyeron significativamente en los monos expuestos a dióxido de cloro de 9.5 mg/kg-día. Así, este estudio identifica un NOAEL de 3.5 mg/kg-día y un LOAEL de 9.5 mg/kg-día, para alteraciones en los niveles de hormona tiroidea en monos expuestos al dióxido de cloro en el agua potable durante 4-6 semanas. *Para este estudio, el NOAEL, es decir el nivel más bajo en el que no se observan efectos adversos es de 3.5 mg/kg-día, es decir 7 a 14 veces más alto que el usado para prevenir o de tratamiento ante el COVID 19 propuesto por la COMUSAV.*

Abdel-Rahman y col. (1984b) expusieron grupos de cuatro ratas macho Sprague-Dawley a dosis logarítmicamente consecutivas de 0, 0.1, 1, 10 y 100 mg/kg-día. Estos investigadores evaluaron el peso corporal de las ratas y algunas variables hematológicas como: fragilidad osmótica, hematocrito, y hemoglobina. Sin embargo, la falta de una relación consistente entre la dosis y las alteraciones hematológicas y el pequeño número de animales (solo cuatro machos/grupo) confunden la interpretación del estudio, lo que dificulta obtener conclusiones definitivas de este trabajo. De igual forma, Couri y Abdel-Rahman (1980) realizaron una investigación en ratas Sprague-Dawley (cuatro machos/grupo) con 4 niveles de dióxido de cloro además del testigo (dosis equivalentes de: 0, 0.1, 1, 10 ó 100 mg/kg-día) y estudiaron los niveles de glutatión reductasa en sangre, glutatión peroxidasa y niveles de catalasa en eritrocitos. Sin embargo, al igual que con Abdel-Rahman et al. (1984b), la relación inconsistente entre la dosis y la magnitud de las alteraciones en el sistema dependiente del glutatión dificulta la interpretación de sus resultados. Además, no está claro si estos efectos son biológicamente significativos, lo que excluyó la determinación de una NOAEL y una LOAEL para estos estudios. Por otro lado, Moore y Calabrese (1982) expusieron grupos de 10 ratones A/J o C57L/J (sexo no especificado) a 0 ó 19 mg/kg-día durante 30 días y no observaron alteraciones significativas en los parámetros hematológicos (hemograma completo, recuento de reticulocitos, actividad de glucosa-6-fosfato y fragilidad osmótica) en ninguna de las cepas de ratón.

## Efecto del dióxido de cloro sobre el desarrollo reproductivo.

Carlton y col. (1991) administraron dosis diarias por sonda, equivalentes a: 0, 2.5, 5.0, ó 10 mg/kg-día, de dióxido de cloro en agua desionizada a grupos de 12 ratas Long-Evans macho, durante 56 días antes del apareamiento y durante un período de apareamiento de 10 días. Grupos de 24 ratas hembra recibieron las mismas dosis por sonda durante 14 días antes del apareamiento,

785

durante el período de apareamiento y durante la gestación y la lactancia. No se observaron alteraciones significativas en la mortalidad, los signos clínicos, las tasas de fertilidad, los parámetros de los espermatozoides, la duración de la gestación, las muertes prenatales, el tamaño medio de la camada o el peso medio de las crías. Tampoco se observaron alteraciones significativas en el peso de los órganos del tracto reproductivo en las ratas macho F1. En las ratas hembra F1, hubo disminuciones estadísticamente significativas en los pesos absolutos y relativos de la vagina en el grupo de 10 mg/kg-día, pero no hubo diferencias en los pesos corporales terminales o los pesos uterinos y ováricos. No se midieron alteraciones consistentes relacionadas con el dióxido de cloro en los niveles de T3 ó T4 en las ratas macho y hembra F0 y en las ratas macho F1 (niveles hormonales medidos en los días 17, 28 y 40 postnatales). *Este estudio identifica un NOAEL de 10 mg/kg-día para efectos reproductivos en ratas que reciben dosis de dióxido de cloro por sonda. Esta NOAEL es 20 a 40 veces más elevado que la usada para fines de prevenir o de tratamiento ante el COVID 19.*

En un estudio de toxicidad para el desarrollo realizado por Suh et al. (1983), a grupos de seis a ocho ratas hembra Sprague-Dawley se les administró 0, 0.1, 1 y 10 mg / kg-día, durante 2.5 meses antes del apareamiento con machos no expuestos y durante los días de gestación 0-20; las madres se sacrificaron al día 20 de gestación. Este estudio identifica un NOAEL de 1 mg/kg-día y LOAEL de 10 mg / kg-día, para efectos de desarrollo en la descendencia de ratas expuestas al dióxido de cloro en el agua potable. *En este caso el NOAEL es 2 a 4 veces más elevado a la recomendada y usada para prevenir o de tratamiento ante el COVID 19.*

Toth et al. (1990) examinaron la toxicidad del dióxido de cloro en el desarrollo neurológico en las ratas encapuchadas Long-Evans expuestas postnatalmente. Este estudio identifica una LOAEL de 14 mg/kg-día para el parámetro desarrollo del cerebro en ratas expuestas postnatalmente. Mobley y col. (1990) expusieron grupos de 12 ratas hembra Sprague-Dawley a 0 ó 14 mg/kg-día. En el día 42 posterior a la concepción, no hubo alteraciones significativas en la captación total de T3 o T4, T4 libre o T3. El día en que abrieron los ojos no se vio afectado significativamente por la exposición al dióxido de cloro. Por lo tanto 14 mg/kg-día es el LOAEL para la disminución del peso de la camada y la actividad exploratoria.

En un estudio realizado por Orme et al., (1985) diseñado para evaluar la toxicidad del dióxido de cloro en la tiroides, grupos de ratas hembra Sprague-Dawley fueron expuestos dosis equivalentes de 0, 1, 3 y 14 mg/kg-día durante 2 semanas antes del apareamiento y durante la gestación y la lactancia. Este estudio identifica un NOAEL de 3 mg/kg-día, y un LOAEL de 14 mg/kg-día para efectos neuroconductuales. *El estudio de Orme et al. (1985) muestra un NOAEL de 6 a 12 veces más elevado que la dosis usada para prevenir o de tratamiento ante el COVID 19.*

Taylor y Pfohl (1985) expusieron grupos de 13-16 ratas hembra Sprague-Dawley a 0 y 14 mg/kg-día de dióxido de cloro y reportan un LOAEL para efectos neuroconductuales, disminución del peso cerebral y número de células en la descendencia de ratas expuestas al dióxido de cloro en el agua potable y en ratas expuestas postnatalmente al dióxido de cloro por sonda nasogástrica, de 14 mg/kg-día. *Un nivel 28 a 56 veces más elevado que la dosis usada para prevenir o de tratamiento ante el COVID 19.*

786

### Estudios de carcinogenicidad con la ingestión de dióxido de cloro.

Miller et al. (1986) probaron el potencial carcinogénico del agua potable desinfectada con dióxido de cloro utilizando tres ensayos a corto plazo. Después de la desinfección con dióxido de cloro, las muestras de agua (que contenían 0.5 mg/L de residuos de dióxido de cloro) se concentraron 2,000 y 4,000 veces usando un proceso de resina macrorreticular. Se administraron por vía oral a grupos de 14 a 34 ratones SENCAR (no se especifica el sexo) 0.5 ml del concentrado 4000 × en emulforado al 2% por tres veces a la semana durante 2 semanas, seguido de exposición tópica a 1.0 g de 12 tetradecanilforbal-13-acetato (TPA) en acetona aplicado a la piel dorsal 3 veces/semana durante 20 semanas y luego sacrificados. No se observaron aumentos significativos, en comparación con los controles de vehículo, en el número de tumores de piel o en el número de tumores por animal.

En un ensayo de adenoma de pulmón realizado por Miller et al. en 1986, evaluaron en grupos de 20 ratones macho y 20 hembras de la cepa A, los cuales recibieron dosis de 0.25 ml por sonda de concentrados de 2,000 y 4,000 veces concentrado al 2%, 3 veces por semana durante 8 semanas seguidas en un período de observación de 16 semanas. En este ensayo el número de animales con adenomas pulmonares y el número de adenomas por animal no se alteraron significativamente en comparación con los testigos. Miller et al. (1986) también examinaron el desarrollo de focos hepáticos en ratas en un ensayo a corto plazo. En este estudio, grupos de ratas parcialmente hepatectomizadas recibieron una dosis única de agua concentrada (no se informa la concentración de dióxido de cloro) en emulfora al 2%, seguida una semana después de la administración de 500 ppm de fenobarbital sódico en agua potable durante 56 días; los animales se sacrificaron el día 70. Un grupo testigo recibió agua no desinfectada. No se observaron aumentos significativos en la incidencia de focos de β-glutamiltranspeptidasa, la cual es un indicador de trastornos hepáticos. *Los estudios revisados hasta la fecha no reportan ninguna evidencia de que el dióxido de cloro pueda causar efectos cancerígenos.*

### Estudios de Genotoxicidad

Se han encontrado resultados tanto positivos como negativos en estudios de genotoxicidad in vitro. Por un lado, el dióxido de cloro no aumentó las aberraciones cromosómicas en las células de fibroblastos de hámster chino, pero sí aumentó la mutación inversa en Salmonella typhimurium (con activación) (Ishidate et al., 1984). Sin embargo, las muestras de agua desinfectadas con dióxido de cloro no indujeron mutaciones inversas en S. *typhimurium* con o sin activación (Miller et al., 1986). Los ensayos de aberración cromosómica de micronúcleo y médula ósea in vivo en ratones Swiss CD-1 a los que se les administró de 0.1 a 0.4 mg de dióxido de cloro por sonda durante 5 días consecutivos fueron negativos, al igual que un ensayo de anomalías en la cabeza del esperma en ratones B6C3F1 a los que se les administraron 0.1 a 0.4 mg por sonda por 5 días consecutivos (0, 3.2, 8 y 16 mg/kg-día) (Meier et al., 1985). Hayashi y col. (1988) informaron resultados positivos en el ensayo de micronúcleos en ratones ddY después de una única inyección intraperitoneal de 3.2 a 25 mg/kg de dióxido de cloro.

### Mecanismos de acción del dióxido de cloro en dosis elevadas.

*Es muy probable que el daño oxidativo a los eritrocitos y la producción de metahemoglobina en dosis elevadas de dióxido de cloro, por encima de las dosis que se usan para prevenir y de tratamiento ante el COVID 19, estén relacionados con sus propiedades oxidantes (U.S. EPA, 1994d).* Se cree que el clorito es la especie intermedia responsable de muchos de los efectos hematológicos del dióxido de cloro, debido a su producción más eficiente de metahemoglobina, el agotamiento del glutatión de los glóbulos rojos (RBC) y la alteración de la fragilidad de los eritrocitos.

En una serie de experimentos, Bercz, et al. (1982, 1986); y Harrington et al. (1986) sugirieron que el dióxido de cloro aumenta la unión del yoduro de la dieta al tejido y contenido gastrointestinal, produciendo una deficiencia funcional de yoduro. Bercz y col. (1982) encontraron niveles reducidos de tiroxina circulante en monos que bebían más de 9.5 mg/kg de dióxido de cloro al día. En un estudio de seguimiento, Harrington et al. (1986) demostraron aumentos en la absorción de yoduro de tiroides y un rebote en los niveles de tiroxina en monos que un año después de una exposición por 8 semanas a aproximadamente 5 mg/kg-día de dióxido de cloro en el agua potable. A diferencia de los monos, las ratas mostraron disminuciones relacionadas con la dosis en los niveles de tiroxina y ninguna alteración en la absorción de yoduro de tiroides después de una exposición de 8 semanas a 10 mg/kg de dióxido de cloro al día en el agua potable. *Estas dosis son excesivamente altas (20 a 40 veces más elevadas) con relación a las que se usan en el tratamiento preventivo o de tratamiento de dióxido de cloro en solución contra el COVID 19.*

## Síntesis general de los estudios de toxicidad

*A la fecha no se ha podido demostrar que el dióxido de cloro cause efectos tóxicos al ser humano a los niveles utilizados para prevenir o de tratamiento ante el COVID-19, cuyas dosis van de 0.25 a 0.50 mg/kg-día y están muy por debajo de las concentraciones reportadas como NOAEL en la mayoría de los reportes de investigación sobre dióxido de cloro.*

El estudio crónico de agua potable de Haag (1949) informó disminuciones en la supervivencia de ratas expuestas a 13 mg/kg-día de dióxido de cloro, durante 2 años, pero no se informó la causa de la muerte y no se observaron efectos a concentraciones más bajas. Otros estudios subcrónicos/crónicos examinaron principalmente los parámetros hematológicos. Bercz, et al., (1982) encontraron disminuciones significativas en los niveles séricos de T4 en monos expuestos a 9.5 mg/kg de dióxido de cloro al día en el agua potable durante 4 a 6 semanas. Los efectos hematológicos adversos no pudieron discernirse en Abdel-Rahman et al. (1984b) porque no hubo una relación dosis-efecto consistente. Además, Daniel et al. (1990), Bercz et al. (1982) y Moore y Calabrese (1982) no encontraron alteraciones hematológicas en ratas, monos o ratones, respectivamente. Abdel-Rahman y col. (1984b) y Couri y Abdel-Rahman (1980) informaron de alteraciones en el sistema dependiente del glutatión, en particular, disminuciones en los niveles de glutatión en los eritrocitos, aumentos en la actividad del glutatión peroxidasa y aumentos en los niveles de catalasa en los eritrocitos. Sin embargo, al igual que con los efectos hematológicos que encontró este grupo, faltaron relaciones consistentes entre la dosis y la magnitud de las alteraciones. *Solo en dosis elevadas de dióxido de cloro con niveles 30 veces mayores a los usados para prevenir o de tratamiento ante el COVID-19, se han observado efectos dañinos en ratas o monos.*

788

## Estudio de efectos cancerígenos del dióxido de cloro

Según las pautas actuales (U.S. EPA, 1986a), el dióxido de cloro está clasificado como Grupo D, (no clasificable en cuanto a carcinogenicidad en humanos) debido a que no hay datos que hayan probado su efecto cancerígeno. Según el borrador de las Directrices de Evaluación de Carcinógenos (U.S. EPA, 1996a), la carcinogenicidad humana del dióxido de cloro no se puede determinar porque no se encontraron estudios satisfactorios en humanos o animales que evalúen el potencial carcinogénico crónico del dióxido de cloro. El potencial carcinogénico de los concentrados preparados a partir de agua potable tratada con dióxido de cloro fue estudiado por Miller et al. (1986) y los concentrados de dióxido de cloro no aumentaron la incidencia de adenomas pulmonares en ratones de la cepa A.

## Conclusiones del efecto de la dosis sobre la toxicidad del dióxido de cloro.

En general, los estudios en humanos no han reportado efectos adversos en individuos que consumen bajas concentraciones (0.04-0.15 mg/kg-día) de dióxido de cloro en estudios experimentales (Lubbers et al., 1981, 1982, 1984a) o que consumen agua potable desinfectada con dióxido de cloro (Michael et al., 1981; Tuthill et al., 1982).

El estudio epidemiológico de Kanitz et al. (1996) donde reportan aumentos en el riesgo de varios efectos en el desarrollo (ictericia neonatal, circunferencia craneal pequeña y longitud corporal más corta) en una comunidad con agua potable desinfectada con dióxido de cloro, tiene numerosas limitaciones (incluidas múltiples exposiciones químicas; falta de datos de exposición; falta de control del tabaquismo, la edad y los hábitos nutricionales; y datos de control atípicos), por lo que queda descartado como un estudio serio para obtener conclusiones válidas.

Taylor y Pfohl, 1985; Toth et al., 1990), Orme et al., 1985; Taylor y Pfohl, 1985; Mobley et al., 1990) estudiaron la toxicidad del dióxido de cloro, sobre diversos órganos del cuerpo, en diferentes etapas de desarrollo del animal estudiado, y reportan una LOAEL para estos efectos de 14 mg/kg-día de dióxido de cloro. Por su parte Orme, et al., (1985) identificaron un NOAEL de 3 mg/kg-día. *Esta última, por cierto, se ubica 6 a 12 veces por encima de las dosis utilizadas en seres humanos para prevenir o de tratamiento para el coronavirus COVID 19, propuesto por la COMUSAV.*

## Conclusiones generales

*Los valores más frecuentes a partir de la literatura revisada y citada en este reporte indican que la FEL (Nivel de efectos francos) es de 27 mg/kg-día, la LOAEL (Nivel más bajo que muestra efectos adversos) de 13 mg/kg-día y la NOAEL (Nivel sin efectos adversos observables) resultó ser del orden de 3.0 mg/kg-día. El protocolo sugerido por Kalcker (2020) propone la ingesta de 10 mililitros de una solución de dióxido de cloro a una concentración de 3,000 mg/litro, disueltos en un litro de agua y bebidos durante el día, como estrategia para prevenir y de tratamiento ante el COVID 19, es decir que la ingesta real es de 30 mg/día para adultos con pesos de 50 a 80 kg. Si consideramos un peso promedio de 60 kg, la dosis que se ingiere es de 0.5 mg/kg-día, es decir 6 veces por debajo de la dosis considerada como NOEAL. En otras ocasiones la dosis preventiva para personas no expuestas o muy poco expuestas se ha reducido a solo 5 ml de la solución de 3,000 ppm por día, lo que representa una ingesta de solo 0.25 mg/kg-día. Por lo anterior la revisión de literatura científica confirma que el uso de dióxido de cloro ingerido a una dosis de 0.25 a 0.50 mg/kg-día no representa un riesgo demostrado de toxicidad por ingestión para la salud humana.*

*En cuanto a los síntomas adversos que se han reportado en diversos comunicados y que se citan al inicio de este documento, al realizar una revisión en el International Clinical Trial Registry Plataform (ICTRP), en el sitio: www.clinicaltrial.gov y en bases de datos como: bioRxiv, medRxiv, www.preprints.org, entre otros, no se encontró ningún reporte científico que demuestre o mencione que la ingesta oral de la dilución acuosa de dióxido de cloro haya ocasionado la muerte de algún ser humano, ni evento dañino alguno de sus órganos, aparatos o sistemas.*

## Adendum

*Es importante hacer notar que las Agencias, Comités o entidades encargadas de la supervisión de la salud pública, una vez que se siga demostrando mediante diversos reportes científicos la inocuidad del dióxido de cloro a las dosis adecuadas, deben de destinar recursos para la investigación, en los cuales se incluyan al sector gubernamental, iniciativa privada en su rama de la industria farmacéutica y a la COMUSAV. Dichos recursos son de vital importancia para continuar el estudio de esta molécula del dióxido de cloro, dado que se ha demostrado bajo la experimentación observacional retrospectiva, ser un recurso para el manejo del COVID-19, y teniendo en cuenta que al ser una emergencia médica la actual pandemia, y que pocos o ningún medicamento han demostrado su efectividad contra este virus, debe de dejar de satanizarse sin bases científicas y en lugar de ello debe de ser un tema prioritario de investigación en el medio académico y en los hospitales de todo el mundo. También se tiene que hacer notar que el dióxido de cloro tiene otras aplicaciones ya patentadas en la rama de la medicina y muchas otras que pueden ser estudiadas para la generación de nuevas patentes.*

## Abreviaturas utilizadas en el texto.

**FEL.** El Nivel de efecto franco, por sus siglas en inglés: *Frank effect level*

**LOAEL.** El Nivel más bajo que muestra efectos adversos, por sus siglas en inglés: *Lowest Observed Adverse Effect Level.*

**NOAEL**. Nivel sin efectos adversos observables, por sus siglas en inglés: *Non Observed Adverse Effect Level.*

**CDS.** Solución de dióxido de cloro, por sus siglas en ingles *Chlorine Dioxide Solution.*

**MMS.** Por sus siglas en ingles *Magistral Mineral Solution*; o Solución que contiene la mezcla de una dosis en gotas de clorito de sodio y otra cantidad igual en gotas de ácido cítrico o ácido clorhídrico (1 a 10 gotas de cada una), se esperan 40 segundos a que se lleve a cabo la reacción, se le agrega agua y se ingiere la solución.

**PPB.** Partes por billón, o microgramos de una sustancia contenidos en un litro de agua.

**PPM.** Partes por millón o mg de una sustancia disueltos en un litro de agua.

## Bibliografía citada

1. Abdel-Rahman, MS; Couri, D; Bull, RJ. (1979a) Kinetics of $ClO_2$ and effects of $ClO_2$, $ClO_2^-$, and $ClO_3$ in drinking water on blood glutathione and hemolysis in rat and chicken. J Environ Pathol Toxicol 3:431-449.

2. Abdel-Rahman, MS; Couri, D; Jones, JD. (1979b) Chlorine dioxide metabolism in rat. J Environ Pathol Toxicol 3:421-430.

790

3. Abdel-Rahman, MS; Couri, D; Bull, RJ. (1982) Metabolism and pharmacokinetics of alternate drinking water disinfectants. Environ Health Perspect 46:19-23.

4. Abdel-Rahman, MS; Couri, D; Bull, RJ. (1984b) Toxicity of chlorine dioxide in drinking water. J Am Coll Toxicol 3:277-284.

5. Budavari, S; O'Neil, MJ; Smith, A; et al. (eds). (1989) The Merck index: an encyclopedia of chemicals, drugs, and biologicals, 11th ed. Whitehouse Station, NJ: Merck and Co, Inc.

6. Bercz, JP; Jones, LL; Garner, L; et al. (1982) Subchronic toxicity of chlorine dioxide and related compounds in drinking water in the nonhuman primate. Environ Health Perspect 46:47-55.

7. Bercz, JP; Jones, LL; Harrington, RM; et al. (1986) Mechanistic aspects of ingested chlorine dioxide on thyroid function: impact of oxidants on iodide metabolism. Environ Health Perspect 69:249-255.

8. Carlton, BD; Basaran, AH; Mezza, LE; et al. (1991) Reproductive effects in Long-Evans rats exposed to chlorine dioxide. Environ Res 56:170-177.

9. Couri, D; Abdel-Rahman, MS. (1980) Effect of chlorine dioxide and metabolites on glutathione dependent system in rat, mouse and chicken blood. J Environ Pathol Toxicol 3:451-460.

10. Daniel, FB; Condie, LW; Robinson, M; et al. (1990) Comparative subchronic toxicity studies of three disinfectants. J Am Water Works Assoc 82:61-69.

11. Haag, HB. (1949) The effect on rats of chronic administration of sodium chlorite and chlorine dioxide in the drinking water. Report to the Mathieson Alkali Works from H.B. Haag of the Medical College of Virginia. February 7, 1949.

12. Harrington, RM; Shertzer, HG; Bercz, JP. (1986) Effects of chlorine dioxide on thyroid function in the African green monkey and the rat. J Toxicol Environ Health 19:235-242.

13. Hayashi, M; Kishi, M; Sofuni, T; et al. (1988) Micronucleus test in mice on 39 food additives and eight miscellaneous chemicals. Food Chem Toxicol 26:487-500.

14. Ishidate, M; Sofuni, T; Yoshikawa, K; et al. (1984) Primary mutagenicity screening of food additives currently used in Japan. Food Chem Toxicol 22:623-636.

15. Kalcker, A. L. 2020. Salud prohibida, incurable era ayer. 8ª Edicoin. Edit. Voedia 451 p.

16. Kanitz, S; Franco, Y; Patrone, V; et al. (1996) Associations between drinking water disinfection and somatic parameters at birth. Environ Health Perspect 104:516-520.

17. Lubbers, JR; Chauhan, S; Bianchine, JR. (1981) Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. Fundam Appl Toxicol 1:334-338.

18. Lubbers, JR; Chauhan, S; Bianchine, JR. (1982) Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. Environ Health Perspect 46:57-62.

19. Lubbers, JR; Chauhan, S; Miller, JK; et al. (1984a) The effects of chronic administration of chlorine dioxide, chlorite and chlorate to normal healthy adult male volunteers. J Environ Pathol Toxicol Oncol 5:229-238.

20. Meier, JR; Bull, RJ; Stober, JA; et al. (1985) Evaluation of chemicals used for drinking water disinfection for production of chromosomal damage and sperm-head abnormalities in mice. Environ Mutagen 7:201-211.

21. Michael, GE; Miday, RK; Bercz, JP; et al. (1981) Chlorine dioxide water disinfection: a prospective epidemiology study. Arch Environ Health 36:20-27.

22. Miller, RG; Kopler, FC; Condie, LW; et al. (1986) Results of toxicological testing of Jefferson Parish pilot plant samples. Environ Health Perspect 69:129-139.

23. Mobley, SA; Taylor, DH; Laurie, RD; et al. (1990) Chlorine dioxide depresses T3 uptake and delays development of locomotor activity in young rats. In: Jolley, RL, et al., eds. Water chlorination: chemistry, environmental impact and health effects, vol. 6. Chelsea, MI: Lewis Publications, pp. 347-358.

24. Moore, GS; Calabrese, EJ. (1982) Toxicological effects of chlorite in the mouse. Environ Health Perspect 46:31-37.

25. Orme, J; Taylor, DH; Laurie, RD; et al. (1985) Effects of chlorine dioxide on thyroid function in neonatal rats. J Toxicol Environ Health 15:315-322.

26. Selevan, S. (1997) Comments on Italian study: association between drinking water disinfection and somatic parameters by Kanitz et al., Environ Health Perspect 104(5):516-520, 1996. Memorandum to J. Wiltse, U.S. EPA, Washington, DC, May 7.

27. Suh, DH; Abdel-Rahman, MS; Bull, RJ. (1983) Effect of chlorine dioxide and its metabolites in drinking water on fetal development in rats. J Appl Toxicol 3:75-79.

28. Taylor, DH; Pfohl, RJ. (1985) Effects of chlorine dioxide on the neurobehavioral development of rats. In: Jolley, RL, et al., eds. Water chlorination: chemistry, environmental impact and health effects, vol. 6. Chelsea, MI: Lewis Publications, pp. 355-364.

29. Toth, GP; Long, RE; Mills, TS; et al. (1990) Effects of chlorine dioxide on the developing rat brain. J Toxicol Environ Health 31:29-44.

792

30. Tuthill, RW; Giusti, RA; Moore, GS; et al. (1982) Health effects among newborns after prenatal exposure to $ClO_2$-disinfected drinking water. Environ Health Perspect 46:39-45.

31. U.S. Environmental Protection Agency. (1986a) Guidelines for carcinogen risk assessment. Federal Register 51(185):33992-34003.

32. U.S. Environmental Protection Agency. (1994d) Final draft of the drinking water criteria document on chlorine dioxide, chlorite, and chlorate. Office of Science and Technology, Office of Water, Washington, DC. Office of Research and Development, Washington, DC.

33. U.S. Environmental Protection Agency. (1996a) Proposed guidelines for carcinogen risk assessment. Federal Register 61(79):17960-18011. http://www.epa.gov/nceawww1/cancer.htm

793

# Anexo 3.

EPA

EPA/635/R-00/007

# TOXICOLOGICAL REVIEW
# OF
# CHLORINE DIOXIDE
# AND
# CHLORITE

(CAS Nos. 10049-04-4 and 7758-19-2)

**In Support of Summary Information on the Integrated Risk Information System (IRIS)**

*September 2000*

U.S. Environmental Protection Agency
Washington, DC

795

## DISCLAIMER

This document has been reviewed in accordance with U.S. Environmental Protection Agency policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

This document may undergo revisions in the future. The most up-to-date version will be made electronically via the IRIS Home Page at http://www.epa.gov/iris.

# CONTENTS

FOREWORD . . . . . v

AUTHORS, CONTRIBUTORS, AND REVIEWERS . . . . . vi

1. INTRODUCTION . . . . . 1

2. CHEMICAL AND PHYSICAL INFORMATION RELEVANT TO ASSESSMENTS . . . . . 2

3. TOXICOKINETICS RELEVANT TO ASSESSMENTS . . . . . 3
   3.1. ABSORPTION . . . . . 3
      3.1.1. Gastrointestinal Absorption . . . . . 3
      3.1.2. Respiratory Tract Absorption . . . . . 4
      3.1.3. Dermal Absorption . . . . . 4
   3.2. DISTRIBUTION . . . . . 4
      3.2.1. Chlorine Dioxide . . . . . 4
      3.2.2. Chlorite . . . . . 4
   3.3. METABOLISM . . . . . 5
      3.3.1. Chlorine Dioxide . . . . . 5
      3.3.2. Chlorite . . . . . 5
   3.4. ELIMINATION . . . . . 5
      3.4.1. Chlorine Dioxide . . . . . 5
      3.4.2. Chlorite . . . . . 5

4. HAZARD IDENTIFICATION . . . . . 6
   4.1. STUDIES IN HUMANS—EPIDEMIOLOGY, CASE REPORTS, CLINICAL CONTROLS . . . . . 6
      4.1.1. Oral Exposure . . . . . 6
      4.1.2. Inhalation Exposure . . . . . 9
   4.2. PRECHRONIC AND CHRONIC STUDIES AND CANCER BIOASSAYS IN ANIMALS—ORAL AND INHALATION . . . . . 10
      4.2.1. Oral Exposure . . . . . 10
      4.2.2. Inhalation Exposure . . . . . 16
   4.3. REPRODUCTIVE/DEVELOPMENTAL STUDIES—ORAL AND INHALATION . . . . . 18
      4.3.1. Chlorine Dioxide . . . . . 18
      4.3.2. Chlorite . . . . . 20
   4.4. OTHER STUDIES . . . . . 26

797

## CONTENTS (continued)

4.4.1. Other Carcinogenicity Studies . . . . . 26
4.4.2. Genotoxicity Studies . . . . . 27
4.4.3. Mechanistic Studies . . . . . 28
4.5. SYNTHESIS AND EVALUATION OF MAJOR NONCANCER EFFECTS AND MODE OF ACTION (IF KNOWN)—ORAL AND INHALATION . . . . . 28
4.5.1. Oral Exposure . . . . . 28
4.5.2. Inhalation Exposure . . . . . 30
4.6. WEIGHT-OF-EVIDENCE EVALUATION AND CANCER CHARACTERIZATION—SYNTHESIS OF HUMAN, ANIMAL, AND OTHER SUPPORTING EVIDENCE, CONCLUSIONS ABOUT HUMAN CARCINOGENICITY, AND LIKELY MODE OF ACTION . . . . . 31
4.6.1. Chlorine Dioxide . . . . . 31
4.6.2. Chlorite . . . . . 31
4.7. SUSCEPTIBLE POPULATIONS . . . . . 32
4.7.1. Possible Childhood Susceptibility . . . . . 32
4.7.2. Possible Gender Differences . . . . . 32

5. DOSE-RESPONSE ASSESSMENTS . . . . . 33
5.1. ORAL REFERENCE DOSE (RfD) . . . . . 33
5.1.1. Choice of Principal Study and Critical Effect—With Rationale and Justification . . . . . 33
5.1.2. Methods of Analysis—Including Models (PBPK, BMD, etc.) . . . . . 34
5.1.3. RfD Derivation—Including Application of Uncertainty Factors and Modifying Factors . . . . . 35
5.2. INHALATION REFERENCE CONCENTRATION (RfC) . . . . . 35
5.2.1. Choice of Principal Study and Critical Effect—With Rationale and Justification . . . . . 35
5.2.2. Methods of Analysis—NOAEL/LOAEL . . . . . 36
5.2.3. RfC Derivation—Including Application of Uncertainty Factors and Modifying Factors . . . . . 37
5.3. CANCER ASSESSMENT . . . . . 38
5.3.1. Chlorine Dioxide . . . . . 38
5.3.2. Chlorite . . . . . 38

6. MAJOR CONCLUSIONS IN THE CHARACTERIZATION OF HAZARD AND DOSE RESPONSE . . . . . 38
6.1. HUMAN HAZARD POTENTIAL . . . . . 38
6.2. DOSE RESPONSE . . . . . 40

7. REFERENCES . . . . . 40

APPENDIX A. EXTERNAL PEER REVIEW—SUMMARY OF COMMENTS AND DISPOSITION . . . . . 46

798

# FOREWORD

The purpose of this Toxicological Review is to provide scientific support and rationale for the hazard and dose-response assessment in IRIS pertaining to chronic exposure to chlorine dioxide and chlorite. It is not intended to be a comprehensive treatise on the chemical or toxicological nature of chlorine dioxide and chlorite.

In Section 6, EPA has characterized its overall confidence in the quantitative and qualitative aspects of hazard and dose response. Matters considered in this characterization include knowledge gaps, uncertainties, quality of data, and scientific controversies. This characterization is presented in an effort to make apparent the limitations of the assessment and to aid and guide the risk assessor in the ensuing steps of the risk assessment process.

For other general information about this assessment or other questions relating to IRIS, the reader is referred to EPA's Risk Information Hotline at 513-569-7254.

# AUTHORS, CONTRIBUTORS, AND REVIEWERS

## Chemical Managers/Authors

Yogendra Patel, Ph.D.
OST/HECD
Office of Water
U.S. Environmental Protection Agency
Washington, DC

Diana Wong, Ph.D., D.A.B.T.
OST/HECD
Office of Water
U.S. Environmental Protection Agency
Washington, DC

## Contributing Authors

Lisa Ingerman, Ph.D., D.A.B.T.
Senior Scientist
Syracuse Research Corporation
Portland, OR

Patricia McGinnis, Ph.D., D.A.B.T.
Senior Scientist
Syracuse Research Corporation
Philadelphia, PA

Mark Osier, Ph.D.
Senior Scientist
Syracuse Research Corporation
North Syracuse, NY

## Reviewers

This document and summary information on IRIS have received peer review both by EPA scientists and by independent scientists external to EPA. Subsequent to external review and incorporation of comments, this assessment has undergone an Agencywide review process whereby the IRIS Program Manager has achieved a consensus approval among the Office of Research and Development; Office of Air and Radiation; Office of Prevention, Pesticides, and Toxic Substances; Office of Solid Waste and Emergency Response; Office of Water; Office of Policy, Planning, and Evaluation; and the Regional Offices.

## AUTHORS, CONTRIBUTORS, AND REVIEWERS (continued)

### Internal EPA Reviewers

Annie J. Jarabek
ORD / NCEA
Research Triangle Park, NC

Ginger Moser, Ph.D., D.A.B.T.
ORD / NTD/NHEERL
Research Triangle Park, NC

### External Peer Reviewers

Paul E. Brubaker, Ph.D.
Consultant
Brubaker and Associates

James Edward Klaunig, Ph.D.
Division of Toxicology, Department of Pharmacology and Toxicology
Indiana University School of Medicine

June Dunnick, Ph.D.
Scientist
National Institute of Environmental Health Sciences

Calvin C. Willhite, Ph.D.
State of California, Department of Toxic Substances Control

Summaries of the external peer reviewers' comments and the disposition of their recommendations are in the Appendix.

801

# 1. INTRODUCTION

This document presents background and justification for the hazard and dose-response assessment summaries in the U.S. Environmental Protection Agency (EPA) Integrated Risk Information System (IRIS). IRIS summaries may include an oral reference dose (RfD), inhalation reference concentration (RfC), and a carcinogenicity assessment.

The RfD and RfC provide quantitative information for noncancer dose-response assessments. The RfD is based on the assumption that thresholds exist for certain toxic effects such as cellular necrosis but may not exist for other toxic effects such as some carcinogenic responses. It is expressed in units of mg/kg-day. In general, the RfD is an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious noncancer effects during a lifetime. The inhalation RfC is analogous to the oral RfD, but it provides a continuous inhalation exposure estimate. The inhalation RfC considers toxic effects for the respiratory system (portal of entry) and for effects peripheral to the respiratory system (extra respiratory or systemic effects). It is generally expressed in units of $mg/m^3$.

The carcinogenicity assessment provides information on the carcinogenic hazard potential of the substance in question and quantitative estimates of risk from oral exposure and inhalation exposure. The information includes a weight-of-evidence judgment of the likelihood that the agent is a human carcinogen and the conditions under which the carcinogenic effects may be expressed. Quantitative risk estimates are presented in three ways. The *slope factor* is the result of application of a low-dose extrapolation procedure and is presented as the risk per mg/kg-day. The *unit risk* is the quantitative estimate in terms of either risk per : g/L drinking water or risk per : $g/m^3$ air breathed. Another form in which risk is presented is a drinking water or air concentration providing cancer risks of 1 in 10,000, 1 in 100,000, or 1 in 1,000,000.

Development of these hazard identification and dose-response assessments for chlorine dioxide and chlorite has followed the general guidelines for risk assessment as set forth by the National Research Council (1983). EPA guidelines that were used in the development of this assessment may include the following: *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 1986a); *Guidelines for the Health Risk Assessment of Chemical Mixtures* (U.S. EPA, 1986b); *Guidelines for Mutagenicity Risk Assessment* (U.S. EPA, 1986c); *Guidelines for Developmental Toxicity Risk Assessment* (U.S. EPA, 1991); *Guidelines for Neurotoxicity Risk Assessment* (U.S. EPA, 1998a); *Proposed Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 1996a); *Reproductive Toxicity Risk Assessment Guidelines* (U.S. EPA, 1996b); *Recommendations for and Documentation of Biological Values for Use in Risk Assessment* (U.S. EPA, 1988); (proposed) *Interim Policy for Particle Size and Limit Concentration Issues in Inhalation Toxicity* (U.S. EPA, 1994a); *Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry* (U.S. EPA, 1994b); *Peer Review and Peer Involvement at the U.S. Environmental Protection Agency* (U.S. EPA, 1994c); *Use of the Benchmark Dose Approach in Health Risk Assessment* (U.S. EPA, 1995); *Science Policy Council Handbook: Peer Review* (U.S.

EPA, 1998b); and a memorandum from EPA Administrator, Carol Browner, dated March 21, 1995, Subject: Guidance on Risk Characterization.

Literature search strategies employed for these compounds were based on the CASRN and at least one common name. At a minimum, the following databases were searched: RTECS, HSDB, TSCATS, CCRIS, GENETOX, EMIC, EMICBACK, DART, ETICBACK, TOXLINE, CANCERLINE, MEDLINE, and MEDLINE backfiles. Any pertinent scientific information submitted by the public to the IRIS Submission Desk was also considered in the development of this document.

## 2. CHEMICAL AND PHYSICAL INFORMATION RELEVANT TO ASSESSMENTS

Chlorine dioxide ($ClO_2$; CASRN 10049-04-4) is a yellow to reddish-yellow gas at room temperature that is stable in the dark but is unstable in light. It is a strong oxidizing agent that under oxidant demand conditions is readily reduced to chlorite ($ClO_2^-$; CASRN 7758-19-2), another strong oxidizing agent. The *Drinking Water Criteria Document on Chlorine Dioxide, Chlorite, and Chlorate* (U.S. EPA, 1994d) provides the relevant information concerning dissociation byproducts of chlorine dioxide in water. The strong oxidizing ability of chlorine dioxide makes it useful as a drinking water disinfectant. Other uses of chlorine dioxide include bleaching textiles and wood pulp for paper manufacturing, antimicrobial applications, and reducing loads of adsorbable organic halogenated compounds in industrial effluents. Chlorite is also used for etching printed circuit boards. The physical and chemical properties of chlorine dioxide and chlorite are presented in Table 1.

Chlorine dioxide and chlorite are characterized together in this report because studies conducted with chlorite, the predominant degradation product of chlorine dioxide, are likely relevant to characterizing the toxicity of chlorine dioxide. In addition, studies conducted with chlorine dioxide may be relevant to characterizing the toxicity of chlorite. Chlorine dioxide is fairly unstable and rapidly dissociates, predominantly into chlorite and chloride, and to a lesser extent, chlorate. There is a ready interconversion among these species in water (before administration to animals) and in the gut (after ingestion) (U.S. EPA, 1994d). Therefore, what exists in water or the stomach is a mixture of these chemical species (i.e., chlorine dioxide, chlorite, chlorate) and possibly their reaction products with the gastrointestinal contents.

**Table 1. Physical and chemical properties of chlorine dioxide and chlorite**

| Properties | Chlorine dioxide | Chlorite (sodium salt) |
|---|---|---|
| CAS registry number | 10049-04-4 | 7758-19-2 |
| Molecular formula | $ClO_2$ | $NaClO_2$ |
| Molecular weight | 67.46 | 90.45 |
| Melting point, °C | -59 | decomposes at 180–200 |
| Boiling point, °C | 11 | no data |
| Water solubility, g/L | 3.0 at 25°C and 34 mmHg | 39 at 30°C |
| Specific gravity | 1.642 at 0°C | no data |

Source: Budavari et al., 1989.

# 3. TOXICOKINETICS RELEVANT TO ASSESSMENTS

## 3.1. ABSORPTION

### 3.1.1. Gastrointestinal Absorption

### 3.1.1.1. *Chlorine Dioxide*

After ingestion, chlorine dioxide is rapidly absorbed from the gastrointestinal tract. Levels of radioactive chlorine in plasma peaked 1 hour after Sprague-Dawley rats were administered a single gavage dose of 100 mg/L $^{36}ClO_2$ (approximately 1.4 mg/kg) (Abdel-Rahman et al., 1979a). Peak plasma levels were achieved 2 hours after Sprague-Dawley rats received a gavage dose of 300 mg/L $^{36}ClO_2$ after a 15-day exposure to 100 mg/L chlorine dioxide in drinking water (Abdel-Rahman et al., 1979a). Approximately 30% of the 100 mg/L single gavage dose was excreted in the urine after 72 hours, indicating that at least 30% of the dose was absorbed (Abdel-Rahman et al., 1979a); the absorption rate constant and half time were 3.77/hour and 0.18 hours, respectively (Abdel-Rahman et al., 1982). Since total radioactivity was measured rather than identification of individual chemical entities, it was not clear from these reports whether the parent chlorine dioxide itself or the chlorite, chlorate, or chloride ion degradation products were absorbed.

### 3.1.1.2. *Chlorite*

Chlorite is also rapidly absorbed from the gastrointestinal tract. Peak plasma levels of radiolabeled chlorine were reached 2 hours after administration of a single gavage dose of 10 mg/L $^{36}ClO_2^-$ (approximately 0.13 mg/kg) to Sprague-Dawley rats. Using 72-hour urinary

804

excretion data, it can be assumed that at least 35% of the initial dose was absorbed (Abdel-Rahman et al., 1984a). The absorption rate constant and half-time were 0.198/hour and 3.5 hours, respectively (Abdel-Rahman et al., 1982). Since total radioactivity was measured rather than identification of individual chemical entities, it was not clear from these reports whether the parent chlorine dioxide itself or the chlorite, chlorate, or chloride ion degradation products were absorbed.

### 3.1.2. Respiratory Tract Absorption

No data were located on respiratory tract absorption of chlorine dioxide or chlorite.

### 3.1.3. Dermal Absorption

Scatina et al. (1984) reported on the dermal absorption of Alcide, an antimicrobial compound consisting of solutions of sodium chlorite and lactic acid, which when mixed immediately before use result in the formation of chlorine dioxide. 0.6 g $^{36}$Cl-labeled sodium chlorite as part of the Alcide was used to monitor absorption following application to the shaved backs of 10 female Sprague-Dawley rats. Maximum absorption of $^{36}$Cl into plasma was observed after 72 hours, where a plasma concentration of 69.4 μg% $^{36}$Cl was reached. The absorption half-life was calculated to be 22.1 hours, which corresponds to a rate constant of 0.0314 $hr^{-1}$.

## 3.2. DISTRIBUTION

### 3.2.1. Chlorine Dioxide

Following a single 100 mg/L gavage dose of $^{36}ClO_2$, the $^{36}$Cl was slowly cleared from the blood; the rate constant and half-time for elimination from blood were 0.0156/hour and 43.9 hours, respectively (Abdel-Rahman et al., 1982). Elimination from blood was shortened in Sprague-Dawley rats exposed to chlorine dioxide in drinking water for 2 weeks prior to receiving the 300 mg/L gavage dose of $^{36}ClO_2$; the rate constant and half time were 0.022/hour and 31.0 hours, respectively (Abdel-Rahman et al., 1979a). After removal from the blood, the radiolabel appeared to be widely distributed throughout the body, although the highest concentrations were found in the blood, stomach, and small intestines. The lung, kidney, liver, testes (assessed only in the 300 mg/L group), spleen, thymus, and bone marrow also had high concentrations of radiolabel 72 hours after dosing with 100 mg/L (single dose) or 300 mg/L (with 2-week drinking water exposure to 100 mg/L) (Abdel-Rahman et al., 1979a). Seventy-two hours after a single gavage dose of 100 mg/L $^{36}ClO_2$, most of the $^{36}$Cl label in the plasma was in the form of chloride ion ($Cl^-$) and chlorite; the ratio of chloride to chlorite was 4 to 1 (Abdel-Rahman et al., 1979b).

### 3.2.2. Chlorite

Removal of chlorite from the blood is slow; the rate constant and half-time for elimination of $^{36}$Cl from the blood were 0.0197/hour and 35.2 hours in Sprague-Dawley rats receiving a single gavage dose of 10 mg/L $^{36}ClO_2^-$ (Abdel-Rahman et al., 1982). Seventy-two hours after dosing, the highest concentrations of radiolabel were found in the blood, stomach, testes, skin, lung, kidneys, small intestine, carcass, spleen, brain, bone marrow, and liver (Abdel-Rahman et al., 1982, 1984a).

## 3.3. METABOLISM

### 3.3.1. Chlorine Dioxide

Chloride ion is the ultimate metabolite of chlorine dioxide. Approximately 87% and 80% of radiolabeled chlorine in the urine (collected 0–72 hours after administration) and plasma (collected 72 hours after administration), respectively, are in the form of chloride ion following administration of a single gavage dose of 100 mg/L $^{36}ClO_2$ in rats (Abdel-Rahman et al., 1979b). Chlorite was a major metabolite, accounting for approximately 11% and 21% of urine and plasma $^{36}Cl$, respectively; approximately 2% of the urinary $^{36}Cl$ was in the form of chlorate. An in vivo recovery study by Bercz et al. (1982) suggests that ingested chlorine dioxide is rapidly reduced in the stomach to nonoxidizing species (presumably chloride). Five minutes after chlorine dioxide was instilled into the stomach of a monkey, only 8% of the total oxidizing capacity equivalents of chlorine dioxide was recovered. Bercz et al. (1982) also reported that in vitro chlorine dioxide was rapidly reduced to chloride ion by saliva obtained from anesthetized monkeys.

### 3.3.2. Chlorite

Although fewer data are available on metabolism of chlorite, it is likely that metabolism of chlorite is similar to that of chlorine dioxide. Approximately 85% of the $^{36}Cl$ recovered in the urine of Sprague-Dawley rats 0–72 hours after administration of a single gavage of 10 mg/L $^{36}ClO_2^-$ was in the form of chloride; the remaining 15% was present as chlorite (Abdel-Rahman et al., 1984a).

## 3.4. ELIMINATION

### 3.4.1. Chlorine Dioxide

The radioactive chlorine label was primarily excreted in the urine of rats administered a single gavage dose of 100 mg/L $^{36}ClO_2$ (Abdel-Rahman et al., 1979a). During the first 24 hours after dosing, 18% of the label was excreted in the urine and 4.5% in the feces. Seventy-two hours after dosing, 31% and 10% of the label were excreted in the urine and feces, respectively; the label was not detected in expired air. The parent compound was not detected in the urine; most of the label was in the form of chloride, with smaller amounts as chlorite. The ratio of $^{36}Cl^-$ to $^{36}ClO_2^-$ was 5 to 1 during the first 24 hours and 4 to 1 during the first 72 hours (Abdel-Rahman et al., 1979b).

### 3.4.2. Chlorite

Urine was the primary route of excretion in rats administered a single gavage dose of 10 mg/L $^{36}ClO_2^-$. Twenty-four hours after dosing, 14% of the label was excreted in the urine and

806

0.9% in the feces; 35% and 5% of the label were excreted in the urine and feces, respectively, 72 hours after dosing (Abdel-Rahman et al., 1984a). Approximately 90% of the excreted label was in the form of chloride.

# 4. HAZARD IDENTIFICATION

## 4.1. STUDIES IN HUMANS—EPIDEMIOLOGY, CASE REPORTS, CLINICAL CONTROLS

### 4.1.1. Oral Exposure

### 4.1.1.1. *Chlorine Dioxide*

The short-term toxicity of chlorine dioxide was assessed in two human studies conducted by Lubbers and associates (Lubbers et al., 1981, 1982, 1984a; Bianchine et al., 1981). In the first study (Lubbers et al., 1981; also published as Lubbers et al., 1982), a group of 10 healthy male adults drank 1,000 mL (divided into two 500 mL portions, separated by 4 hours) of a 0 or 24 mg/L chlorine dioxide solution (0.34 mg/kg, assuming a 70 kg reference body weight). In the second study (Lubbers et al., 1984a), groups of 10 adult males were given 500 mL distilled water containing 0 or 5 mg/L chlorine dioxide (0.04 mg/kg-day assuming a reference body weight of 70 kg) for 12 weeks. Neither study found any physiologically relevant alterations in general health (observations and physical examination), vital signs (blood pressure, pulse rate, respiration rate, and body temperature), serum clinical chemistry parameters (including glucose, urea nitrogen, phosphorus, alkaline phosphatase, and aspartate and alanine aminotransferases), serum triiodothyronine (T3) and thyroxine (T4) levels, or hematologic parameters.

### 4.1.1.2. *Chlorite*

Lubbers et al. (1981, 1982, 1984a) also examined the toxicity of chlorite in normal healthy adults in studies that were run concurrently with the chlorine dioxide studies. In the single exposure study (Lubbers et al., 1981, 1982), 10 male adults consumed two 500 mL (separated by 4 hours) solutions containing 2.4 mg/L chlorite (0.034 mg/kg assuming a reference body weight of 70 kg). In a 12-week study (Lubbers et al., 1984a), groups of 10 men drank 500 mL solutions of 0 or 5 mg/L chlorite (0.04 mg/kg-day assuming a 70 kg body weight). No physiologically relevant alterations in general health (observations and physical examination), vital signs, hematologic (including erythrocyte and total and differential leukocyte counts, hemoglobin, hematocrit, and methemoglobin) or serum clinical chemistry (including glucose, electrolytes, calcium, urea nitrogen, enzyme levels, and cholesterol) parameters, or serum T3 or T4 levels were found in either study.

In a companion study, three healthy glucose-6-phosphate dehydrogenase deficient male subjects were given deionized water containing 5 mg/L chlorite (0.04 mg/kg-day assuming a reference body weight of 70 kg) for 12 weeks (Lubbers et al., 1984b). Compared with the

807

control group in Lubbers et al. (1984a), the chlorite exposure did not alter general health, vital signs, hematologic parameters (including erythrocyte and total and differential leukocyte counts, hemoglobin, hematocrit, and methemoglobin) or serum clinical chemistry (including glucose, electrolytes, calcium, urea nitrogen, enzyme levels, and cholesterol) parameters.

#### **4.1.1.3.** *Chlorine Dioxide–Disinfected Water*

Michael et al. (1981), Tuthill et al. (1982), and Kanitz et al. (1996) have examined communities with chlorine dioxide disinfected water. The focus of the Tuthill et al. (1982) and Kanitz et al. (1996) studies was developmental toxicity. Michael et al. (1981) measured hematologic (erythrocyte, leukocyte, and reticulocyte counts, hemoglobin and methemoglobin levels, hematocrit, mean corpuscular volume, and osmotic fragility) and serum chemistry (blood urea nitrogen and total bilirubin levels) parameters in 198 individuals 1 week before the community initiated the chlorine dioxide water treatment program and 10 weeks after initiation. Blood samples were collected at the same times from a control group of 118 individuals not exposed to chlorine dioxide–treated drinking water. The water treatment facility operated only 8 hours/day; water was drawn from storage tanks for the rest of the day. Chlorine dioxide rapidly disappeared from the stored water (within 2–4 hours), and chlorite levels concomitantly increased. Weekly average concentrations (presumably measured during plant operation hours) of chlorine dioxide ranged from 0.25 to 1.11 ppm, and chlorite concentrations ranged from 3.19 to 6.96 ppm (daily mean chlorite concentration was 5.21 ppm). Using measured water consumption rates (1.98 L/day), the study authors estimated that daily chlorite intakes ranged from 0 to 39.4 mg/day (0–0.56 mg/kg-day assuming a 70 kg reference body weight); the mean intake was 10.3 mg/day (0.15 mg/kg-day). The difference between pre- and posttreatment blood urea nitrogen levels was lower in the community with chlorine dioxide–disinfected water than in the control community. However, the study authors noted that this difference was probably because mild dehydration had occurred in the control community, the postinitiation sample was taken during extremely hot weather, and more individuals in the control group had active, outdoor jobs. No other hematologic or serum chemistry alterations were found.

Tuthill et al. (1982) retrospectively compared infant morbidity and mortality data for a community that had utilized "high" levels of chlorine dioxide as a drinking water disinfectant in the 1940s with data of a neighboring community using conventional drinking water chlorination practices. The authors reported average monthly levels of 0.32 ppm of sodium chlorite added post-treatment, but they did not report chlorine dioxide levels in the treated water. Exposure to chlorine dioxide–treated water did not adversely affect fetal, neonatal, postneonatal, or infant mortality, nor did it affect birthweight, sex ratio, or birth condition. Incidence of newborns judged premature by physician assessment was significantly higher in the community with chlorine dioxide–treated water. In reviewing this study, EPA (1994d) concluded there was no increase in the proportion of premature infants when the age of the mother was controlled and that there was a greater postnatal weight loss in infants from the exposed community.

Kanitz et al. (1996) followed 548 births at Galliera Hospital, Genoa, and 128 births at Chiavari Hospital, Chiavari, Italy, during 1988–1989. Data on infant birthweight, body length, cranial circumference, and neonatal jaundice and on maternal age, smoking, alcohol

808

consumption, education, and preterm delivery were collected from hospital records. Women in Genoa were exposed to filtered water disinfected with chlorine dioxide, sodium hypochlorite, or both; trihalomethane levels varied from 8 to 16 ppb in sodium hypochlorite-treated water and 1 to 3 ppb in chlorine dioxide–disinfected water. Levels of chlorine dioxide in the water immediately after treatment were less than 0.3 mg/L, while chlorine residue was less than 0.4 mg/L. Women residing in Chiavari used water pumped from wells, without any disinfection treatment, and served as the comparison group (controls). Odds ratios were determined for the somatic parameters by comparison of groups exposed to chlorine dioxide, sodium hypochlorite, or both with controls and adjusted for maternal education level, income, age, and smoking and for sex of the child. Neonatal jaundice occurred more frequently (odds ratio [OR] = 1.7; 95% confidence interval [CI] = 1.1–3.1) in infants whose mothers resided in the area where surface water was disinfected with chlorine dioxide, when compared with infants with mothers using nondisinfected well water. Infants born to mothers residing in areas where surface water was disinfected had smaller cranial circumference (# 35 cm) (OR = 2.2, 95% CI = 1.4–3.9 for chlorine dioxide; OR = 3.5, 95% CI = 2.1–8.5 for sodium hypochlorite vs. untreated well water; OR = 2.4, 95% CI = 1.6–5.3 for both vs. untreated well water). In addition, these infants had a smaller body length (# 49.5 cm) (OR = 2.0, 95% CI = 1.2–3.3 for chlorine dioxide vs. untreated well water; OR = 2.3, 95% CI = 1.3–4.2 for sodium hypochlorite vs. untreated well water). Risks for low-birthweight infants (# 2,500 g) were reported to be increased in mothers residing in areas using water disinfected with chlorite and chlorine dioxide, but these associations were not statistically significant. For preterm delivery (# 37 weeks), small but not statistically significant increased risks were found among mothers residing in the area using chlorine dioxide. The study authors concluded that infants of women who consumed drinking water treated with chlorine compounds during pregnancy were at higher risk for neonatal jaundice, cranial circumference # 35 cm, and body length # 49.5 cm.

Interpretability of the results of Kanitz et al. (1996) is limited by lack of consideration of exposure and potential confounding variables such as quantity of water consumed during pregnancy, lack of quantitative exposure information, exposure to other chemicals in the water, and nutritional and smoking habits and age distribution of the women. In addition, baseline values for the infant sex ratio and percentage of low-weight births for the comparison group deviate from values presented by the World Health Organization for Italy. For example, the sex ratio (male/female live births * 100) used in the study for the comparison group was 86, but most recent data (for 1996, as cited in WHO, 2000) for Italy indicate a sex ratio value of 113. Although the percentage of low-weight births in the control group for the Kanitz et al. (1996) study was 0.8%, the percentage of low-weight births (< 2,500 g) in Italy for 1994 is 6%. The quality of the untreated well water is not known (i.e., whether it contained any chemical or biological contaminants). The atypical baseline data raise concerns about the control population selected for this study and render any comparison to them by the exposed group difficult to interpret, thereby precluding the ability to draw conclusions (Selevan, 1997).

809

### 4.1.2. Inhalation Exposure

#### 4.1.2.1. *Chlorine Dioxide*

Several case reports of accidental inhalation exposure to chlorine dioxide have been reported in the literature. Elkins (1959) described the case of a bleach tank worker who died after being exposed to 19 ppm chlorine dioxide (52 mg/m$^3$) for an unspecified amount of time; another worker exposed at the same time survived. Elkins also stated that 5 ppm (14 mg/m$^3$) was definitely irritating to humans. In a case reported by Exner-Freisfeld et al. (1986), a woman experienced coughing, pharyngeal irritation, and headache after inhaling an unknown amount of chlorine dioxide inadvertently generated while bleaching flowers. Seven hours after exposure, the woman was hospitalized with cough, dyspnea, tachypnea, tachycardia, rales on auscultation, and marked leukocytosis; a decrease in lung function (reduced vital capacity and 1-second forced expiratory volume) was also reported. Most of these symptoms were alleviated with corticosteroid treatment.

Meggs et al. (1996) examined 13 individuals (1 man and 12 women) 5 years after they were occupationally exposed to chlorine dioxide from a leak in a water purification system pipe. The long-term effects of the accident included development of sensitivity to respiratory irritants (13 subjects), disability with loss of employment (11 subjects), and chronic fatigue (11 subjects). Nasal abnormalities (including injection, telangectasia, paleness, cobblestoning, edema, and thick mucus) were found in all 13 individuals. Nasal biopsies taken from the subjects revealed chronic inflammation with lymphocytes and plasma cells present within the lamina propria in 11 of the 13 subjects; the inflammation was graded as mild in 2 subjects, moderate in 8 subjects, and severe in 1 subject. Nasal biopsies from three control subjects showed chronic inflammation in one subject. The average inflammation grading was statistically higher in the subjects compared with the controls. The number of nerve fibers in the biopsies was higher in the subjects (rare fibers in three subjects, moderate fibers in two subjects, and many fibers in three subjects) than controls, but the difference was not statistically significant.

Gloemme and Lundgren (1957), Ferris et al. (1967), and Kennedy et al. (1991) examined workers occasionally exposed to high concentrations of chlorine dioxide that resulted from equipment failure. Concurrent exposure to chlorine gas and, in some cases, sulfur dioxide confounds interpretation of the results of these studies. Gloemme and Lundgren (1957) examined the respiratory health of 12 workers employed at a sulfite-cellulose production facility. Under normal working conditions, the atmospheric chlorine content was less than 0.1 ppm (chlorine dioxide levels were not measured); however, occasional equipment leakages would result in high levels of chlorine dioxide, chlorine, and/or sulfur dioxide. The workers reported respiratory discomfort (breathlessness, wheezing, irritant cough) and ocular discomfort (conjunctivitis and "halo phenomena") connected with these leakage exposures. A slight, nonspecific chronic bronchitis was diagnosed in 7 of the 12 men. An earlier-observed bronchitis disappeared in one case, suggesting to the study authors that improved working conditions might entail reversal of this disorder.

In the Ferris et al. (1967) study, no significant alterations in pulmonary function (forced vital capacity, maximum expiratory flow, forced expiratory flow, and forced expiratory volume) were observed in 147 men employed (length of employment not reported) at a pulp mill, compared with 124 men employed at a paper mill. The pulp mill workers were exposed to sulfur dioxide or chlorine dioxide and chlorine; the chlorine dioxide concentrations ranged from trace amounts to 2 ppm (average concentrations ranged from trace amounts to 0.25 ppm), and chlorine concentrations ranged from trace amounts to 64 ppm (average concentrations ranged from trace amounts to 7.4 ppm). When the pulp mill workers were divided into workers exposed to sulfur dioxide and those exposed to chlorine or chlorine dioxide, significantly higher incidences of shortness of breath and excess phlegm were found in the chlorine/chlorine dioxide workers.

In the Kennedy et al. (1991) study of 321 pulp mill workers exposed to chlorine and chlorine dioxide, significant increases in the incidence of wheezing, wheezing accompanied by breathlessness, and work-related wheezing were observed, compared with 237 workers at a rail maintenance yard. Personal time-weighed average (TWA) exposure concentration for chlorine at the pulp mill ranged from 5 to 14 ppm, whereas TWA for chlorine dioxide was below 0.1 ppm. However, 60% of the pulp mill workers reported one or more chlorine or chlorine dioxide "gassing" incidents. No significant differences in tests of pulmonary function were observed between the two groups. The pulp mill workers were divided into two groups based on self-reported accidental exposures to high levels of chlorine/chlorine dioxide gas ("gassing"). In the workers reporting one or more incidents of gassing, the prevalence of wheezing and missed work because of chest illness was higher than in the pulp mill workers not reporting gassing incidents. Additionally, the incidence of airflow obstruction (as measured by a decrease in midmaximal flow rate and the ratio of 1-second forced expiratory volume to forced vital capacity) was higher in nonsmokers and former smokers reporting gassing incidents compared with smokers also reporting gassing incidents.

#### 4.1.2.2. *Chlorite*

No human inhalation exposure data for chlorite were located.

## 4.2. PRECHRONIC AND CHRONIC STUDIES AND CANCER BIOASSAYS IN ANIMALS—ORAL AND INHALATION

### 4.2.1. Oral Exposure

#### 4.2.1.1. *Chlorine Dioxide*

Although the subchronic/chronic toxicity of chlorine dioxide has been investigated in a number of studies, only Daniel et al. (1990) and Haag (1949) examined a wide range of endpoints. The other studies (Bercz et al., 1982; Abdel-Rahman et al., 1984b; Couri and Abdel-Rahman, 1980; Moore and Calabrese, 1982) focused on the hematologic system. To date, no studies have examined the carcinogenic potential of chlorine dioxide.

Daniel et al. (1990) exposed groups of 10 male and 10 female Sprague-Dawley rats to chlorine dioxide in drinking water for 90 days at concentrations of 0, 25, 50, 100, or 200 mg/L. These concentrations correspond to administered doses of 0, 2, 4, 6, or 12 mg/kg-day chlorine dioxide for males and 0, 2, 5, 8, or 15 mg/kg-day chlorine dioxide for females (calculated by the study authors using water consumption and body weight data). No exposure-related deaths were reported. Exposure to 200 mg/L resulted in significant reductions in terminal body weights and body weight gain (26%–29% lower than controls). Significant reductions in water consumption were observed in the males exposed to $ 50 mg/L and in females exposed to $ 25 mg/L; decreases in food consumption were also observed in the 200 mg/L males. Absolute liver weights were decreased in males at $ 50 mg/L, and absolute spleen weights were decreased in females at $ 25 mg/L. No consistent alterations in hematologic parameters (erythrocyte and total and differential leukocyte counts, hemoglobin levels, hematocrit, and mean corpuscular volume measured) were observed. Serum lactate dehydrogenase and aspartate aminotransferase levels were decreased and serum creatinine levels were increased in the males exposed to 100 or 200 mg/L; no other alterations in serum chemistry parameters were consistently found. A significant increase in incidence of nasal lesions (goblet cell hyperplasia and inflammation of nasal turbinates) was found in males exposed to $ 25 mg/L and in females at $100 mg/L. The study authors postulated that these lesions were likely caused by inhalation of chlorine dioxide vapors at the drinking water sipper tube or from off-gassing of the vapors after drinking rather than ingestion of the drinking water. Thus, 25 mg/L (2 mg/kg-day) can be described as a lowest-observed-adverse-effect level (LOAEL), but the toxicological significance of the nasal lesions is not known. Respiratory tract pathologies have not been reported in other oral studies and the effect may possibly be an artifact of treatment.

In a chronic toxicity study by Haag (1949), groups of seven male and seven female rats were exposed to 0, 0.5, 1, 5, 10, or 100 mg/L chlorine dioxide in drinking water (0.07, 0.13, 0.7, 1.3, or 13 mg/kg-day as calculated by U.S. EPA, 1994d) for 2 years. Survival in the 100 mg/L group was significantly decreased. No chlorine dioxide-related alterations were observed in the histopathologic examination of representative animals (2–6/sex) from each group. Thus, a no-observed-adverse-effect level (NOAEL) of 10 mg/L (1.3 mg/kg-day) and a frank effect level (FEL) (based on decreased survival) of 100 mg/L (13 mg/kg-day) can be identified from this study.

The Bercz et al. (1982) study used a rising-dose design in which each animal served as its own control. Five male and seven female adult African green monkeys (*Cercopithecus aethiops*) were exposed to 0, 30, 100, and 200 mg/L chlorine dioxide for 4–6 weeks. The study authors estimated chlorine dioxide administered doses to be 3.5 and 9.5 mg/kg-day in the 30 and 100 mg/L groups, respectively. Exposure to 200 mg/L resulted in erythema and ulceration of the oral mucosa, mucous nasal discharge, and avoidance of drinking water; exposure to 200 mg/L was terminated after 1 week because some of the animals showed signs of dehydration. No significant alterations in hematologic clinical chemistry (erythrocyte, total and differential leukocyte, and reticulocyte counts, hemoglobin levels, hematocrit, osmotic fragility, and methemoglobin levels) or serum clinical chemistry (creatinine, blood urea nitrogen [BUN], alkaline phosphatase, lactate dehydrogenase, and alanine and aspartate aminotransferase) parameters or body weight gain were observed. Serum T4 levels were significantly decreased in the 100 mg/L chlorine dioxide-exposed monkeys after 6 weeks of exposure. Thus, this study identifies a NOAEL of 30 mg/L (3.5 mg/kg-day) and a LOAEL of 100 mg/L (9.5 mg/kg-day) for alterations in thyroid hormone levels in monkeys exposed to chlorine dioxide in the drinking water for 4–6 weeks.

Abdel-Rahman et al. (1984b) exposed groups of four male Sprague-Dawley rats to 0, 1, 10, 100, or 1,000 mg/L chlorine dioxide in the drinking water 20 hours/day for 11 months (doses of 0.10, 1, 10, and 100 mg/kg-day are estimated using a reference body weight of 0.523 kg and reference water intake of 0.062 L/day and adjusting for intermittent exposure). Significant reductions in body weight gain were observed in the 1,000 mg/L group at 2, 5, 7, 10, and 11 months and in all groups during months 10 and 11. A number of statistically significant hematologic alterations were observed; however, the magnitude of the alterations does not appear to be dose related. Osmotic fragility was decreased in the 100 and 1,000 mg/L groups after 2, 4, 7, or 9 months of exposure and in the 10 mg/L group only after 9 months of exposure. Erythrocyte counts were decreased in the 1 and 1,000 mg/L groups after 9 months of exposure, but not after 7 months. Reduced hematocrit and hemoglobin levels were observed in all groups at 9 months; hematocrit levels were significantly increased the 100 and 1,000 mg/L groups at 7 months. Mean corpuscular hemoglobin concentrations were increased in the 100 and 1,000 mg/L groups after 9 months. Blood glutathione levels were significantly reduced in the 1, 10, and 1,000 mg/L groups at 2 months; the 1 and 10 mg/L groups after 4 months; the 1 mg/L group after 7 months; and the 100 mg/L group after 9 months. DNA synthesis (assessed using $^3$H-thymidine incorporation) was significantly reduced in the kidneys of rats exposed to 100 mg/L, decreased in the testes of rats in the 10 and 100 mg/L groups, and increased in the intestinal mucosa of rats exposed to 10 or 100 mg/L chlorine dioxide; thymidine incorporation was not significantly altered in the liver. The lack of a consistent relationship between dose and hematologic alterations and the small number of animals (four males/group) confound interpretation of the study.

Couri and Abdel-Rahman (1980) found significant increases in blood glutathione reductase levels in Sprague-Dawley rats (four males/group) exposed to 10, 100, or 1,000 mg/L chlorine dioxide in drinking water 20 hours/day, 7 days/week for up to 1 year (0, 0.1, 1, 10, or 100 mg/kg-day using reference body weights and drinking water intakes of 0.523 kg and 0.062 L/day, respectively, and adjusting for intermittent exposure). After 12 months of exposure, the erythrocyte glutathione reductase levels in rats exposed to 1, 10, 100, or 1,000 mg/L were similar to those of controls, but the levels of erythrocyte glutathione peroxidase were significantly increased at 100 and 1,000 mg/L. Erythrocyte glutathione concentrations were significantly decreased at 1, 10, and 100 mg/L after 6 months and at 1,000 mg/L after 12 months of exposure. Erythrocyte catalase levels were increased in the 1,000 mg/L group after 6 and 12 months of exposure and decreased in the 1 and 10 mg/L groups after 6 months of exposure.

In similarly exposed Swiss Webster mice (six males/group) (estimated doses of 0.18, 1.8, 18, and 180 mg/kg-day [as calculated by U.S. EPA, 1994d] for 1, 10, 100, and 1,000 mg/L chlorine dioxide, respectively, drinking water concentrations), glutathione peroxidase levels were decreased at 100 mg/L and increased at 1,000 mg/L after 12 months of exposure, and glutathione levels were decreased at 10 and 100 mg/L after 12 months (Couri and Abdel-Rahman, 1980).

Catalase levels were increased in the 10, 100, and 1,000 mg/L groups after 12 months of exposure. As with the Abdel-Rahman et al. (1984b) study, the inconsistent relationship between the dose and the magnitude of the alterations in the glutathione-dependent system makes interpretation of the results of this study difficult; additionally, it is not clear if these effects are biologically significant, precluding determination of a NOAEL and LOAEL for these studies.

Moore and Calabrese (1982) exposed groups of 10 A/J or C57L/J mice (sex not specified) to 0 or 100 ppm chlorine dioxide in drinking water for 30 days (0 or 19 mg/kg-day using a reference body weight of 0.0316 kg and water intake of 0.0078 L/day). No significant alterations in hematologic parameters (complete blood count, reticulocyte count, glucose-6-phosphate activity, and osmotic fragility) were observed in either mouse strain.

#### 4.2.1.2. *Chlorite*

The database for chlorite subchronic/chronic systemic toxicity consists of the Harrington et al. (1995a) subchronic study, the Haag (1949) chronic study, and the Bercz et al. (1982), Abdel-Rahman et al. (1984b), Couri and Abdel-Rahman (1980), and Moore and Calabrese (1982) studies, which examined a limited number of endpoints. Kurokawa et al. (1986) is the only study that examined the carcinogenic potential of ingested chlorite.

Harrington et al. (1995a) administered doses of 0, 10, 25, or 80 mg/kg-day sodium chlorite (equivalent to 0, 7.4, 19, or 60 mg chlorite/kg-day, respectively) via gavage to Crl:CD (SD) BR rats (15/sex/group) for 13 weeks. In the 60 mg/kg-day group, four animals died during treatment and both sexes exhibited salivation, significantly decreased erythrocyte counts, and decreased total serum protein levels. The males receiving 60 mg/kg-day exhibited significantly decreased hematocrit and hemoglobin levels and increased methemoglobin and neutrophil levels, whereas in the females, methemoglobin levels were significantly decreased. Possible reasons for the decrease in methemoglobin in females, which is unexpected considering the known oxidative effects of sodium chlorite, were not discussed by the study authors. The following observations were also noted in the 60 mg/kg-day group: morphological changes in erythrocytes in some animals of both sexes, significant increases in relative adrenal and spleen weights in the males, increases in absolute and relative spleen and adrenal weight in females, and increases in relative liver and kidney weights in the females. Body weight and food consumption were not affected by treatment. Histopathologic alterations in the 60 mg/kg-day group included squamous epithelial hyperplasia, hyperkeratosis, ulceration, chronic inflammation, and edema in the stomachs of seven males and eight females. At 19 mg/kg-day, the following alterations were reported: occasional salivation in two males, hematologic alterations in males (increased methemoglobin levels and neutrophil count, decreased lymphocyte count), increases in absolute and relative spleen and adrenal weights in females, and histologic alterations in the stomach of two males, similar to those seen in the high-dose group. The increase in absolute splenic weight was attributed to morphological alterations in erythrocytes, but no explanation was provided for alterations in absolute adrenal weight. The NOAEL in this study is determined to be 7.4 mg/kg-day, and the LOAEL is 19 mg/kg-day for stomach lesions and increases in spleen and adrenal weights in rats subchronically treated with sodium chlorite.

In a chronic study by Haag (1949), groups of rats (seven/sex/group) were exposed to 0, 1, 2, 4, 8, 100, or 1,000 mg/L chlorite in the drinking water (0, 0.09, 0.18, 0.35, 0.7, 9.3, or 81 mg/kg-day, as calculated by U.S. EPA, 1994d) for 2 years. Animals exposed to chlorite concentrations of 100 or 1,000 mg/L exhibited treatment-related renal pathology, characterized by distention of the glomerular capsule and appearance of a pale pinkish staining material in the renal tubules. These effects were also observed in a group of animals administered sodium chloride at a concentration equimolar to 1,000 mg sodium chlorite/L. The study author concluded that the renal pathology was a nonspecific salt effect, but this observation does not alter the observation that concentrations of 100 mg/L or higher led to adverse effects. Based on renal effects, this study identifies a NOAEL of 8 mg/L (0.7 mg/kg-day) and a LOAEL of 100 mg/L (9.3 mg/kg-day). The study was limited because an insufficient number of animals were tested per group, pathology was conducted on a small number of animals, and it did not provide adequate evaluations of more sensitive parameters, which would have been more useful in the overall assessment of chronic toxicity.

Two similarly designed studies, by Abdel-Rahman et al. (1984b) and Couri and Abdel-Rahman (1980), tested the hematotoxicity of chlorite in rats. Groups of four male Sprague-Dawley rats were exposed to 0, 10, or 100 mg/L chlorite in drinking water 20 hours/day, 7 days/week for up to 1 year (0, 1, or 10 mg/kg-day using a reference body weight of 0.523 kg and water intake rate of 0.062 L/day) and adjusting for intermittent exposure. At all measuring periods (after 2, 5, 7, 10, and 11 months of exposure), there were significant decreases in body weight gain in the 100 mg/L group; body weight gain also was decreased in the 10 mg/L group at 10 and 11 months. The study authors do not note whether water consumption was affected. No consistent alterations in erythrocyte count, hematocrit, or hemoglobin levels were observed. Mean corpuscular hemoglobin concentration was increased at both exposure levels after 7 months of exposure, but not after 9 months. Osmotic fragility was significantly decreased at 10 and 100 mg/L after 7 and 9 months of exposure. DNA synthesis (as measured by $^3$H-thymidine incorporation) was decreased in the liver and testes at 10 and 100 mg/L, decreased in the intestinal mucosa at 100 mg/L, and increased in the intestinal mucosa at 10 mg/L. Blood glutathione reductase activity was significantly increased at 10 and 100 mg/L after 6 months of exposure and decreased at 10 mg/L after 12 months. Blood glutathione peroxidase was not altered after 6 months of exposure, but after 12 months it was decreased in both groups. Significant decreases in blood glutathione levels were observed in both groups. Blood catalase activity was decreased after 6 months of exposure in the 10 and 100 mg/L groups and increased in the 10 mg/L groups after 12 months. The lack of a consistent dose-effect relationship, small numbers of animals, and small magnitude of effects complicate interpretation of the results.

Moore and Calabrese (1982) also examined the hematotoxicity of chlorite. In this study, groups of 11–23 A/J or C57L/J mice (sex not specified) were exposed to 0, 1, 10, or 100 ppm sodium chlorite (0, 0.75, 7.5, or 75 ppm chlorite) in drinking water for 30 days. Significant increases in mean corpuscular volume, osmotic fragility, and glucose-6-phosphate activity were observed in both strains of mice exposed to 100 ppm; no other alterations in hematologic parameters were observed. This study identifies a NOAEL of 10 ppm sodium chlorite (1.9 mg/kg-day chlorite using a reference body weight of 0.0316 kg and water intake of 0.0078 L/day)

815

and a LOAEL of 100 ppm sodium chlorite (19 mg/kg-day) for hematologic effects in mice exposed to chlorite in drinking water for 30 days.

Using a rising-dose study protocol, Bercz et al. (1982) examined the effects of subchronic exposure to sodium chlorite in drinking water on hematologic and serum clinical chemistry parameters. Five male and seven female adult African green monkeys (*C. aethiops*) were exposed to 0, 25, 50, 100, 200, or 400 mg/L chlorite in drinking water for 4–6 weeks; the study authors estimated the dose for the 400 mg/L group to be 58.4 mg/kg-day. Each animal served as its own control. A number of statistically significant, dose-related alterations in hematologic and serum clinical chemistry parameters were observed. These included decreases in erythrocyte levels and cell indices, increases in aspartate aminotransferase (increases were subclinical), slight decreases in hemoglobin levels, and slight increases in reticulocyte count and methemoglobin levels. The data were not presented in a manner that would allow identification of threshold doses for the hematologic alterations. Other hematologic and clinical chemistry parameters and body weight were not affected. Serum T4 levels were significantly reduced in the 400 mg/L group.

To assess the renal toxicity of sodium chlorite, Moore and Calabrese (1982) exposed groups of 55–60 male C57L/J mice to 0, 4, 20, or 100 ppm sodium chlorite (0, 3, 15, or 75 ppm chlorite) in the drinking water for 30, 90, or 190 days. No significant alterations in body weight gain, absolute or relative kidney weights, water consumption, or kidney histology were observed.

In an oral carcinogenicity study conducted by Kurokawa et al. (1986) (mouse data were also presented in Yokose et al., 1987), groups of male and female F344 rats and B6C3F1 mice (50/sex/species/group) were exposed to sodium chlorite in the drinking water for 85 or 80 weeks (with a 5-week recovery period) (Yokose et al., 1987). The sodium chlorite concentrations were 0, 300, or 600 ppm for rats and 0, 250, or 500 ppm for mice. Using water consumption and body weight data, the study authors estimated the doses to be 18 and 32 mg/kg-day in male rats and 28 and 41 mg/kg-day in female rats. All groups of rats were infected with the Sendai virus. No adverse effect on survival was observed in the rats. A slight dose-related decrease in body weight gain was observed (body weight gain in the high-dose group was within 10% of controls). No chlorite-related increases in tumor incidence were observed in the rats.

For mice, daily doses of 0, 48, and 95 mg sodium chlorite/kg-day (0, 36, and 71 mg chlorite/kg-day) were calculated by EPA (1994d). In the mice, there were no significant chlorite-related alterations in survival or body weight gain; increased mortality was observed in the male control group, which was attributed to severe fighting. Significant increases in liver and lung tumors were observed in the male mice. Incidence of hyperplastic nodules in the liver was significantly increased in the low- and high-dose groups relative to controls (3/35 [reported as 6/35 in Yokose et al., 1987], 14/47, 11/43, in the control, low-, and high-dose groups, respectively) and combined incidence of liver hyperplastic nodules and hepatocellular carcinoma was increased in the low-dose group (7/35, 22/47, and 17/43, respectively). Incidence of lung adenoma (0/35, 2/47, and 5/43, respectively) and combined incidence for lung adenoma and adenocarcinoma (0/35, 3/47, and 7/43, respectively) were significantly increased in the high-dose group compared with controls. The study authors noted that incidences of liver hyperplastic

816

nodules and lung adenomas in the treated animals were within the range of historical controls in their laboratory and in the National Toxicology Program laboratories. The high mortality in the control males because of fighting may have contributed to the low tumor incidence in the concurrent control group, making statistical comparisons between concurrent controls and treated animals difficult to interpret. In the female mice, the only significant alteration in tumor incidence was a significantly lower incidence of malignant lymphoma/leukemia in the high-dose group (7/47, 5/50, 1/50, respectively). This study is considered inadequate for assessing carcinogenicity because of the relatively short exposure duration (80 weeks) and the high incidence of early mortality in the concurrent control males from excessive fighting.

### 4.2.2. Inhalation Exposure

#### 4.2.2.1. *Chlorine Dioxide*

Paulet and Desbrousses (1970) conducted four studies to investigate toxicity of inhaled chlorine dioxide in rats and rabbits (strains not specified): (1) 5 male and 5 female rats were exposed to 10 ppm chlorine dioxide (28 mg/m$^3$) 2 hours/day for 30 days; (2) 10 male rats, 10 female rats, and 4 rabbits were exposed to 5 ppm chlorine dioxide (14 mg/m$^3$) 2 hours/day for 30 days; (3) 10 male and 10 female rats were exposed to 2.5 ppm chlorine dioxide (6.9 mg/m$^3$) 7 hours/day for 30 days; and (4) 8 rabbits were exposed to 2.5 ppm chlorine dioxide (6.9 mg/m$^3$) 4 hours/day for 45 days. The weekly exposure frequency was not reported—presumably it was 5 days/week. Control groups with equal numbers of animals were used for each study. The following adverse effects were observed at 10 ppm: nasal discharge and red eyes, localized bronchopneumonia with desquamation of the alveolar epithelium, and significantly increased blood erythrocyte and leukocyte levels. Similar, but less severe, respiratory tract effects were observed at 5 ppm; there were no alterations in erythrocyte or leukocyte levels at this concentration. Lymphocytic infiltration of the alveolar spaces, alveolar vascular congestion, hemorrhagic alveoli, epithelial erosions, and inflammatory infiltrations of the bronchi were observed in the rats exposed to 2.5 ppm. The study authors noted that body weight gain was "slightly slowed" (data not presented) and the erythrocyte and leukocyte levels were 85% and 116% of controls, respectively (statistical analysis not reported), in the rats exposed to 2.5 ppm. In rabbits exposed to 2.5 ppm chlorine dioxide, hemorrhagic alveoli and congested capillaries were observed in the lungs. Body weight gain was not adversely affected, and erythrocyte and leukocyte levels were 80% and 116% of controls (statistical analysis not reported; the study authors state that the cell counts "changed very little"). Another group of rats and rabbits were sacrificed 15 days after termination of the 2.5 ppm exposure regimens. Recovery from the pulmonary lesions was evident in these animals. The liver was not adversely affected in the rats or rabbits following exposure to 2.5, 5, or 10 ppm chlorine dioxide. This study identifies a LOAEL of 2.5 ppm (6.9 mg/m$^3$) for thoracic effects (alveolar congestion and hemorrhage and bronchial inflammation) in rats (7 hours/day for 30 days) and pulmonary effects (alveolar hemorrhage and capillary congestion) in rabbits (4 hours/day for 45 days).

In a follow-up study by Paulet and Desbrousses (1972), groups of eight Wistar rats (sex not reported) were exposed to 1 ppm chlorine dioxide (2.8 mg/m$^3$) 5 hours/day, 5 days/week for 2 months. The study authors noted that weight gain and erythrocyte and leukocyte levels were

817

not affected, but they did not present concurrent control data. Vascular congestion and peribronchiolar edema were observed in the lungs of chlorine dioxide-exposed rats; no alterations in the epithelium or parenchyma were observed. This subchronic study identifies a LOAEL of 1 ppm (2.8 mg/m$^3$) for respiratory effects in rats.

In a second series of studies conducted by Paulet and Desbrousses (1974), groups of 10–15 rats (sex and strain not reported) were exposed to 5, 10, or 15 ppm chlorine dioxide (14, 28, or 41 mg/m$^3$) for 15-minute periods two or four times/day for 1 month. Control groups were similarly exposed to room air. At 15 ppm, 1/10 and 1/15 rats exposed two or four times/day, respectively, died; body weight loss was observed in both groups. Histologic alterations observed at this exposure level included nasal and ocular inflammation and discharge, bronchitis, and catarrhous lesions of the alveoli with peribronchiolar infiltrations (more pronounced in the four times/day group). The alveolar lesions were reversible; 15 days after exposure termination, the lung histology was similar to that of controls. No histologic alterations were observed in the liver. At 10 ppm, alveolar irritation and decreases in body weight gain were observed. No adverse effects on clinical signs, body weight gain, or histopathology of the lungs were observed at 5 ppm. Exposure to chlorine dioxide did not adversely affect hematologic parameters. This study identifies a NOAEL of 5 ppm (14 mg/m$^3$) and LOAEL of 10 ppm (28 mg/m$^3$) for lung damage following intermittent exposure for 15-minute periods, two or four times/day for 4 weeks.

Dalhamn (1957) conducted a series of inhalation studies to assess toxicity of chlorine dioxide in the rat (sex and strain not reported). In the first study, a group of three rats was exposed once a week for 3 minutes to decreasing concentrations of chlorine dioxide (3,400 ppm [9,500 mg/m$^3$] in week 1, 1,100 ppm [3,000 mg/m$^3$] in week 2, and 800 ppm [2,200 mg/m$^3$] in week 3); a second group of three rats served as controls. Respiratory distress and decreased body weight were observed in the chlorine dioxide-exposed rats. Bronchopneumonia and hyperemia of the renal corticomedullary junction were observed in two of three rats; the renal hyperemia was also observed in the control group (2/3). In the second study, exposure to 260 ppm (720 mg/m$^3$) chlorine dioxide for 2 hours resulted in ocular discharge, epistaxis, death (1/4 rats), pulmonary edema, and circulatory engorgement. In the third study, groups of five rats were exposed to 0 or approximately 10 ppm chlorine dioxide (28 mg/m$^3$) 4 hours/day for 9 days in a 13-day period. Death (3/5 rats), rhinorrhea, "embarrassed respiration," and weight loss were observed in the chlorine dioxide-exposed rats. Respiratory infection with acute renal and hepatic congestion also were observed. The fourth study involved exposure of groups of five rats to 0 or approximately 0.1 ppm chlorine dioxide (0.28 mg/m$^3$) 5 hours/day for 10 weeks (frequency of exposure not reported). No effects on body weight gain were observed and no histologic alterations were observed in the lungs, kidneys, or liver. The Dalhamn studies identified a NOAEL of 0.1 ppm (0.28 mg/m$^3$) in rats exposed 5 hours/day for 10 weeks and a LOAEL of 10 ppm (28 mg/m$^3$) for respiratory tract irritation in rats exposed 4 hours/day for approximately 2 weeks.

### 4.2.2.2. *Chlorite*

No animal inhalation or intratracheal installation data were located for chlorite.

## 4.3. REPRODUCTIVE/DEVELOPMENTAL STUDIES—ORAL AND INHALATION

### 4.3.1. Chlorine Dioxide

Carlton et al. (1991) administered daily gavage doses of 0, 2.5, 5, or 10 mg/kg chlorine dioxide in deionized water to groups of 12 male Long-Evans rats for 56 days prior to mating and throughout the 10-day mating period. Groups of 24 female rats received the same gavage doses for 14 days prior to mating, during the mating period, and throughout gestation and lactation. No significant alterations in mortality, clinical signs, fertility rates, sperm parameters, length of gestation, prenatal deaths, mean litter size, or mean pup weights were observed. A statistically significant delay in the day of eye opening was observed in pups from the 10 mg/kg-day group, but the study authors did not consider this effect to be biologically significant because it was not dose related (16.70, 15.59, 16.26, and 15.95 days in the 0, 2.5, 5, and 10 mg/kg-day groups, respectively). No significant alterations in reproductive tract organ weights were observed in the F1 male rats. In the F1 female rats, there were statistically significant decreases in absolute and relative vagina weights in the 10 mg/kg-day group, but no differences in terminal body weights or uterine and ovarian weights. No consistent chlorine dioxide-related alterations in T3 or T4 levels were measured in the F0 male and female rats and F1 male rats (hormone levels measured on postnatal days 17, 28, and 40). This study identifies a NOAEL of 10 mg/kg-day for reproductive effects in rats receiving gavage doses of chlorine dioxide.

In a developmental toxicity study by Suh et al. (1983), groups of six to eight female Sprague-Dawley rats were administered 0, 1, 10, or 100 mg/L chlorine dioxide in the drinking water (0, 0.1, 1, and 10 mg/kg-day using a reference body weight of 0.35 kg and water intake of 0.046 L/day) for 2.5 months prior to mating with unexposed males and during gestational days 0–20; the dams were killed on gestational day 20. A slight, nonsignificant decrease in maternal body weight gain was observed in the 10 and 100 mg/L groups. There was a statistically significant trend for decreasing number of implants per litter and number of live fetuses per dam. Total fetal weights and male fetal weights were significantly increased in the 100 mg/L group compared with controls; crown-rump length was not significantly affected. Incidences of skeletal anomalies did not significantly differ between groups. This study identifies a NOAEL of 10 mg/L (1 mg/kg-day) and LOAEL of 100 ppm (10 mg/kg-day) for developmental effects in the offspring of rats exposed to chlorine dioxide in the drinking water.

Toth et al. (1990) examined the neurodevelopmental toxicity of chlorine dioxide in the postnatally exposed Long-Evans hooded rats. Groups of four male and four female pups per litter received daily gavage doses of 0 or 14 mg/kg chlorine dioxide on postnatal days 1–20. The chlorine dioxide pups weighed significantly less than controls at ages 11, 21, and 35 days. No significant alterations in cerebellum or olfactory bulb weights were observed on postnatal days 11, 21, or 35. Forebrain weights were significantly lower in the chlorine dioxide-exposed pups on postnatal days 21 and 35. This reduction in forebrain weight was accompanied by reductions

819

in protein content on postnatal days 21 and 35 and reduced DNA content on postnatal day 35. The ratio of protein content to forebrain weight was decreased on postnatal days 11, 21, and 35; the protein content to cerebellum weight was increased on postnatal day 35. The ratio of DNA content to brain part weight was not significantly affected in the chlorine dioxide-exposed pups. No alterations in counts of branches of apical dendrites of cerebral cortical layer 5 pyramidal cells were observed, but dendritic spine counts in the Krieg's area 18 (a visual association region of the cortex) were significantly decreased. No gross lesions, loss of myelin, or changes in cells staining positive for Nissl substance in the forebrain, cerebellum, or brainstem were observed in the brains of chlorine dioxide-exposed pups. No significant alterations in T3 or T4 levels or free T4 index were observed on postnatal days 11, 21, and 35. This study identifies a LOAEL of 14 mg/kg-day for altered brain development (decreased forebrain weight and protein content) in postnatally exposed rats.

Mobley et al. (1990) exposed groups of 12 female Sprague-Dawley rats to 0 or 100 ppm chlorine dioxide in the drinking water (0 or 14 mg/kg-day using a reference body weight of 0.35 kg and water intake of 0.046 L/day) for 10 days prior to mating with unexposed males and during the gestation and lactation periods (until postconception days 35–42). No significant alterations in litter size were observed. At birth, the litter weight of the chlorine dioxide-exposed group was significantly lower than that of controls. Chlorine dioxide exposure significantly decreased exploratory activity on postconception days 36–39, but not on days 39–41. Although serum T3 and T4 levels were not significantly altered in the chlorine dioxide-exposed pups (assessed on postconception days 37 and 38), a significant decrease in T3 uptake was observed. Free T3 and T4 levels were lower in the chlorine dioxide group, but the difference was not statistically significant. On postconception day 42, there were no significant alterations in total T3 or T4, free T4, or T3 uptake. The day of eye opening was not significantly affected by chlorine dioxide exposure. Thus, 100 ppm (14 mg/kg-day) is a LOAEL for decreased litter weight and exploratory activity.

In a study conducted by Orme et al. (1985) designed to assess toxicity of chlorine dioxide on the thyroid, groups of female Sprague-Dawley rats were exposed to 0, 2, 20, or 100 mg/L in the drinking water (doses of 0, 1, 3, and 14 mg/kg-day were estimated by U.S. EPA, 1994d) for 2 weeks prior to mating and throughout gestation and lactation. In a companion study, groups of 5-day-old Sprague-Dawley pups (dams were not exposed) received gavage doses of 0 or 14 mg/kg-day chlorine dioxide on postnatal days 5–20. No significant alterations in pup weight were observed in the pups exposed in utero; the postnatally exposed pups weighed significantly less than controls on postnatal days 14–21. Age of eye opening was not affected by chlorine dioxide exposure. Locomotor activity was consistently decreased in the 100 mg/L group, but the decrease was not statistically significant. In the 14 mg/kg-day gavaged group, activity was significantly decreased on postnatal days 18–19; on days 15–17 and 20, activity levels were similar to controls. In the 100 mg/L group, there was a significant decrease in T3 and T4 levels; T4 levels were also significantly decreased in the 14 mg/kg-day group. In all groups, there was a significant correlation between T4 levels and locomotor activity. T4 levels were not significantly altered in the chlorine dioxide–exposed dams. This study identifies a NOAEL of 20 mg/L (3 mg/kg-day) and a LOAEL of 100 mg/L (14 mg/kg-day) for neurobehavioral effects (decreased

T3 and T4 levels and delayed development) in the offspring of rats exposed to chlorine dioxide in drinking water.

Taylor and Pfohl (1985) exposed groups of 13–16 female Sprague-Dawley rats to 0 or 100 ppm chlorine dioxide in drinking water (0 or 14 mg/kg-day calculated using a reference body weight of 0.35 kg and water intake of 0.046 L/day) for 14 days prior to breeding and throughout gestation and lactation. Groups of male pups from unexposed dams were administered 0 or 14 mg/kg chlorine dioxide via gavage from postnatal days 5 to 20. No significant alterations in maternal or pup body weights were observed in the group receiving 100 ppm in the drinking water. A significant decrease in whole brain weight, primarily because of a decrease in cerebellar weight, was observed in the 21-day-old offspring of dams receiving 100 ppm in the drinking water. A decrease in cerebellar total DNA content also was observed; the difference was caused by a decrease in total number of cells rather than in cell density. A nonsignificant decrease in locomotor activity (assessed at 10–20 days of age) was observed in the 100 ppm offspring. A significant decrease in exploratory behavior was observed in the 100 ppm offspring at 60 days of age. In the pups receiving gavage doses of chlorine dioxide, significant decreases in body weight, absolute and relative whole brain and forebrain weights, and forebrain DNA content and total cell number were observed in the 21-day-old pups; cerebellum and forebrain DNA content and total cell number were also significantly decreased in the 11-day-old pups. Significant decreases in home cage and wheel-running activity at ages 18–19 and 10 days, respectively, also were observed in the pups receiving gavage doses of chlorine dioxide. Thus, the LOAEL for neurobehavioral effects, decreased brain weight, and cell number in the offspring of rats exposed to chlorine dioxide in drinking water and in rats postnatally exposed to chlorine dioxide via gavage is 14 mg/kg-day.

### 4.3.2. Chlorite

The Chemical Manufacturers Association (CMA) conducted a two-generation study to examine reproductive, developmental neurotoxicity, and hematologic endpoints in rats exposed to sodium chlorite (CMA, 1996). Thirty male and 30 female Sprague-Dawley rats of the OFA(SD)IOPS-Caw strain (F0) generation received drinking water containing 35, 70, or 300 ppm sodium chlorite (concentrations of sodium chlorite in the drinking water were apparently adjusted to compensate for the 81.4% purity of the test material) for 10 weeks and were then paired (1M:1F) for mating. A similar group received purified water and served as controls. Males were exposed throughout mating and then were sacrificed. Exposure for the females continued through mating, pregnancy, and lactation until necropsy following weaning of their litters. Sodium chlorite concentrations were adjusted downward during lactation to offset increases in the volume of water consumed so that a constant intake (mg/kg-day) could be maintained. Twenty-five males and females from each of the first 25 litters to be weaned in a treatment group were chosen to produce the F1 generation. The F1 pups were continued on the same treatment regimen as their parents. At approximately 14 weeks of age, they were mated to produce the F2a generation. Because of a reduced number of litters in the 70 ppm F1-F2a generation, the F1 animals were remated following weaning of the F2a to produce the F2b generation. Pregnant F1 females were allowed to litter and rear the F2a and F2b generations until weaning at postnatal day 21. Based on sodium chlorite intake (in mg/kg-day) calculated by the study authors from measured water consumption and body weight, and adjusting for the molecular weight of sodium in sodium chlorite, doses for the F0 animals were 0, 3, 5.6, and 20 and 0, 3.8, 7.5, and 28.6 mg/kg-day chlorite for males and females, respectively. For the F1 animals, doses were 0, 2.9, 5.9, and 22.7 mg/kg-day chlorite for the males and 0, 3.8, 7.9, and 28.6 mg/kg-day chlorite for the females. Numerous parameters were measured or calculated, including body weight, food and water consumption, estrus cycle in the F0 and F1 rats, and hematology and T3 and T4 levels in the F1 rats (blood samples collected from 1 male and 1 female from the first 20 F1 litters at age 25 days and another group at 13 weeks). Other parameters measured were gestation duration, litter size, pup sex, pup body weight, pup developmental landmarks, number alive/dead pups in the F1 and F2 generations, total caudal sperm number and percent motile, morphology by computer-assisted sperm motility analysis in the F0 and F1 rats, and organ weight and histopathologic examination of the brain, pituitary gland, liver, adrenal gland, spleen, thymus, kidneys, and reproductive organs of all F0 and F1 controls and high-dose animals. An additional group of F1 pups was chosen for neurohistopathology on postnatal day 11 (examination of the brain and spinal cord) or postnatal day 60 (sensory ganglia, dorsal and ventral nerve roots, and several peripheral nerves and muscles). Another group of F1 rats was examined for neurotoxicological endpoints (motor activity in a "Figure 8" Activity System and neuropathology on postnatal day 60, auditory startle in the SR-Screening System, learning and memory retention in a water E-maze). A functional observational battery (FOB) was also conducted on the pups undergoing auditory and learning assessments. This group was composed of 2 males and 2 females from 20 litters, and exposure was discontinued after weaning. Reevaluation of the auditory startle response was conducted in 20 males and 20 females in the F2a and F2b generations.

There were reductions in water consumption, food consumption, and body weight gain in both sexes in all generations at various times throughout the experiment (e.g., during premating, pregnancy, gestation, postweaning), primarily in the 70 and 300 ppm groups. The authors attributed these reductions to lack of palatability of the drinking water solution, but did not show data to support this contention. Significant alterations related to treatment at 300 ppm include reduced absolute and relative liver weight in F0 females and F1 males and females, reduced pup survival (increase in number of pups found dead and/or killed prematurely during lactation) and reduced body weight at birth and throughout lactation in F1 and F2 rats, lower thymus and spleen weight in both generations, lowered incidence of pups exhibiting normal righting reflex and with eyes open on postnatal day 15, alteration in clinical condition in F2 animals chosen for neurotoxicity, decrease in absolute brain weight for F1 males and F2 females, delay in sexual development in males (preputial separation) and females (vaginal opening) in F1 and F2 rats, and lower red blood cell parameters in F1 rats. The reported alterations in pup sexual maturation measures might be due to reduced pup body weight, but a definitive conclusion cannot be drawn. In the 70 ppm groups, reduced absolute and relative liver weight in F0 females and F1 males was observed. Minor, statistically significant changes in hematologic data at the 35 and 70 ppm concentrations (generally 1%–7%) in the F1 rats appear to be within normal ranges based on historical data and are therefore not considered clinically or biologically significant or adverse. In addition, a significant decrease in maximum response to an auditory startle stimulus was noted in the 70 and 300 ppm groups on postnatal day 24, but not on postnatal day 60. Analysis of the

822

E-maze data by EPA personnel indicated possible alterations in learning behavior in the 70 ppm group, but the differences from the conclusions of the report could not be resolved.

The CMA (1996) study is adequate in that it was conducted with sufficient numbers of animals of both sexes and examined numerous endpoints. The study is acceptable and consistent with EPA testing guidelines that were in effect at the time of the study (U.S. EPA, 1991). However, there are several limitations to this study. Lack of pair-watered and pair-fed control animals confounds the results and precludes definitive conclusions as to whether the alterations in food and water consumption and body weight are related to water palatability or a direct toxic effect of the agent. Developmental landmarks (e.g., vaginal opening in F2a group) were not reported for all groups. Grip strength and landing foot splay were not included in the FOB. Discontinuation of exposure for the animals undergoing neurotoxicity testing minimizes the likelihood of finding a positive effect and precludes comparison of the data with those of other rats with continued exposure. Although the study employed an exposure regimen consistent with testing guidelines and should potentially detect adverse effects on the developing nervous system, discontinuation of exposure after weaning reduces the opportunity to detect neurological effects from continuous or lifetime exposures similar to those expected from lifetime drinking water exposure in humans.

Interpretation of the neurobehavioral tests is limited. The report lacks detailed descriptions of experimental methods (e.g., size of the arena, length of observations) and positive control data (including estimates of variability) for the FOB. Positive control studies for the motor activity and E-maze studies used high doses of the validation chemicals, were not adequate to show the sensitivity of the methods, and showed only that effects of the chemicals at maximally toxic doses could be recognized. Variability in the startle response data was high. The high variability and problems in calibrating and operating the automated startle apparatus (as presented in the report) would tend to decrease the sensitivity of the test to detect a difference between control and treated groups, because differences in startle amplitude would have to be larger to attain statistical significance. In some cases, inappropriate statistical analyses were applied. For example, repeated-measures techniques were apparently not used to account for the fact that the rats were tested repeatedly, and it is not clear how nonparametric rank data were analyzed or why a log transformation was applied to the learning data. The NOAEL for this study is 35 ppm (2.9 mg/kg-day chlorite) and the LOAEL is 70 ppm (5.9 mg/kg-day chlorite) based on lowered auditory startle amplitude and altered liver weights in two generations.

Groups of 12 male Long-Evans rats were exposed to 0, 1, 10, or 100 ppm sodium chlorite (0, 0.7, 7, and 70 ppm chlorite) in the drinking water for 56 days prior to mating and throughout a 10-day mating period (Carlton and Smith, 1985; Carlton et al., 1985, 1987). Groups of 24 female rats were exposed to the same sodium chlorite drinking water concentrations for 14 days prior to mating, during the mating period, and throughout gestation and lactation. Doses of 0, 0.075, 0.75, and 7.5 mg/kg-day were estimated by EPA (1994d). No significant alterations in body weight gain or water consumption were observed. There was a wide degree of variability among fertility rates for the different groups (67%–96%), but no dose-related alterations in fertility rates were observed. No significant alterations in litter survival rates, median day of eye opening, or median day of observed vaginal patency were observed. Additionally, no alterations

823

were observed in gross and histopathologic examination of reproductive tract tissues, hematologic parameters, or testis, epididymis, and caudal epididymis weights. No significant alterations in sperm count or percentage of sperm mobility were observed. A trend toward decreased sperm mean progressive movement was observed in the 100 ppm group, but the velocity was not significantly different from controls. The percentage of abnormal sperm in sodium chlorite-exposed rats did not differ from controls. No significant alterations in T3 and T4 hormone levels were observed in the F0 males or females. T3 and T4 levels were measured in the F1 males and females on postnatal days 17 (males only), 21, and 40; significant decreases in hormone levels were consistently observed at 100 ppm at days 21 and 40. This study identifies a NOAEL of 10 ppm (0.75 mg/kg-day) and a LOAEL of 100 ppm (7.5 mg/kg-day) for altered thyroid hormone levels in the offspring of rats exposed to sodium chlorite in drinking water.

Carlton and Smith (1985) and Carlton et al. (1985, 1987) conducted two follow-up studies to further investigate the effect of sodium chlorite on sperm parameters. In these studies, groups of 12 male rats received drinking water containing 0, 100, or 500 ppm sodium chlorite (0, 70, and 370 ppm chlorite) or 0, 1, 10, or 100 ppm sodium chlorite (0, 0.7, 7, and 70 ppm chlorite) for 72–76 days. Water consumption was significantly decreased (28%) in the 500 ppm group; in other groups, water consumption was similar to that of controls. Estimated doses of 0.075, 0.75, 7.5, and 27 mg/kg-day were calculated for the 1, 10, 100, and 500 ppm groups, respectively. No significant alterations in body weight gain were observed in the sodium chlorite-exposed rats. As in the first experiment, there were no significant alterations in sperm count, percentage of sperm mobility, or mean progressive movement. However, there was a trend toward decreased progressive movement in the 100 and 500 ppm groups. When the three experiments were combined, there was a statistically significant reduction of direct progressive movement at 100 and 500 ppm. A significant increase in abnormal sperm was observed in the 100 and 500 ppm groups; the most common morphological abnormalities were frayed tails, open hooks, and amorphous sperm heads. Collectively, these studies identify a NOAEL of 10 ppm (0.75 mg/kg-day) and LOAEL of 100 ppm (7.5 mg/kg-day) for reproductive effects in rats exposed to sodium chlorite in drinking water.

Couri et al. (1982) exposed groups of 7–13 pregnant Sprague-Dawley rats to 0%, 0.1%, 0.5%, or 2% sodium chlorite (0%, 0.07%, 0.4%, and 1.5% chlorite) in the drinking water during gestational days 8–15. The litters were either delivered at term or by cesarean section on gestational day 22. Using the daily doses of 0, 34, 163, and 212 mg sodium chlorite/rat/day calculated by the study authors and an estimated body weight (midpoint of gestation day 1 body weights [0.280 kg] plus one-half of the body weight gain), doses of 0, 95, 590, and 820 mg/kg-day sodium chlorite (0, 70, 440, and 610 mg/kg-day chlorite) were calculated. Another group of four pregnant rats received daily gavage doses of 200 mg/kg sodium chlorite on gestational days 8–15. Profuse vaginal and urethral bleeding and 100% mortality were observed in the rats receiving 200 mg/kg gavage doses. No deaths were observed in the rats receiving sodium chlorite via drinking water. Weight loss and decreases in food and water consumption were observed at the 0.5% and 2% concentrations; decreased water consumption was also observed in the 0.1% group. Irregular blood cells, ruptured cells, and hemolysis were observed in the 2% and 200 mg/kg-day groups. Significant decreases in crown-rump length were observed in litters term-delivered in the 0.1%, 0.5%, and 2% groups and in the 0.5% group cesarean-delivered on gestational day 22. Fetal weights were not adversely affected. An increase in the number of resorbed and dead fetuses was observed in litters delivered on gestational day 22 in the 0.1%, 0.5%, and 2% groups; two litters out of five were totally resorbed in the 2% group. Postnatal growth and the incidences of soft tissue and skeletal malformations were not adversely affected by in utero exposure to sodium chlorite. This study identifies a FEL of 0.1% for resorbed and dead fetuses and decreases in crown–rump length in the offspring of rats exposed to 0.1% sodium chlorite (70 mg/kg-day chlorite) in drinking water.

Groups of six to nine female Sprague-Dawley rats were administered 0, 1, or 10 mg/L chlorite in the drinking water (0, 0.1, or 1 mg/kg-day calculated using a reference body weight of 0.35 kg and water intake of 0.046 L/day) for 2.5 months prior to mating with unexposed males and during gestational days 0–20; the dams were killed on gestational day 20 (Suh et al., 1983). No significant alterations in general appearance or maternal body weight gain were observed. No significant alterations in number of implants (total and per dam), resorptions, or dead fetuses were observed. No difference in fetal body weights was observed. Crown-rump length was significantly higher in the 10 mg/L group compared with controls, but the difference was very small and is probably not biologically significant. Chlorite exposure did not significantly alter incidence of skeletal anomalies. This study identifies a NOAEL of 10 mg/L (1 mg/kg-day) for developmental toxicity in the offspring of rats exposed to chlorite in the drinking water.

Mobley et al. (1990) exposed groups of 12 female Sprague-Dawley rats to 0, 20, or 40 ppm chlorite in the drinking water (doses of 0, 3, and 6 mg/kg-day were estimated by U.S. EPA, 1994d) for 10 days prior to mating with unexposed males and during gestation and lactation until postnatal days 42–53. Chlorite exposure did not adversely affect litter size or pup weight gain. Significant, consistent decreases in exploratory activity were observed in the 40 ppm group on postnatal days 36–39, but not on days 39–41. In the 20 ppm group, there were significant decreases in activity on days 36 and 37, but not on days 38–40. No significant alterations in serum T3 or T4 levels were observed in the 37–38- or 42-day-old postconception pups. However, the free T4 levels were significantly increased in the 40 ppm group. The day of eye opening in the 20 and 40 ppm groups was similar to that of controls. A review of the results of this study relative to the findings of the newer developmental studies in the database suggests that the NOAEL for neurodevelopmental behavioral effects in rats exposed to chlorite in drinking water for this study is 20 ppm (3 mg/kg-day) and the LOAEL is 40 ppm (6 mg/kg-day).

Moore et al. (1980) (data also presented in Moore and Calabrese, 1982) exposed groups of pregnant female A/J mice to 0 or 100 ppm sodium chlorite in drinking water throughout gestation and lactation; 21 control and 12 exposed dams had litters. EPA (1994d) estimated that the 100 ppm sodium chlorite (75 ppm chlorite) concentration corresponds to a dose of 22 mg/kg-day. A decrease in the conception rate (number of females positive for vaginal plug/number of females producing litters) was observed in the chlorite group (39% vs. 56% in controls); the statistical significance was not reported. No statistically significant alterations in gestation length, litter size, number of pups dead at birth, and number of pups alive at weaning were observed. Pup growth was adversely affected, as shown by significant decreases in average pup weaning weight and birth to weaning growth rate. This study identifies a LOAEL of 100 ppm

825

(22 mg/kg-day) for developmental effects in the offspring of mice exposed to chlorite in the drinking water.

Harrington et al. (1995b) treated groups of 16 female New Zealand white rabbits with technical-grade sodium chlorite (80.6% purity) via their drinking water at levels of 0, 200, 600, or 1,200 ppm from gestation days 7–20, followed by terminal sacrifice at day 28. Water concentrations were maintained at the same levels throughout pregnancy and were not adjusted for changes in volume of water consumed. Based on measured water consumption, the study authors calculated a mean daily intake of approximately 0, 10, 26, or 40 mg/kg-day chlorite (corrected for purity and adjusted by the weight of the salt). Clinical condition, maternal body weight, and food and water consumption were measured daily. At necropsy, gravid uterine weights, number of corpora lutea, number of implantation sites, and live and dead fetuses were recorded. Live fetuses were weighed, examined for external abnormalities, sexed, and dissected, and a gross visceral examination was performed. Skeletal examinations were also performed. Abnormalities were categorized as minor or major, and the latter were thought to impair survival or fitness. Commonly observed variations were also recorded. The study authors did not state which malformations fell into each of these categories. There was no mortality, although two rabbits (one from each of the control and 26 mg/kg-day groups) were sacrificed in extremis because of a clinical condition unrelated to treatment. A significant decrease in water consumption during the treatment period was observed in the 26 and 40 mg/kg-day groups, and a decrease during treatment days 16–20 of pregnancy was observed in the 10 mg/kg-day group. The study authors attributed the decreases in consumption to lack of palatability of the drinking water solution, although no supporting data were presented. Food consumption was decreased in the 26 and 40 mg/kg-day groups during days 7–11 of pregnancy. Body weight gain of treated animals was decreased on days 7–19, although by day 26 these groups showed no differences from controls in body weight gain.

The authors concluded there were no treatment-related effects on pregnancy incidence, number of implantations, number of preimplantation losses, fetal sex ratio, number of live fetuses, or fetal visceral or structural abnormalities. Data for specific malformations and variations were not shown; instead, data were presented as the number or mean percentage of fetuses with major or minor external and visceral or skeletal abnormalities. The number and mean percentage of major external and visceral and skeletal abnormalities were increased in the 26 and 40 mg/kg-day groups (external/visceral: 6.6% and 2.9%, respectively, vs. 1.5% in controls; skeletal: 5.4% and 0%, respectively, vs. 0% in controls). Mean fetal weights in the 26 and 40 mg/kg-day groups were slightly decreased (< 9% relative to controls). In the 26 and 40 mg/kg-day groups, the incidence of minor skeletal abnormalities (13.9 and 14.2 for the 26 and 40 mg/kg-day groups, respectively, vs. 7.7% in controls) and skeletal variants related to incomplete fetal bone ossification (such as of the pubis and sternebrae) was higher than for controls. The authors state in their discussion that these alterations in fetal body weight and delayed ossification indicate embryonic growth retardation. The NOAEL for this study is 200 ppm (10 mg/kg-day chlorite) and the LOAEL is 600 ppm (26 mg/kg-day chlorite) based on decreased fetal weight and delayed skeletal ossification, decreased food and water consumption in the dams, and decreased body weight gain in the dams. Although this study employed sufficient numbers of animals and administered chlorite by a route relevant to human exposure, uncertainties exist in

826

interpretation of the results because of inadequate reporting of the number and types of specific abnormalities and variations. There is additional uncertainty as to whether the decreases in food and water consumption and body weight gain in the dams are caused by unpalatability or a direct toxic effect of the chlorite.

## 4.4. OTHER STUDIES

### 4.4.1. Other Carcinogenicity Studies

#### 4.4.1.1. *Chlorine Dioxide*

The potential for chlorine dioxide to induce proliferative epidermal hyperplasia was examined by Robinson et al. (1986). Groups of five dorsally shaved female SENCAR mice were placed in chambers filled with 0, 1, 10, 100, 300, or 1,000 ppm liquid chlorine dioxide; the chambers were designed to prevent the head from getting wet and to prevent inhalation of vapors. The animals were exposed 10 minutes/day for 4 days. A significant increase in interfollicular epidermal thickness was observed in the 1,000 ppm group, but not at the lower concentrations. Increases in total cell numbers and basal cell numbers in skin sections were observed in both the 300 and 1,000 ppm groups. In a second study, groups of 40 mice were immersed in 0 or 1,000 ppm chlorine dioxide for 10 minutes; animals (5/group) were killed 1, 2, 3, 4, 5, 8, 10, or 12 days postexposure. A significant increase in interfollicular epidermis thickness was observed at all time periods, with the highest values at 10 and 12 days postexposure. The authors concluded that even short-term dermal exposure to high concentrations of chlorine dioxide is capable of inducing hyperplastic responses in the mouse skin.

Miller et al. (1986) tested the carcinogenic potential of drinking water disinfected with chlorine dioxide using three short-term assays. Following disinfection with chlorine dioxide, the water samples (containing 0.5 mg/L chlorine dioxide residue) were concentrated 2,000× or 4,000× using a macroreticular resin process. In a mouse initiation-promotion assay, groups of 14–34 SENCAR mice (sex not specified) were orally administered 0.5 mL of the 4000× concentrate in 2% emulphor 3 times/week for 2 weeks followed by topical exposure to 1.0 : g 12-tetradecanylphorbal-13-acetate (TPA) in acetone applied to the dorsal skin 3 times/week for 20 weeks and then sacrificed. No significant increases, compared with vehicle controls, in the number of skin tumors or the number of tumors per animal were observed.

In a lung adenoma assay (Miller et al., 1986), groups of 20 male and 20 female Strain A mice received 0.25 mL gavage doses of 2000× or 4000× concentrates in 2% emulphor 3 times/week for 8 weeks followed by a 16-week observation period. The number of animals with lung adenomas and the number of adenomas per animal were not significantly altered compared with vehicle controls.

Miller et al. (1986) also examined the development of liver foci in rats in a short-term assay. In this study, groups of partially hepatectomized rats received a single dose of concentrated water (chlorine dioxide concentration not reported) in 2% emulphor followed 1 week later by administration of 500 ppm sodium phenobarbital in drinking water for 56 days;

animals were sacrificed on day 70. A control group received nondisinfected water. No significant increases in incidence of ( -glutamyltranspeptidase foci were observed.

#### 4.4.1.2. *Chlorite*

Kurokawa et al. (1984) also conducted dermal carcinogenicity studies. In a study to assess the ability of chlorite to act as a complete carcinogen, groups of 20 female SENCAR mice were exposed twice weekly for 51 weeks to 20 mg/mL sodium chlorite in acetone. The solution (0.2 mL; 100 mg/kg sodium chlorite per application) was applied to the shaved backs of the mice. The sodium chlorite exposure did not result in increased tumor incidence. To test the ability of chlorite to act as a tumor promoter, a single initiating dose of 20 : mol of dimethylbenzanthracene (DMBA) was applied to the skin of 20 SENCAR mice. The DMBA application was followed by a 51-week exposure to sodium chlorite (as described for the complete carcinogen study). Tumor incidence was 6/20 (30%) compared with 0/20 in mice that received DMBA followed by acetone treatments for 51 weeks. Squamous cell carcinomas were observed in 5/20 animals in the chlorite group. However, the results were not statistically significant.

### 4.4.2. Genotoxicity Studies

#### 4.4.2.1. *Chlorine Dioxide*

Both positive and negative results have been found in in vitro genotoxicity studies. Chlorine dioxide did not increase chromosome aberrations in Chinese hamster fibroblast cells but did increase reverse mutation in *Salmonella typhimurium* (with activation) (Ishidate et al., 1984). However, water samples disinfected with chlorine dioxide did not induce reverse mutations in *S. typhimurium* with or without activation (Miller et al., 1986). In vivo micronucleus and bone marrow chromosomal aberration assays in Swiss CD-1 mice administered 0.1–0.4 mg chlorine dioxide via gavage for 5 consecutive days were negative, as was a sperm-head abnormality assay in B6C3F1 mice administered 0.1–0.4 mg via gavage for 5 consecutive days (0, 3.2, 8, and 16 mg/kg-day) (Meier et al., 1985). Hayashi et al. (1988) reported positive results in the micronucleus assay in ddY mice following a single intraperitoneal injection of 3.2–25 mg/kg chlorine dioxide.

#### 4.4.2.2. *Chlorite*

Genotoxicity of chlorite was assessed in several in vitro and in vivo assays. In in vitro assays, chlorite induced reverse mutations in *S. typhimurium* (with activation) and chromosome aberrations in Chinese hamster fibroblast cells (Ishidate et al., 1984). In general, the results of the in vivo assays were negative. In the micronucleus assays, negative results were found in ddY mice following an oral gavage dose of 37.5–300 mg/kg chlorite single injection (Hayashi et al., 1988) and in Swiss CD-1 mice administered 0.25–1 mg chlorite via gavage for 5 consecutive days (0, 8, 20, and 40 mg/kg-day) (Meier et al., 1985). Using the same dosages, Meier et al. also reported negative results in the bone marrow chromosomal aberration assay in Swiss CD-1 mice and in the sperm-head abnormality assay in B6C3F1 mice. Positive results were found in the

828

micronucleus assay in ddY mice when the chlorite was administered via intraperitoneal injection (7.5–60 mg/kg) (Hayashi et al., 1988).

### 4.4.3. Mechanistic Studies

EPA (1994d) has extensively discussed the mechanism of action whereby chlorine dioxide and chlorite produce hematologic and systemic effects. The mechanisms are still incompletely understood. Oxidative damage to the erythrocyte and production of methemoglobin are most likely related to their properties as oxidants (U.S. EPA, 1994d). Chlorite is thought to be the intermediate species responsible in many of the hematologic effects of chlorine dioxide because of its more efficient production of methemoglobin, depletion of red blood cell (RBC) glutathione, and alteration of erythrocyte fragility.

In a series of experiments, Bercz and co-workers (1982, 1986); and Harrington et al. (1986) suggested that chlorine dioxide increases binding of dietary iodide to gastrointestinal tissue and contents, producing a functional iodide deficiency. Bercz et al. (1982) found decreased levels of circulating thyroxine in monkeys drinking water containing > 9.5 mg/kg-day chlorine dioxide, but not 44 mg/kg-day chlorite, for 4–6 weeks. In a follow-up study, Harrington et al. (1986) demonstrated increases in thyroid iodide uptake and a rebound in thyroxine levels in monkeys 1 year after an 8-week exposure to approximately 5 mg/kg-day chlorine dioxide in drinking water. Unlike monkeys, rats showed dose-related declines in thyroxine levels and no alteration in thyroid iodide uptake following an 8-week exposure to 10 mg/kg-day chlorine dioxide in drinking water.

Whether either or both of these mechanisms are operable in inducing reproductive, developmental, and neurodevelopmental effects is not known. One could also speculate that hypothyroidism, induced by chlorine dioxide alteration of iodide uptake in the gastrointestinal tract, might contribute to alterations in maternal or neonatal behavior. Alternative, as yet unknown mechanisms are also plausible because few definitive mechanistic data are available. Additional research is needed to understand whether the parent chlorine dioxide and/or its oxychlorine degradation products induce delays and alterations in fetal/neonatal neurodevelopment and behavior through disturbance in maternal thyroid function or directly within the embryo itself.

## 4.5. SYNTHESIS AND EVALUATION OF MAJOR NONCANCER EFFECTS AND MODE OF ACTION (IF KNOWN)—ORAL AND INHALATION

### 4.5.1. Oral Exposure

#### 4.5.1.1. *Chlorine Dioxide*

The subchronic/chronic toxicity of chlorine dioxide has not been adequately assessed. The Haag (1949) chronic drinking water study reported decreases in survival in rats exposed to 13 mg/kg-day chlorine dioxide for 2 years, but the cause of death was not reported and no effects were observed at lower concentrations. The small number of animals tested and the limited

829

number and lack of sensitive endpoints examined make interpretation of this study difficult. Daniel et al. (1990) found increases in incidence of nasal lesions in rats exposed to $ 25 mg/L chlorine dioxide (2 mg/kg-day) in drinking water for 90 days; no other adverse effects were observed. However, it is not known if the nasal lesions resulted from inhaling chlorine dioxide vapors at the drinking water sipper tube or from off-gassing of the vapors after drinking. No other studies have reported similar effects. Other subchronic/chronic studies primarily examined hematologic parameters. Bercz et al. (1982) found significant decreases in serum T4 levels in monkeys exposed to 9.5 mg/kg-day chlorine dioxide in the drinking water for 4–6 weeks. Adverse hematologic effects could not be discerned in Abdel-Rahman et al. (1984b) because there was no consistent dose-effect relationship. Additionally, Daniel et al. (1990), Bercz et al. (1982), and Moore and Calabrese (1982) did not find hematologic alterations in rats, monkeys, or mice, respectively. Abdel-Rahman et al. (1984b) and Couri and Abdel-Rahman (1980) reported alterations in the glutathione-dependent system, in particular, decreases in erythrocyte glutathione levels, increases in glutathione peroxidase activity, and increases in erythrocyte catalase levels. However, as with the hematologic effects this group found, consistent relationships between dose and magnitude of the alterations were lacking.

A number of studies have consistently found developmental effects following in utero exposure or postnatal gavage administration of 14 mg/kg-day chlorine dioxide. The effects include altered brain development (decreases in forebrain and/or cerebellum DNA content, ratio of protein content to forebrain weight, and dendritic spine counts in a visual association area of the cerebral cortex) (Toth et al., 1990; Taylor and Pfohl, 1985), decreased locomotor or exploratory activity (Orme et al., 1985; Taylor and Pfohl, 1985), and increased T3 uptake (Mobley et al., 1990). Orme et al. (1985) found decreases in T3 and T4 levels in in utero and postnatally exposed pups; however, other studies did not find alterations in T3 and T4 levels in similarly exposed animals (Toth et al., 1990; Carlton et al., 1991).

The available data indicate that the critical effect of chlorine dioxide is neurodevelopmental toxicity.

### 4.5.1.2. *Chlorite*

A number of studies have examined the subchronic/chronic toxicity of chlorite; however, only the Harrington et al. (1995a) study examined a wide range of endpoints. This study identified a NOAEL and LOAEL of 7.4 and 19 mg/kg-day, respectively, for stomach lesions and alterations in spleen and adrenal weights in rats receiving gavage doses of sodium chlorite. The bolus administration of sodium chlorite might have contributed to the stomach lesions; these effects might not have been observed if the sodium chlorite had been administered in the drinking water. Haag (1949) found renal effects in rats drinking 9.3 mg/kg-day chlorite (NOAEL of 0.7 mg/kg-day); interpretation of the results of this study is limited by the small numbers of animals that underwent pathological examination and the limited number of endpoints examined. Abdel-Rahman et al. (1984b) and Couri and Abdel-Rahman (1980) found decreases in osmotic fragility, blood glutathione levels, and blood catalase activity in rats exposed to 1 and 10 mg/kg-day chlorite in drinking water. It is unclear, however, if these effects are statistically or biologically significant. In contrast, Moore et al. (1980) and Moore and Calabrese (1982) found

830

increases in osmotic fragility in mice exposed to 22 mg/kg-day chlorite in drinking water. Bercz et al. (1982) found decreases in erythrocyte and hemoglobin levels and decreases in T4 levels in monkeys exposed to 58.4 mg/kg-day chlorite.

As with chlorine dioxide, developmental toxicity appears to be the most sensitive effect of oral chlorite exposure. At exposure levels of 3 mg/kg-day and 6 mg/kg-day, Mobley et al. (1990) found significant decreases in exploratory activity in rat pups exposed to chlorite in utero. The changes at 3 mg/kg-day were small, whereas changes observed at 6 mg/kg-day were more consistent with findings from several other studies. Similarly, lowered auditory startle response and reduced liver weight were observed at 6 mg/kg-day, but not at 3 mg/kg-day, in rats in a two-generation study (CMA, 1996). At higher concentrations (19–28 mg/kg-day), decreases in fetal/pup body weight have been observed in mice and rabbits (Moore et al., 1980; Moore and Calabrese, 1982; Harrington et al., 1995b). Data from Carlton and Smith (1985) and Carlton et al. (1987) suggest that sperm may be a sensitive target of toxicity. Reductions in sperm progressive movement and increases in abnormal sperm have been observed in rats exposed to 7.5 mg/kg-day chlorite in drinking water for 72–76 days. However, the CMA (1996) two-generation study did not find any alterations in reproductive performance in rats exposed to 22.7 mg/kg-day chlorite in drinking water.

### 4.5.2. Inhalation Exposure

#### 4.5.2.1. *Chlorine Dioxide*

Several human studies have examined the toxicity of inhaled chlorine dioxide (Gloemme and Lundgren, 1957; Elkins, 1959; Ferris et al., 1967; Exner-Freisfeld et al., 1986; Kennedy et al., 1991; Meggs et al., 1996). Despite the limitations of these studies (including poor exposure assessment, small number of subjects, and concomitant exposure to chlorine and/or sulfur dioxide), they consistently demonstrate that the respiratory tract is a very sensitive target of toxicity.

A series of studies by Paulet and Desbrousses (1970, 1972, 1974) and Dalhamn (1957) examined the acute and subchronic toxicity of chlorine dioxide in rats and rabbits. As with the human studies, the respiratory tract is the most sensitive target of toxicity. The effects include alveolar congestion and hemorrhage, bronchial inflammation, and peribronchiolar edema. A NOAEL for these effects has not been identified; the lowest LOAEL is 1 ppm (2.8 mg/m$^3$) in rats exposed to chlorine dioxide 5 hours/day, 5 days/week for 2 months (Paulet and Desbrousses, 1972).

#### 4.5.2.2. *Chlorite*

No data are available on the toxicity of inhaled chlorite.

## 4.6. WEIGHT-OF-EVIDENCE EVALUATION AND CANCER CHARACTERIZATION—SYNTHESIS OF HUMAN, ANIMAL, AND OTHER SUPPORTING EVIDENCE, CONCLUSIONS ABOUT HUMAN CARCINOGENICITY, AND LIKELY MODE OF ACTION

### 4.6.1. Chlorine Dioxide

Under the current guidelines (U.S. EPA, 1986a), chlorine dioxide is classified as Group D, not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996a), the human carcinogenicity of chlorine dioxide cannot be determined because no satisfactory human or animal studies assessing the chronic carcinogenic potential of chlorine dioxide were located.

No human or animal studies assessing the carcinogenic potential of chlorine dioxide were located. The carcinogenic potential of concentrates prepared from drinking water treated with chlorine dioxide was tested by Miller et al. (1986). The concentrates did not increase incidence of lung adenomas in Strain A mice, skin tumor frequency in mice, or incidence of gamma-glutamyl transpeptidase positive foci (a measure of preneoplastic changes) in rat livers. Robinson et al. (1986) found significant increases in skin thickness in SENCAR mice immersed in chlorine dioxide, suggesting that high concentrations of chlorine dioxide are capable of inducing hyperplastic responses in the mouse skin.

Both positive and negative results have been found in genotoxicity studies of chlorine dioxide. Exposure to chlorine dioxide did not induce chromosomal aberrations in vitro, but it did increase occurrence of reverse mutations (Ishidate et al., 1984). In vivo assays did not find increases in micronucleus induction, chromosomal aberrations, or sperm-head abnormalities following oral exposure (Meier et al., 1985), but they did find increases in micronuclei induction after intraperitoneal injection (Hayashi et al., 1988).

### 4.6.2. Chlorite

Under the current guidelines (U.S. EPA, 1986a), chlorite is classified as Group D, not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996a), the human carcinogenicity of chlorite cannot be determined because of a lack of human data and limitations in animal studies.

No human studies assessing the carcinogenic potential of chlorite were located. Chlorite was tested for potential carcinogenicity in rat and mouse drinking water studies (Kurokawa et al., 1986; Yokose et al., 1987). These studies do not provide sufficient evidence to draw conclusions as to the carcinogenic potential of chlorite in humans. In the rat study (Kurokawa et al., 1986), exposure to sodium chlorite did not significantly increase the incidence of tumors. The short exposure duration (85 weeks) and high incidence of Sendai viral infection in control and exposed rats limit the use of this study to assess carcinogenicity.

832

In the mouse drinking water study (Kurokawa et al., 1986; Yokose et al., 1987), significant increases in liver and lung tumors were observed in male mice. Combined incidence of hepatocellular nodules and hepatocellular carcinomas was increased in the low-dose group, and combined incidence of lung adenomas and adenocarcinomas was elevated in the high-dose group relative to concurrent controls. However, these tumor incidences were within the range of values of historical controls in the study laboratory and in the National Toxicology Program laboratories (Kurokawa et al., 1986). This study is considered inadequate for assessing carcinogenicity because of the relatively short exposure duration (80 weeks) and the high incidence of early mortality in the concurrent control males from excessive fighting, making statistical comparisons between concurrent controls and treated animals difficult to interpret. No increases in tumor incidence were seen in female mice in this study.

Chlorite has been shown to be mutagenic in in vitro assays for reverse mutations and chromosome aberrations (Ishidate et al., 1984) and in an in vivo assay of micronucleus induction in which mice received an intraperitoneal injection of sodium chlorite (Hayashi et al., 1988). In vivo assays for micronucleus induction, chromosome aberrations, and sperm-head abnormalities were negative in mice receiving gavage doses of chlorite for 5 days (Meier et al., 1985; Hayashi et al., 1988).

## 4.7. SUSCEPTIBLE POPULATIONS

### 4.7.1. Possible Childhood Susceptibility

### 4.7.1.1. *Chlorine Dioxide and Chlorite*

Developmental delays have been observed in animal studies following in utero and postnatal exposure to ingested chlorine dioxide or chlorite, suggesting that infants and children may be more likely than adults to experience adverse effects following exposure to these chemicals, although the reasons for this increased sensitivity are not fully understood. It is well recognized that neurological development continues after birth and that gastrointestinal uptake of many nutrients and chemicals is greater in the neonate than the adult.

### 4.7.2. Possible Gender Differences

### 4.7.1.2. *Chlorine Dioxide and Chlorite*

No data are available to suggest there are gender differences in the toxicity of chlorine dioxide or chlorite.

833

# 5. DOSE-RESPONSE ASSESSMENTS

## 5.1. ORAL REFERENCE DOSE (RfD)

### 5.1.1. Choice of Principal Study and Critical Effect—With Rationale and Justification

In general, human studies have not found adverse effects in individuals consuming low concentrations (0.04–0.15 mg/kg-day) of chlorine dioxide or chlorite in experimental studies (Lubbers et al., 1981, 1982, 1984a) or consuming drinking water disinfected with chlorine dioxide (Michael et al., 1981; Tuthill et al., 1982). An epidemiology study by Kanitz et al. (1996) found increases in the risk of several developmental effects (neonatal jaundice, small cranial circumference, and shorter body length) in a community with chlorine dioxide-disinfected drinking water. However, the Kanitz et al. (1996) study has numerous limitations (including multiple chemical exposures; lack of exposure data; lack of control for smoking, age, and nutritional habits; and atypical control data), making it difficult to interpret the study findings.

In animals, the most sensitive effect following oral exposure to chlorine dioxide or chlorite is neurodevelopmental delay. In utero exposure to chlorine dioxide or postnatal gavage administration of chlorine dioxide has resulted in altered brain development (decreases in brain weight, protein content, and cell number) (Taylor and Pfohl, 1985; Toth et al., 1990) and decreased locomotor or exploratory activity (Orme et al., 1985; Taylor and Pfohl, 1985; Mobley et al., 1990). The LOAEL for these effects is 14 mg/kg-day chlorine dioxide (Orme et al., 1985; Taylor and Pfohl, 1985; Mobley et al., 1990; Toth et al., 1980); Orme et al. (1985) identified a NOAEL of 3 mg/kg-day.

Neurobehavioral effects (lowered auditory startle amplitude, decreased brain weight, and decreased exploratory activity) are also the most sensitive endpoints following oral exposure to chlorite (Mobley et al., 1990; CMA, 1996). The LOAEL identified in the Mobley et al. (1990) developmental toxicity study and the CMA (1996) two-generation developmental toxicity study is 6 mg/kg-day chlorite; Mobley et al. (1990) also found significant decreases in exploratory activity at 3 mg/kg-day, but the difference between activity in this group and the controls was small. Thus, the NOAEL for neurobehavioral effects is 3 mg/kg-day chlorite. At higher concentrations (22–28 mg/kg-day chlorite), decreases in fetal/pup body weight have also been observed in mice and rabbits (Moore and Calabrese, 1982; Moore et al., 1980; Harrington et al., 1995b).

Chlorine dioxide in drinking water rapidly degrades to chlorite; in the Michael et al. (1981) study, chlorine dioxide rapidly disappeared from the stored water (within 2–4 hours) and chlorite levels concomitantly increased. Once absorbed, chlorine dioxide and chlorite are cleared from the blood at similar rates and are similarly distributed throughout the body (Abdel-Rahman et al., 1979b, 1982). Additionally, chloride is the major in vivo degradation product of both chlorine dioxide and chlorite. Available data suggest that chlorine dioxide and chlorite have similar targets of toxicity and potencies. Therefore, the toxicity information for chlorite is relevant to deriving an RfD for chlorine dioxide.

The CMA (1996) two-generation study was selected as the critical study for the development of an RfD for both chlorine dioxide and chlorite. Both in its study report (CMA 1996) and in a later journal article (Gill et al., 2000), CMA reported that the study defined a NOAEL of 70 ppm (6 mg/kg-day chlorite) and a LOAEL of 300 ppm (28.6 mg/kg-day chlorite) based on hematologic toxicity. For the reasons outlined below, EPA disagrees with CMA's choice of NOAEL and LOAEL values. Alterations in multiple endpoints define the LOAEL-NOAEL boundary in the CMA study. Effects observed included statistically significant decreases in pup body weight, absolute brain weight, liver weight, and lowered startle amplitude at the 28.6 mg/kg-day dose. Statistically significant decreases in auditory startle amplitude (F1 and F2 generations) and absolute and relative liver weights (F0 and F1) occurred at 6 mg/kg-day. Although different responses were found for auditory startle (as indicated by measures of amplitude, latency, and habituation), this is not unexpected given that these measures examine different aspects of nervous system function and thus can be differently affected. Transient alterations in neurofunctional (or neurochemical) measures, such as in the auditory startle response, can occur without neuropathological changes and are considered of neurotoxic concern (U.S. EPA, 1998a). Some of effects observed at 6 mg/kg-day and 28.6 mg/kg-day occurred in both sexes and in more than one generation. These effects are considered toxicologically significant, which is consistent with EPA guidelines for reproductive, developmental, and neurotoxicity risk assessment (U.S. EPA, 1991, 1996b, 1998a). The NOAEL for this study is 3 mg/kg-day chlorite and the LOAEL is 6 mg/kg-day chlorite based on lowered auditory startle amplitude and decreased liver weight.

Although the CMA (1996) study is adequate, having been conducted with sufficient numbers of animals of both sexes at multiple dose levels showing a range of effects, and having examined numerous endpoints, there are several limitations. Lack of pair-watered and pair-fed control animals confounds the results and precludes making definitive conclusions as to whether the alterations in food and water consumption and body weight are related to water palatability or a direct toxic effect of the agent. Discontinuation of exposure for the animals undergoing neurotoxicity testing limits the likelihood of finding a positive effect, precludes comparison of the data with those of other rats with continued exposure, and does not reflect the expected lifetime exposure by humans to these chemicals in drinking water. In addition, a lack of detailed description of experimental methods and positive control data (including estimates of variability), and in some cases inappropriate statistical analysis, limits interpretation of the neurobehavioral tests.

The principal study is supported by the developmental studies by Orme et al. (1985), Taylor and Pfohl (1985), Mobley et al. (1990), and Toth et al. (1990), wherein rats administered chlorite or chlorine dioxide at similar dosages in drinking water also showed alterations in exploratory and locomotor behavior and reduced brain weights (NOAELs of 3 mg/kg-day; LOAELs of 14 mg/kg-day).

### 5.1.2. Methods of Analysis—Including Models (PBPK, BMD, etc.)

The NOAEL/LOAEL approach was used to derive RfDs for chlorine dioxide and chlorite. The RfD was derived using the NOAEL of 3 mg/kg-day identified in the CMA (1996)

835

study. This dose was determined from the nominal water concentration based on measured water consumption and adjusted for the molecular weight of the salt, so that doses are expressed as the chlorite ion. (For example, males administered 35 ppm had intakes of sodium chlorite equivalent to 3.9 mg/kg-day. Adjusting for the molecular weight of sodium chlorite [MW = 90.5] relative to the chlorite ion [MW = 67.5] gives the NOAEL dose of 3 mg/kg-day chlorite.)

### 5.1.3. RfD Derivation—Including Application of Uncertainty Factors and Modifying Factors

The RfDs for chlorine dioxide and chlorite were derived by dividing the NOAEL of 3 mg/kg-day by an uncertainty factor of 100. This composite factor includes a factor of 10 to account for uncertainties associated with interspecies extrapolation and a factor of 10 for intrahuman variability. Because the critical effect is a developmental effect in a database that includes chronic studies, it is not necessary to use an uncertainty factor to account for use of a less-than-lifetime study. A default modifying factor of 1 is applied. The resultant RfD is $3 \times 10^{-2}$ mg/kg-day:

$$\text{RfD} = 3 \text{ mg/kg-day} \div 100 = 3 \times 10^{-2} \text{ mg/kg-day.}$$

## 5.2. INHALATION REFERENCE CONCENTRATION (RfC)

### 5.2.1. Choice of Principal Study and Critical Effect—With Rationale and Justification

#### 5.2.1.1. *Chlorine Dioxide*

Human studies examining toxicity of inhaled chlorine dioxide are limited to several case reports (Elkins, 1959; Exner-Freisfeld et al., 1986; Meggs et al., 1996) and occupational exposure studies (Gloemme and Lundgren, 1957; Ferris et al., 1967; Kennedy et al., 1991) that involved concurrent exposure to chlorine and possibly sulfur dioxide. Although these studies cannot be used to establish risk assessment values, the results of these studies consistently demonstrate that the respiratory tract is a very sensitive target of chlorine dioxide toxicity.

A series of studies by Paulet and Desbrousses (1970, 1972, 1974) and Dalhamn (1957) examined the acute and subchronic toxicity of chlorine dioxide in rats and rabbits. The earliest Paulet and Desbrousses (1970) study identified a LOAEL of 2.5 ppm chlorine dioxide (6.9 mg/m$^3$) for thoracic effects (alveolar congestion and hemorrhage; bronchial inflammation) in rats exposed 7 hours/day (presumably 5 days/week) for 30 days and pulmonary effects (alveolar hemorrhage and capillary congestion) in rabbits exposed 4 hours/day (presumably 5 days/week) for 45 days; a NOAEL was not identified. A follow-up study by this group attempted to identify a threshold for respiratory effects (Paulet and Desbrousses, 1972). This study identified a LOAEL of 1 ppm (2.8 mg/m$^3$) for pulmonary effects (vascular congestion and peribronchiolar edema) in rats exposed 5 hours/day, 5 days/week for 2 months; a NOAEL was not identified. The Dalhamn (1957) study identified a NOAEL of 0.1 ppm chlorine dioxide (0.28 mg/m$^3$) for lung damage in rats exposed 5 hours/day (frequency of weekly exposure not reported) for 10

836

weeks; a LOAEL of 10 ppm (28 mg/m$^3$) for respiratory tract irritation was identified in rats exposed 4 hours/day for 9 days in a 13-day period.

Collectively, the results of the human and animal studies suggest that the respiratory tract is the critical target. The Paulet and Desbrousses (1970, 1972) studies were selected as cocritical studies. The 1972 study identified the lowest LOAEL for a sensitive endpoint (respiratory tract effects); however, the study duration (2 months) is shorter than the typical subchronic study (approximately 90 days) and only one exposure concentration was tested. The 1970 study is used to support the identification of the critical effect and critical concentrations; this study tested several concentrations in two species for durations of 30 or 45 days.

#### 5.2.1.2. *Chlorite*

An RfC for chlorite is not recommended at this time. No human or animal studies examining the toxicity of inhaled chlorite were located. Although the available human and animal data on inhaled chlorine dioxide support the derivation of an RfC for this chemical, these data cannot be used to derive an RfC for chlorite. Under ambient conditions, airborne chlorite is likely to exist as a particulate, whereas inhalation exposure to chlorine dioxide is as a gas. Based on their physical and chemical properties, it is anticipated that inhaled chlorine dioxide and chlorite would have very different modes of exposure. Therefore, the potential hazards associated with exposure to these two chemicals are also very different. In the absence of data demonstrating parallels in pharmacokinetic behavior following inhalation exposure—as are available following oral exposure—derivation of an RfC for chlorite from the available data for chlorine dioxide is not recommended.

### 5.2.2. Methods of Analysis—NOAEL/LOAEL

#### 5.2.2.1. *Chlorine Dioxide*

The NOAEL/LOAEL approach was used to calculate the RfC for chlorine dioxide. A benchmark concentration (BMC) analysis could not be conducted because the report of the Paulet and Desbrousses (1970, 1972) studies did not include incidence data.

The RfC was derived using the Paulet and Desbrousses (1970, 1972) studies as co-critical studies. From the LOAEL of 1 ppm for pulmonary effects in rats identified in the Paulet and Desbrousses (1972) study, concentration in mg/m$^3$ was calculated using a molecular weight of 67.46 and the assumption of 25°C and 760 mmHg:

$$\text{LOAEL} = 1 \text{ ppm} \times 67.46/24.45 = 2.8 \text{ mg/m}^3 \text{ (Paulet and Desbrousses, 1972 - rats).}$$

The duration-adjusted LOAEL (LOAEL$_{\text{ADJ}}$) was calculated by multiplying the LOAEL by the daily exposure duration (5 hours/day) and the weekly exposure frequency (5 days/week):

$$\text{LOAEL}_{\text{ADJ}} = 2.8 \text{ mg/m}^3 \times 5 \text{ hours/24 hours} \times 5 \text{ days/7 days} = 0.41 \text{ mg/m}^3 \text{ (rat).}$$

837

The human equivalent concentration (HEC) for the LOAEL ($LOAEL_{HEC}$) was calculated by multiplying the $LOAEL_{ADJ}$ by the regional gas dose ratio for the thoracic region of the respiratory tract ($RGDR_{TH}$). The $RGDR_{TH}$ was calculated using the following equation:

$$RGDR_{TH} = \frac{\left[\frac{MV}{SA}\right]_A}{\left[\frac{MV}{SA}\right]_H}$$

where MV is the minute volume in rats (0.118 $m^3$/min; 0.17 $m^3$/day) and humans (13.8 $m^3$/min; 20 $m^3$/day) and SA is the surface area of the thoracic region in rats (3461.6 $cm^2$) and humans (640,581 $cm^2$).

$LOAEL_{HEC}$ = 0.41 mg/$m^3$ × [(0.118 $m^3$/min / 3461.6 $cm^2$) / (13.8 $m^3$/min / 640,581 $cm^2$);

$LOAEL_{HEC}$ = 0.41 mg/$m^3$ × 1.57 = 0.64 mg/$m^3$.

Similarly, for the Paulet and Desbrousses (1970) study, using values of 1.10 $m^3$/min for the minute volume and 59,100 $cm^2$ for the surface area of the thoracic region of rabbits, the calculation of the $LOAEL_{HEC}$ is as follows:

LOAEL = 2.5 ppm × 67.46/24.45 = 6.9 mg/$m^3$.

$LOAEL_{ADJ}$ = 6.9 mg/$m^3$ × 4 hours/24 hours × 5 days/7 days = 0.82 mg/$m^3$.

$LOAEL_{HEC}$ = 0.82 mg/$m^3$ × [(1.10 $m^3$/min / 59,100 $cm^2$) / (13.8 $m^3$/min / 640,581 $cm^2$);

$LOAEL_{HEC}$ = 0.82 mg/$m^3$ × 0.596 = 0.49 mg/$m^3$.

### 5.2.3. RfC Derivation—Including Application of Uncertainty Factors and Modifying Factors

#### 5.2.3.1. *Chlorine Dioxide*

The RfC for chlorine dioxide is derived by dividing the $LOAEL_{HEC}$ thoracic effects by an uncertainty factor of 3,000. This uncertainty factor comprises a factor of 10 to account for extrapolation of a chronic RfC from a subchronic study, 3 for interspecies extrapolation using dosimetric adjustments, 10 for intrahuman variability, and 10 to account for extrapolation from a LOAEL for mild effects and for the lack of inhalation developmental and reproductive toxicity studies. EPA's policy is to limit the size of the composite uncertainty factor to 3,000 in recognition of the lack of independence of these factors (U.S. EPA, 1994b). The LOAEL to NOAEL and database uncertainties are therefore coalesced into one uncertainty factor of 10. The composite uncertainty factor for this RfC is therefore 3,000. No modifying factor is used for this assessment.

$$RfC = 0.64\ mg/m^3 \div 3{,}000 = 2 \times 10^{-4}\ mg/m^3.$$

or

$$RfC = 0.49\ mg/m^3 \div 3{,}000 = 2 \times 10^{-4}\ mg/m^3.$$

As can be seen, the same value for the RfC can be calculated using the LOAEL from either of the key studies. Note that this is the same value as was verified by the RfC workgroup in 1990, as no new data were available.

## 5.3. CANCER ASSESSMENT

### 5.3.1. Chlorine Dioxide

The oral and inhalation databases are inadequate to assess the carcinogenicity of chlorine dioxide in humans or animals; thus, derivation of an oral slope factor and inhalation unit risk level is precluded.

### 5.3.2. Chlorite

The oral and inhalation databases are inadequate to assess the carcinogenicity of chlorite in humans or animals; thus, derivation of an oral slope factor and inhalation unit risk level is precluded.

# 6. MAJOR CONCLUSIONS IN THE CHARACTERIZATION OF HAZARD AND DOSE RESPONSE

## 6.1. HUMAN HAZARD POTENTIAL

Chlorine dioxide and chlorite are strong oxidizing agents used as drinking water disinfectants and to bleach textile and wood pulp for paper manufacturing. Chlorine dioxide and chlorite are rapidly absorbed from the gastrointestinal tract and slowly cleared from the blood. Chlorine dioxide and chlorite, primarily in the form of chloride, are widely distributed throughout the body and predominantly excreted in the urine. Chloride is the major urinary "metabolite" for both chlorine dioxide and chlorite. No data are available on the pharmacokinetics of inhaled or dermally applied chlorine dioxide or chlorite.

In general, human ingestion studies have found no adverse effects in adults and neonates living in areas with chlorine dioxide-disinfected water. However, these studies are fraught with methodological problems, such as lack of characterization of exposure to other agents in the drinking water and control of potential confounding factors. These studies do little to confirm a possible association between exposure to chlorine dioxide and chlorite and adverse reproductive or developmental outcome in humans. Inhalation exposure to chlorine dioxide results in respiratory irritation in humans. However, these studies also poorly characterize exposure, and the occupational exposure studies involve concomitant exposure to chlorine and/or sulfur dioxide.

Animal toxicity databases for chlorine dioxide and chlorite is fairly comprehensive, composed of subchronic and chronic studies, reproductive and developmental studies, and toxicokinetic and mechanistic information. Multiple animal studies have shown similar alterations in neurodevelopmental endpoints, such as brain weight and behavioral measures. The majority of these studies have used sufficient numbers of animals and employed routes of exposure (gavage and drinking water) relevant to human exposure. The majority of the developmental studies have utilized rats and have shown a fairly consistent definition of the NOAEL/LOAEL.

Reproductive studies in male animals are not consistent in demonstrating alterations in spermatogenic indices, that is, abnormal morphology or motility; however, reported effects seem to appear at doses higher than the adverse developmental effects. Similarly, clinically or toxicologically significant alterations in hematologic parameters occur at higher doses.

The mode of action for induction of adverse neurodevelopmental effects is not known. It is also not known whether the rat is an adequate model for toxicity of chlorine dioxide and chlorite in humans. However, this species is widely used to characterize reproductive and developmental effects in humans.

Animal studies have demonstrated that the respiratory tract is the most sensitive target of toxicity following inhalation exposure to chlorine dioxide. No animal inhalation studies are available for chlorite.

No human studies assessing the carcinogenic potential of chlorine dioxide or chlorite were located. Chlorine dioxide carcinogenicity has not been tested in animal bioassays. Chlorite was not shown to increase tumor incidences in rats and mice; these studies are considered inadequate for assessing human carcinogenicity because the exposure was for less than a lifetime, a high incidence of Sendai virus was found in the rats, and mortality was high in the mouse control group because of excessive fighting.

Areas of scientific uncertainty in this assessment include the mode of action of chlorine dioxide and chlorite in producing adverse effects on multiple organ systems, including reproductive, developmental, and hematologic effects. Inherent in the uncertainty over the mode of action is identification of the susceptible populations or subgroups, and additional research in this area would help to better quantify the additional risk to these groups. Well-designed and conducted epidemiologic studies in communities with drinking water disinfected with these chemicals would decrease uncertainty in the utilization of animal models for determination of human health effects.

## 6.2. DOSE RESPONSE

Quantitative estimates of human risk as a result of low-level chronic chlorine dioxide or chlorite oral exposure are based on animal experiments, because no adequate human exposure data are available. Neurodevelopmental toxicity is the primary effect in offspring of rats exposed to chlorine dioxide or chlorite in drinking water. Quantitative estimates of human risk as a result of low-level chronic chlorine dioxide inhalation exposure are based on animal experiments, because no adequate human inhalation data are available. The respiratory tract appears to be the primary target of toxicity in human and animal studies.

The oral RfD for chlorine dioxide or chlorite is $3 \times 10^{-2}$ mg/kg-day. This is 1/100 of the NOAEL, using neurodevelopmental toxicity in a two-generation rat study as the indicator of adverse effects. Overall confidence in this RfD assessment is medium to high. Confidence in the CMA (1996) principal study is medium. Although the study design and analytical approaches are consistent with EPA testing guidelines, some limitations in the design and conduct of the study exist. Confidence in the database is high because there are studies in multiple species, chronic duration studies in males and females, reproductive/developmental toxicity studies, and a multigenerational study. The threshold for adverse effects is consistently defined among the animal studies.

The inhalation RfC for chlorine dioxide is $2 \times 10^{-4}$ mg/m$^3$. This concentration is 1/3,000 of the HEC for thoracic effects in rats (Paulet and Desbrousses, 1970, 1972). No human or animal data were located for chlorite that could be used to derive an RfC. Overall confidence in the RfC for chlorine dioxide is low. The studies by Paulet and Desbrousses (1970, 1972) identify only a LOAEL in rats and rabbits for adverse lung effects in 60- and 45-day studies and lack experimental detail. There were no adequate subchronic or chronic inhalation studies that examined extrarespiratory effects, and no acceptable developmental or reproductive studies on inhaled chlorine dioxide.

## 7. REFERENCES

Abdel-Rahman, MS; Couri, D; Bull, RJ. (1979a) Kinetics of $ClO_2$ and effects of $ClO_2$, $ClO_2^-$, and $ClO_3$ in drinking water on blood glutathione and hemolysis in rat and chicken. J Environ Pathol Toxicol 3:431-449.

Abdel-Rahman, MS; Couri, D; Jones, JD. (1979b) Chlorine dioxide metabolism in rat. J Environ Pathol Toxicol 3:421-430.

Abdel-Rahman, MS; Couri, D; Bull, RJ. (1982) Metabolism and pharmacokinetics of alternate drinking water disinfectants. Environ Health Perspect 46:19-23.

841

Abdel-Rahman, MS; Couri, D; Bull, RJ. (1984a) The kinetics of chlorite and chlorate in the rat. J Am Coll Toxicol 3:261-267.

Abdel-Rahman, MS; Couri, D; Bull, RJ. (1984b) Toxicity of chlorine dioxide in drinking water. J Am Coll Toxicol 3:277-284.

Bercz, JP; Jones, LL; Garner, L; et al. (1982) Subchronic toxicity of chlorine dioxide and related compounds in drinking water in the nonhuman primate. Environ Health Perspect 46:47-55.

Bercz, JP; Jones, LL; Harrington, RM; et al. (1986) Mechanistic aspects of ingested chlorine dioxide on thyroid function: impact of oxidants on iodide metabolism. Environ Health Perspect 69:249-255.

Bianchine, JR; Lubbers, JR; Chauhan, S; et al. (1981) Study of chlorine dioxide and its metabolites in man. Final report on EPA Grant No. 805643. EPA-600/1-82-068. Available from: National Technical Information Service, Springfield, Virginia; PB82-109356.

Budavari, S; O'Neil, MJ; Smith, A; et al. (eds). (1989) The Merck index: an encyclopedia of chemicals, drugs, and biologicals, 11th ed. Whitehouse Station, NJ: Merck and Co, Inc.

Carlton, BD; Smith, MK. (1985) Reproductive effects of alternate disinfectants and their by-products. In: Jolley, RL, et al., eds. Water chlorination: environmental impact and health effects, vol. 5. Chelsea, MI: Lewis Publications, pp. 295-305.

Carlton, BD; Habash, DL; Barsaran, AH; et al. (1987) Sodium chlorite administration in Long-Evans rats: reproductive and endocrine effects. Environ Res 42:238-245.

Carlton, BD; Basaran, AH; Mezza, LE; et al. (1991) Reproductive effects in Long-Evans rats exposed to chlorine dioxide. Environ Res 56:170-177.

Chemical Manufacturers Association. (CMA) (1996) Sodium chlorite: drinking water rat two-generation reproductive toxicity study. Quintiles Report Ref. CMA/17/96.

Couri, D; Abdel-Rahman, MS. (1980) Effect of chlorine dioxide and metabolites on glutathione dependent system in rat, mouse and chicken blood. J Environ Pathol Toxicol 3:451-460.

Couri, D; Miller, CH; Bull, RJ; et al. (1982) Assessment of maternal toxicity, embryotoxicity and teratogenic potential of sodium chlorite in Sprague-Dawley rats. Environ Health Perspect 46:25-29.

Dalhamn, T. (1957) Chlorine dioxide: toxicity in animal experiments and industrial risks. Arch Ind Health 15:101-107.

Daniel, FB; Condie, LW; Robinson, M; et al. (1990) Comparative subchronic toxicity studies of three disinfectants. J Am Water Works Assoc 82:61-69.

842

Elkins, HB. (1959) The chemistry of industrial toxicology, 2nd ed. New York: Wiley and Sons, pp. 89-90.

Exner-Freisfeld, H; Kronenberger, H; Meier-Sydow, J; et al. (1986) Intoxication from bleaching with sodium chlorite. The toxicology and clinical course [German with English abstract]. Dtsch Med Wochenschr 111(50):1927-1930.

Ferris, BG, Jr; Burgess, WA; Worcester, J. (1967) Prevalence of chronic respiratory disease in a pulp mill and a paper mill in the United States. Br J Ind Med 24(1):26-37.

Gill, MW, Swanson, MS; Murphy, SR, et al. (2000) Two-generation reproduction and developmental neurotoxicity study with sodium chlorite in the rat. J Appl Toxicol 20:291-303.

Gloemme, J; Lundgren, KD. (1957) Health hazards from chlorine dioxide. Arch Ind Health 16:169-176.

Haag, HB. (1949) The effect on rats of chronic administration of sodium chlorite and chlorine dioxide in the drinking water. Report to the Mathieson Alkali Works from H.B. Haag of the Medical College of Virginia. February 7, 1949.

Harrington, RM; Shertzer, HG; Bercz, JP. (1986) Effects of chlorine dioxide on thyroid function in the African green monkey and the rat. J Toxicol Environ Health 19:235-242.

Harrington, RM; Romano, RR; Gates, D; et al. (1995a) Subchronic toxicity of sodium chlorite in the rat. J Am Coll Toxicol 14:21-33.

Harrington, RM; Romano, RR; Irvine, L. (1995b) Developmental toxicity of sodium chlorite in the rabbit. J Am Coll Toxicol 14:109-118.

Hayashi, M; Kishi, M; Sofuni, T; et al. (1988) Micronucleus test in mice on 39 food additives and eight miscellaneous chemicals. Food Chem Toxicol 26:487-500.

Ishidate, M; Sofuni, T; Yoshikawa, K; et al. (1984) Primary mutagenicity screening of food additives currently used in Japan. Food Chem Toxicol 22:623-636.

Kanitz, S; Franco, Y; Patrone, V; et al. (1996) Associations between drinking water disinfection and somatic parameters at birth. Environ Health Perspect 104:516-520.

Kennedy, SM; Enarson, DA; Janssen, RG; Chan-Yeung, M. (1991) Lung health consequences of reported accidental chlorine gas exposures among pulpmill workers. Am Rev Respir Dis 143:74-79.

Kurokawa, Y; Takamura, N; et al. (1984) Studies on the promoting and complete carcinogenic activities of some oxidizing chemicals in skin carcinogenesis. Cancer Lett 24:299-304.

843

Kurokawa, Y; Takamura, S; Konishi, Y; et al. (1986) Long-term in vivo carcinogenicity tests of potassium bromate, sodium hypochlorite, and sodium chlorite conducted in Japan. Environ Health Perspect 69:221-235.

Lubbers, JR; Chauhan, S; Bianchine, JR. (1981) Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. Fundam Appl Toxicol 1:334-338.

Lubbers, JR; Chauhan, S; Bianchine, JR. (1982) Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. Environ Health Perspect 46:57-62.

Lubbers, JR; Chauhan, S; Miller, JK; et al. (1984a) The effects of chronic administration of chlorine dioxide, chlorite and chlorate to normal healthy adult male volunteers. J Environ Pathol Toxicol Oncol 5:229-238.

Lubbers, JR; Chauhan, S; Miller, JK; et al. (1984b) The effects of chronic administration of chlorite to glucose-6-phosphate dehydrogenase deficient healthy adult male volunteers. J Environ Pathol Toxicol Oncol 5:239-242.

Meggs, WJ; Elsheik, T; Metzger, WJ; et al. (1996) Nasal pathology and ultrastructure in patients with chronic airway inflammation (RADS and RUDS) following an irritant exposure. Clin Toxicol 34:383-396.

Meier, JR; Bull, RJ; Stober, JA; et al. (1985) Evaluation of chemicals used for drinking water disinfection for production of chromosomal damage and sperm-head abnormalities in mice. Environ Mutagen 7:201-211.

Michael, GE; Miday, RK; Bercz, JP; et al. (1981) Chlorine dioxide water disinfection: a prospective epidemiology study. Arch Environ Health 36:20-27.

Miller, RG; Kopler, FC; Condie, LW; et al. (1986) Results of toxicological testing of Jefferson Parish pilot plant samples. Environ Health Perspect 69:129-139.

Mobley, SA; Taylor, DH; Laurie, RD; et al. (1990) Chlorine dioxide depresses T3 uptake and delays development of locomotor activity in young rats. In: Jolley, RL, et al., eds. Water chlorination: chemistry, environmental impact and health effects, vol. 6. Chelsea, MI: Lewis Publications, pp. 347-358.

Moore, GS; Calabrese, EJ. (1982) Toxicological effects of chlorite in the mouse. Environ Health Perspect 46:31-37.

Moore, GS; Calabrese, EJ; Leonard, DA. (1980) Effects of chlorite exposure on conception rate and litters of A/J strain mice. Bull Environ Contam Toxicol 25:689-696.

Orme, J; Taylor, DH; Laurie, RD; et al. (1985) Effects of chlorine dioxide on thyroid function in neonatal rats. J Toxicol Environ Health 15:315-322.

Paulet, G; Desbrousses, S. (1970) On the action of $ClO_2$ at low concentrations on laboratory animals. Arch Mal Prof 31(3):97-106.

Paulet, G; Desbrousses, S. (1972) On the toxicology of chlorine dioxide. Arch Mal Prof 33(1-2):59-61.

Paulet, G; Desbrousses, S. (1974) Action of a discontinuous exposure to chlorine dioxide ($ClO_2$) on the rat [French with English translation.]. Arch Mal Prof 35:797-804.

Robinson, M; Bull, RJ; Schmaer, M; Long, RF. (1986) Epidermal hyperplasia in the mouse skin following treatment with alternate drinking water disinfectants. Environ Health Perspect 69:293-300.

Scatina, J; Abdel-Rahman, MS; Gerges, SE; et al. (1984) Pharmacodynamics of Alcide, a new antimicrobial compound, in rat and rabbit. Fundam Appl Toxicol 4:479-484.

Selevan, S. (1997) Comments on Italian study: association between drinking water disinfection and somatic parameters by Kanitz et al., Environ Health Perspect 104(5):516-520, 1996. Memorandum to J. Wiltse, U.S. EPA, Washington, DC, May 7.

Suh, DH; Abdel-Rahman, MS; Bull, RJ. (1983) Effect of chlorine dioxide and its metabolites in drinking water on fetal development in rats. J Appl Toxicol 3:75-79.

Taylor, DH; Pfohl, RJ. (1985) Effects of chlorine dioxide on the neurobehavioral development of rats. In: Jolley, RL, et al., eds. Water chlorination: chemistry, environmental impact and health effects, vol. 6. Chelsea, MI: Lewis Publications, pp. 355-364.

Toth, GP; Long, RE; Mills, TS; et al. (1990) Effects of chlorine dioxide on the developing rat brain. J Toxicol Environ Health 31:29-44.

Tuthill, RW; Giusti, RA; Moore, GS; et al. (1982) Health effects among newborns after prenatal exposure to $ClO_2$-disinfected drinking water. Environ Health Perspect 46:39-45.

U.S. Environmental Protection Agency. (1986a) Guidelines for carcinogen risk assessment. Federal Register 51(185):33992-34003.

U.S. Environmental Protection Agency. (1986b) Guidelines for the health risk assessment of chemical mixtures. Federal Register 51(185):34014-34025.

U.S. Environmental Protection Agency. (1986c) Guidelines for mutagenicity risk assessment. Federal Register 51(185):34006-34012.

U.S. Environmental Protection Agency. (1988) Recommendations for and documentation of biological values for use in risk assessment. Prepared by Environmental Criteria and Assessment

Office, Office of Health and Environmental Assessment, Cincinnati, OH. EPA 600/6-87/008. Available from: National Technical Information Service, Springfield, VA, PB88-179874/AS.

U.S. Environmental Protection Agency. (1991) Guidelines for developmental toxicity risk assessment. Federal Register 56(234):63798-63826.

U.S. Environmental Protection Agency. (1994a) Interim policy for particle size and limit concentration issues in inhalation toxicity: notice of availability. Federal Register 59(206):53799.

U.S. Environmental Protection Agency. (1994b) Methods for derivation of inhalation reference concentrations and application of inhalation dosimetry. Prepared by Environmental Criteria and Assessment Office, Office of Health and Environmental Assessment, Research Triangle Park, NC. EPA/600/8-90/066F.

U.S. Environmental Protection Agency. (1994c) Peer review and peer involvement at the U.S. Environmental Protection Agency. Signed by the U.S. EPA Administrator, Carol M. Browner, dated June 7, 1994.

U.S. Environmental Protection Agency. (1994d) Final draft of the drinking water criteria document on chlorine dioxide, chlorite, and chlorate. Office of Science and Technology, Office of Water, Washington, DC. Office of Research and Development, Washington, DC.

U.S. Environmental Protection Agency. (1995) Use of the benchmark dose approach in health risk assessment. EPA/630/R-94/007.

U.S. Environmental Protection Agency. (1996a) Proposed guidelines for carcinogen risk assessment. Federal Register 61(79):17960-18011. http://www.epa.gov/nceawww1/cancer.htm

U.S. Environmental Protection Agency. (1996b) Reproductive toxicity risk assessment guidelines. Federal Register 61(212):56274-56322. http://www.epa.gov/ORD/WebPubs/repro/

U.S. Environmental Protection Agency. (1998a) Guidelines for neurotoxicity risk assessment. Federal Register 63(93):26926-26954. http://www.epa.gov/nceawww1/nurotox.htm

U.S. Environmental Protection Agency. (1998b) Science policy council handbook: peer review. Prepared by the Office of Science Policy, Office of Research and Development, Washington, DC. EPA 100-B-98-001.

World Health Organization, Regional Office for Europe. (2000) Health for All Statistical Database. Online. European Public Health Information Network for Eastern Europe. http://www.euphin.dk/hfa/Phfa.asp

Yokose, Y; Uchida, K; Nakae, D; et al. (1987) Studies of carcinogenicity of sodium chlorite in B6C3F1 mice. Environ Health Perspect 76:205-210.

846

# APPENDIX A. EXTERNAL PEER REVIEW— SUMMARY OF COMMENTS AND DISPOSITION

The support document and IRIS summary for chlorine dioxide and chlorite have undergone both internal peer review performed by scientists within EPA and a more formal external review performed by scientists in accordance with EPA guidance on peer review (U.S. EPA, 1994c). Comments made by the internal reviewers were addressed prior to submitting the documents for external peer review and are not part of this appendix. The external peer reviewers were tasked with providing written answers to general questions on the overall assessment and on chemical-specific questions in areas of scientific controversy or uncertainty. A summary of significant comments made by the external reviewers and EPA's response to these comments follows.

**Question 1.** Are you aware of any other data/studies that are relevant (i.e., useful for hazard identification or dose-response assessment) for the assessment of the adverse health effects, both cancer and noncancer, of this chemical?

**Comments:** Two reviewers did not find any new relevant studies that would have any impact on the conclusions of this document. Four additional references were mentioned by the two other reviewers. One reviewer concurred that the results of the EPA evaluation agree with IARC (vol. 52, 1991), and there is inadequate evidence for the carcinogenicity of sodium chlorite in experimental animals. One reviewer commented on sensitive subgroups of the population and potential effects on blood chemistry parameters in renal dialysis patients when chlorine dioxide was used as a disinfectant. Also, one reviewer suggested a statement should be made on whether chlorite can be designated as a tumor promoter based on an initiation/promotion study on mouse skin (Kurokawa et al., 1984) and if the promoting activity is related to epidermal hyperplasia induction after topical exposure to sodium chlorite.

***Response to Comments:*** The effects of chlorine dioxide and chlorite on human subjects and blood chemistry are described in the *Drinking Water Criteria Document on Chlorine Dioxide, Chlorite, and Chlorate* (U.S. EPA, 1994d) and in this Toxicological Review. All relevant ingestion studies, including the additional studies mentioned by the reviewers, have been evaluated in the drinking water criteria document, which was used in preparing this Toxicological Review. Changes seen in the tumor promoter study on mouse skin were not statistically significant.

**Question 2.** For RfD, RfC, and cancer, where applicable, have the most appropriate critical effects been chosen? For the cancer assessment, are the tumors observed biologically significant?

**Comments:** Two reviewers reiterated that it would appear that NOAELs around 3 mg/kg-day for the neurodevelopmental and behavioral effects are the most appropriate to develop the RfD for the oral exposure route, that the selection of the Paulet and Desbrousses (1972) study

847

for developing the RfC for chlorine dioxide is appropriate, and also that there is still no adequate evidence for the carcinogenicity of chlorine dioxide or chlorite. Other reviewers also stated that there are inadequate cancer data for risk assessment. One reviewer commented that an independent pathology group should review the histopathology diagnoses in the CMA (1996) study.

***Response to Comments:*** The CMA (1996) study was vigorously subjected to independent peer review at EPA and by external reviewers. It was also reviewed by the stakeholders. Additional review of the histopathology diagnoses was not performed because the most sensitive endpoints (neurofunctional effects) were not histologic in nature.

**Question 3.** For RfD and RfC and cancer, have the appropriate studies been chosen as principal?

**Comments:** The external reviewers reiterated that appropriate studies were chosen for chlorine dioxide and chlorite. One reviewer stated that actual study reports cited were not available for review; the reviewer also suggested review of additional studies for irritating effects of chlorine dioxide in humans and questioned whether humans were more sensitive than rodents to chlorine dioxide.

***Response to Comments:*** EPA cited the suggested studies as appropriate within the text. Studies describing irritating effects of chlorine dioxide in humans are described in the text. Data on the comparative sensitivity of rodents and humans to chlorine dioxide are not available. The 10-fold uncertainty factor for animal to human extrapolation was deemed an appropriate adjustment for this data gap.

**Question 4.** Studies included in the RfD and RfC and cancer under the heading "Supporting/Additional Studies" are meant to lend scientific justification for the designation of critical effect by including any relevant pathogenesis in humans, any applicable mechanistic information, any evidence corroborative of the critical effects, or to establish the comprehensiveness of the data base with respect to various endpoints. Should some studies be removed?

**Comments:** Reviewers indicated that additional and supporting studies cited for the RfD, RfC, and cancer assessments are appropriate and that no studies should be removed. One reviewer commented that he would question the quality and utility of studies that were conducted 50 years ago when quality assurance procedures and chemical production procedures and specifications were not what they are today. One reviewer asked whether any attempts were made to obtain histopathology slides from the unpublished Haag et al. (1949) studies.

***Response to Comments:*** EPA agrees that no additional and supporting studies should be removed from this document. EPA did not attempt to acquire the histopathology slides from the unpublished Haag et al. (1949) chronic studies of chlorine dioxide in rats since they are older studies.

**Question 5.** Are there other data that should be considered in developing the uncertainty factors or the modifying factor? Do you consider that the data support use of different (default) values than those proposed?

**Comments:** One reviewer was unaware of any additional or other data that should be considered in developing the uncertainty factors for chlorine dioxide or chlorite. One reviewer questioned whether it would be useful to review/discuss the risk analysis that supports the use of chlorine dioxide and sodium chlorite as indirect food additives or as components of consumer products such as mouthwash or toothpaste. A comment was made that the report should compare lifetime animal and human oral exposures to chlorine dioxide or chlorite on the basis of mg/kg body weight and mg/mL body surface. One reviewer commented that patients on extracorporeal hemodialysis using home equipment may be potentially exposed to 70–90 times the residues exposed by adults who merely consume the water. A question was raised on the data available to support selection of an uncertainty factor that takes into account for those individuals with deficient glucose-6-phosphate dehydrogenase activity and neonates with sluggish methemoglobin reductase activity.

***Response to Comments:*** EPA agrees with a reviewer that additional or other data are not warranted for this risk assessment. EPA followed the customary guideline for risk assessment for development of an RfD derivation. EPA did not examine chlorine dioxide or chlorite as indirect food additives or as components of consumer products such as mouthwash or toothpaste. EPA discussed individuals with deficiency in glucose-6-phosphate dehydrogenase and methemoglobin reductase as a potential susceptible subpopulation in the drinking water criteria document (U.S. EPA, 1994d). EPA thinks that an uncertainty factor of 100 is adequate to protect this group as well as the 80,000 Americans on renal dialysis.

**Question 6.** Do the confidence statements and weight-of-evidence statements present a clear rationale and accurately reflect the utility of the principal study and the comprehensiveness of the data? Do these statements make sufficiently apparent all the underlying assumptions and limitations of these assessments? If not, what needs to be added?

**Comments:** External reviewers indicated that the confidence and weight-of-evidence statements were clearly and rationally presented. One reviewer indicated that the comprehensiveness of the data was adequately presented and the underlying assumptions and limitations of the assessments were sufficently presented. One reviewer mentioned that the confidence statements for the RfC for chlorine dioxide should indicate whether humans are more susceptible to chlorine dioxide.

***Response to Comments:*** Adequate information is not available to determine if humans are more susceptible. EPA has applied a 10-fold uncertainty factor for extrapolation from animals to humans to address this area of uncertainty.

**Question 7.** Is the weight of evidence for cancer assigned at the appropriate level (where applicable)?

849

**Comments:** External reviewers indicated that cancer assessment was not applicable for chlorine dioxide and chlorite, as the data are inadequate. One reviewer commented that a statement should be made concerning the designation of sodium chlorite as a tumor promoter in mouse skin under the conditions examined in the Kurokawa et al. (1984) study.

***Response to Comments:*** The reviewers agreed that the cancer assessment was assigned at the appropriate level. EPA does not agree that such a statement should be made as the increased tumor incidence did not attain statistical significance.

# Anexo 4.

# TRABAJO DE INVESTIGACION EXPERIMENTAL REALIZADO POR LA ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA.

Asoc. Ecuatoriana de Medicos Expertos en Medicina Integrativa
A.E.M.E.M.I.

# DIOXIDO DE CLORO UNA TERAPEUTICA EFECTIVA PARA EL TRATAMIENTO DEL SARS COV2 (COVID 19)

PRESENTADO POR AEMEMI

Guayaquil, mayo 2020

Factura: 002-993-000000607

20200901009D00195

## DILIGENCIA DE RECONOCIMIENTO DE FIRMAS N° 20200901009D00195

Ante mí, NOTARIO(A) RICARDO RENATO VASQUEZ LEIVA de la NOTARÍA NOVENA , comparece(n) CARMEN DORITA SARMIENTO BARBA portador(a) de CÉDULA 0909353526 de nacionalidad ECUATORIANA, mayor(es) de edad, estado civil DIVORCIADO(A), domiciliado(a) en GUAYAQUIL, POR SUS PROPIOS DERECHOS en calidad de COMPARECIENTE; quien(es) declara(n) que la(s) firma(s) constante(s) en el documento que antecede , es(son) suya(s), la(s) misma(s) que usa(n) en todos sus actos públicos y privados, siendo en consecuencia auténtica(s), para constancia firma(n) conmigo en unidad de acto, de todo lo cual doy fe. La presente diligencia se realiza en ejercicio de la atribución que me confiere el numeral noveno del artículo dieciocho de la Ley Notarial -. El presente reconocimiento no se refiere al contenido del documento que antecede, sobre cuyo texto esta Notaria, no asume responsabilidad alguna. – Se archiva un original. GUAYAQUIL, a 6 DE MAYO DEL 2020, (11:17).

CARMEN DORITA SARMIENTO BARBA
CÉDULA: 0909353526

NOTARIO(A) RICARDO RENATO VASQUEZ LEIVA
NOTARÍA NOVENA DEL CANTÓN GUAYAQUIL

Fecha de [illegible]:

Yo [illegible] con Cédula [illegible] y [illegible] cantidad de años de edad, una vez que se nos ha socializado las bondades de MMS y del CDS gas dióxido de cloro como tratamiento para COVID-19 explicado por los Doctores de AEMEMI y Coordinado por Dr. Roberto García Aplicaremos el protocolo F cada 15 min tomas 8 de 20 gotas según respuesta y se pasará al protocolo C 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos: Firma de consentimiento........................ .......

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrío | | | | |
| Dolor Muscular | | | | |
| Artralgia | | | | |
| Cefalea | | | | |
| Dolor torácico al respirar | | | | |
| Dificultad para respirar | | | | |
| Vómitos | | | | |
| Diarreas | | | | |
| Dolor de Garganta | | | | |
| Ardor de garganta | | | | |
| Anosmia | | | | |
| Ageusia | | | | |
| Conjuntivitis | | | | |
| Tos | | | | |
| Fiebre | | | | |
| Otros | | | | |
| | | | | |

Observación del paciente al tratamiento:

______________________________________________________________

______________________________________________________________

El tratamiento que brindará los miembros de la Aememi es gratuito

Dr. Mauricio Quiñonez M. Dra. Carmen Sarmiento E. Dr. Roberto García F.

Presidente AEMEMI Secretaria de AEMEMI Vocal de AEMEMI



SUPERIOR

DOCTOR MÉDICO

[illegible]

SARMIENTO MANUEL

BARBA REINERIA

GUAYAQUIL
2017-01-04
FECHA DE EXPIRACIÓN
2027-01-04



REPÚBLICA DEL ECUADOR

DIRECCIÓN GENERAL DE REGISTRO CIVIL
IDENTIFICACIÓN Y CEDULACIÓN

CÉDULA DE CIUDADANÍA DISCAPACIDAD

No. 090935352-6

[illegible]EPCION

[illegible]-03-29

ECUATORIANA

SEXO MUJER

ESTADO CIVIL DIVORCIADO



0039 F

0039 - 106

0909383628

SARMIENTO BARBA CARMEN DORITA

GUAYAS

GUAYAQUIL

3

URDANETA

ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS
EN MEDICINA INTEGRATIVA
AEMEMI

# DIOXIDO DE CLORO: UNA ALTERNATIVA EFECTIVA PARA EL TRATAMIENTO DEL SARS-CoV2 (COVID -19)

Mg. Roberto García Espinoza, Dra. Carmen Sarmiento Barba
Colaboradores:
Mg. Sarita Montoya Carvajal
Dr. Edwin Andrade Vilela
Mg. Sonia Moreira V.
Mg. MT. María Robles U.
Lcda. Lucia Jara Chamba. Apoyo estadístico

## Resumen

La pandemia de covid-19 ha producido un golpe fuerte al sistema sanitario a nivel mundial y Latinoamérica, Ecuador es el segundo país con mayor número de contagios y muertes por esta enfermedad. Frente a los diferentes obstáculos de la medicina convencional y a las medidas tardías tomadas por el sistema de salud ecuatoriano de cara a la emergencia sanitaria, la Asociación de Médicos Expertos en Medicina Integrativa (AEMEMI) y educandos de Andreas Kalcker han visto la urgencia de tomar partida en esta lucha por la salud de los ecuatorianos. En este escenario se evidencio la efectividad y toxicidad del Dióxido de cloro en pacientes sintomáticos respiratorios y positivos para SARS-CoV2 (covid-19) a través de un estudio cuasi-experimental en 104 pacientes donde se describió lo observado en relación a uso de CDS. Se constató que el grupo más afectado por Covid-19 corresponde a edades entre 30 y 50 años, siendo el sexo femenino el más prevalente en relación al masculino, en este estudio donde la población femenina fue la que acepto este tratamiento experimental con CDS, por eso nuestras estadísticas arrojan este resultado que se contrapone a las cifras de afectación por covid 19, donde observamos que es más la población masculina la que fallece en datos estadística mundial. En cuanto a la sintomatología destaca la pérdida del olfato n=48, seguidos de los

seca n=45, dolor de garganta n=41, mialgia n=49, fiebre n=40, dolor de espaldas n=40, cefalea n=37, perdida de sabores n=36, falta de apetito n=32 dificultad para respirar n=17, escalofrios n=16, diarrea n=12, y vomito n=3, siendo esta la sintomatología inicial obteniendo evidente reducción general de síntomas del 82,2% al cuarto día de tratamiento y el restante 18.8% presento secuelas leves como tos seca y dorsalgia, cabe resaltar que no se registró mortalidad ni efectos adversos en este grupo estudiado. Es prioritario realizar otras investigaciones mediante análisis estadisticos avanzados donde se incluyan criterios a todos los pacientes como pruebas de laboratorio, imágenes, y asegurar una muestra amplia estratificando la gravedad critica, moderada y leve a fin de demostrar de manera certera la efectividad y bajos efectos tóxicos de este Mineral.

## INTRODUCCION

Tomando en cuenta la evidencia sobre el dióxido de cloro, con propiedades antivirales y sus casi inexistentes efectos adversos, AEMEMI en base a la experiencia de los médicos con esta sustancia, sugiere este mineral cuyos beneficios pueden ser prometedores para la situación por la que atraviesa el Ecuador. El Dr. Roberto García Espinoza, con 35 años de experiencia y con formación del ejercicio profesional de medicina integrativa por más de 15 años; ha propuesto el uso de CDS como tratamiento para las personas que han sido afectadas por el covid-19 en la ciudad de Guayaquil por presenta el mayor número de contagios del país, por lo cual llama a colaborar a Doctores experimentados en Medicina Integrativa para hacer el ensayo clínico en población afectada, recibe respuesta afirmativa de los colegas: Dra. Carmen Sarmiento Barba con Mas de 22 años de practica en esta Medicina, al igual que la Dra. Sarita Montoya Carvajal. Dra. Sonia Moreira Vera, epidemióloga con larga experiencia en temas de enfermedades infectocontagiosas. Dr. Edwin Andrade Vilela Especialista en Medicina Atención Primaria de Salud, más adelante se integra Mg.Maria Robles Urgilez,con experiencia y diplomado en Medicina Tropical, enfermedades inmunodeficiencia como VIH-Side. Y colabora en la elaboración de datos estadísticos la Lcda. Lucia Jara.

El presente ensayo clínico brinda un tratamiento alternativo contra el Covid- 19, con el fin de determinar efectos benéficos, así como su toxicidad mediante un estudio observacional, prospectivo de serie de casos.

El objetivo General

Evidenciar la efectividad y toxicidad del CDS en pacientes sintomáticos respiratorios y positivos para SARS-CoV2 (covid-19).

Objetivos específicos

- Socializar los beneficios del dióxido de cloro frente a infecciones virales a personas con sintomatología asociada a covid-19 y a trabajadores de la salud.
- Evaluar la utilidad y toxicidad del dióxido de cloro en pacientes con sintomatología relacionada a covid-19.
- Describir la mejoría de los síntomas en los pacientes al ingerir dióxido de cloro (CDS) según los protocolos establecidos por la asociación de médicos A.E.M.E.M.I.
- Proponer un esquema de tratamiento con dióxido de cloro a las autoridades sanitarias.

## CARACTERISTICAS QUIMICAS DEL DIOXIDO DE CLORO:

El dióxido de cloro ($CLO_2$) es gas de color amarillo verdoso obtenido a partir de la mezcla de clorito de sodio al 25% ($NACLO_2$) y ácido clorhídrico al 4% (HCL), este gas tiene un punto de ebullición de 11°C y se caracteriza por ser altamente soluble en agua y por no hidrolizarse en ella. El dióxido de cloro no deja residuos ni llega a acumularse en el cuerpo a largo plazo.

## COMPORTAMIENTO DEL CDS EN EL ORGANISMO

El dióxido de cloro (CDS) al ser ingerido rápidamente se libera y se absorbe por las mucosas estomacales en su mayoría para luego alcanzar la sangre. El dióxido de cloro tiene un comportamiento similar al del oxígeno ya que tiene una afinidad por la acidez (Efecto Bohr). El dióxido de cloro al encontrar un ambiente ácido se disocia en oxígeno y cloro, el cloro al ser muy electronegativo reaccionara con un átomo de sodio para formar cloruro de sodio (NACL), el oxígeno reaccionara oxidando los patógenos eliminándolos al desestabilizar su pared celular (bacterias) y la envoltura y cápside proteica (virus).

"Resulta ser que además de los organismos patógenos, la mayoría de las sustancias toxicas para el cuerpo son ácidas o tienen radicales positivos oxidables, los tumores malignos necesitan para crecer de medio ácido y los tejidos enfermos acumulan residuos ácidos, mismos que luego les molestan en su función, por lo que teóricamente una buena ración de este "antiácido selectivo" corregiría la situación de enfermedad. En los estudios del Dióxido de clorina con malaria, los pacientes pasaban de un estadio totalmente enfermo a un estadio sano en unas 4 horas, lo cual resulta bastante rápido." (Ruiz A. 2009)

Las células humanas no tienen paredes celulares y son aparentemente no afectadas. Es probable que nuestra piel y nuestro cuerpo estén protegidos de los efectos oxidativos generales del ClO2 por los muchos agentes reductores en nuestras células y sangre como la catalasa, el glutatión, superóxido dismutasa, vitaminas E, C, A, complejo B, ácido úrico, zinc y selenio. Este es probablemente el mismo mecanismo de protección interno que previene el daño del oxígeno y los radicales libres. Las bacterias y los virus no contienen la mayoría de estos compuestos reductores (Alliger, H....).

El dióxido de cloro al tener un potencial oxidativo de 0,95 V tiene la capacidad de eliminar todo tipo de patógeno unicelular sin afectar nuestro cuerpo ya que las células requieren 1.2V para ser destruidas. Gracias a su potencial oxidativo el dióxido de cloro tiene la habilidad de eliminar metales pesados como el aluminio y el mercurio.

El dióxido de cloro no solo elimina patógenos selectivamente, sino que aporta oxigeno aumentando la saturación y alcalinizando el cuerpo al secuestrar los iones hidrógeno para luego formar agua. El aumento de oxigeno se traducirá en energía al estimular a las mitocondrias para la formación de ATP.

## ENSAYOS CLINICOS

No se cuenta con intervenciones científica publicadas sobre el tratamiento con CDS, los pacientes involucrados en la presente investigación participaron de manera voluntaria autorizando con el respectivo consentimiento informado, cabe recalcar que formula fue usada primero en médicos de la organización. Los médicos de la AEMEMI pretenden dar una esperanza de vida a los grupos de población poco favorecidos en la atención de salud con recursos económicos bajos que no han podido acceder a una atención médica adecuada en los diferentes sistemas de salud de la cuidad que se encuentran colapsados por la alta demanda de pacientes contagiados. Además de ayudar con al sistema de salud pública en la pronta recuperación y alivio de la sintomatología de los pacientes infectados. Se pretende que este sea un precursor de futuras investigaciones a nivel de Latinoamérica y el mundo que fortalezcan los beneficios que brinda el CDS; para el beneficio de la humanidad especialmente de personas de mediano y bajo nivel económico pues esta fórmula puede estar al alcance de cualquier bolsillo debido a su bajo costo, considerando el número de muertes y morbilidad causada por esta pandemia.

DOY FE: que la(s) copia(s) que antecede(n) constante(s) en 1 foja(s) útiles es fiel y exacta(s) al ORIGINAL que me fue exhibido y que devuelvo al interesado.
Dr. Renato Vásquez Leiva
NOTARIA NOVENA DEL CANTÓN GUAYAQUIL

## PRACTICA CLINICA

La infección por el virus de la influenza en el aire de los ratones se puede prevenir con dióxido de cloro gaseoso (ClO2).

Este estudio demostró que ClO2 redujo la función de la hemaglutinina (HA) del virus de la influenza A (H1N1) de manera dependiente de la concentración, el tiempo y la temperatura. El científico N. Ogata tuvo éxito en la inactivación del virus de la influenza al inhibir su capacidad de unión a receptores (Ogata N. 2012)

María e. Alvarez y R. O'brien en su investigación "Mechanisms of Inactivation of Poliovirus by Chlorine Dioxide and Iodine" mostraron que ambos compuestos tienen actividad antiviral al reaccionar con la capcide del poliovirus alterando el pH, encontraron también diferencias en el mecanismo de acción. El yodo actúa deteriorando la capacidad de anclaje del virus a las células mientras que el dióxido de cloro también inactivo al virus de las células infectadas al reaccionar con el ARN viral deteriorando la capacidad del genoma reduciendo la incorporación de uridina en el nuevo ARN viral (Alvarez M; O'brien R., 1982).

Y S Chen y J M Vaughn también estudiaron la inactivación del rotavirus en humanos y simios usando dióxido de cloro y encontraron que a concentraciones de 0.2mg/L a un de pH 6 los virus eran rápidamente inactivados comparando su efectividad con el ozono en un medio alcalino (CHEN Y., VAUGHN J. 1990).

Actualmente existe otro estudio aprobado por US National Library of Medicine titulado Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19 donde se revisara, mediante una investigación prospectiva de casos, la eficacia del dióxido de cloro oral en el tratamiento de pacientes con infección por COVID 19. La investigación se llevará a cabo entre abril y junio de 2020 con un diseño cuasi experimental en Colombia y Madrid.

## TOXICIDAD DEL CDS

Muchas evaluaciones han demostrado que los compuestos de ClO2 no son tóxicos. Cinco décadas de uso no han indicado ningún efecto adverso sobre la salud. Las pruebas de toxicología incluyen ingestión de ClO2 en el agua potable, adiciones a cultivo de tejidos, inyecciones en la sangre, desinfección de semillas, desinfección de huevos de insectos, inyecciones debajo de la piel de animales y en el cerebro de ratones, administradas a más de 1500 ratas e inyecciones en los tallos de las plantas. Test "estándar" incluyen, mutación de Ames, hámster chino, Ojos de conejo, abrasión de la piel, farmacodinámica y Teratología (Alliger, H). Aunque la toxicidad subcrónica / crónica del dióxido de cloro se ha investigado en varios estudios, solo Daniel et al. (1990) y Haag (1949) examinaron una amplia gama de puntos finales. Los otros estudios (Bercz et al., 1982; Abdel-Rahman et al., 1984b; Couri y Abdel-Rahman, 1980; Moore y Calabrese, 1982) se centraron en el sistema hematológico. Hasta la fecha, ningún estudio ha examinado el potencial carcinogénico del dióxido de cloro. Estudios en humanos mostró que no hubo efectos nocivos importantes al ingerir 24ppm/L CLO2 por 12 semanas. (Judith R et al. 1982)

"El ClO2, el llamado "biocida ideal" por qué la solución que mata microbios rápidamente no causa ningún daño a los humanos ni a los animales". "El tiempo de eliminación (del patógeno) es proporcional al cuadrado del tamaño característico de un cuerpo, por lo tanto los pequeños se eliminarán extremadamente rápido. Por ejemplo, el tiempo de muerte de una bacteria es del orden de milisegundos en una solución de 300 ppm de ClO2. Por lo tanto, unos pocos minutos de tiempo de contacto es suficiente para matar a todas las bacterias, pero lo suficientemente corto para mantener la penetración de ClO2 en los tejidos vivos de un organismo mayor de forma segura. "(Noszticzius Z. Et al 2013).

Investigaciones sobre el CLO2 han especificado que cuando se forma por activación el dióxido de cloro, una pequeña porción de él se transforma en su conjugado, que casualmente es el ácido hipocloroso, la sustancia que los neutrófilos y macrófagos vierten sobre los microbios para combatirlos. De allí su efecto antibiótico (Ruiz A. 2009)

## DISEÑO DE LA INVESTIGACION

El estudio se llevó a cabo en Ecuador en la ciudad de Guayaquil, desde el 26 de marzo a 10 de abril del 2020 mediante un estudio cuasi-experimental descriptico, prospectivo de serie de casos cuya selección de la muestra fue de tipo no probabilística, por conveniencia, considerando a los mismo pacientes la población y muestra donde participaron 104 personas, de manera voluntaria, incluye pruebas positivas para covid-19, sintomáticos respiratorios para la enfermedad, así como de individuos que tuvieron contacto con personas infectadas. El grupo de médicos socializo con cada paciente los beneficios y toxicidad conocida del dióxido de cloro (CDS) el cual se entregó, explicando las dosis a ingerir, así como su periodicidad de la formula, dando seguimiento los posteriores días al tratamiento y analizar resultados.

Criterios de inclusión:

a. Covid 19 positivos

b. Algunos de los síntomas característicos de covid 19

C. Edad entre 18 y 80 años

Criterios de exclusión:

a. Covid 19 negativos b.

b. Insuficiencia renal IV / VI.

c. Insuficiencia cardiaca congestiva.

d. Pacientes que toman anticoagulantes, particularmente Warfarina sódica

Doy Fe [illegible]

e. niños menores de 14 años y mayores de 14 sin consentimiento de los padres

Tratamiento propuesto

Se recomiendo tomar el protocolo F o C, o ambos dependidos de la gravedad del paciente y del criterio médico. A continuación, se describe los diferentes protocolos:

| | |
|---|---|
| **PROTOCOLO F** | • Diluir 20ml de CDS en 500ml de agua<br>• Tomar 65 ml c/15 min x 2 horas<br>DESCANSAR 2 HORAS<br>• Diluir 10ml de CDS en 500ml de agua |
| **PROTOCOLO C** | • Diluir 10ml de CDS en 500ml de agua<br>• Tomar 63 ml c/hora 8 tomas |

- En pacientes positivos graves y sintomáticos tomar dosis de ataque o protocolo F por 2 o 3 días según síntomas y mejoría, pasar a dosis de *mantenimiento o protocolo C y tomar por 7 días más.*
- En pacientes que hayan tenido contacto con casos positivos tomar dosis de mantenimiento o protocolo C de 5 a 10 días.
- En niños menores de 5 años se debe dividir la dosis a la mitad igual 10 días de tratamiento
- Se recomienda inclusive tomar hasta 20 días de tratamiento dependiendo de la patología
- Además, se puede administrar por vía parenteral en casos especiales. La dosis es de 30ml de CDS en 250 ml de solución salina 0.9% a 14 gotas por minuto.

Recomendaciones

- Paciente o cualquier persona que vaya a iniciar tratamiento debe haber ingerido alimentos media hora antes.

- No se recomienda la ingestión en niños menores de 1 año debido que la madre a través de la leche materna pasa el ácido láurico que tiene un afecto antiviral.
- Mantener una adecuada alimentación, hidratación y control del metabolismo.

Posibles precauciones y contraindicaciones

El dióxido de cloro reacciona con antioxidantes y diversos ácidos, por lo que no se recomienda el uso de la vitamina C o ácido ascórbico durante el tratamiento, debido a que anula la eficacia del CDS en la eliminación de patógenos (el efecto antioxidante de uno impide la oxidación selectiva de otro). Por lo tanto, no es aconsejable tomar antioxidantes durante los días de tratamiento. En los casos de pacientes con tratamiento de warfarina, se debe comprobar constantemente los valores para evitar casos de sobredosis, ya que se ha comprobado que el dióxido de cloro mejora el flujo sanguíneo.

Si bien el CDS es muy soluble en el agua, presenta la ventaja que no se hidroliza, por lo que no genera trihalometanos tóxicos que son precursores cancerígenos.

Doy FE: que la(s) copia(s) que antecede(n) constante(s) en 1 foja(s) útiles es fiel y exacta(s) al ORIGINAL que me fue exhibido y que devuelvo al interesado.

Dr. Renato Vásquez Leiva
NOTARÍA NOVENA DEL CANTÓN GUAYAQUIL

**RESULTADOS**

**Tabla # 1.** Frecuencia De Casos Por Síntomas Covid-19.

| SINTOMAS | MUJERES | HOMBRES | TOTAL |
|---|---|---|---|
| FIEBRE | 18 | 14 | 32 |
| ESCALOFRIO | 7 | 7 | 14 |
| DOLOR MUSCULAR | 33 | 29 | 62 |
| TOS SECA | 42 | 37 | 79 |
| DOLOR DE CABEZA | 18 | 19 | 37 |
| DOLOR DE ESPALDA | 37 | 33 | 69 |
| DIFICULTAD AL RESPIRAR | 11 | 17 | 28 |
| VOMITO | 2 | 6 | 8 |
| DIARREA | 6 | 11 | 17 |
| DOLOR DE GARGANTA | 20 | 25 | 45 |
| PERDIDA DEL OLFATO | 35 | 32 | 68 |

| | | | |
|---|---|---|---|
| **PERDIDA DE SABORES** | 19 | 20 | 39 |
| **FALTA DE APETITO** | 16 | 14 | 31 |

Fuente: Consentimiento informado de pacientes

Análisis: En relación a la sintomatología destaca la tos seca n=79, seguidos de dolor de espaida n=69, pérdida del olfato n=68, mialgia n=62, dolor de garganta n=45, cefalea n=37, fiebre n=32, falta de apetito n=31, dificultad para respirar n=28, escalofríos n=14, diarrea n=17, y vomito n=8.

Tabla # 2.

| **DISTRIBUCION DE LA POBLACION SEGÚN GRUPO ETAREOS** | | | | | | |
|---|---|---|---|---|---|---|
| **EDAD** | **SEXO** | | | | **TOTAL** | **PORCENTAJE** |
| | **FEMENINO** | **%** | **MASCULINO** | **%** | | |
| >10 años | 3 | 2,9 | 4 | 3,8 | **7** | 6,7 |
| 11 - 20 | 6 | 5,8 | 3 | 2,9 | **9** | 8,7 |
| 21 – 30 | 7 | 6,7 | 7 | 6,7 | **14** | 13,5 |
| 31 - 40 | 12 | 11,5 | 7 | 6,7 | **19** | 18,3 |
| 41 - 50 | 9 | 8,7 | 13 | 12,5 | **22** | 21,2 |
| 51 - 60 | 7 | 6,7 | 10 | 9,6 | **17** | 16,3 |
| 61 - 70 | 5 | 4,8 | 3 | 2,9 | **8** | 7,7 |
| 71 – 80 | 5 | 4,8 | 2 | 1,9 | **7** | 6,7 |
| < 80 | 1 | 1,0 | 0 | 0,0 | **1** | 1,0 |
| **TOTAL** | **55** | **52,9** | **49** | 47,1 | **104** | 100,0 |

Fuente: Consentimiento informado de pacientes

Grafico 1.-


Distribucion De La Poblacion Por Grupos Etareos

**Análisis:** se observa que mayor prevalencia entre 10 a 50 años con el 21,2% de los casos (n= 22); seguidos de 31 a 40 años con el 18,3% (n= 19) y 51 y 60 años con el 16,3% (n= 17) el restante grupo de distribuye de forma similar disminuyendo en edades extremas de la vida como menores de 10 años y adultos mayores de más de 71 años.

[illegible] copia(s) [illegible]
constante(s) en [illegible] foja(s) útiles [illegible]
y exacta(s) al ORIGINAL que [illegible]
y que devolví al interesado
Dr. [illegible] Vásquez [illegible]
NOTARIA NOVENA DEL CANTON GUAYAQUIL

Grafico 2.-


Distribucion de casos Covid 19 por sexo

**Análisis:** se observa que el sexo femenino es el grupo más afectado con el 52,9% el sexo masculino representa el 47%.

Tabla 3.- Distribución De Sintomatología según Dia de Tratamiento (Dia 1)

| SINTOMAS | MUJERES | HOMBRES | TOTAL |
|---|---|---|---|
| FIEBRE | 40 | 28 | 68 |
| ESCALOFRIO | 16 | 14 | 30 |
| DOLOR MUSCULAR | 41 | 31 | 72 |
| TOS SECA | 45 | 38 | 83 |
| DOLOR DE CABEZA | 37 | 38 | 75 |
| DOLOR DE ESPALDA | 40 | 38 | 78 |
| DIFICULTAD AL RESPIRAR | 17 | 22 | 39 |
| VOMITO | 3 | 10 | 13 |
| DIARREA | 12 | 17 | 29 |
| DOLOR DE GARGANTA | 41 | 40 | 81 |
| PERDIDA DEL OLFATO | 49 | 40 | 89 |
| PERDIDA DE SABORES | 36 | 33 | 69 |
| FALTA DE APETITO | 32 | 25 | 57 |

**Fuente: Consentimiento informado de pacientes**

Grafico 3.-

**Sintomas primer dia tratamiento con DCS**



Análisis: En relación a la sintomatologia en pérdida del olfato n=89, seguido de tos seca n=83, dolor de garganta n=81 dolor de espalda n=78, fiebre n=68 mialgia n=72, cefalea n=75, perdida de sabores n=69, falta de apetito n=57, dificultad para respirar n=39, escalofríos n=30.

En cuanto al sexo femenino destaca la pérdida del olfato n=49, seguido de tos seca n=45, dolor de garganta n=41, mialgia n=49, fiebre n=40, dolor de espalda n=40, cefalea n=37, perdida de sabores n=36, falta de apetito n=32, dificultad para respirar n=17, escalofríos n=16, diarrea n=12, y vomito n=3, lo que se asemeja al grupo masculino.

Tabla # 4.- Distribución De Sintomatología según Dia de Tratamiento (Dia 2)

| SINTOMAS | MUJERES | HOMBRES | TOTAL |
|---|---|---|---|
| **FIEBRE** | 12 | 11 | **23** |
| **ESCALOFRIO** | 3 | 6 | **9** |
| **DOLOR MUSCULAR** | 35 | 31 | **66** |
| **TOS SECA** | 41 | 37 | **78** |
| **DOLOR DE CABEZA** | 14 | 15 | **29** |
| **DOLOR DE ESPALDA** | 37 | 31 | **68** |
| **DIFICULTAD AL RESPIRAR** | 12 | 18 | **30** |
| **VOMITO** | 2 | 5 | **7** |
| **DIARREA** | 4 | 10 | **14** |
| **DOLOR DE GARGANTA** | 14 | 24 | **38** |
| **PERDIDA DEL OLFATO** | 44 | 38 | **82** |
| **PERDIDA DE SABORES** | 18 | 22 | **40** |
| **FALTA DE APETITO** | 13 | 14 | **27** |

Fuente: Consentimiento informado de pacientes

Grafico # 4.-



Doy FE: que la(s) copia(s) que antecede(
constante(s) en ........ foja(s) útil
y exacta(s) al ORIGINAL que me fue
y que devuelvo al interesado.

Dr. Renato Vásquez
NOTARIA NOVENA DEL CANTÓN

Análisis: En relación a la sintomatología destaca la pérdida del olfato n=82, seguido de tos seca n=78, dolor de espalda n=68, mialgia n=66, dolor de garganta n=38, perdida de sabores n=40, dificultad para respirar n=30, cefalea n=29, falta de apetito n=27, fiebre n=23, escalofríos n=16, *diarrea n=14, y vomito* n=7.

Tabla # 5. Distribución De Sintomatología según Dia de Tratamiento (Dia 3)

| SINTOMAS | MUJERES | HOMBRES | TOTAL |
|---|---|---|---|
| FIEBRE | 2 | 3 | 5 |
| ESCALOFRIO | 1 | 2 | 3 |
| DOLOR MUSCULAR | 23 | 25 | 48 |
| TOS SECA | 39 | 37 | 76 |
| DOLOR DE CABEZA | 3 | 4 | 7 |
| DOLOR DE ESPALDA | 33 | 29 | 62 |
| DIFICULTAD AL RESPIRAR | 5 | 10 | 15 |
| VOMITO | 1 | 2 | 3 |
| DIARREA | 3 | 5 | 8 |
| DOLOR DE GARGANTA | 5 | 10 | 15 |
| PERDIDA DEL OLFATO | 13 | 19 | 32 |
| PERDIDA DE SABORES | 3 | 5 | 8 |
| FALTA DE APETITO | 4 | 4 | 8 |

Fuente: Consentimiento informado de pacientes

Grafico # 5.



Análisis: En relación a la sintomatología destaca la tos seca n=76, dolor de espalda n=62, mialgia n=48, pérdida del olfato n=32, dolor de garganta n=15, dificultad para respirar n=15, perdida de sabores n=8, falta de apetito n=8, diarrea n=8cefalea n=7, fiebre n=5 , escalofríos n=3, y vomito n=3.

Tabla # 6. Distribución De Sintomatología según Dia de Tratamiento (Dia 4)

| SINTOMAS | MUJERES | HOMBRES | TOTAL |
|---|---|---|---|
| FIEBRE | 1 | 0 | 1 |
| ESCALOFRIO | 0 | 1 | 1 |
| DOLOR MUSCULAR | 14 | 16 | 30 |
| TOS SECA | 35 | 27 | 62 |
| DOLOR DE CABEZA | 1 | 1 | 2 |
| DOLOR DE ESPALDA | 22 | 27 | 49 |
| DIFICULTAD AL RESPIRAR | 2 | 4 | 6 |
| VOMITO | 0 | 0 | 0 |
| DIARREA | 3 | 1 | 4 |
| DOLOR DE GARGANTA | 0 | 1 | 1 |
| PERDIDA DEL OLFATO | 5 | 3 | 8 |
| PERDIDA DE SABORES | 1 | 0 | 1 |
| FALTA DE APETITO | 2 | 0 | 2 |

Fuente: Consentimiento informado de pacientes

Doy FE: que la(s) copia(s) que antecede(n) constante(s) en ______ foja(s) útiles es fiel y exacta(s) al ORIGINAL que me fue exhibido y que devuelvo al interesado.

Dr. Renato Vásquez Leiva
NOTARIA NOVENA DEL CANTON GUAYAQUIL

Grafico # 6.-



Análisis: En relación a la sintomatología destaca la tos seca n=62, dolor de espalda n=49, mialgia n=30, pérdida del olfato n=8, dificultad para respirar n=6, diarrea n=4, cefalea n=2, falta de apetito n=2, fiebre n=1, escalofríos n=1, dolor de garganta n=1, perdida de sabores n=1 y vomito n=0.

Tabla # 8

**DISTRIBUCION DE 11 PACIENTES INGRESADOS EN ESTUDIO SOBRE CDS CON EXAMENES HEMATOLOGICOS Y TAC DEL 24 DE MARZO AL 10 DE ABRIL 2020-AEMEMI 2020**

| LINFOCITO | NEUTROFILO | DIMERO D | FERRITINA | HDL | TGO | TGP | TTP | TP | PCR | IgM | IgG | UREA | CREATININA | RX | TAC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40.1 % | X103/UL | 0.3 | 49.36 | 0 | 20 | 19 | 21.2 | 10 | 0 | 260* | 1178* | 18 | 0.65 | NO | NO |
| 39.5 % | 48.4 | 0.2 | 117.80* | 0 | 24 | 33 | 34.4 | 11.2 | 0 | 62* | 1603* | 19 | 0.89 | NO | NO |
| 50.1 %* | 42.9 | 245* | 773* | 40 | 40* | 182* | 0 | 0 | 0.6 | 0 | 0 | 23 | 0.71 | NO | SI |
| 37.5 % | 52.3 | 115* | 656* | 251* | 40* | 74* | 0 | 0 | 0.2 | 0 | 0 | 21 | 0.78 | NO | NO |

| | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.9 %* | 70.3* | | 605,6 * | 0 | 15 | | | | 39.6* | | | 15 | | NO | SI |
| 47% | 46,5 | 0 | 262* | 146.33 * | 40* | 69 * | 0 | | 0.10 | 0 | 0 | 22 | 0 | NO | NO |
| 30.7 % | 61 | 0.30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NO | % |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SI | SI |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SI | NO |
| 5.4%* | 90.9* | 8.5 | 934.8 * | 0 | 25 | 22 | 0 | 0 | 11.10* | 0 | 0 | 0 | 0 | NO | NO |
| 22.3 %* | 64.8 | 1.5 | 434.9 * | | 23 | 28 | 31.8 | 10.4 | 0.28 | IGE 68/135 | 25* | 35 | 0.71 | NO | NO |
| 47.3 % | 42 | 172 | 775.9 * | 167.85 * | 32 | | 11.20 | 127 | 0.41 | | | | 1.24 | | |

Análisis: se observa que los biomarcadores de al menos el 70% de los pacientes (n=12) donde se realizaron pruebas de laboratorio como FERRITINA, DOMERO D, PCR, TGO, TGP resultaron alteradas en el ensayo clínico así como la inversión de la formula linfocitos y neutrófilos.

* alteración según resultado de laboratorio

| Linfopenia y linfocitosis | eutrolif | imero | erritin | HDL | TGO | TGP | PCR | IGM | IGG | TAC |
|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 2 | 2 | 8 | 3 | 3 | 3 | 2 | 2 | 3 | 3 |
| 33,33 | 16,67 | 16,67 | 66,67 | 25,00 | 25,00 | 25,00 | 16,67 | 16,67 | 25,00 | 25,00 |

Grafico 3 8

Doy FE: que la(s) [illegible] que antecede(n) constante(s) en 1 [illegible]
y exacta(s) al ORIGINAL que [illegible]
y que devuelvo [illegible]

Dr. Ra[illegible]
NOTARÍA NOVE[illegible]



Análisis: se observa que la ferritina fue el biomarcador con mas alteraciones en el grupo de estudio de pacientes que realizaron las pruebas de laboratorio y refleja el 66,7%, seguidos de la Inversión de linfocitos 33,3%, HDL 25%, TGP 25%, Neutrófilo con el 16,6%, DIMERO D 16,6 %, PCR 16,6, IGM 16, 6, IGG 25%.

Tabla # 10 Proporción de los pacientes cuyo síntomas al cuarto dia de tratamiento donde demuestra la reducción de los

| | Manifestaciones iniciales | Síntomas 4 dia | % | Reducción |
|---|---|---|---|---|
| **FIEBRE** | 68 | 1 | 1,5 | -98,53 |
| **ESCALOFRIO** | 30 | 1 | 3,3 | -96,67 |
| **DOLOR MUSCULAR** | 72 | 30 | 42 | -58,33 |
| **TOS SECA** | 83 | 62 | 75 | -25,3 |
| **DOLOR DE CABEZA** | 75 | 2 | 2,7 | -97,33 |
| **DOLOR DE ESPALDA** | 78 | 49 | 63 | -37,18 |
| **DIFICULTAD AL RESPIRAR** | 39 | 6 | 15 | -84,62 |
| **VOMITO** | 13 | 0 | 0 | -100 |
| **DIARREA** | 29 | 4 | 14 | -86,21 |
| **DOLOR DE GARGANTA** | 81 | 1 | 1,2 | -98,77 |
| **PERDIDA DEL OLFATO** | 89 | 8 | 9 | -91,01 |
| **PERDIDA DE SABORES** | 69 | 1 | 1,4 | -98,55 |
| **FALTA DE APETITO** | 57 | 2 | 3,5 | -96,49 |

Como se observan en las tablas # 10 existe una disminución general de 82,2 % de la sintomatología por covid19, posterior a administrar el tratamiento con Dióxido de cloro al cuarto día de tratamiento, el restante 18.8% presento secuelas leves como tos seca 75% y dorsalgia 63%, mialgia 42%, y del 15%, al 1,4% presento dificultad para respirar, perdida del olfato, diarrea, anorexia, escalofríos, cefalea, fiebre, ageusia consecutivamente. Cabe destacar que ninguno de estos pacientes falleció y no se asegurar con certeza que los síntomas diarreicos descritos en la literatura por CDS sean causados por la ingesta del mismo ya que la sintomatología por Covid-19 es variada incluso con síntomas digestivos sobre cuadro diarreicos, además son pacientes que ingresaron al estudio con este cuadro, por ende, se puede establecer que la diarrea es a causa de cuadro viral.

Así mismo es importe mencionar que el 11,53 % de los pacientes se realizaron exámenes de laboratorio y TAC de tórax, se identifica que el 66% de los pacientes recental alteraciones de ferritina, seguidas de linfopenia y leucopenia. Además, el 40 % de los pacientes presentaron síntomas de covid19 y el 30 % corresponden a contactos de los pacientes los cuales se incluyeron en el estudio. Lo cual limita el estudio, la mayor parte de pacientes incorporados en el estudio son de bajos recursos económicos y no cuentan con medios económicos para la realización de las pruebas confirmatorias ni de evolución, sin embargo, es evidente la mejoría clínica de esta serie de casos.

## CONCLUSIONES Y RECOMENDACIONES

Se constató que el grupo más afectado por Covid-19 en este estudio corresponde a edades entre 30 y 50 años, siendo el sexo femenino el más afectado.( se considera aquí, que fueron las mujeres las mas preocupadas por su salud, y las que aceptaron someterse a este estudio experimental con CDS)

En relación a la sintomatología destaca una reducción sintomática posterior a los cuatro días de tratamiento de la fiebre de 98,5%, escalofríos 96,7%, mialgias 58,3%, cefalea 97,3%, dorsalgia 37,2%, dificultad para respirar 84,6%, vómito 100%, diarrea 86,2%, odinofagia 98,8%, anosmia 91%, ageusia 98,6%, anorexia 96,5%

Doy FE: que la(s) copia(s) que [illegible]
constante(s) [illegible]
y exacta(s) al ORIGINAL que me [illegible]
y que devuelvo al Interesado

Existe una disminución general de 82,2 % de la sintomatología por covid19, posterior a administrar el tratamiento con Dióxido de cloro al cuarto día de tratamiento, el restante 18.8% presento secuelas leves como tos seca y dorsalgia.

El biomarcador más alterado en el grupo de estudio de pacientes que realizaron las pruebas de laboratorio fue la ferritina con el 66,7%, seguidos Inversión de linfocitos 33,3%, HDL 25%, TGP 25%, Neutrofilia con el 16,6%, DIMERO D 16,6 %, PCR 16,6, IGM 16, 6, IGG 25%.

No se registraron fallecimientos en este grupo de estudio, tampoco notificaciones de efectos tóxicos y adversos.

Con estas observaciones es relevante que las Autoridades sanitarias del ecuador permitan el acceso alternativo como coadyuvante en el tratamiento de para SARS-CoV2 para evitar tasa de mortalidad elevadas en el país, se propone usar el dióxido de cloro a mayor escala.

## BIBLIOGRAFIA

- Norio Ogata. (2012). *Inactivation of influenza virus haemagglutinin by chlorine dioxide: oxidation of the conserved tryptophan 153 residue in the receptor-binding site.* Recuperado de https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.044263-0

- Alliger, H. (s. f.). *1 An Overall View o f ClO 2* (pag 11). Recuperado de http://www.frontierpharmvet.com/clo2.pdf

- Judith R. Lubbers, Sudha Chauan, and Joseph R. Bianchine. (1982). *Controlled Clinical Evaluations of Chlorine Dioxide, Chlorite and Chlorate in Man* (v 46). Recuperado de https://andreaskalcker.com/wp-content/uploads/2016/04/2.-Controlled-Clinical-Evaluations-of-Clo2-in-Man.pdf

- Zoltán Noszticzius, Maria Wittmann, , Kristóf Kály-Kullai, Zoltán Beregvári, István Kiss, 3 László Rosivall, and János Szegedi . (2013, Noviembre 5). US National Library of Medicine National Institutes of Health. Recuperado 12 de abril de 2020, de https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815415/

875

- Daniel, FB; Condie, LW Robinson, M; et al (1990) Comparative subchronic toxicity studies of three disinfectants. J Am Water Works Assoc 82:61-69.

- Yogendra Patel, Ph.D. , Diana Wong, Ph., U. S. E. P. A. (2000). *TOXICOLOGICAL REVIEW OF CHLORINE DIOXIDE AND CHLORITE.* Recuperado de https://andreaskalcker.com/wp-content/uploads/2016/04/3.-EPA-Review-Toxicity-of-ClO2.pdf

- Alfredo Ruiz, Dr. (2009). Efectos del dióxido de cloro en enfermedades rebeldes a los tratamientos convencionales (pag 8). Recuperado de https://clinicamontetabor.files.wordpress.com/2014/02/investivacic3b3n-sobre-el-msm.pdf

- Maria E. Alvarez and R. T. O'brien,Mechanisms of Inactivation of Poliovirus by Chlorine Dioxide and Iodine. (1982). *American Society for Microbiology*, *44*, 3-8. Recuperado de https://www.ncbi.nlm.nih.gov/pmc/articles/PMC242149/pdf/aem00180-0060.pdf

- YU-SHIAW CHENI ,JAMES M. VAUGHN. (1990). Inactivation of Human and Simian Rotaviruses by Chlorine Dioxide. *American Society for Microbiology*, *vol* 56(no.5), 2-4. Recuperado de https://www.ncbi.nlm.nih.gov/pmc/articles/PMC184410/pdf/aem00086-0169.pdf

## CONCLUSIONES

Con este estudio se comprobó que el Dióxido de cloro a las dosis adecuadas a intervención temprana( fases1,2 y 3) en pacientes con pruebas y sintomatología covid.19 remitió el 97%, y el 3% de pacientes en fase con CID, no necesitaron hospitalización, sólo soporte médico y seguimiento en casa, continuo, de ahí la importancia de que debe ser un Medico conocedor de la fisiopatología humana, el que maneje la administración y supervisión del paciente covid 19 positivo y sus contactos, para obtener los resultados terapéuticos deseados y no se malverse el buen uso terapéutico de esta formulación como es el Dióxido de cloro.ya que es el facultativo si paciente esta en fase 4-5 de covid 19,quien realiza la derivación hospitalaria en caso de ser necesario.

Con fines de investigación y por la premura de salvar vidas, hemos realizado estudio con CDS para covid 19 durante 10 días a las dosis ya citadas anteriormente, pero damos la recomendación que toma debe ser de 21 días de tratamiento.

## RECOMENDACIONES

Detectar en fase precoz cuando la sintomatología recién empieza covid 19.

Educar a la población en cuanto aceptar que tienen esta sintomatología, ya que la negación por estigmatización, hace que avance la enfermedad y paciente acude cuando tiene insuficiencia respiratoria.

Valorar con exámenes de Biometría hemática como te llega el paciente, las condiciones clínicas del mismo, y luego del tratamiento con CDS hacer otra biometría Hemática.

El uso del Dióxido de cloro como preventivo es 100% eficaz y sin efectos colaterales, con este trabajo de investigación lo hemos comprobado, por lo tanto, recomendamos que se siga replicando la investigación, para que así se escuche las voces de los beneficiados que es la humanidad, y salir de esta pandemia a la brevedad posible.

Suscriben este trabajo de Investigación sobre el uso del CDS como tratamiento para Covid 19:

Dr. Roberto Edmundo García Espinoza. C.I 0101415958------------------------

Dra. Carmen Dorita Sarmiento Barba. C.I.0909353525------------------------

Dra. Sarita Marisol Montoya Carvajal C.I 0907715841------------------------ S. M. Montoya C.

Dr. Edwin Enrique Andrada Vilela C.I.0801616392------------------------

Dra. Sonia Honoria Moreira Vera C.I.0912565161------------------------

Dra. María Dolores Robles Urgilez C.I.0919589457------------------------

Lcda. Fabiola Lucía Jara Chamba, C.I 1104351544------------------------

Doy FE que [illegible]

ANEXOS

Foto # 1: **Evidencia el uso Intravenosos de dióxido de cloro** en paciente **con Covid 19.**

Foto # 2: Evidencia el uso **Intravenosos** de **dióxido de** cloro, uso preventivo.

Doy FE [illegible]

**Foto # 3: Entrevista con el Viceministro salud del Ecuador Dr. Carrasco, donde se sugiere uso de dióxido de cloro en pacientes con Covid 19.**

Foto # 4: AEMEMI frente a la lucha tratando pacientes con Covid 19

Foto # 5. Familia agradecida que fue tratada con dióxido de cloro para Covid 19.

Foto # 6: el uso Intravenosos de dióxido de cloro en paciente con Covid 19.

**Foto # 7: Miembros activos de AENEMI participando en el tratamiento con de dióxido de cloro en paciente con Covid 19.**

Foto # 8: **AEMEMI** participando activamente en el tratamiento con de dióxido de cloro en paciente con Covid 19 Positivo-Preparación y entrega gratuita del mineral

Foto # 9: **Entrega de dióxido de cloro preparado para uso en pacientes con Covid 19 positivo.**



Foto # 10: **Miembros activos de AEMEMI participando en el tratamiento con dióxido de cloro en paciente con Covid 19.**

Foto # 11: Contactos pacientes Covid19- positivo firmando consentimiento informado para el Uso de DSC

Foto # 12: Miembros activos de AEMEMI movilizando para visita domiciliaria entregando además tratamiento con de dióxido de cloro en pacientes con Covid 19.

**Foto # 13: AEMEMI realizando seguimiento en el tratamiento con dióxido de cloro en paciente con Covid 19**

## FICHA DE RECOLECCION DE DATOS Y SU CONSENTIMIENTO INFORMADO DE PACIENTES COVID19

Guayaquil 26 de marzo 2020

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA

## GRUPO AEMEMI ECUADOR Dr. ROBERTO GARCIA COORDINADOR

## Consentimiento voluntario

NOMBRE:

DIRECCION:

TELEFONO:

Grupo Sanguíneo

Prueba COVID-19 ..... NO...... Fecha de inicio sintomas: 2020

Fecha de nacimiento:

Yo con Cedula de Identidad de años de edad, una vez que se nos ha socializado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores de AEMEMI y Coordinado por Dr. Roberto García indicado el protocolo F cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos: Firma de consentimiento ..........................

| **Síntomas antes del tratamiento** | **Síntomas 1 día del tratamiento** | **Síntomas 2 día del tratamiento** | **Síntomas 3 día del tratamiento** | **Síntomas 4 día del tratamiento** |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrío | | | | |
| Dolor Muscular | | | | |
| Artralgia | | | | |
| Cefalea | | | | |
| Dolor torácico al respirar | | | | |
| Dificultad para respirar | | | | |
| Vómitos | | | | |
| Diarreas | | | | |
| Dolor de Garganta | | | | |
| Ardor de garganta | | | | |
| Anosmia | | | | |
| Ageusia | | | | |
| Conjuntivitis | | | | |
| Tos | | | | |
| Fiebre | | | | |
| Otros | | | | |
| | | | | |

Observación del paciente al tratamiento:

________________________________________

________________________________________

**El tratamiento que brindara los miembros de la Aememi es gratuito**

Dr. Mauricio Quiñonez M. — Presidente AEMEMI

Dra. Carmen Sarmiento E. — Secretaria de AEMEMI

Dr. Roberto García E — Vocal de AEMEMI

ASOCIACIÓN ECUATORIANA DE MÉDICOS EXPERTOS EN
MEDICINA INTEGRATIVA

**EL TRATAAMIENTO ES TOTALMENTE GRATUITO**

# ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

## Coordinado con Grupo [redacted] Y AEMEMI ECUADOR Dr.R. GARCIA

### Consentimiento voluntario

Tipo Sanguineo O+

Prueba COVID-19 SI........ NO........Fecha DE SINTOMAS INICIO ............

INICIA TTO CDS. SI ... NO ... CUANTOS MIENBROS SON .... TOMAN CDS SI ... NO ......

Yo...Janeth Malagon... con Cedula de identidad...0918955519... de.... años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina Integrativa.

Numero de posibles contactos...4 Firma de consentimiento...

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | | | X |
| Escalofrío | | | | X |
| Dolor Muscular | | | | X |
| Tos seca | | | | X |
| Dolor de cabeza | ✓ | ✓ | | X |
| Dolor de espalda | | | | X |
| Dificultad al respirar | | | | X |
| Vomitos | ✓ | | | X |
| Diarreas | ✓ | ✓ | | X |
| Dolor de Garganta | ✓ | ✓ | | ✓ |
| Perdida olfato | | | | ✓ |
| Perdida sabores | | | | X |
| Falta de apetito | | | | X |

Observación del paciente al tratamiento:

..........................................................................................

PCR [illegible] [illegible] Mejoría [illegible] [illegible]

Dr. Mauricio Quiñonez
**Presidente AEMENI**

Dr. Roberto García
**Vocal AEMENI**

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE** [illegible] **TELEF** 09858014832

**Consentimiento voluntario GRUPO SANGUINEO** O Rh+

Prueba COVID-19 SI...... [✓ NO]...... Fecha DE SINTOMAS INICIO 20-3-2020 Acude a [illegible]

TTO CDS [✓ SI]. NO ... **No DE MIENBROS** 3 **TOMAN CDS X CONTACTO FAMILIAR +** sin familia con del gas Dióxido

Yo Jose Luis [illegible] Miranda **con Cedula de identidad** 0103800827 **de** 44 **años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido** de cloro" como *tratamiento para COVID-19 Explicado por los Doctores Mauricio* Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa

Numero de posibles contactos... 3 Firma de consentimiento... ...........

| Sintomas antes del tratamiento | Sintomas 1 dia del tratamiento | Sintomas 2 dia del tratamiento | Sintomas 3 dia del tratamiento | Sintomas 4 dia del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | | | |
| Escalofrio | ✓ | | | |
| Dolor Muscular | | | | |
| Tos seca | ✓ | ✓ | ✓ | ✓ |
| Dolor de cabeza | ✓ | ✓ | ✓ | ✓ |
| Dolor de espalda | ✓ | | | |
| Dificultad al respirar | ✓ Dejo como que [illegible] algo<br>[illegible] | | | |
| Vómitos | | | | |
| Diarreas | ✓ [illegible] | | | |
| Dolor de Garganta | ✓ | | | |
| Perdida olfato | ✓ | | | |
| Perdida sabores | ✓ | | | |
| Falta de apetito | ✓ | | | |

Observación del paciente al tratamiento:

..........................................................................

Dr. Mauricio Quiñonez
Presidente AEMEMI

Dr. Roberto García
Vocal AEMEMI

887

ASOCIACIÓN ECUATORIANA DE MÉDICOS EXPERTOS EN
MEDICINA INTEGRATIVA
[illegible]
[illegible]
[illegible]

**EL TRATAAMIENTO ES TOTALMENTE GRATUITO**

# ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

## Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA

**DIREC. PACIENTE** Pascuales Puna y [illegible] **TELEF** 0994419534

**Consentimiento voluntario GRUPO SANGUINEO** O RH+

Prueba COVID-19 SI....... [✓ NO]...... Fecha DE SINTOMAS INICIO 20-3-2020 [illegible]

TTO CDS. [✓ SI] NO ... No DE MIENBROS 1 TOMAN [✓ CDS] X CONTACTO FAMILIAR + Abuelo + Henry Danny

Yo [illegible] Parrales con Cedula de identidad 0927632146 de 28 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para *COVID-19 Explicado por los Doctores* Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos 2 Firma de consentimiento........................................

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | | | |
| Escalofrío | | | | |
| Dolor Muscular | ✓ | ✓ | | |
| Tos seca | ✓ | ✓ | ✓ | ✓ |
| Dolor de cabeza | | | | |
| Dolor de espalda | ✓ | ✓ | ✓ | ✓ |
| Dificultad al respirar | ✓ leve | | | |
| Vómitos | ✓ | | | |
| Diarreas | ✓ | | | |
| Dolor de Garganta | ✓ | | | |
| Perdida olfato | ✓ | ✓ | | |
| Perdida sabores | | | | |
| Falta de apetito | ✓ | | | |

Observación del paciente al tratamiento:

.................................................................................................................................

Doy FE: que la(s) copia(s) que [illegible] compulsa(s) [illegible] foja(s) [illegible] conforme(s) al ORIGINAL que me [illegible] fue exhibido al interesado.

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto García
**Vocal AEMEMI**

ASOCIACIÓN ECUATORIANA DE MÉDICOS EXPERTOS EN
MEDICINA INTEGRATIVA

8/04/2020

**EL TRATAAMIENTO ES TOTALMENTE GRATUITO**

# ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE.** Carlos Alban Wima... **TELEF.** 09 826 9338

## Consentimiento voluntario

Prueba COVID-19 SI...X. NO........Fecha DE SINTOMAS INICIO ...3 Semanas

INICIA TTO CDS. SI ... NO ... CUANTOS MIENBROS SON .... TOMAN CDS SI ... NO ......

Yo. Carlos Alban W. con Cedula de identidad 1712412536 de.... años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos 4 Firma de consentimiento..........

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | | | |
| Escalofrío | ✓ | | | |
| Dolor Muscular | | | | |
| Tos seca | ✓ | | | |
| Dolor de cabeza | ✓ | | | |
| Dolor de espalda | ✓ | | | |
| Dificultad al respirar | ✓ | | | |
| Vómitos | | | | |
| Diarreas | ✓ | | | |
| Dolor de Garganta | [illegible] Seco | | | |
| Perdida olfato | ✓ | | | |
| Perdida sabores | ✓ | | | |
| Falta de apetito | ✓ | | | |

Observación del paciente al tratamiento:

..................................................................

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto García
Vocal AEMEMI

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE** Pascuales **TELEF.** 0994419534

**Consentimiento voluntario GRUPO SANGUINEO** O Rh-

Prueba COVID-19 SI ✓ [✓ NO] Fecha DE SINTOMAS INICIO 28-3-2020

TTO CDS. [✓ SI] NO ... No DE MIENBROS 6 TOMAN CDS X CONTACTO FAMILIAR [illegible]

Daysy Medina

Yo Marcos con Cedula de identidad 0922038117 de 34 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos 6 Firma de consentimiento

| Sintomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | | | |
| Escalofrío | | | | |
| Dolor Muscular | ✓ | ✓ | ✓ | ✓ |
| Tos seca | ✓ | ✓ | ✓ | |
| Dolor de cabeza | ✓ | | | |
| Dolor de espalda | ✓ | ✓ | ✓ | ✓ |
| Dificultad al respirar | | | | |
| Vómitos | | | | |
| Diarreas | | | | |
| Dolor de Garganta | ✓ | ✓ | | |
| Perdida olfato | ✓ | ✓ | | |
| Perdida sabores | ✓ | | | |
| Falta de apetito | ✓ | | | |

Observación del paciente al tratamiento:

Dr. Mauricio Quiñonez
Presidente AEMEMI

Dr. Roberto García
Vocal AEMEMI

ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA

**EL TRATAAMIENTO ES TOTALMENTE GRATUITO**

# ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE** Sauces 9 Mz 553 Villa 4 **TELEF.** 0996003076

**Consentimiento voluntario GRUPO SANGUINEO** O Rh+

Prueba COVID-19 SI…… [✓ NO]…… Fecha DE SINTOMAS INICIO 30-3-2020

TTO CDS. SI … NO … No DE MIENBROS … TOMAN CDS X CONTACTO FAMILIAR + Hija + Hijo

Mauricio Edilberto

Yo Quiñones Mendoza con Cedula de identidad 0701264597 de [illegible] años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 *Explicado por los Doctores Mauricio* Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

*Numero de posibles contactos* 2… *Firma de consentimiento*……………………

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | ✓ | | |
| *Escalofrío* | ✓ | ✓ | ✓ | |
| Dolor Muscular | ✓ | ✓ | ✓ | ✓ |
| Tos seca | ✓ | ✓ | ✓ | ✓ |
| Dolor de cabeza | ✓ | ✓ | | |
| Dolor de espalda | ✓ | ✓ | ✓ | ✓ |
| *Dificultad al respirar* | ✓ | ✓ | ✓ | |
| Vómitos | ✓ | ✓ | | |
| Diarreas | ✓ | ✓ | ✓ | ✓ |
| Dolor de Garganta | ✓ | ✓ | | |
| Perdida olfato | ✓ | ✓ | ✓ | ✓ |
| Perdida sabores | ✓ | ✓ | ✓ | |
| Falta de apetito | ✓ | ✓ | | |

Observación del paciente al tratamiento.

Se aplicó [illegible] Vitamina [illegible] 8 Abril 2020

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto García
Vocal AEMEMI

JUNTA DE BENEFICENCIA
DE GUAYAQUIL

# LABORATORIO CLINICO

| | | | |
|---|---|---|---|
| **Nombre:** | QUINONEZ MENDOZA , MAURICIO EDILBERTO | | |
| **Historia:** | 4888923 | **Orden No.** | 2004203014 |
| **Fecha ingreso:** | 20/04/2020 08:33:21 | **Origen:** | EMERGENCIA HRG |
| **Fecha impresion:** | 20/04/2020 12:35:48 | **Solicitado por:** | Dr. |
| | | **Sala:** | |
| | | **Cama:** | |

*1er trimestre 0.9 - 1.5 ng/dL*
*2do trimestre 0.8 - 1.3 ng/dL*
*3er trimestre 0.7 - 1.2 ng/dL*

| *EXAMEN* | *RESULTADO* | *UNIDADES* | *RANGO DE REFERE* |
|---|---|---|---|
| CORTISOL PLASMATICO AM | 14.6 | µg/dL | [ 4.8 - 19.5 ] |
| INSULINA | 9.6 | µUI/mL | [ 6.0 - 19.0 ] |
| FERRITINA | 434.00 | ng/mL | *[ 30.00 - 400.00 ]* |
| IgE | 68.1 | UI/mL | [ 0.0 - 100.0 ] |

REALIZADO POR: ADOLFO BYRON BRAVO
20/04/2020 10:33:50

## *GASES VENOSOS*

GASOMETRIA VENOSA

| | | |
|---|---|---|
| pH VENOSO | 7.254 | |
| PCO2 VENOSO | 61.6 | mm/Hg |
| PO2 VENOSO | 88.1 | mm/Hg |
| HCO3 VENOSO | 26.6 | mmol/l |
| TCO2 VENOSO | 18.7 | mmol/l |
| BE VENOSO | -1.9 | mmol/l |
| O2SAT VENOSO | 89 | % |

DRA. KAROL QUIÑONEZ

REALIZADO POR: ANDREA DESIRE MEZA
20/04/2020 09:34:21

## *COAGULACION*

| | | | |
|---|---|---|---|
| TTP | 31.6 | seg | [ 22.0 - 43.0 ] |
| DIMERO D | 1.5 | ng/ml | [ 0.2 - 0.5 ] |

* VALORES FUERA DE RANGO

892

JUNTA DE BENEFICENCIA
DE GUAYAQUIL

## LABORATORIO CLINICO

**Nombre:** QUINONEZ MENDOZA , MAURICIO EDILBERTO
**Historia:** 4660923
**Fecha ingreso:** 20/04/2020 08:33:21
**Fecha impresion:** 20/04/2020 12:35:46
**Orden No.** 2004203014
**Origen:** EMERGENCIA HRG
**Solicitado por:** Dr.
**Sala:**
**Cama:**

REALIZADO POR: ADOLFO BYRON BRAVO
20/04/2020 12:17:21 CECILIA RUIZ
20/04/2020 12:04:41

| EXAMEN | RESULTADO | UNIDADES | RANGO DE REFERENCIA |
|---|---|---|---|
| | **ELECTROLITOS** | | |
| MAGNESIO | 1.94 | mg/dl | [ 1.80 - 2.40 ] |
| CALCIO | 8.9 | mg/dl | [ 8.6 - 10.0 ] |

REALIZADO POR: ADOLFO BYRON BRAVO
20/04/2020 10:20:53

ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE** [illegible] V. 18 **TELEF.** 0969221563

**Consentimiento voluntario** **GRUPO SANGUINEO** ..................

Prueba COVID-19 SI...... [✓ NO]...... Fecha DE SINTOMAS INICIO 28-3-2020

TTO CDS. [✓ SI]... NO ... No DE MIENBROS .... TOMAN CDS X CONTACTO FAMILIAR + ...contacto

Yo Luis Daniel Zeas León ............ con Cedula de identidad 0950132217 de 27 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos..... Firma de consentimiento..............................

| Sintomas antes del tratamiento | Sintomas 1 día del tratamiento | Sintomas 2 día del tratamiento | Sintomas 3 día del tratamiento | Sintomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrío | | | | |
| Dolor Muscular | | | | |
| Tos seca | | | | |
| Dolor de cabeza | | | | |
| Dolor de espalda | | | | |
| Dificultad al respirar | | | | |
| Vómitos | | | | |
| Diarreas | | | | |
| Dolor de Garganta | | | | |
| Perdida olfato | | | | |
| Perdida sabores | | | | |
| Falta de apetito | | | | |

Observación del paciente al tratamiento:

..............................................................

Doy FE: [illegible]

Dr. Mauricio Quiñonez
Presidente AEMEMI

Dr. Roberto García
Vocal AEMEMI

A.E.M.E.M.I.

**ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA**

FECHA: MARZO-6-DEL 2020

NOMBRES: Luis Daniel Zeas León

FECHA DE NACIMIENTO: 03-08-1993

DESDE CUANDO SE SIENTE ENFERMO: desde 10 días

¿TUVO CONTACTO CON PERSONAS QUE TIENEN EXAMEN DE COVID 19 POSITIVO?: NO

NOMBRE DE ESA PERSONA

¡USTED SE HA HECHO EXAMEN DE COVID19? NO

SEÑALE QUE TIENE:

FIEBRE: ✓

ESCALOFRIOS:

DOLOR MUSCULAR: ✓

DOLOR HUESOS:

DOLOR DE CABEZA: ✓

DOLOR EN PECHO AL RESPIRAR:

DIFICULTAD PARA RESPIRAR:

VOMITO:

DIARREA:

DOLOR DE GARGANTA:

ARDOR DE GARGANTA:

NO SIENTE LOS SABORES DE COMIDAS:

NO SIENTE LOS OLORES:

OTRO SINTOMA:

Yo Luis Zeas León autorizo recibir tratamiento con CDS Y MMS para tratamiento y prevención de COVID 19, el mismo que tendrá lugar en mi domicilio, y sera monitoreado por AEMEMI

FIRMA

C.I. 0950132217-7

DIRECCIÓN ORQUIDEAS MZ [illegible]

[illegible] 0968322564

895

La información de esta sección será de uso exclusivo del Funcionario/a del Registro Civil, en el momento de la inscripción.

1) OFICINA DE REGISTRO CIVIL DE: ..................

2) PROVINCIA: ..................

CANTÓN: ..................

PARROQUIA URBANA O RURAL: ..................

3) FECHA DE INSCRIPCIÓN: Año / Mes / Día

4) CÓDIGO SECUENCIAL O ACTA DE INSCRIPCIÓN:

(Debe ser el mismo que consta en el libro de inscripciones)

## A) DATOS DEL FALLECIDO/A

5) NÚMERO DE CÉDULA DE CIUDADANÍA O IDENTIDAD/PASAPORTE/OTROS

Uso Establecimientos de Salud, Médicos Particulares, Médicos Legistas y Registro Civil

0910352147

6) APELLIDOS Y NOMBRES

Rojas Vera Carlos Virgilio

7) NACIONALIDAD

Ecuatoriana ☑ 1

Extranjera ☐ 2 → ..................

Nombre del País

8) SEXO

Hombre ☑ 1 Mujer ☐ 2

9) FECHA DE NACIMIENTO

1968 11 04

Año Mes Día

10) FECHA DE FALLECIMIENTO

2020 04 01

Año Mes Día

11) HORA DE NACIMIENTO. Aplica si la defunción ocurrió el mismo día del nacimiento o al siguiente día.

___ / ___ Hora Minutos

12) HORA DE FALLECIMIENTO. Aplica si la defunción ocurrió el mismo día del nacimiento o al siguiente día.

___ / ___ Hora Minutos

13) EDAD AL FALLECER

En minutos (Si es menor de una hora) ☐☐ 0

En Horas (Si es menor de 1 día) ☐☐ 1

En Días (Si es menor de 1 mes) ☐☐ 2

En Meses (Si es menor de 1 año) ☐☐ 3

Años 051 4

14) RESIDENCIA HABITUAL

Guayas

Provincia

Guayaquil

Cantón

Tarqui

Parroquia urbana o rural

Coop. Sanpedro Mz Villa

Dirección domiciliaria

15) INFORMACIÓN DE QUIEN SOLICITA EL IEDG

..................

Apellidos y Nombres

.................. Teléfono Convencional .................. Teléfono celular

..................

Correo electrónico

16) ESTADO CIVIL Y/O CONYUGAL

Soltero /a ☑ 1

Casado /a ☐ 2

Divorciado /a ☐ 3

Viudo /a ☐ 4

Unión de hecho ☐ 5

Unión Libre ☐ 6

Separado /a ☐ 7

17) NIVEL DE INSTRUCCIÓN Y ALFABETISMO (Información proporcionada por el solicitante del IEDG) (Aplica para el fallecido de 5 años y más)

17.1) Último nivel de instrucción aprobado

Ninguno ☐ 0

Centro de Alfabetización ☐ 1

Primaria ☐ 2

Educación Básica ☑ 3

Secundaria ☐ 4

Educación Media/Bachillerato ☐ 5

Superior no universitario ☐ 6

Superior Universitario ☐ 7

Postgrado ☐ 8

17.2) Alfabetismo

¿SABÍA LEER Y ESCRIBIR?

SÍ 1 ☑

NO 2 ☐

18) AUTOIDENTIFICACIÓN ÉTNICA DEL FALLECIDO/A SEGÚN SU CULTURA Y COSTUMBRES (Información proporcionada por el solicitante del IEDG)

Indígena ☐ 1

Afroecuatoriano /a Afrodescendiente ☐ 2

Negro /a ☐ 3

Mulato /a ☐ 4

Montubio /a ☐ 5

Mestizo /a ☑ 6

Blanco /a ☐ 7

Otro ☐ 8

## 19) LUGAR DE OCURRENCIA DEL FALLECIMIENTO

19.1) Lugar de ocurrencia de la muerte

1. Establecimiento de salud ☒ 1

2. Casa ☐ 2

3. Casa (Fallecido tenía atención médica ambulatoria o seguimiento en un establecimiento de salud de enfermedades crónicas o terminales) ☐ 3

4. Centro geriátrico/Casas hogares/Ancianatos (Fallecido tenía atención médica ambulatoria o seguimiento en un establecimiento de salud de enfermedades crónicas o terminales) ☐ 4

5. Centro geriátrico/Casas hogares/Ancianatos (Cuenta con médico) ☐ 5

6. Otro (Indique el lugar en la pregunta 19.4) ☐ 6

19.2) ¿El fallecido/a recibió cuidados paliativos?

SI ☐ 1 NO ☐ 2

19.3) Establecimiento de salud que brindó la atención médica ambulatoria o seguimiento al fallecido/a. (Aplica si en la pregunta 19.1 marcó casilla 3 o 4 caso contrario continúe con la pregunta 19.4).

..................

19.3.1) Nombre del Establecimiento de Salud

19.3.2) Provincia 19.3.3) Cantón 19.3.4) Parroquia

19.4) Identificación del lugar donde ocurrió el fallecimiento:

000916

HOSPITAL DEL DÍA MARIANA DE JESÚS

19.4.1) Nombre del lugar

GUAYAS GUAYAQUIL

19.4.2) Provincia 19.4.3) Cantón

FEBRES CORDERO

19.4.4) Parroquia urbana o rural

LA 27 AVA. Y ROSENDO AVILES 042728190

19.4.5) Dirección 19.4.6) Teléfono

CÓDIGO 090104

NOTA: ESTE DOCUMENTO Y SU TRAMITACIÓN SON GRATUITOS

896

INTERLAB
INTERNATIONAL LABORATORIES SERVICES
INTERLAB S.A.
El Laboratorio Clínico de su confianza
Director Tecnico: Dr. Jorge Macias Loor
LABORATORIO PRINCIPAL ATENCION 24 HORAS
Direccion: Cdla. Unión y Progreso Calle N número 11 y av. Fco. de Orellana
PBX: 2594010

**Paciente:** REYES YAGUAL, CARLOS JULIO

**Médico:** DR(a): d

**Página:** 1 d

**Fecha:** 2

**Orden No.:** 5646173

**Edad:** 31 Años

**Género:**

| NOMBRE ESTUDIO | RESULTADO | UNIDADES | R.REFEREN |
|---|---|---|---|
| | **BIOLOGIA MOLECULAR** | | |
| (*) Coronavirus - Co-Vid 19 por PCR<br>Tecnica: PCR en Tiempo Real | POSITIVO | | |
| (*) *COVID-19 (Coronavirus) Screening* | DETECTADO | | |

RESULTADO CONFIRMADO Y VERIFICADO

Método: REACCION EN CADENA DE LA POLIMERASA EN TIEMPO REAL

Muestra: Hisopado *nasofaringeo y orofaringeo*

Método de extración: Hig Pure Viral Acid Nucleic Kit Roche.

Amplificación y detección específica por Método de Reacción en Cadena de la Polimerasa en Tiempo Real (RT-qPCR) utilizando cebadores (primers) y sondas específicos para un fragmento específico de una región conservada del gen E. Este ensayo permite la detección de SARS y el Virus Wuhan 2019 CoV así como virus respiratorios asociados (Sarbecovirus).

No presenta reacción cruzada con virus humanos respiratorios comunes como: CoV NL63, 229E, HKU, OC43 o MERS.

Resultado: POSITIVO

Interpretación: La muestra amplifica con los cebadores y sondas especificas del virus; Wuhan 2019 CoV Virus DETECTABLE.

Prueba procesada en laboratorio externo

Tecnica: RT - PCR en tiempo real

Nota: Se considera el Punto(.) como separador decimal.

Atentamente.

Jorge Macias Loor

Dr. Jorge Macias Loor

Doy FE: que la(s) copia(s) que [illegible] constante(s) en ... foja(s) [illegible] y exacta(s) al ORIGINAL que me fue [illegible] y que devolvió al interesado.

Dr. [illegible]
NOTARIO [illegible]

SIN VALOR LEGAL, PARA ESE EFECTO DEBE ACERCARSE AL LABORATORIO PRINCIPA

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

# ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE** Cooperativa San Pedro Mz [illegible] Villa 24 **TELEF.**........

**Consentimiento voluntario GRUPO SANGUINEO** ........

Prueba COVID-19 [✓ SI]...... NO...... Fecha DE SINTOMAS INICIO 11-3-2020

TTO CDS. SI [✓ NO].. No DE MIENBROS 5 TOMAN CDS X CONTACTO FAMILIAR + ........

Yo Carlos Julio Reyes Yaguel ........con Cedula de identidad 0910532177 de 52 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto Garcia indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

[illegible]

Numero de posibles contactos..... Firma de consentimiento.........

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | ✓ | ✓ | |
| Escalofrío | ✓ | ✓ | ✓ | |
| Dolor Muscular | ✓ | ✓ | ✓ | |
| Tos seca | ✓ | ✓ | ✓ | |
| Dolor de cabeza | ✓ | ✓ | ✓ | |
| Dolor de espalda | ✓ | ✓ | ✓ | |
| Dificultad al respirar | ✓ | ✓ | ✓ | |
| Vómitos | ✓ | ✓ | ✓ | |
| Diarreas | ✓ | ✓ | ✓ | |
| Dolor de Garganta | ✓ | ✓ | ✓ | |
| Perdida olfato | ✓ | ✓ | ✓ | |
| Perdida sabores | ✓ | ✓ | ✓ | |
| Falta de apetito | ✓ | ✓ | ✓ | |

Observación del paciente al tratamiento:

........................................................................

Dr. Mauricio Quiñonez
Presidente AEMEMI

Dr. Roberto Garcia
Vocal AEMEMI

AEMEMI

**ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA.**

**FECHA: MARZO** 6 **DEL 2020**

**NOMBRES:** Luis Zivichay

**FECHA DE NACIMIENTO:** 3 Julio 1961

**DESDE CUANDO SE SIENTE ENFERMO:**

**¿TUVO CONTACTO CON PERSONAS QUE TIENEN EXAMEN DE COVID 19 POSITIVO?:**

**NOMBRE DE ESA PERSONA**

**¡USTED SE HA HECHO EXAMEN DE COVID19?** NO

**SEÑALE QUE TIENE:**

**FIEBRE:**

**ESCALOFRIOS:**

**DOLOR MUSCULAR:**

**DOLOR HUESOS:**

**DOLOR DE CABEZA:**

**DOLOR EN PECHO AL RESPIRAR:**

**DIFICULTAD PARA RESPIRAR:**

**VOMITO:**

**DIARREA:**

**DOLOR DE GARGANTA:**

**ARDOR DE GARGANTA:**

**NO SIENTE LOS SABORES DE COMIDAS:**

**NO SIENTE LOS OLORES:**

**OTRO SINTOMA:**

Doy FE: que la(s) copia(s) que antecede(n) contenida(s) en 1 hoja(s) útiles es fiel (copia) del ORIGINAL que me fue exhibido y devuelto al interesado.

Dr. Renán Vásquez [illegible]
NOTARIA [illegible] DEL CANTON GUAYAQUIL

Yo Luis Zivichay autorizo recibir tratamiento con CDS Y MMS para tratamiento y prevención de COVID 19, el mismo que tendrá lugar en mi domicilio, y será monitoreado por AEMEMI.

FIRMA

C.I. [illegible]-3

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

# ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE**........................................................ **TELEF**..................

**Consentimiento voluntario GRUPO SANGUINEO** ..................

Prueba COVID-19 SI....... [✓ NO]...... Fecha DE SINTOMAS INICIO ...29-3-2020

TTO CDS. SI ... NO ... No DE MIENBROS .... TOMAN CDS X CONTACTO FAMILIAR + .........

Yo....S.Delochay..................con Cedula de identidad.0102624513 de 59 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos...... Firma de consendimiento..............................

| Sintomas antes del tratamiento | Sintomas 1 dia del tratamiento | Sintomas 2 día del tratamiento | Sintomas 3 día del tratamiento | Sintomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrío | | | | |
| Dolor Muscular | | | | |
| Tos seca | | | | |
| Dolor de cabeza | | | | |
| Dolor de espalda | | | | |
| Dificultad al respirar | | | | |
| Vómitos | | | | |
| Diarreas | | | | |
| Dolor de Garganta | | | | |
| Perdida olfato | | | | |
| Perdida sabores | | | | |
| Falta de apetito | | | | |

Observación del paciente al tratamiento:

.......................................................................................................

Dr. Mauricio Quiñonez
Presidente AEMEMI

Dr. Roberto Garcia
Vocal AEMEMI

ACUERDO MINISTERIAL DEL MSP No. 0150
Nov. 2017

ASOCIACIÓN ECUATORIANA DE MÉDICOS EXPERTOS EN MEDICINA INTEGRATIVA
M.S.P. Acuerdo Ministerial 0150 - 2017
Teléfonos: [illegible]
Dirección: Cdla Guayacanes Mz [illegible]

**EL TRATAAMIENTO ES TOTALMENTE GRATUITO**

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE** El Recreo La Herradura Mz A3 S7 **TELEF** 26/ Marzo 0991346725

### Consentimiento voluntario

Prueba COVID-19 SI........ NO........Fecha DE SINTOMAS INICIO 26/ Marzo

INICIA TTO CDS. SI ... NO ... CUANTOS MIENBROS SON .... TOMAN CDS SI ... NO ......

Yo José Vinces Pilay con Cedula de identidad 0907529952 de 60 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos 12 Firma de consentimiento

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | ✓ | | |
| Escalofrío | | | | |
| Dolor Muscular | ✓ | ✓ | ✓ | |
| Tos seca | ✓ | ✓ | ✓ | |
| Dolor de cabeza | ✓ | ✓ | | |
| Dolor de espalda | ✓ | ✓ | ✓ | ✓ |
| Dificultad al respirar | | | | |
| Vomitos | | | | |
| Diarreas | | ✓ | | |
| Dolor de Garganta | ✓ | | | |
| Perdida olfato | ✓ | ✓ | | |
| Perdida sabores | ✓ | | | |
| Falta de apetito | ✓ | | | |

Observación del paciente al tratamiento:

..............................................................................................

Doy FE que la(s) copia(s) que antecede(n) constante(s) en ____ foja(s) útiles es fiel y exacta(s) al ORIGINAL que me fue exhibido y que devolví al interesado

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto García
**Vocal AEMEMI**

901

A.E.M.E.M.I.

ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA.

FECHA: MARZO 6 DEL 2020

NOMBRES: Freddy Zeas León

FECHA DE NACIMIENTO: 09 - 05 - 1995

DESDE CUANDO SE SIENTE ENFERMO: Desde 10 días.
¿TUVO CONTACTO CON PERSONAS QUE TIENEN EXAMEN DE COVID 19 POSITIVO?: NO
NOMBRE DE ESA PERSONA
!USTED SE HA HECHO EXAMEN DE COVID19? NO
SEÑALE QUE TIENE:
FIEBRE: ✓
ESCALOFRIOS:
DOLOR MUSCULAR:
DOLOR HUESOS:
DOLOR DE CABEZA: ✓
DOLOR EN PECHO AL RESPIRAR:
DIFICULTAD PARA RESPIRAR:
VOMITO:
DIARREA: ✓
DOLOR DE GARGANTA: ✓
ARDOR DE GARGANTA:
NO SIENTE LOS SABORES DE COMIDAS:
NO SIENTE LOS OLORES: ✓
OTRO SINTOMA:

Yo Freddy Zeas León autorizo recibir tratamiento con CDS Y MMS para tratamiento y prevención de COVID 19, el mismo que tendrá lugar en mi domicilio, y será monitoreado por AEMEMI.

FIRMA 0950132134
C.I. Freddy Zeas

[illegible]
[illegible]

ASOCIACIÓN ECUATORIANA DE MÉDICOS EXPERTOS EN MEDICINA INTEGRATIVA

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

# ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE.** [illegible] 112 [illegible] villa 18 **TELEF.** 0969835017

**Consentimiento voluntario GRUPO SANGUINEO** ..................

Prueba COVID-19 SI....... [✓ NO]...... Fecha DE SINTOMAS INICIO ..........

TTO CDS. [✓ SI].. NO ... No DE MIENBROS .... TOMAN CDS X CONTACTO FAMILIAR + ..........

Yo...Freddy Zeas León..................con Cedula de identidad 0550132134 de 25 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 *Explicado por los Doctores Mauricio* Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos...... Firma de consentimiento..........................

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | | | |
| Escalofrío | | | | |
| Dolor Muscular | | | | |
| Tos seca | | | | |
| Dolor de cabeza | ✓ | | | |
| Dolor de espalda | | | | |
| Dificultad al respirar | | | | |
| Vómitos | | | | |
| Diarreas | ✓ | | | |
| Dolor de Garganta | ✓ | | | |
| Perdida olfato | ✓ | | ✓ | |
| Perdida sabores | | | | |
| Falta de apetito | | | | |

Observación del paciente al tratamiento:

..........................................................................

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto García
**Vocal AEMEMI**

903

**EL TRATAAMIENTO ES TOTALMENTE GRATUITO**

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE.............................................................. TELEF...........................**

**Consentimiento voluntario GRUPO SANGUINEO** ..................

Prueba COVID-19 SI....../. [✓ NO]...... Fecha DE SINTOMAS INICIO .....29 - 3 - 2020

TTO CDS. [✓ SI].. NO ... No DE MIENBROS .... TOMAN CDS X CONTACTO FAMILIAR + Contacto

Bruno David

Yo......Viles.........Tonego.....con Cedula de identidad.0957618960 de..7 años de

edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos...... Firma de consentimiento...................................................

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | | | |
| Escalofrío | | | | |
| Dolor Muscular | | | | |
| Tos seca | | | | |
| Dolor de cabeza | ✓ | | | |
| Dolor de espalda | ✓ | | | |
| Dificultad al respirar | | ✓ | | |
| Vómitos | | | | |
| Diarreas | | | | |
| Dolor de Garganta | ✓ | | | |
| Perdida olfato | ✓ | | | |
| Perdida sabores | | ✓ | | |
| Falta de apetito | | | | |

Observación del paciente al tratamiento.

..............................................................................................................................

Dr. Mauricio Quiñonez
Presidente AEMEMI

Dr. Roberto García
Vocal AEMEMI

904

ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

## Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA

**DIREC. PACIENTE** 2 Av. idem ma[illegible] villa 20 **TELEF.** 099 458 0999

**Consentimiento voluntario GRUPO SANGUINEO** ……………………

Prueba COVID-19 SI…… [✓ NO.]…… Fecha DE SINTOMAS INICIO ……30 - 3 - 2020

TTO CDS [✓ SI]. NO … No DE MIENBROS …. TOMAN CDS X CONTACTO FAMILIAR + Sintomatico

Yo Jenny Nelson Guaman Poveda ……con Cedula de identidad 0921070900 de 38 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa

Numero de posibles contactos…… Firma de consentimiento……………………………

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrío | | | | |
| Dolor Muscular | ✓ | | | |
| Tos seca | | ✓ | ✓ | ✓ |
| Dolor de cabeza | ✓ | | | |
| Dolor de espalda | | | | |
| Dificultad al respirar | | | | |
| Vómitos | | | | |
| Diarreas | | | | |
| Dolor de Garganta | ✓ | | | |
| Perdida olfato | ✓ | ✓ | | |
| Perdida sabores | ✓ | ✓ | ✓ | |
| Falta de apetito | ✓ | | | |

Observación del paciente al tratamiento:

……………………………………………………………………

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto García
**Vocal AEMEMI**

905

AEMEMI

ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA.

FECHA: MARZO 6 DEL 2020

NOMBRES: Jerry Nelson Quiroz Poveda.

FECHA DE NACIMIENTO: 20/05/1982

DESDE CUANDO SE SIENTE ENFERMO:
¿TUVO CONTACTO CON PERSONAS QUE TIENEN EXAMEN DE COVID 19 POSITIVO?: NO
NOMBRE DE ESA PERSONA
¡USTED SE HA HECHO EXAMEN DE COVID19? NO
SEÑALE QUE TIENE:
FIEBRE:
ESCALOFRIOS:
DOLOR MUSCULAR: ✓
DOLOR HUESOS:
DOLOR DE CABEZA: ✓
DOLOR EN PECHO AL RESPIRAR:
DIFICULTAD PARA RESPIRAR:
VOMITO:
DIARREA:
DOLOR DE GARGANTA: ✓
ARDOR DE GARGANTA: ✓
NO SIENTE LOS SABORES DE COMIDAS: ✓
NO SIENTE LOS OLORES: ✓
OTRO SINTOMA: pérdida apetito

Yo Jerry Quiroz Poveda. autorizo recibir tratamiento con CDS Y MMS para tratamiento y prevención de COVID 19, el mismo que tendrá lugar en mi domicilio, y será monitoreado por AEMEMI.

FIRMA
C.I. 0921070900

Dirección: [illegible]
Celular: 098450[illegible]

A.E.M.E.M.I.
ACUERDO MINISTERIAL DEL MSP No 0150
Nov 2017

ASOCIACIÓN ECUATORIANA DE MÉDICOS EXPERTOS EN
MEDICINA INTEGRATIVA
M.S.P. Acuerdo Ministerial 0150 - 2017
Teléfonos [illegible]
Dirección: [illegible] Guayaquil [illegible]

NOTARÍA NOVENA DEL CANTÓN

**EL TRATAAMIENTO ES TOTALMENTE GRATUITO**

# ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

## Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA

**DIREC. PACIENTE** Batán [illegible] **TELEF.**

**Consentimiento voluntario GRUPO SANGUINEO** 0 Rh

Prueba COVID-19 SI....... [✓ NO]...... Fecha DE SINTOMAS INICIO 20-3-2020

Diabetico

TTO CDS [✓ SI]... NO ... No DE MIEMBROS .... TOMAN CDS X CONTACTO FAMILIAR + [illegible]

Yo Narciso Bienvenido Castillo [illegible] con Cedula de identidad 17 1181895 3 de 42 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos...... Firma de consentimiento..........................................

Fecha

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | ✓ | | |
| Escalofrío | ✓ | | | |
| Dolor Muscular | ✓ | ✓ | ✓ | ✓ |
| Tos seca | ✓ | ✓ | ✓ | ✓ |
| Dolor de cabeza | ✓ | | ✓ | |
| Dolor de espalda | ✓ | ✓ | ✓ | ✓ |
| Dificultad al respirar | ✓ | ✓ | ✓ | ✓ |
| Vómitos | | | | |
| Diarreas | ✓ | ✓ | ✓ | |
| Dolor de Garganta | ✓ | ✓ | ✓ | ✓ |
| Perdida olfato | ✓ | ✓ | ✓ | |
| Perdida sabores | ✓ | ✓ | ✓ | |
| Falta de apetito | ✓ | ✓ | ✓ | |

Observación del paciente al tratamiento:
[illegible]

Fecha 20-4-2020

Por [illegible]

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto García
**Vocal AEMEMI**

Doy FE que la(s) copia(s) que antecede(n) constante(s) en 1 foja(s) [illegible] ORIGINAL que me fue devuelta al interesado

907

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

# ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE.** [illegible] Pane / [illegible] **TELEF.** 0994414534

**Consentimiento voluntario** **GRUPO SANGUINEO** O Rh

Prueba COVID-19 SI....... [✓ NO]...... Fecha DE SINTOMAS INICIO 28-3-2020

TTO CDS. [✓ SI] . NO ... No DE MIENBROS/ 2 TOMAN [✓ CDS] X CONTACTO FAMILIAR Abuela [illegible]

Yo [illegible] Jesus Sanches Deschula ....con Cedula de identidad 966601136 ............ de 3 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos...... Firma de consentimiento ........................................

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrío | | | | |
| Dolor Muscular | | | | |
| Tos seca | ✓ | ✓ | ✓ | ✓ |
| Dolor de cabeza | | | | |
| Dolor de espalda | | | | |
| Dificultad al respirar | | | | |
| Vómitos | | | | |
| Diarreas | | | | |
| Dolor de Garganta | | | | |
| Perdida olfato | | | | |
| Perdida sabores | | | | |
| Falta de apetito | | | | |

Observación del paciente al tratamiento:

.................................................................................................................................

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto Garcia
Vocal AEMEMI

908

ASOCIACIÓN ECUATORIANA DE MÉDICOS EXPERTOS EN
MEDICINA INTEGRATIVA

A.E.M.E.M.I.
ACUERDO MINISTERIAL [illegible] No. [illegible]
Nov. 2017

**EL TRATAAMIENTO ES TOTALMENTE GRATUITO**

# ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

## Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA

**DIREC. PACIENTE** Pascuales [illegible] **TELEF.** [illegible]

**Consentimiento voluntario GRUPO SANGUINEO** O RH+

Prueba COVID-19 SI....... [✓ NO]...... Fecha DE SINTOMAS INICIO 26-3-2020

TTO CDS. [✓ SI].. NO ... No DE MIENBROS 10 TOMAN CDS X CONTACTO FAMILIAR + .........

Yo [illegible] Pallma ........con Cedula de identidad 0919084210 de 23 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" *como tratamiento para COVID-19 Explicado por los Doctores Mauricio* Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos 10 Firma de consentimiento.........................................

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrío | | | | |
| Dolor Muscular | | | | |
| Tos seca | ✓ mucho | ✓ | ✓ | ✓ |
| Dolor de cabeza | ✓ | | | |
| Dolor de espalda | | ✓ | | |
| Dificultad al respirar | | | | |
| Vómitos | | | | |
| Diarreas | | | | |
| Dolor de Garganta | | | | |
| Perdida olfato | | | | |
| Perdida sabores | | | | |
| Falta de apetito | | | | |

Observación del paciente al tratamiento:
.................................................................................................................................

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Doy FE que la(s) copia(s) que antecede(n) ... constante(s) en ... foja(s) útiles ... y exacta(s) al ORIGINAL que me fue exhibido y que devuelvo al interesado.

Dr. Roberto García
Vocal AEMEMI

909

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE** Pascuales [illegible] **TELEF** 0985224960

**Consentimiento voluntario** **GRUPO SANGUINEO** O RH+

Prueba COVID-19 SI NO X Fecha DE SINTOMAS INICIO 24-3-2020

TTO CDS: [✓ SI] NO **No DE MIENBROS** .... TOMAN CDS X CONTACTO FAMILIAR + ~~Hermano~~ esposa de padre

Yo Hernan Felipe Dominguez con Cedula de identidad [illegible] de 6 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 da 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos 4 Firma de consentimiento....................

| Sintomas antes del tratamiento | Sintomas 1 día del tratamiento | Sintomas 2 día del tratamiento | Sintomas 3 día del tratamiento | Sintomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | | | |
| Escalofrío | ✓ | | | |
| Dolor Muscular | ✓ | | | |
| Tos seca | ✓ | ✓ | ✓ | ✓ |
| Dolor de cabeza | ✓ | ✓ | ✓ | ✓ |
| Dolor de espalda | ✓ | ✓ | | |
| Dificultad al respirar | ✓ | ✓ | ✓ | ✓ |
| Vómitos | | ✓ | | |
| Diarreas | | | | |
| Dolor de Garganta | ✓ | | | |
| Perdida olfato | ✓ | ✓ | | |
| Perdida saboras | ✓ | ✓ | | |
| Falta de apetito | | | | |

Observación del paciente al tratamiento:

..........................................................................

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto Garcia
[illegible] AEMEMI

910

ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE**........................................................ **TELEF**..........................

**Consentimiento voluntario GRUPO SANGUINEO** ....................

Prueba COVID-19 SI....... NO..X.. Fecha DE SINTOMAS INICIO 26 Marzo 2020.

TTO CDS. SI .X NO ... **No DE MIENBROS** 2 TOMAN CDS X CONTACTO FAMILIAR + 3

Yo...Paul Pincay...Vidores...........con Cedula de identidad...0916522939..... de 41 años de edad, una vez que se nos ha socializado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos 20 Firma de consentimiento...................................

| Sintomas antes del tratamiento | Sintomas 1 día del tratamiento | Sintomas 2 día del tratamiento | Sintomas 3 día del tratamiento | Sintomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrío | | | | |
| Dolor Muscular | X | X | X | |
| Tos seca | X | X | X | X |
| Dolor de cabeza | X | | | |
| Dolor de espalda | X | X | X | |
| Dificultad al respirar | X | X | | |
| Vómitos | | | | |
| Diarreas | X | X | X | |
| Dolor de Garganta | X | X | X | X |
| Perdida olfato | X | X | X | X |
| Perdida sabores | X | X | X | X |
| Falta de apetito | | | | |

Observación del paciente al tratamiento:

..........................................................................................

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto García
**Vocal AEMEMI**

911

ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE.......................................................... TELEF.......................**

**Consentimiento voluntario GRUPO SANGUINEO ....................**

Prueba COVID-19 SI....... NO.X.. Fecha DE SINTOMAS INICIO 23/[illegible] 2020.

TTO CDS. SI .X NO ... No DE MIENBROS 5. TOMAN CDS X CONTACTO FAMILIAR + SI Sintomatico

Yo.Gabriel Eduardo [illegible].con Cedula de identidad.0961.38.169...... de 40 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado al protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos.40 Firma de consentimiento........................................

| Sintomas antes del tratamiento | Sintomas 1 día del tratamiento | Sintomas 2 día del tratamiento | Sintomas 3 día del tratamiento | Sintomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrio | | | | |
| Dolor Muscular | X | X | | |
| Tos seca | | | | |
| Dolor de cabeza | X | | | |
| Dolor de espalda | X | X | | |
| Dificultad al respirar | X | X | X | X |
| Vómitos | X | | | |
| Diarreas | X | X | | |
| Dolor de Garganta | X | | | |
| Perdida olfato | X | X | | |
| Perdida sabores | X | X | | |
| Falta de apetito | X | | | |

Observación del paciente al tratamiento:
..........................................................................................................

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto García
Vocal AEMEMI

ASOCIACIÓN ECUATORIANA DE MÉDICOS EXPERTOS EN
MEDICINA INTEGRATIVA

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

# ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

## Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA

**DIREC. PACIENTE** Pascuales **TELEF.** 0 985224560

**Consentimiento voluntario GRUPO SANGUINEO** O RH.

Prueba COVID-19 ~~SI~~ [✓ NO] Fecha DE SINTOMAS INICIO 28-3-2020

TTO CDS. [✓ SI] ... NO . No DE MIENBROS 6. TOMAN CDS X CONTACTO FAMILIAR + [illegible]

Klever Antonio

Yo Desiderio [illegible] con Cedula de identidad 0918749527 de 38 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos 6 Firma de consentimiento ...............

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrío | ✓ | | | |
| Dolor Muscular | ✓ | ✓ | ✓ | ✓ |
| Tos seca | ✓ | ✓ | ✓ | |
| Dolor de cabeza | ✓ | | | |
| Dolor de espalda | ✓ | ✓ | ✓ | ✓ |
| Dificultad al respirar | | | | |
| Vómitos | | | | |
| Diarreas | ✓ | | | |
| Dolor de Garganta | ✓ | ✓ | | |
| Perdida olfato | ✓ | ✓ | | |
| Perdida sabores | ✓ | ✓ | | |
| Falta de apetito | ✓ | | | |

Observación del paciente al tratamiento:
...............

Doy FE: que la(s) copia(s) que antecede(n) constante(s) ... es(son) fiel(es) y exacta(s) al ORIGINAL que se me exhibió y que devuelvo al interesado

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto García
**Vocal AEMEMI**

Dr. Rene [illegible]
NOTARIA [illegible] DEL CANTON [illegible]

913

[illegible] GRATUITO

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**[illegible] con Grupo CDS [redacted] AEMEMI ECUADOR Dr.A. GARCIA**

Consentimiento voluntario

[illegible] 4 [illegible] [illegible]

[illegible] 4 [illegible] 6 [illegible]

Dereck Reyes [illegible] 0959511859 [illegible] 5 [illegible]

[illegible]

ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE**.......................................... **TELEF**......................

**Consentimiento voluntario GRUPO SANGUINEO** ....................

Prueba COVID-19 [✓ SI]...... [✓ NO]...... Fecha DE SINTOMAS INICIO 26-3-2022

TTO CDS [✓ SI].. NO ... **No DE MIENBROS** .... TOMAN CDS X CONTACTO FAMILIAR + Positivo

Yo...[illegible]...con **Cedula de identidad**.0918675661... de 43 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto Garcia indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos..... Firma de consentimiento..........................................

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrío | | | | |
| Dolor Muscular | ✓ | ✓ | ✓ | ✓ |
| Tos seca | | | | |
| Dolor de cabeza | ✓ | | | |
| Dolor de espalda | ✓ | | | |
| Dificultad al respirar | ✓ | ✓ | | |
| Vómitos | | | | |
| Diarreas | ✓ | | | |
| Dolor de Garganta | | | | |
| Perdida olfato | ✓ | ✓ | | |
| Perdida sabores | | | | |
| Falta de apetito | ✓ | | | |

Observación del paciente al tratamiento:

....................................................................................................

Doy FE: que la(s) copia(s) que antecede(n) ... foja(s) útiles es fiel conforme ... al ORIGINAL que me fue exhibido y que devolví al interesado.

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto García
**Vocal AEMEMI**

915

A.E.M.E.M.I.

ACUERDO MINISTERIAL DEL MSP No. 0155
Nov. 2017

ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA.

FECHA: MARZO 3 DEL 2020

NOMBRES: Vargas Romero Galo.

FECHA DE NACIMIENTO: 01 febrero 2020

DESDE CUANDO SE SIENTE ENFERMO: Desde hace solo,
¿TUVO CONTACTO CON PERSONAS QUE TIENEN EXAMEN DE COVID 19 POSITIVO?: si,
NOMBRE DE ESA PERSONA se cruzan mucha areas Hospitalarias,
USTED SE HA HECHO EXAMEN DE COVID19?: NO
SEÑALE QUE TIENE:
FIEBRE:
ESCALOFRIOS:
DOLOR MUSCULAR: ✓
DOLOR HUESOS:
DOLOR DE CABEZA: ✓
DOLOR EN PECHO AL RESPIRAR:
DIFICULTAD PARA RESPIRAR: ✓
VOMITO:
DIARREA: ✓
DOLOR DE GARGANTA:
ARDOR DE GARGANTA:
NO SIENTE LOS SABORES DE COMIDAS:
NO SIENTE LOS OLORES:
OTRO SINTOMA:

Yo Galo Vargas Romero autorizo recibir tratamiento con CDS Y MMS para tratamiento y prevención de COVID 19, el mismo que tendrá lugar en mi domicilio, y será monitoreado por AEMEMI.

FIRMA
C.I 0918675661

Dra. Sonia Moreira Vera
Do[illegible] Cirugía
[illegible] 32

Guayaquil 25 de Marzo 2020 **EL TRATAAMIENTO ES TOTALMENTE GRATUITO**

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA *INTEGRATIVA TRABAJO DE INVESTIGACION*

**Coordinado con Grupo CDS QUITO Y AEMEMI ECUADOR Dr.R. GARCIA**

### Consentimiento voluntario

Prueba COVID-19. SI....... [✓ NO]......Fecha DE SINTOMAS INICIO ............

INICIA TTO. CDS. SI ... NO ... CUANTOS MIENBROS SON .... TOMAN CDS SI ... NO .....

Yo Jimmy Eduardo Salinas Bodero 60 años.............con Cedula de Identidad..0701503609 de.... años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS *"gas dióxido de cloro"* como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García Indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina Integrativa.

Numero de posibles contactos..................
Firma de consentimiento..............................

| *Síntomas antes del tratamiento* | *Síntomas 1 día del tratamiento* | *Síntomas 2 día del tratamiento* | *Síntomas 3 día del tratamiento* | *Síntomas 4 día del tratamiento* |
|---|---|---|---|---|
| Fiebre | ✓ | | | |
| Escalofrío | | | | |
| Dolor Muscular | ✓ | ✓ | ✓ | ✓ |
| Tos seca | | | | |
| Dolor de cabeza | ✓ | ✓ | | |
| Dolor de espalda | ✓ | ✓ | ✓ | ✓ |
| Dificultad al respirar | | | | |
| Vomitos | | | | |
| Diarreas | | | | |
| Dolor de Garganta | ✓ | ✓ | | |
| Perdida olfato | ✓ | | | |
| Perdida sabores | ✓ | | | |

Observación del paciente al tratamiento:
Resh Acepto

APP. Diabetes + Hipertension Arterial + Problemas Renales

**Dr. Mauricio Quiñonez**
**Presidente AEMENI**

**Dr. Roberto García**
**Vocal AEMENI**

[illegible] M2 1042 V39

AEMEMI

ASOCIACION ECUATORIANA DE MÉDICOS EXPERTOS EN MEDICINA INTEGRATIVA

Dr. Renato Vásquez Leiva

**EL TRATAAMIENTO ES TOTALMENTE GRATUITO**

# ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

## Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA

**DIREC. PACIENTE** Pascuales **TELEF.** 0994419534

**Consentimiento voluntario GRUPO SANGUINEO** ..................

Prueba COVID-19 SI...... [✓ NO]...... Fecha DE SINTOMAS INICIO 28-3-2020 cont.

TTO CDS. SI... NO ... No DE MIENBROS .... TOMAN CDS X CONTACTO FAMILIAR + [illegible] Positiva

Yo [illegible] con Cedula de identidad 0924426653 de 30 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicará tratamiento de Medicina integrativa.

Numero de posibles contactos...... Firma de consentimiento...................................

| Síntomas antes del tratamiento | Síntomas 1 día del tratamiento | Síntomas 2 día del tratamiento | Síntomas 3 día del tratamiento | Síntomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrío | | | | |
| Dolor Muscular | ✓ | | | |
| Tos seca | ✓ | ✓ | ✓ | ✓ |
| Dolor de cabeza | ✓ | ✓ | ✓ | |
| Dolor de espalda | ✓ | | | |
| Dificultad al respirar | | ✓ | ✓ | ✓ |
| Vómitos | | | | |
| Diarreas | | | | |
| Dolor de Garganta | ✓ | ✓ | | |
| Perdida olfato | ✓ | ✓ | | |
| Perdida sabores | ✓ | ✓ | | |
| Falta de apetito | ✓ | ✓ | | |

Observación del paciente al tratamiento.........................................................

Doy FE: que la(s) copia(s) que antecede(n) constante(s) en 1 foja(s) útiles es fiel y exacta(s) al ORIGINAL que me fue exhibido y que devuelvo al interesado

06 MAY

Dr. Renato Vásquez Leiva
NOTARÍA NOVENA DEL CANTÓN GUAYAQUIL

Dr. Mauricio Quiñonez
**Presidente AEMEMI**

Dr. Roberto García
**Vocal AEMEMI**

EL TRATAAMIENTO ES TOTALMENTE GRATUITO

**ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION**

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE** [illegible] **TELEF** 0554479534

**Consentimiento voluntario** **GRUPO SANGUINEO** A Rh+

Prueba COVID-19 [✓ SI]...... NO...... Fecha DE SINTOMAS INICIO 20 - 3 - 2020

TTO CDS [✓ SI] NO .. **No DE MIENBROS/**2 TOMAN [✓ CDS] X CONTACTO FAMILIAR + [illegible]

Yo [illegible]...con Cedula de identidad 0906233980 de 62 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS "gas dióxido de cloro" como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto García indicado el protocolo F, cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C, 20 gotas cada hora. Se aplicara tratamiento de Medicina integrativa.

Numero de posibles contactos 10 Firma de consentimiento......................

| Sintomas antes del tratamiento | Sintomas 1 día del tratamiento | Sintomas 2 día del tratamiento | Sintomas 3 día del tratamiento | Sintomas 4 día del tratamiento |
|---|---|---|---|---|
| Fiebre | ✓ | ✓ | | |
| Escalofrío | ✓ | ✓ | | |
| Dolor Muscular | ✓ | ✓ | ✓ | |
| Tos seca | ✓ | ✓ | | |
| Dolor de cabeza | ✓ | ✓ | ✓ | ✓ |
| Dolor de espalda | ✓ | ✓ | | ✓ 7-5 C |
| Dificultad al respirar | ✓ | ✓ | ✓ | ✓ |
| Vómitos | ✓ | ✓ | ✓ | |
| Diarreas | ✓ | ✓ | | |
| Dolor de Garganta | ✓ | ✓ | ✓ | |
| Perdida olfato | ✓ | ✓ | ✓ | |
| Perdida sabores | ✓ | ✓ | ✓ | |
| Falta de apetito | ✓ | ✓ | ✓ | |

Observación del paciente al tratamiento.

...................................................

Dr. Mauricio Quiñonez
Presidente AEMEMI

Dr. Roberto Garcia
[illegible] AEMEMI

919

EL TRATAMIENTO ES TOTALMENTE GRATUITO

## ASOCIACION ECUATORIANA DE MEDICOS EXPERTOS EN MEDICINA INTEGRATIVA TRABAJO DE INVESTIGACION

**Coordinado con Grupo AEMEMI ECUADOR Dr. ROBERTO GARCIA**

**DIREC. PACIENTE** [illegible] **TELEF** 0998599553

**Consentimiento voluntario GRUPO SANGUINEO** ........

Prueba COVID-19 SI .... [✓ NO] .... Fecha DE SINTOMAS INICIO 24 - 3 - 2020

TTO CDS [✓ SI] NO ... No DE MIENBROS .... TOMAN CDS X CONTACTO FAMILIAR [illegible]

YO [illegible] con Cedula de identidad........ de 71 años de edad, una vez que se nos ha sociabilizado las bondades del MMS y del CDS gas dióxido de cloro como tratamiento para COVID-19 Explicado por los Doctores Mauricio Quiñonez y Dr. Roberto Garcia indicado el protocolo F cada 15 min tomas 8 de 20 gotas según respuesta y se pasara al protocolo C 20 gotas cada hora. Se aplicara tratamiento de Medicina integrativa 10 - 4 - 2020 [illegible] 43 %

Numero de posibles contactos..... Firma de consentimiento. ........

| Sintomas antes del tratamiento | Sintomas 1 dia del tratamiento | Sintomas 2 dia del tratamiento | Sintomas 3 dia del tratamiento | Sintomas 4 dia del tratamiento |
|---|---|---|---|---|
| Fiebre | | | | |
| Escalofrío | | | | |
| Dolor Muscular | ✓ | ✓ | | |
| Tos seca | ✓ | ✓ | | |
| Dolor de cabeza | ✓ | ✓ | ✓ | ✓ |
| Dolor de espalda | ✓ | ✓ | ✓ | ✓ |
| Dificultad al respirar | ✓ | ✓ | ✓ | ✓ |
| Vómitos | | | | |
| Diarreas | | ✓ | | |
| Dolor de Garganta | ✓ | ✓ | | |
| Perdida olfato | ✓ | ✓ | | |
| Perdida sabores | ✓ | ✓ | | |
| Falta de apetito | ✓ | ✓ | | |

Observación del paciente durante el ........

Dr. Mauricio Quiñonez
Presidente AEMEMI

Roberto García
[illegible]

# Anexo 5.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

# *In vivo* evaluation of the antiviral effect of $ClO_2$ in chicken embryos inoculated with avian infectious bronchitis coronavirus

Zambrano-Estrada, Xóchitl[a], Domínguez-Sánchez, Carlos[b], Banuet-Martínez, Marina[b], Guerrero de la Rosa, Fabiola[b], García-Gasca, Teresa[c], Acevedo-Whitehouse, Karina[b]

[a] Laboratory of Veterinary Diagnostic Pathology. School of Natural Sciences. Autonomous University of Queretaro. Av. De las Ciencias S/N. Juriquilla, Queretaro. Qro. C.P.76230. Mexico,

[b] Unit for Basic and Applied Microbiology. School of Natural Sciences. Autonomous University of Queretaro. Anillo Vial Fray Junípero Serra, Querétaro, Qro. C.P. 76140

[c] Laboratory of Cellular Biology. School of Natural Sciences. Autonomous University of Queretaro. Av. De las Ciencias S/N. Juriquilla, Queretaro. Qro. C.P. 76230. Mexico

**Corresponding author:** Karina Acevedo-Whitehouse (karina.acevedo.whitehouse@uaq.mx)

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

## Abstract

The need for safe and effective antiviral treatments is pressing, particularly given the number of viral infections that are prevalent in animal and human populations, often causing devastating economic losses and mortality. In the context of the current coronavirus pandemic, which has highlighted how devastating the effects of a virus can be on a naïve population, it is imperative to have rigorous and unbiased data on the efficacy and safety of potential antiviral treatments, particularly those that have demonstrated virucidal effects as a disinfectant, are being considered for use despite warnings on their potential toxicity, but no not have empirical evidence of their antiviral effect *in vivo*. Here, we tested the effect of chlorine dioxide ($ClO_2$) on chick embryos infected with avian infectious bronchitis coronavirus (IBV). We determined virus-induced mortality on 10-day old embryos inoculated with $10^4$ mean $EID_{50}$/mL of attenuated Massachusetts and Connecticut IBV strains. We determined viral titres using RT-qPCR and conducted histopathological examination of various tissues and organs. Viral titres were 2.4-fold lower and mortality was reduced by half in infected embryos that were treated with $ClO_2$. Infection led to developmental abnormalities regardless of treatment. Lesions typical of IBV infections were observed in all inoculated embryos, but severity tended to be lower in $ClO_2$-treated embryos. We found no gross or microscopic evidence of toxicity caused by $ClO_2$ at the doses used herein. Our study shows that $ClO_2$ could be a safe and viable option for controlling avian coronavirus, and raises the possibility that similar effects could be observed in other organisms.

## Keywords

Chlorine dioxide, $ClO_2$, coronavirus, IBV, antiviral, chick embryo

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

## Introduction

Since its start in January 2020, the COVID19 outbreak quickly reached pandemic proportions with a steep rise in mortality and mounting pressure on health services worldwide, as well as marked damage to the economy (Duan et al., 2020; Nicola et al., 2020). The pandemic has evidenced that our available repertoire of antiviral drugs is insufficient. Existing antiviral [remdesivir (Wang et al., 2020) and lopinavir/ritonavir (Kim et al., 2020; Lim et al., 2020)], anti-inflammatory [dexamethasone (Villar et al., 2020)], and immunomodulatory drugs [chloroquine (Borba et al., 2020), hydroxychloroquine (Meo et al., 2020; Sinha and Balayla, 2020), and ivermectin (Caly et al., 2020; Heidary and Gharebaghi, 2020)], have been proposed as treatment following clinical trials. However, except for dexamethasone, none of these drugs are currently recommended by the World Health Organization to treat COVID19 patients other than outside the context of clinical trials due to serious side effects (WHO, 2020). Despite this recommendation, remdesivir has already been approved in some countries for emergency use in patients with severe COVID19 symptoms, as it decreases the duration of hospitalization and shows a modest reduction of mortality rates in severely afflicted patients (Beigel et al., 2020). However, given that this drug costs 2,430 USD per treatment[1], it is unlikely to be a sustainable option for developing countries, such as those in Latin America, where the number of new COVID19 cases continues to grow steadily. With nearly 38 million confirmed infections worldwide and more than one million deaths at the time of writing this paper, the need for effective and safe options to treat COVID19 patients is urgent.

The surge in COVID19 cases and the lack of effective treatments have led to a growing number of informal reports and testimonials across social networks regarding the oral and intravenous use of

---

[1] https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/an-open-letter-from-daniel-oday-chairman--ceo-gilead-sciences

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

chlorine dioxide ($ClO_2$) solution as an efficacious treatment of COVID19. In an unprecedented move, the Senate of Bolivia authorized the extraordinary use of $ClO_2$ to "manufacture, sell, supply and use $ClO_2$ to prevent and treat COVID19" (law PL N° 219/2019-2020 CS approved 15 July 2020). This situation has sparked concern from health agencies of various countries regarding the potential toxicity of using this disinfectant as a treatment, given that $ClO_2$ has strong oxidative properties. Chlorine dioxide, a gas that is highly soluble in water, has been known since 1946 for its broad antimicrobial properties (Sigstam et al., 2014), for which it is commonly used to purify water for human consumption, decontaminate produce and other food items (López-Gálvez et al., 2018), and disinfect surgical instruments (Doona et al., 2014). According to the Food and Drug Administration (FDA) of the US, consuming $ClO_2$ can lead to adverse effects such as 'vomiting, diarrhoea, dehydration, abdominal pain, metahemaglobinemia and systemic failures that could potentially lead to death'. However, an impartial review of the scientific peer-reviewed literature reveals few case reports of human patients presenting adverse effects after consumption of $ClO_2$, none of which were fatal, and in all cases reversed completely after treatment (Kishan, 2009; Bathina et al., 2013; Romanovsky et al., 2013; Loh and Shafi, 2014). Published studies on $ClO_2$ toxicity have reported null to mild effects in adult humans and other animals (e.g. Lubbers et al., 1982; Akamatsu et al., 2012; Ma et al., 2017) and have stressed that toxicity is strongly dose-dependent (Bercz et al., 1982; Hose et al., 1989; Ma et al., 2017). Interestingly, despite the voiced concerns, there are two drugs based on acidified sodium chloride (a precursor for generation of $ClO_2$, named NP001 and WF10) that have been used intravenously in humans to treat diverse conditions, including diabetic foot ulcer and amyotrophic lateral sclerosis (ALS), without reporting adverse reactions (Yingsakmongkol et al., 2011; Yingsakmongkol, 2013; Miller et al., 2015; Maraprygsavan et al., 2016).

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

The virucidal effect of $ClO_2$ when used as a disinfectant of water and hard surfaces is well documented. Specifically, there is evidence of virucidal activity against echovirus (Zhong et al., 2017), enterovirus (Jin et al., 2013), poliovirus (Simonet and Gantzer, 2006), rotavirus (Chen and Vaughn, 1990), norovirus (Lim et al., 2010; Montazeri et al., 2017), calicivirus (Montazeri et al., 2017), and coronavirus (Wang et al., 2005). However, to date, there are few publications that explore potential antiviral effects *in vitro* and *in vivo*. One of the few studies available found that mice that were exposed to influenza A virus in an environment that contained aerosolized $ClO_2$ had significantly lower mortality than mice that were solely exposed to Influenza A virus (Ogata and Shibata, 2008). The authors reported that the antiviral effect was due to denaturation of hemaglutinin and neuraminidase glicoproteins, a finding that concurs with previous studies that explain the virucidal mechanism of action of $ClO_2$ due to oxidation of amino acid residues that are key for cell entry (Noss and Olivieri, 1985; Ison et al., 2006; Stewart et al., 2008). More recently, the antiviral mechanism of action of $ClO_2$ was investigated *in vitro* using pig alveolar macrophages and MARC-145 cells exposed to the porcine reproductive and respiratory syndrome virus (PRRSV1), finding that the chemical also inhibits the synthesis of pro-inflammatory molecules that contribute to the pathogenesis of this disease (Zhu et al., 2019). The authors concluded that viral synthesis of RNA and proteins was impeded by $ClO_2$, leading to a reduction in viral replication. Despite these studies, to date there has been no published report of an *in vivo* assessment of the antiviral effect of $ClO_2$. Here, we have investigated the effect of a $ClO_2$ solution in 10-day old chick embryos inoculated with attenuated avian infectious bronchitis coronavirus (IBV) Massachusetts and Connecticut vaccine strains, which are pathogenic for birds during their embryonic stages of development (Tsai et al., 2016).

## Methods

### Chick embryo inoculation

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

We used 30 10-day old SPF RossxRoss chick embryos (Pilgrims, Mexico) incubated at 38°C and 65-70% humidity (Guy, 2015). Embryos were placed at random within the incubator to avoid any slight variation in humidity and temperature that could affect results. Prior to starting the experiment, all embryos were candled to ensure their viability, and were examined daily to search for evidence of death (presence of blood ring or lack of visible eggshell membrane blood vessels). Five chick embryos were assigned to each of the six experimental groups and treated accordingly (see Table 1). In all cases, embryos were inoculated via the chorioallanotic sac, as recommended for avian coronavirus replication (Jordan and Nassar, 1973; Escorcia et al., 2002). Before inoculation, the eggshell was disinfected with 70% ethanol and 3.5% iodine (Guy, 2015). Using the tip of sterile scissors, a hole was drilled in the eggshell over a 1 $cm^2$ transparent tape film and a sterile 1ml syringe with a 28-g 5/16" needle was used to administer the treatment directly into the allantoic cavity as indicated in Table 1. All procedures were carried out aseptically. After inoculation, the drilled hole was sealed with a drop of glue and the embryo was returned to the incubator. Inoculation of every embryo was performed by a single person to ensure experimental variation was kept at a minimum. Embryos were candled daily to determine mortality. As there was no death recorded within the first 24 h post-inoculation, none of the embryos were discarded from the experiment.

### Macroscopic examination

Seven days after inoculation, embryos were sacrificed according to the American Veterinary Medical Association guidelines on humane treatment and euthanasia of chick embryos over 13 days of age (AVMA 2020). The embryos were placed at 4 °C for 4 h to ensure blood coagulation and avoid contamination of the allantoic fluid (Guy, 2015). Next, each egg was placed on a firm

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

surface with the air chamber facing upwards. The eggshell over the air chamber was disinfected with 70% ethanol and 3.5% iodine (Guy, 2015) and using sterile scissors, the eggshell and chorioallantoic membrane were removed to expose the allanotic fluid. A sterile pipette was used to aspirate 750 µl of the fluid and transfer it to a sterile cryovial before storage at −70 °C. Next, the embryo was removed from the eggshell using sterile dissection forceps and placed in a sterile Petri dish to be photographed.

Each embryo was cleaned with distilled water to remove any remaining albumin, vitellus and amniotic fluid before its mass was determined with a precision scale (±0.1 mg). Embryonic axis length was measured with digital callipers (± 0.1 cm). After decapitation with a sterile scalpel blade, each embryo was examined for macroscopic lesions typically caused by avian coronavirus, such as cutaneous haemorrhages, stunting, curving, urate deposits in the kidney and feather alterations (Escorcia et al., 2002; Alexander D.J. and D.A. Senne, 2008). Chick embryos were considered to have died during the experiment when there was evidence of disconnected or detached blood vessels of the chorioallantoic membrane or their organs exhibited imbibition of haemoglobin. Further evidence of mortality was determined by examining the presence of autolysis at microscopic examination.

For each chick embryo, both femurs were dissected and their length was determined and averaged with a digital calliper as a surrogate measure of chick development. We collected samples of all organs and tissues, including those known to be affected by the Massachusetts and Connecticut strains of avian coronavirus, namely trachea, lung, proventricle, duodenum, liver, kidneys and the Bursa of Fabricius (Escorcia et al., 2002; Cavanagh, 2003, 2007; Tsai et al., 2016), and those reportedly affected by exposure to $ClO_2$, namely thyroid (Bercz et al., 1982; Harrington et al., 1986), thymus, spleen and bone marrow (EPA, 2000).

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

Microscopic examination

Samples were cut longitudinally at their mid-section and immersed in 10% buffered formalin, pH 7.4. Fixed samples were paraffin-embedded and sectioned at 3 µm with a microtome before being stained with haematoxylin-eosin for microscopic examination. The slides were observed under the microscope at 40X and 100X.

To assess haematopoietic status, bone marrow preparations were used for a 200-cell differential count to classify the marrow precursors and to determine the myeloid:erythroid (M/E) ratio for each embryo. This ratio was obtained by dividing the sum of all the granulocytic cells by the sum of all the erythrocytic cells (Schalm and Jain, 1986).

Virus quantitation by RT-qPCR

The virus was quantified in the allantoid fluid with an RT-qPCR protocol (Naguib et al., 2017). Briefly, RNA was extracted by adding 700 µL of Trizol (Invitrogen) to 500 µL of each sample. The sample was incubated for 10 min at ambient temperature. Next, 200 µL of chloroform were added, mixed by inversion, and centrifuged at 12,000 g for 10 min at 4 °C. The aqueous phase was transferred to a sterile microtube, and 500 µL of isopropanol were added. The sample was centrifuged at 12,000 g for 10 min at 4 °C prior to decanting the supernatant. The pellet was washed with 500 µL of cold 70% ethanol, centrifuged at 7,500 g for 5 min at 4 °C and the supernatant was removed completely. The dry pellet was resuspended in 12 µL of nuclease-free water and centrifuged at 7,500 g for 1 min at 4 °C. Quantity and quality of the extracted RNA was examined in a Nanodrop (Qiagen) spectrophotometer and all samples were diluted to 35 ng/mL RNA before retrotranscription.

cDNA synthesis was performed with oligo dT and MLV reversotranscriptase (Invitrogen)according to the manufacturer's instructions. Briefly, we used 8 µL of RNA, 1 µL of Oligo DT (50 ng/µL), 1 µL of

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

10 mM dNTP and 2 µL of nuclease-free $H_2O$. The reactions were incubated at 65 °C for 5 min and placed on ice for 1 min. Seven µL of the kits cDNA synthesis mix, which contains 4 µL 5X First-Strand Buffer, 2 µL 0.1 M DTT and 1 µL RNAse and DNAse free $H_2O$, were added prior to mixing by pipetting and incubating at ambient temperature (~25 °C) for 2 min. We added 1 µL pf SuperScript II RT, mixed by pipetting and incubated at ambient temperature for 10 min. The reactions were incubated at 42 °C for 50 min and inactivated at 70 °C for 15 min. All cDNA samples were stored at -20°C until used.

A 100 bp fragment of the avian coronavirus N gene was amplified using primers IBV-pan_FW-1 (5'-CAG TCC CDG ATG CNT GGT A) and IBV-pan_RV (5'-CC TTW SCA GMA ACM CAC ACT) (Naguib et al., 2017). Quantitation was done with SYBR Green qPCR (Qiagen) in a real-time thermal cycler (CFX connect, Biorad) under the following protocol: 45 °C for 10 min, initial denaturation at 95 °C for 10 min and 35 cycles of 95 °C for 15 s, 52 °C for 15 s, and 68 °C for 30 s, with a final extension step at 68 °C for 10 min. We used a cDNA sample extracted from 500 µL of the vaccine as a positive control (the vaccine contained $10^4$ mean embryo infective dose ($EID_{50}$)/mL of coronavirus strains Massachusetts and Connecticut). A linear regression was used to calculate the correlation coefficient ($R^2 = 0.99$) and the slope value ($b = -5.062$) of the RNA copy number and Cq values using a 10-fold dilution of the vaccine ($10^4$ to $10^{-1}$; see standard curve in Supplementary material). The number of viral RNA copies (hereafter viral load) was determined by comparing the Cq against this standard curve (Naguib et al., 2017). All cDNA samples were diluted 1:10 prior to running the qPCR assays.

## Statistical analyses

Contingency tables were built to investigate differences in the number of dead *vs*. live chick embryos between experimental groups. The relative risk of developing virus-related lesions between treated and un-treated embryos was calculated using Fisher exact tests to estimate

930

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

significance. Body mass, morphometrics, viral load, and lesion severity were compared among groups by one-way ANOVA and post-hoc Tukey HSD tests. All analyses were performed in R version 3.6.3 (R Core Team, 2016). Contingency tables, Fisher exact p-values and odds ratios were calculated with R package Epitools version 0.5-10.1.

Bioethics statement

This study was carried out in compliance with the American Veterinary Medical Association (AVMA) guide for humane treatment of chick embryos and approved by the Autonomous University of Queretaro Research Ethics Committee.

**Results**

Avian coronavirus RNA was detected in all of the embryos that were inoculated with the vaccine (n=15, in all cases Cq <40). The viral load varied significantly between treatments (ANOVA; $F_{2,12}$=4.421, p=0.036; Fig. 1), being 2.4 times higher in the untreated embryos. The average viral load of $ClO_2$-treated chicks was $10^{4.3}$/mL, range: $10^{3.66} – 10^{5.03}$ and of untreated chicks was $10^{4.83}$/mL, range: $10^{4.52} – 10^{5.01}$, respectively (Tukey HSD, Group E *vs*. F, p = 0.03). There were no differences in the viral load between both $ClO_2$-treated groups (p>0.05).

Embryo mortality varied among groups (Fig. 2) and differed significantly between virus-inoculated and virus-free embryos (Pearson's $Chi^2$ = 7.78; p = 0.004), reaching 80 % (4/5) of mortality in the viral control group (Group F). In the groups that contained viral-inoculated embryos treated with $ClO_2$, 1/5 (20 %) of the infected embryos in the low dosage group (Group D) and 2/5 (40 %) of the infected embryos in the high dosage group (Group E) died. In the groups that were not infected

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

with the virus, there was only one death observed, in the group that received the high dosage of $ClO_2$ (Group C).

Body mass, embryonic axis length and femur length differed between the virus-inoculated and virus free-groups, regardless of $ClO_2$ treatment. All of the virus-inoculated embryos exhibited dwarfing and had, on average, 38% lower mass ($t = 21.15$, $df = 29.40$, $p = 2.2 \times 10^{-16}$; Fig. 3A), 10% shorter axis length ($t = 58.43$, $df = 29.26$, $p = 2.2 \times 10^{-16}$; Fig. 3B), and 20% shorter femur length ($t = 8.49$, $df = 23.34$, $p = 1.4 \times 10^{-8}$; Fig 3C) than the virus-free groups. When analysing growth in the virus-inoculated groups, mass was significantly higher in embryos that were treated with $ClO_2$ ($t = -2.74$, $df = 12.98$, $p = 0.017$). Body length of virus-inoculated chicks did not vary according to $ClO_2$ treatment ($p > 0.1$). See supplementary material for photographs of the embryos.

Lesions previously described in embryos infected with avian coronavirus were observed at post mortem examination. Namely, curling, the presence of white caseous material (urates), thickened amnion and allantoic membranes that adhered to the embryos, oedematous serous membranes, epidermal congestion, and subcutaneous haemorrhage (Table 2). Virus-inoculated embryos that were treated with $ClO_2$ had a lower risk of epidermal congestion (RR = 0.4; Wald 95% CI: 0.187-0.855; $p = 0.04$), haemorrhage (RR = 0.1; Wald 95% CI: 0.016 - 0.642; $p = 0.002$), curling (RR = 0.019; Wald 95% CI: 0.125 - 0.844; $p = 0.017$) and thickened membranes (RR = 0; $p = 0.003$) than untreated infected embryos. All the embryos had a pale liver and mildly congested lungs, regardless of their experimental group. Pale enlarged kidneys were observed in the virus-inoculated groups but not in the virus-free groups, regardless of $ClO_2$-treatment (see Table 2).

Microscopic lesions compatible with avian IBV infection were observed in various organs in all virus-inoculated groups (Fig. 4). The severity of the lesions was either similar or slightly lower in the embryos that had been treated with $ClO_2$ than in the embryos that did not receive any

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

treatment (Table 3). Two exceptions were the kidneys and the duodenum. In the kidneys, swelling and degeneration of renal tubular epithelium was more common and more severe in the infected chicks that were administered $ClO_2$ than in the infected embryos that did not receive $ClO_2$, although the former presented mitotic cells. The duodenal villi of the embryos in the IBV-infected groups were longer (ANOVA; $F_{5,18} = 5.62$, $p = 0.003$), and their base was wider (ANOVA; $F_{5,18} = 13.65$, $p = 1.39 \times 10^{-05}$) than embryos from the none-infected groups, and they were moderately congested. Duodenal villous atrophy varied amongst groups (ANOVA; $F_{5,18} = 5.71$, $p = 0.003$) and *post-hoc* comparisons revealed that the significant differences were E *vs.* B (p = 0.021) and E *vs.* C (p = 0.001). The percent of bursal lymphoid tissue decreased markedly in the virus-inoculated embryos (ANOVA; $F_{5,12} = 3.58$, $p = 0.033$; see Fig. 4). Virus-inoculated embryos showed mild apoptosis in the thymus and heterophilic infiltration. Amongst the six experimental groups, all of the embryos examined presented subacute heterophilic bursitis, and pulmonary interstitial multifocal heterophilic foci with congestion (Table 3).

There were no observable alterations to the architecture and integrity of the tissues of non-infected embryos that were administered $ClO_2$ (Experimental groups B and C), nor was any difference in the area ($\mu m^2$) of the thyroid ($p>0.1$). $ClO_2$-treated groups showed a slightly higher myeloid to erythroid ratio in the bone marrow than the experimental control group and the viral control group, although the difference was not statistically significant (ANOVA; $F_{5,15} = 2.33$, $p = 0.094$).

## Discussion

The use of chlorine dioxide ($ClO_2$) as a disinfectant is well established, and its virucidal effects are reported against a wide range of enveloped and non-enveloped viruses that can affect human and domestic animal health. To date, its informal use as an antiviral drug is polemical, and there are no

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

published studies that have explored the antiviral action of this substance following oral or parenteral administration. We have investigated the antiviral effect of 30 ppm and 300 ppm $ClO_2$ solutions (both concentrations below the reported NOAEL; Bercz et al., 1982) in chick embryos infected with avian infectious bronchitis coronavirus (IBV) strains. We observed a reduction in viral titre in infected embryos that were treated with $ClO_2$. Mortality decreased substantially in the $ClO_2$-treated embryos, although alterations to chick development were prevalent regardless of treatment.

Virulent avian IBV strains typically have a burst size of 10 to 100 infective units per cell (Robb and Bond, 1979), which appear in culture within six hours and can reach peak virus titres of $10^{6.5}$–$10^{8.5}$ $TCID_{50}$ after 36 hours (Otsuki et al., 1979). The vaccine strains used here have lower replication efficiencies as they are attenuated (Tsai et al., 2020), but they are capable of replicating and causing damage in chick embryos (Tsai et al., 2016). With 2,000 infective units (200 µl of $10^4$ infective units/mL) inoculated into each embryo, the $ClO_2$ treatments decreased viral load 2.4-fold compared to the infected non-treated embryos, representing an average difference of 42,711 infective units. This result could be explained by two mechanisms described for $ClO_2$. Firstly, direct destruction or neutralization of the virions exposed to $ClO_2$, could have occurred due to denaturing of their envelope glycoproteins following oxidation of amino acid residues(Noss and Olivieri, 1985; Ison et al., 2006; Ogata and Shibata, 2008). Secondly, viral replication efficiency could have decreased due to $ClO_2$–induced biochemical changes in the extra- or intracellular milieu impeding the synthesis of viral RNA and proteins (see Enjuanes et al., 2006; Zhu et al., 2019). These proposed mechanisms of action are not mutually exclusive.

The effects of reduced viral titres in the infected embryos were evident, with a 50 to 75% reduction in mortality in the treated embryos treated with 300 ppm and 30 ppm of $ClO_2$, respectively. However, developmental abnormalities were observed in the majority of the infected

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

embryos, including the groups that received $ClO_2$ treatment. Namely, dwarfing, assessed by body mass, axis length, and femur length were significantly lower in all infected embryos, as expected to occur in IBV infections (Balasubramaniam et al., 2013). In contrast, curling – also caused by avian IBV (Wickramasinghe et al., 2011; Mork et al., 2014) – was virtually absent in the embryos that received $ClO_2$ after infection. Alterations associated con IBV infection were observed in the proventriculus, spleen, liver, but specifically in kidneys, trachea and lung. (Butcher et al., 1990; Cook et al., 2012) were observed in most of the infected embryos, including those that were administered $ClO_2$. However, for most of these abnormalities, severity was lower or similar in the $ClO_2$-treated groups. One exception was the pathology observed in the kidneys, where lesions indicative of nephrosis were more severe and frequent in the IBV-infected embryos treated with $ClO_2$ than in the IBV-infected non-treated embryos. Such lesions in the kidneys are unlikely to be due to the $ClO_2$ treatment itself, given that none of the non-infected embryos that were administered $ClO_2$ showed any abnormality in the kidneys. Similarly, atrophy of the duodenal villi was highest in the inoculated group that was administered a high dose of $ClO_2$, but absent in the non-infected groups that only received $ClO_2$. If duodenal atrophy and nephropathogenicity in IBV-infected embryos are mitigated by inflammatory responses (Chhabra et al., 2018), it is possible that the observed tubular damage reflected $ClO_2$-driven downregulation of acute inflammation that allowed virion replication in the tubular epithelium and in the duodenal villi. This scenario could be plausible if we consider that a recent study that investigated the antiviral effect of $ClO_2$ in pig alveolar macrophages and African green monkey kidney cells infected with the porcine reproductive and respiratory syndrome virus (PRRSV1) *in vitro*, reported downregulation of pro-inflammatory cytokines IL-1, IL-6 and TNF-α (Zhu et al., 2019). The drug NP001 (a chemical precursor of $ClO_2$) exerts strong anti-inflammatory responses by inhibiting macrophage activation in humans, even after a single dose (Miller et al., 2014). In turn, WF10, a strong oxidizing agent

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

that is related to $ClO_2$ (Veerasarn et al., 2004), induces apoptosis of inflammatory cells and downregulates pro-inflammatory genes (Giese et al., 2004; Yingsakmongkol et al., 2011). Interestingly, the affected renal tubules had mitotic cells, suggestive of regeneration as a reparative response to damage of the renal tubular epithelium (Toback, 1992; Fujigaki, 2012; Lombardi et al., 2016). This possibility will need to be explored further in the animal model used in our study. Unfortunately, knowledge of IBV pathogenesis, immune responses and tissue reparation in the embryonated egg is limited. In hatched birds, IBV can impact lymphocyte populations by inducing apoptosis, thus impeding virus clearance (Caron, 2010). We found some evidence of this effect, as the virus-inoculated embryos had a reduced percent of bursal lymphoid tissue.

Taken together, our results indicate that $ClO_2$ limited viral replication but as the embryos were only administered a single dose of a $ClO_2$ solution rather than repeated doses, not all virions were eliminated. The viruses that remained viable after administration of the $ClO_2$ were able to replicate, yielding lower viral titres, and the damage that they caused to the embryos was less severe and ultimately led to less mortality than in the untreated infected embryos. Repeated administrations of $ClO_2$ solution might have reduced the viral load further, plausibly leading to even less virus-induced damage, a possibility that we could not explore in this model. However, an important result of our study was the lack of evidence of tissue damage caused by $ClO_2$ itself. Only one (20%) of the uninfected embryos treated with the high dose of $ClO_2$ died, and this difference was not statistically significant to the experimental control. It is possible that the death was due to other causes, as a 20% embryo mortality rate is considered normal in aviculture (Romanoff, 1972; Fasenko & O´Dea, 2008).

Further studies should aim to test the antiviral effect of $ClO_2$ in hatched chicks, which have a more mature immune system, and where repeated administrations are easier to procure. However, it is

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

promising that we found an evident effect against IBV without any significant adverse effect or evidence of toxicity to the chick embryos. Much research needs to be done before it is possible to generalize and extrapolate our findings to other viruses and animal hosts. However, in the context of the current COVID-19 crisis, with near to none viable, accessible and safe therapeutic option available, it might be prudent to consider conducting controlled double-blind and randomized studies on the antiviral effect of $ClO_2$ in COVID-19 patients.

## Statement of conflict of interest

The authors declare they do not have any conflict of interest regarding this submission.

## Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Author contributions

K.A-W. and T.G-G. conceived the idea. K.A-W. supervised the experiments, performed statistical analyses and wrote the manuscript. X.Z-E. performed all gross examinations and histopathology analyses. C.D-S. conducted molecular assays and artwork. M.B-M. and F.G-D performed the inoculation experiments and assisted during necropsies. All authors participated in the discussion of results.

## Acknowledgments

We thank Luis A. Soto-García and Karla Zamora y Cuevas for their help with photographic and video documentation of the experiment.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

## References

Akamatsu, A., Lee, C., Morino, H., Miura, T., Ogata, N., Shibata, T., 2012. Six-month low level chlorine dioxide gas inhalation toxicity study with two-week recovery period in rats. J. Occup. Med. Toxicol. 7, 2. doi:10.1186/1745-6673-7-2

Alexander D.J. and D.A. Senne, 2008. A Laboratory Manual for the Isolation, Identification and Characterization of Avian Pathogens, American Association of Avian Pathologists. ISBN:9780978916374

AVMA, 2020. Guidelines for the Euthanasia of Animals. American Veterinary Medicine Association. ISBN:978-1-882691-54-8.

Balasubramaniam, A., Sukumar, K., Suresh, P., Puvarajan, B., 2013. Molecular characterisation of membrane glycoprotein and 5b protein of nephropathogenic infectious bronchitis virus. Vet. World. doi:10.14202/vetworld.2013.857-861

Bathina, G., Yadla, M., Burri, S., Enganti, R., Prasad Ch, R., Deshpande, P., Ch, R., Prayaga, A., Uppin, M., 2013. An unusual case of reversible acute kidney injury due to chlorine dioxide poisoning. Ren. Fail. 35, 1176–1178. doi:10.3109/0886022X.2013.819711

Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., Hohmann, E., Chu, H.Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R.W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T.F., Paredes, R., Sweeney, D.A., Short, W.R., Touloumi, G., Lye, D.C., Ohmagari, N., Oh, M.-D., Ruiz-Palacios, G.M., Benfield, T., Fätkenheuer, G., Kortepeter, M.G., Atmar, R.L., Creech, C.B., Lundgren, J., Babiker, A.G., Pett, S., Neaton, J.D., Burgess, T.H., Bonnett, T., Green, M., Makowski, M., Osinusi, A., Nayak, S., Lane, H.C., 2020. Remdesivir for the Treatment of Covid-19 - Final Report. N. Engl. J. Med. doi:10.1056/NEJMoa2007764

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

Bercz, J.P., Jones, L., Garner, L., Murray, D., Ludwig, D.A., Boston, J., 1982. Subchronic toxicity of chlorine dioxide and related compounds in drinking water in the nonhuman primate. Environ. Health Perspect. 46, 47–55. doi:10.1289/ehp.824647

Borba, M.G.S., Val, F.F.A., Sampaio, V.S., Alexandre, M.A.A., Melo, G.C., Brito, M., Mourão, M.P.G., Brito-Sousa, J.D., Baía-da-Silva, D., Guerra, M.V.F., Hajjar, L.A., Pinto, R.C., Balieiro, A.A.S., Pacheco, A.G.F., Santos, J.D.O., Naveca, F.G., Xavier, M.S., Siqueira, A.M., Schwarzbold, A., Croda, J., Nogueira, M.L., Romero, G.A.S., Bassat, Q., Fontes, C.J., Albuquerque, B.C., Daniel-Ribeiro, C.T., Monteiro, W.M., Lacerda, M.V.G., 2020. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw. open. doi:10.1001/jamanetworkopen.2020.8857

Butcher, G.D., Winterfield, R.W., Shapiro, D.P., 1990. Pathogenesis of H13 nephropathogenic infectious bronchitis virus. Avian Dis. 34, 916–921.

Caly, L., Druce, J.D., Catton, M.G., Jans, D.A., Wagstaff, K.M., 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 *in vitro*. Antiviral Res. doi:10.1016/j.antiviral.2020.104787

Caron, L.F., 2010. Etiology and immunology of infectious bronchitis virus. Rev. Bras. Cienc. Avic. doi:10.1590/S1516-635X2010000200007

Cavanagh, D., 2007. Coronavirus avian infectious bronchitis virus. Vet. Res. 38, 281–297. doi:10.1051/vetres:2006055

Cavanagh, D., 2003. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathol. 32, 567–582.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

doi:10.1080/03079450310001621198

Chen, Y.S., Vaughn, J.M., 1990. Inactivation of human and simian rotaviruses by chlorine dioxide. Appl. Environ. Microbiol. 56, 1363–1366. doi:10.1128/AEM.56.5.1363-1366.1990

Chhabra, R., Ball, C., Chantrey, J., Ganapathy, K., 2018. Differential innate immune responses induced by classical and variant infectious bronchitis viruses in specific pathogen free chicks. Dev. Comp. Immunol. 87, 16–23. doi:10.1016/j.dci.2018.04.026

Cook, J.K.A., Jackwood, M., Jones, R.C., 2012. The long view: 40 years of infectious bronchitis research. Avian Pathol. 41, 239–250. doi:10.1080/03079457.2012.680432

Doona, C.J., Feeherry, F.E., Setlow, P., Malkin, A.J., Leighton, T.J., 2014. The Portable Chemical Sterilizer (PCS), D-FENS, and D-FEND ALL: novel chlorine dioxide decontamination technologies for the military. J. Vis. Exp. e4354. doi:10.3791/4354

Duan, H., Wang, S., Yang, C., 2020. Coronavirus: limit short-term economic damage. Nature. doi:10.1038/d41586-020-00522-6

Enjuanes, L., Almazán, F., Sola, I., Zuñiga, S., 2006. Biochemical aspects of coronavirus replication and virus-host interaction. Annu. Rev. Microbiol. 60, 211–230. doi:10.1146/annurev.micro.60.080805.142157

EPA, 2000. Toxicological Review of Chlorine dioxide and Chlorite. CAS Nos. 10049-04-4 and 7758-19-2. U.S. Environmental Protection Agency Washington, DC. http://www.epa.gov/iris.

Escorcia, M., Fortoul, T.I., Petrone, V.M., Galindo, F., López, C., Téllez, G., 2002. Gastric gross and microscopic lesions caused by the UNAM-97 variant strain of infectious bronchitis virus after the eighth passage in specific pathogen-free chicken embryos. Poult. Sci. 81, 1647–1652. doi:10.1093/ps/81.11.1647

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

Fasenko, G.M., O´Dea, E.E., 2008. Evaluating Broiler Growth and Mortality in Chicks with Minor Navel Conditions at Hatching. Poult. Sci. 87,594–597. doi: 10.3382/ps.2007-00352

Fujigaki, Y., 2012. Different modes of renal proximal tubule regeneration in health and disease. World J. Nephrol. 1, 92–99. doi:10.5527/wjn.v1.i4.92

Giese, T., McGrath, M.S., Stumm, S., Schempp, H., Elstner, E., Meuer, S.C., 2004. Differential effects on innate versus adaptive immune responses by WF10. Cell. Immunol. 229, 149–158. doi:10.1016/j.cellimm.2004.08.001

Guy, J.S., 2015. Isolation and Propagation of Coronaviruses in Embryonated Eggs, in: Maier, H.J., Bickerton, E., Britton, P. (Eds.), Coronaviruses: Methods and Protocols, Methods in Molecular Biology. Springer Protocols. New York. doi:10.1007/978-1-4939-2438-7_7

Harrington, R.M., Shertzer, H.G., Bercz, J.P., 1986. Effects of chlorine dioxide on thyroid function in the African green monkey and the rat. J. Toxicol. Environ. Health 19, 235–242. doi:10.1080/15287398609530923

Heidary, F., Gharebaghi, R., 2020. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J. Antibiot. (Tokyo). doi:10.1038/s41429-020-0336-z

Hose, J.E., Di Fiore, D., Parker, H.S., Sciarrotta, T., 1989. Toxicity of chlorine dioxide to early life stages of marine organisms. Bull. Environ. Contam. Toxicol. 42, 315–319. doi:10.1007/BF01699954

Ison, A., Odeh, I.N., Margerum, D.W., 2006. Kinetics and mechanisms of chlorine dioxide and chlorite oxidations of cysteine and glutathione. Inorg. Chem. 45, 8768–8775. doi:10.1021/ic0609554

Jin, M., Shan, J., Chen, Z., Guo, X., Shen, Z., Qiu, Z., Xue, B., Wang, Y., Zhu, D., Wang, X., Li, J., 2013.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

Chlorine dioxide inactivation of enterovirus 71 in water and its impact on genomic targets. Environ. Sci. Technol. 47, 4590–4597. doi:10.1021/es305282g

Jordan, F.T., Nassar, T.J., 1973. The combined influence of age of embryo and temperature and duration of incubation on the replication and yield of avian infectious bronchitis (IB) virus in the developing chick embryo. Avian Pathol. 2, 279–294. doi:10.1080/03079457309353804

Kim, J.-W., Kim, E.J., Kwon, H.H., Jung, C.Y., Kim, K.C., Choe, J.-Y., Hong, H.-L., 2020. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. Korean J. Intern. Med. doi:10.3904/kjim.2020.224

Kishan, H., 2009. Chlorine dioxide-induced acute hemolysis. J. Med. Toxicol. Off. J. Am. Coll. Med. Toxicol.

Lim, J., Jeon, S., Shin, H.Y., Kim, M.J., Seong, Y.M., Lee, W.J., Choe, K.W., Kang, Y.M., Lee, B., Park, S.J., 2020. Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: The application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J. Korean Med. Sci. doi:10.3346/jkms.2020.35.e79

Lim, M.Y., Kim, J.-M., Ko, G., 2010. Disinfection kinetics of murine norovirus using chlorine and chlorine dioxide. Water Res. 44, 3243–3251. doi:10.1016/j.watres.2010.03.003

Loh, J.M.R., Shafi, H., 2014. Kikuchi-Fujimoto disease presenting after consumption of "Miracle Mineral Solution" (sodium chlorite). BMJ Case Rep. 2014. doi:10.1136/bcr-2014-205832

Lombardi, D., Becherucci, F., Romagnani, P., 2016. How much can the tubule regenerate and who does it? An open question. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. -

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

Eur. Ren. Assoc. 31, 1243–1250. doi:10.1093/ndt/gfv262

López-Gálvez, F., Randazzo, W., Vásquez, A., Sánchez, G., Decol, L.T., Aznar, R., Gil, M.I., Allende, A., 2018. Irrigating Lettuce with Wastewater Effluent: Does Disinfection with Chlorine Dioxide Inactivate Viruses? J. Environ. Qual. 47, 1139–1145. doi:10.2134/jeq2017.12.0485

Lubbers, J.R., Chauan, S., Bianchine, J.R., 1982. Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. Environ. Health Perspect. 46, 57–62. doi:10.1289/ehp.824657

Ma, J.-W., Huang, B.-S., Hsu, C.-W., Peng, C.-W., Cheng, M.-L., Kao, J.-Y., Way, T.-D., Yin, H.-C., Wang, S.-S., 2017. Efficacy and Safety Evaluation of a Chlorine Dioxide Solution. Int. J. Environ. Res. Public Health 14. doi:10.3390/ijerph14030329

Maraprygsavan, P., Mongkolsuk, J., Arnhold, J., Kuehne, F.-W., 2016. The chlorite-based drug WF10 constantly reduces hemoglobin A1c values and improves glucose control in diabetes patients with severe foot syndrome. J. Clin. Transl. Endocrinol. 4, 53–58. doi:10.1016/j.jcte.2016.05.001

Meo, S.A., Klonoff, D.C., Akram, J., 2020. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur. Rev. Med. Pharmacol. Sci. doi:10.26355/eurrev_202004_21038

Miller, R.G., Block, G., Katz, J.S., Barohn, R.J., Gopalakrishnan, V., Cudkowicz, M., Zhang, J.R., McGrath, M.S., Ludington, E., Appel, S.H., Azhir, A., 2015. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol. Neuroimmunol. neuroinflammation 2, e100. doi:10.1212/NXI.0000000000000100

Miller, R.G., Zhang, R., Block, G., Katz, J., Barohn, R., Kasarskis, E., Forshew, D., Gopalakrishnan, V., McGrath, M.S., 2014. NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 601–

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

609. doi:10.3109/21678421.2014.951940

Montazeri, N., Manuel, C., Moorman, E., Khatiwada, J.R., Williams, L.L., Jaykus, L.-A., 2017. Virucidal Activity of Fogged Chlorine Dioxide- and Hydrogen Peroxide-Based Disinfectants against Human Norovirus and Its Surrogate, Feline Calicivirus, on Hard-to-Reach Surfaces. Front. Microbiol. 8, 1031. doi:10.3389/fmicb.2017.01031

Mork, A.-K., Hesse, M., Abd El Rahman, S., Rautenschlein, S., Herrler, G., Winter, C., 2014. Differences in the tissue tropism to chicken oviduct epithelial cells between avian coronavirus IBV strains QX and B1648 are not related to the sialic acid binding properties of their spike proteins. Vet. Res. 45, 67. doi:10.1186/1297-9716-45-67

Naguib, M.M., El-Kady, M.F., Lüschow, D., Hassan, K.E., Arafa, A.-S., El-Zanaty, A., Hassan, M.K., Hafez, H.M., Grund, C., Harder, T.C., 2017. New real time and conventional RT-PCRs for updated molecular diagnosis of infectious bronchitis virus infection (IBV) in chickens in Egypt associated with frequent co-infections with avian influenza and Newcastle Disease viruses. J. Virol. Methods 245, 19–27. doi:10.1016/j.jviromet.2017.02.018

Nicola, M., Alsafi, Z., Sohrabi, C., Kerwan, A., Al-Jabir, A., Iosifidis, C., Agha, M., Agha, R., 2020. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int. J. Surg. doi:10.1016/j.ijsu.2020.04.018

Noss, C.I., Olivieri, V.P., 1985. Disinfecting capabilities of oxychlorine compounds. Appl. Environ. Microbiol. 50, 1162–1164. doi:10.1128/AEM.50.5.1162-1164.1985

Ogata, N., Shibata, T., 2008. Protective effect of low-concentration chlorine dioxide gas against influenza A virus infection. J. Gen. Virol. 89, 60–67. doi:10.1099/vir.0.83393-0

Otsuki, K., Noro, K., Yamamoto, H., Tsubokura, M., 1979. Studies on avian infectious bronchitis

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

virus (IBV). II. Propagation of IBV in several cultured cells. Arch. Virol. 60, 115–122. doi:10.1007/BF01348027

R Core Team, 2016. R Development Core Team. R A Lang. Environ. Stat. Comput.

Robb, J.A., Bond, C.W., 1979. Coronaviridae, in: Fraenkel-Conrat, H., Wagner, R.R. (Eds.), Comprehensive Virology. Springer, Boston. doi:https://doi.org/10.1007/978-1-4684-3563-4_3

Romanoff, A., Romanoff, A., 1972. Spontaneous malformations, in: Romanoff, A.L. (Ed.), Pathogenesis of the avian embryo: an analysis of causes of malformations and prenatal death. Wiley-Interscience, New York. ISBN:978-0471732402

Romanovsky, A., Djogovic, D., Chin, D., 2013. A case of sodium chlorite toxicity managed with concurrent renal replacement therapy and red cell exchange. J. Med. Toxicol. Off. J. Am. Coll. Med. Toxicol. 9, 67–70. doi:10.1007/s13181-012-0256-9

Schalm, O.W., Jain, N.C., 1986. Schalm's veterinary hematology, 4th editio. ed. Lea & Febiger, Philadelphia.

Sigstam, T., Rohatschek, A., Zhong, Q., Brennecke, M., Kohn, T., 2014. On the cause of the tailing phenomenon during virus disinfection by chlorine dioxide. Water Res. 48, 82–89. doi:10.1016/j.watres.2013.09.023

Simonet, J., Gantzer, C., 2006. Degradation of the Poliovirus 1 genome by chlorine dioxide. J. Appl. Microbiol. 100, 862–870. doi:10.1111/j.1365-2672.2005.02850.x

Sinha, N., Balayla, G., 2020. Hydroxychloroquine and covid-19. Postgrad. Med. J. doi:10.1136/postgradmedj-2020-137785

Stewart, D.J., Napolitano, M.J., Bakhmutova-Albert, E. V, Margerum, D.W., 2008. Kinetics and

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

mechanisms of chlorine dioxide oxidation of tryptophan. Inorg. Chem. 47, 1639–1647. doi:10.1021/ic701761p

Toback, F.G., 1992. Regeneration after acute tubular necrosis. Kidney Int. 41, 226–246. doi:10.1038/ki.1992.32

Tsai, C.-T., Tsai, H.-F., Wang, C.-H., 2016. Detection of infectious bronchitis virus strains similar to Japan in Taiwan. J. Vet. Med. Sci. 78, 867–871. doi:10.1292/jvms.15-0609

Tsai, C.-T., Wu, H.-Y., Wang, C.-H., 2020. Genetic sequence changes related to the attenuation of avian infectious bronchitis virus strain TW2575/98. Virus Genes 56, 369–379. doi:10.1007/s11262-020-01753-5

Veerasarn, V., Khorprasert, C., Lorvidhaya, V., Sangruchi, S., Tantivatana, T., Narkwong, L., Kongthanarat, Y., Chitapanarux, I., Tesavibul, C., Panichevaluk, A., Puribhat, S., Sangkittipaiboon, S., Sookpreedee, L., Lertsanguansinchai, P., Phromratanapongse, P., Rungpoka, P., Trithratipvikul, S., Lojanapiwat, B., Ruangdilokrat, S., Ngampanprasert, P., 2004. Reduced recurrence of late hemorrhagic radiation cystitis by WF10 therapy in cervical cancer patients: a multicenter, randomized, two-arm, open-label trial. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 73, 179–185. doi:10.1016/j.radonc.2004.05.007

Villar, J., Añón, J.M., Ferrando, C., Aguilar, G., Muñoz, T., Ferreres, J., Ambrós, A., Aldecoa, C., Suárez-Sipmann, F., Thorpe, K.E., Jüni, P., Slutsky, A.S., Ferrando, C., Mellado-Artigas, R., Fernández, J., Hernández, M., Castellá, M., Castro, P., Badia, J.R., Aguilar, G., Carbonell, J.A., Badenes, R., Tornero, C., Ferreres, J., Blasco, M.L., Carbonell, N., Serrano, A., Juan, M., Gómez-Herreras, J.I., López, M.L., Ambrós, A., Martín, C., Del Campo, R., Puig-Bernabeu, J., Ferrer, C., De Andrés, J., Muñoz, T., Serna-Grande, P., Tamayo, G., Martínez-Ruíz, A., Bilbao-Villasante, I., Villar, J., Fernández, R.L., Calvo, C.P., Vidal, Á., Añón, J.M., Figueira, J.C., Asensio,

946

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

M.J., Maseda, E., Suárez-Sipmann, F., Ramasco, F., Varela-Durán, M., Díaz-Parada, P., Trenado-Álvarez, J., Fernández, M.M., Aldecoa, C., Rico-Feijoo, J., Fernández, L., Sánchez-Ballesteros, J., Blanco-Schweizer, P., Martínez, D., Soler, J.A., Slutsky, A.S., Jüni, P., Thorpe, K.E., Thomas, R., Wysocki, K., De Verno, P., Lakhanpal, G., Juando-Prats, C., 2020. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: Study protocol for a randomized controlled superiority trial. Trials. doi:10.1186/s13063-020-04643-1

Wang, X.-W., Li, J.-S., Jin, M., Zhen, B., Kong, Q.-X., Song, N., Xiao, W.-J., Yin, J., Wei, W., Wang, G.-J., Si, B.-Y., Guo, B.-Z., Liu, C., Ou, G.-R., Wang, M.-N., Fang, T.-Y., Chao, F.-H., Li, J.-W., 2005. Study on the resistance of severe acute respiratory syndrome-associated coronavirus. J. Virol. Methods 126, 171–177. doi:10.1016/j.jviromet.2005.02.005

Wang, Yeming, Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., Wang, Yi, Ding, D., Wu, F., Tang, X., Ye, X., Ye, Y., Liu, B., Yang, J., Yin, W., Wang, A., Fan, G., Zhou, F., Liu, Z., Gu, X., Xu, J., Shang, L., Zhang, Y., Cao, L., Guo, T., Wan, Y., Qin, H., Jiang, Y., Jaki, T., Hayden, F.G., Horby, P.W., Cao, B., Wang, C., 2020. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. doi:10.1016/S0140-6736(20)31022-9

Wickramasinghe, I.N.A., de Vries, R.P., Gröne, A., de Haan, C.A.M., Verheije, M.H., 2011. Binding of avian coronavirus spike proteins to host factors reflects virus tropism and pathogenicity. J. Virol. 85, 8903–8912. doi:10.1128/JVI.05112-11

WHO, 2020. Corticosteroids for COVID-19. World Health Organization. WHO/2019-nCoV/Corticosteroids/2020.1. https://www.who.int/publications/i/item/WHO-2019-nCoV-

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

Corticosteroids-2020.1

Yingsakmongkol, N., 2013. Clinical outcomes of WF10 adjunct to standard treatment of diabetic foot ulcers. J. Wound Care 22, 130-132,134-136. doi:10.12968/jowc.2013.22.3.130

Yingsakmongkol, N., Maraprygsavan, P., Sukosit, P., 2011. Effect of WF10 (immunokine) on diabetic foot ulcer therapy: a double-blind, randomized, placebo-controlled trial. J. foot ankle Surg. Off. Publ. Am. Coll. Foot Ankle Surg. 50, 635–640. doi:10.1053/j.jfas.2011.05.006

Zhong, Q., Carratalà, A., Ossola, R., Bachmann, V., Kohn, T., 2017. Cross-Resistance of UV- or chlorine dioxide-resistant echovirus 11 to other disinfectants. Front. Microbiol. 8, 1928. doi:10.3389/fmicb.2017.01928

Zhu, Z., Guo, Y., Yu, P., Wang, X., Zhang, X., Dong, W., Liu, X., Guo, C., 2019. Chlorine dioxide inhibits the replication of porcine reproductive and respiratory syndrome virus by blocking viral attachment. Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis. 67, 78–87. doi:10.1016/j.meegid.2018.11.002

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

## Figures



**Figure 1.** Virus RNA copy number in the allantoic fluid of the infected embryos per treatment group. Virus copy number was calculated by the geometric mean of the triplicate Cq value referred to the standard curve (see methods). Experimental groups D to F contained virus-inoculated embryos (D: Low dose of $ClO_2$, E: High dose of $ClO_2$, F. Viral control). For details on treatments, see Table 1.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.



**Figure 2.** Chick embryo mortality during the experiment. Experimental groups A to C contained virus-free embryos (A: Experimental control, B: Low dose of $ClO_2$, C: High dose of $ClO_2$); experimental groups D to F contained virus-inoculated embryos (D: Low dose of $ClO_2$, E: High dose of $ClO_2$, F. Viral control). For details on treatments, see Table 1.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.



**Figure 3.** Chick embryo development at the end of the experiment (day 17 of incubation). A) mass, B) body axis, C) femur length. Experimental groups A to C contained virus-free embryos (A: Experimental control, B: Low dose of $ClO_2$, C: High dose of $ClO_2$); experimental groups D to F contained virus-inoculated embryos (D: Low dose of $ClO_2$, E: High dose of $ClO_2$, F. Viral control). For details on treatments, see Table 1.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license. COMUSAV194



**Figure 4.** Histology of selected tissues from 17-day-old chick embryos. In each row, microphotograph pairs show H&E-stained representative tissues of non-infected (left) and infected embryos (right), A) Bursa of Fabricio (100X). Infected embryos showed severe lymphoid depletion, with approximately 10% of active lymphoid tissue and abundant heterophils. B) Bone marrow (400 X). Infected embryos showed an increase in erythroid cellularity ne, C) Spleen (400 X), Infected embryos showed reticuloendothelial hyperplasia, D) Duodenum (400 X). Infected embryos showed mild villous atrophy, E) Proventricle (40X). Infected embryos showed epithelial hyperplasia with desquamation and hyaline material, F) Proventricle (400X). Image shows the increased length of the proventricular folds and mitotic cells indicative of epithelial

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

regeneration, G) Kidney (400X). Infected embryos showed swelling, cell detritus and protein within the tubules, and basophilic material compatible with urate crystals, H) Liver (400X). Infected embryos showed glucogenic degeneration, I) Trachea (400X). Infected embryos showed hyperplasia and epithelial degeneration. Scale = 50 μm in all panels except for E (scale = 500 μm).

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

**Table 1.** Experimental groups used to assess the *in vivo* antiviral effect of high and low concentrations of ClO2 solution in chick embryos. The table shows the number of embryos included in each group. (LD: Low dose, HD: High dose)

| **Group** | **N** | **Treatment** |
|---|---|---|
| Group A (Experimental control) | 5 | 200 µl of sterile 0.9% saline solution |
| Group B ($ClO_2$ LD) | 5 | 100 µl of sterile $ClO_2$ solution (30 ppm[1]) and 100 µl of sterile 0.9% saline solution |
| Group C ($ClO_2$ HD) | 5 | 100 µl of sterile $ClO_2$ solution (300 ppm[2]) and 100 µl of sterile 0.9% saline solution |
| Group D (Virus + $ClO_2$ LD) | 5 | 100 µl of resuspended avian coronavirus vaccine and 100 µl of sterile $ClO_2$ solution (30 ppm) |
| Group E (Virus + $ClO_2$ HD) | 5 | 100 µl of resuspended avian coronavirus vaccine and 100 µl of sterile $ClO_2$ solution (300 ppm) |
| Group F (Viral control) | 5 | 100 µl of resuspended live attenuated avian coronavirus vaccine (Bron Blen® Merial, containing $10^4$ of mean embryo infective dose ($EID_{50}$)/mL of coronavirus strains Massachusetts and Connecticut) and 100 µl of sterile 0.9% saline solution |

---

[1] This concentration is 10 times below the no-observed-adverse-effect level (NOAEL; 3.5 mg/kg per day) determined for $ClO_2$ (Bercz et al. 1982), considering an embryonic mass of 10 g at the time of inoculation.

[2] This concentration is equal to the NOAEL considering an embryonic mass of 10 g at the time of inoculation.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.13.336768. this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

**Table 2. Macroscopic abnormalities observed at necropsy in the chick embryos.** The table shows the number of embryos in each group that presented each lesion. (LD: Low dose, HD: High dose)

| | Dwarfing | Curling | White caseous material | Thickened membranes | Oedema | Epidermal congestion | Pale and enlarged kidneys |
|---|---|---|---|---|---|---|---|
| Group A (Experimental control) | 0/5$^f$ | 0/5$^f$ | 0/5$^f$ | 0/5$^f$ | 0/5 | 0/5$^f$ | 0/5 |
| Group B ($ClO_2$ LD) | 0/5$^f$ | 0/5$^f$ | 0/5$^f$ | 0/5$^f$ | 0/5 | 0/5$^f$ | 0/5 |
| Group C ($ClO_2$ HD) | 0/5$^f$ | 0/5$^f$ | 1/5$^f$ | 0/5$^f$ | 0/5 | 2/5 | 0/5 |
| Group D (Virus + $ClO_2$ LD) | 5/5$^a$ | 1/5 | 1/5$^f$ | 0/5$^f$ | 0/5 | 2/5 | 5/5$^{f,a}$ |
| Group E (Virus + $ClO_2$ HD) | 5/5$^a$ | 0/5$^f$ | 1/5$^f$ | 0/5$^f$ | 0/5 | 2/5 | 3/5$^a$ |
| Group F (Viral control) | 5/5$^a$ | 4/5$^a$ | 4/5$^a$ | 4/5$^a$ | 1/5 | 5/5$^a$ | 1/5 |

634

[a]: Indicates a significant difference to the experimental control

[f]: Indicates a significant difference to the viral control

955

**Table 3. Microscopic abnormalities related to avian coronavirus infection in the chick embryos.** (LD: Low dose, HD: High dose)

| | A (Exp. control) | B ($ClO_2$ LD) | C ($ClO_2$ HD) | D (Virus + $ClO_2$ LD) | E (Virus + $ClO_2$ HD) | F (Viral control) |
|---|---|---|---|---|---|---|
| Trachea | - | Mild hyperplasia | Mild hyperplasia | Karyorexis, focal hyperplasia | Moderate congestion | Mild hyperplasia |
| Lung | Mild to moderate congestion | Moderate congestion, interstitial oedema | Mild to moderate congestion, interstitial oedema | Moderate to severe congestion, karyolysis | Mild to moderate congestion, moderate oedema | Mild to moderate congestion, severe to moderate oedema |
| Proventricle | - | - | - | Moderate hyperplasia | Mild hyperplasia | Moderate hyperplasia, mild congestion |
| Duodenum | - | - | - | Moderate congestion | | Mild diffuse congestion, atrophy of intestinal villi |
| Liver | - | - | - | Gluogenic degeneration, mild congestion | Gluogenic degeneration, mild congestion | Gluogenic degeneration, moderate congestion, periportal eosinophilic material |
| Kidneys | - | - | - | Degeneration w/ regeneration, congestion, mild heterophilic infiltration, urates | Degeneration w/ regeneration, congestion, mild heterophilic infiltration, urates | Haemorrhage, multifocal heterophilic infiltration, urates |
| Spleen | - | - | - | Reticuloendothelial hyperplasia | Reticuloendothelial hyperplasia | Reticuloendothelial hyperplasia |
| Bursa of Fabricius | Subacute heterophilic bursitis | Subacute heterophilic bursitis | Subacute heterophilic bursitis | Subacute heterophilic bursitis | Subacute heterophilic bursitis | Subacute heterophilic bursitis |

# Anexo 6.

# TOXICIDAD DEL DIOXIDO DE CLORO Y DEL CLORITO

Prof. Dr. D. Pablo Campra Madrid. Licenciado en Ciencias Biológicas y Dr. en Ciencias Químicas

Universidad de Almería (España) pcampra@ual.es

***Resumen: Los niveles y condiciones de toxicidad del dióxido de cloro y del clorito han sido determinados por numerosos estudios e informes emitidos por organismos oficiales, en particular del gobierno norteamericano. De acuerdo con dichos informes, no hay base experimental para afirmar que exista riesgo de reacciones adversas al administrar dosis potencialmente terapéuticas por debajo de 3mg/kg/día a organismos humanos.***

La toxicidad por vía oral y por inhalación del gas dióxido de cloro, y de su precursor y producto de reducción, el ion clorito, han sido caracterizadas en numerosos estudios publicados en las últimas décadas en la literatura científica. Los primeros estudios fueron promovidos por la USA-EPA (Agencia de Protección Ambiental de EEUU), con el objeto de determinar los niveles de seguridad para la potabilización de agua de consumo urbano. En este sentido, la EPA ha venido encargando investigaciones y emitiendo informes toxicológicos desde los años 80s, que han permitido caracterizar el perfil toxicológico y los niveles de seguridad, que han sido referencia para el resto de agencias norteamericanas como el Departamento de Salud (ASTDR) y la FDA, y por extensión por otras agencias internacionales que se han hecho eco de dichos informes técnicos. Cabe aclarar que en ellos se asume que los datos experimentales de toxicidad del dióxido de cloro son por aproximación extensibles al clorito, y viceversa, dada la elevada reactividad del dióxido de cloro, y su rápida reducción a clorito en medio acuoso, por lo que éste último se considera un subproducto posible contaminante resultante de la desinfección con dióxido de cloro, junto a cloratos y percloratos.

Así por ejemplo, en una revisión toxicológica sobre estas sustancias emitida por la US-EPA en el 2000 (Agencia de Protección Ambiental)[1], se hizo una revisión de datos experimentales provenientes en su mayor parte de ensayos con animales[2]. A partir de revisiones sucesivas, y basándose finalmente en un estudio encargado por la EPA para determinar la toxicidad a largo plazo, y en varias generaciones de ratones incluyendo grupos sensibles (durante el celo, lactancia y parto) (Gill et al., 2000)[3], la agencia ambiental y posteriormente el Departamento de Salud de EEUU[4] determinaron los niveles toxicológicos experimentales para a una exposición crónica por via oral (>90 dias) de dióxido de cloro y clorito. Estos son: un NOAEL de 3 mg/kg/día de ion clorito equivalente (*non observed adverse effects level* o la dosis máxima en la cual no se han observado efectos adversos) y un LOAEL de 5,7 mg/kg/dia (*lowest observed adverse effects level*, la dosis mínima en la cual se observó alguna toxicidad). Es decir, suponiendo un peso de un adulto de 70 kg, la cantidad diaria con la cual la EPA no encontró efecto adverso para consumo oral seria de 210 mg de dióxido de cloro (o ion clorito equivalente) al día.

---

[1] US Environmental Protection Agency. *Toxicological Review of Chlorine Dioxide and Chlorite.* Sept. 2000. Disponible en: https://cfpub.epa.gov/ncea/iris/iris_documents/documents/toxreviews/0648tr.pdf

Basándose en estos dos parámetros de toxicidad (NOAEL y LOAEL), obtenidos experimentalmente a partir de ensayos con animales, la EPA realiza posteriormente diversos ajustes a la baja para derivar de ellos la dosis de referencia (RfD) para la toxicidad crónica en humanos (>90 dias) de estas sustancias[5]. Para ello se aplica al valor experimental NOAEL de 3 mg/kg/día un factor de incertidumbre de 100, resultando un valor de referencia de RfD = 0,03 mg/kg/día. Este RfD no procede directamente por tanto de experimentación alguna, y su finalidad es contar con un margen amplio de seguridad para el consumo humano habitual, a cambio de una elevada incertidumbre. Este factor incluye una incertidumbre de 1/10 para la posible diferencia interespecífica con animales, y otro factor añadido de 1/10 para la posible variabilidad humana. Sin embargo, el RfD establecido por la EPA se refiere a dosis de dióxido de cloro a emplear para desinfección de agua potable destinada a consumo urbano. La propia EPA define el ámbito de aplicación este parámetro: *"En general, la RfD es una estimación (con incertidumbre que abarca quizás un orden de magnitud) de una exposición diaria a la población humana (incluidos los subgrupos sensibles) que probablemente no tenga un riesgo apreciable de efectos deletéreos* ***DURANTE TODA LA VIDA****. No se debe concluir categóricamente que todas las dosis por debajo de* la *RfD son "aceptables" (o estarán libres de riesgo) y que todas las dosis que superen la RfD son "inaceptables" (o darán lugar a efectos adversos)."* Es decir, lo RfD no pueden considerarse límites de riesgo aplicables **para usos terapéuticos** y exposiciones agudas o subcrónicas (<90dias) a grupos de pacientes en situaciones controladas. Mientras esos límites no se determinen determinarse experimentalmente en ensayos clínicos debidamente controlados, la referencia de toxicidad deben ser los niveles experimentales NOAEL y LOAEL y no los RfDs para agua potable de uso comunitario de la EPA.

---

[2] En los estudios sobre la toxicidad del $ClO_2$ por via oral que se hacen en animales generalmente no se les administra dióxido de cloro (que se evapora con facilidad si la temperatura del agua del bebedero es superior a 11°C y por tanto resulta difícil de cuantificar), sino que se les da a beber una solución de clorito de sodio con concentración conocida, y se estima la dosis diaria ingerida. Sin embargo, sí existen otros estudios de toxicidad por inhalación de CLO2 en ratones.

[3] Gill, M.W., Swanson, M.S., Murphy, S.R. and Bailey, G.P. (2000), Two-generation reproduction and developmental neurotoxicity study with sodium chlorite in the rat. J. Appl. Toxicol., 20: 291-303. doi:10.1002/1099-1263(200007/08)20:4<291::AID-JAT658>3.0.CO;2-Y

[4] ATSDR, US Department of Health and Human Services. *Toxicological Profile for Chlorine Dioxide and Chlorite*. Sept. 2004. Disponible en: https://www.atsdr.cdc.gov/ToxProfiles/tp160.pdf

[5] https://www.epa.gov/iris/reference-dose-rfd-description-and-use-health-risk-assessments

**Estudios y niveles de toxicidad del dióxido de cloro/clorito por via oral (adaptado de USA-ASTDR, 2004)**



@Dr. Pablo Campra

En la figura 1 (adaptada del informe de la Agencia para sustancias tóxicas (US-ASTDR, 2004) del Departamento de Saludo de los EEUU) se han superpuesto los límites NOAEL y LOAEL a la representación de estudios de toxicidad revisados en el informe. Por encima de un LOAEL de 5,7 mg/kg/día son de esperar reacciones adversas, y por otro lado, por debajo del NOAEL de 3 mg/kg/día es muy improbables que acontezcan. La línea azul inferior representa los niveles máximos de residuo de desinfectante (MRDL) establecidos por la EPA para agua potable, 0.08 mg/l.

### *Estudios en humanos*

Los escasos estudios clínicos publicados sobre ensayos para determinar la toxicidad del dióxido de cloro en humanos apuntan sin embargo a que un factor de incertidumbre de 100 para determinar el RfD estaría sobrevalorando la toxicidad real en humanos en más de un orden de magnitud, y que los niveles de toxicidad NOAEL y LOAEL procedentes de estudios animales reflejan con mucha mayor aproximación la toxicidad observada en ensayos humanos. Así, por ejemplo, en el primer ensayo clínico exhaustivo encargado por la EPA (Lubbers et al, 1981)[6], se determinó la ausencia de toxicidad crónica a niveles de 5 mg/dia (equivalente a 0,07 mg/kg/dia) y de toxicidad aguda a 24 mg/l (equivalente a 0,34mg/kg/dia). Posteriormente se han publicado algunos ensayos clínicos controlados basados en la administración de formulaciones de diferentes denominaciones (NP001, WF10, TCDO), pero cuyo principio activo es el clorito sódico. En un ensayo clínico en Fase I para caracterizar la toxicidad aguda del clorito sódico puro (NP001) (Miller et al, 2014)[7] se emplearon dosis únicas crecientes de (0.2, 0.8, 1.6 and 3.2 mg/kg/día). Todas las dosis fueron en general seguras y bien toleradas, y no hubo eventos adversos serios ni variaciones en parámetros clínicos relevantes. En otros ensayos en Fase II con enfermos de esclerosis lateral amiotrófica ELA (Miller et al, 2015)[8]. Se administró sódico en una sola dosis diaria por vía intravenosa, durante 6 meses de forma intermitente. Los ciclos duraban de 3 a 5 días consecutivos (exposición subaguda), administrándose un ciclo por mes. El estudio dio como resultado una **evidencia de clase I de que el clorito sódico**

---

[6] J R Lubbers, S Chauhan, J K Miller, J R Bianchine. The effects of chronic administration of chlorine dioxide, chlorite and chlorate to normal healthy adult male volunteers. J Environ Pathol Toxicol Oncol . 1984 Jul;5(4-5):229-38. https://pubmed.ncbi.nlm.nih.gov/6520728/

[7] Miller RG, Zhang R, Block G, et al. NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:601–609.

[8] Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A; Phase 2 Trial NP001 Investigators. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3).

**fue "en general, seguro y bien tolerado"**, excepto por dolor en el lugar de la infusión y mareo transitorio. En conclusión, a partir de los datos de estos ensayos, se puede afirmar que la dosis máxima sin reacciones adversas (NOAEL) en aplicaciones subagudas (3-5 días) puede establecerse en 2 mg/kg/dia, mientras los efectos adversos pudieron observarse a partir de un LOAEL de 4,2mg/kg/dia.

### *Toxicidad de dosis potencialmente terapéuticas contra la COVID19*

Aun no existen ensayos clínicos publicados sobre la aplicación terapéutica de clorito o dióxido de cloro frente a la COVID19. Si tomamos como referencia las comunicaciones orales hechas públicas por personal médico asociado en la COMUSAV[9], y el único informe médico disponible hasta la fecha, hecho público online por la AEMEMI[10] de Ecuador, las dosis terapéuticas que están siendo aconsejadas para el tratamiento adyuvante de la COVID-19 en Hispanoamérica son muy inferiores a los límites de toxicidad mínima determinados experimentalmente (NOAEL y LOAEL)[11]. En la Figura 2 se reflejan las dosis tóxicas mínimas detectadas en diferentes estudios (en rojo), así como las dosis con potencial terapéutico donde es muy improbable que se detecten reacciones adversas en aplicaciones subagudas (>28 días). Como referencia se muestran también las dosis de referencia (RfD) y el límite máximo de desinfectante dióxido de cloro y contaminante clorito establecido por la EPA para el agua potable MDRL (en azul). Como puede verse, por debajo del NOAEL de 3 mg/Kg/dia no existen datos experimentales que permitan afirmar que existe un riesgo para la salud. En la escala horizontal se reflejan las dosis diarias estimadas para un adulto de 70kg. En ambas figuras 1 y 2 no se incluyen los estudios en humanos citados (Miller et al, 2015; 2014), cuyos niveles NOAEL y LOAEL estarían por debajo de los determinados por la EPA.

---

[9] Véanse, por ejemplo, comunicación de los Drs. Aparicio y Moncada (https://drive.google.com/file/d/1FUaQJlNKxZywgLdQjJz8eRXFvznBWY15/view y https://drive.google.com/file/d/1Zbw8D-EPmslDebx0b0eUDsP4vCBPKygd/view)

[10] Dioxido de cloro: una alternativa efectiva para el tratamiento del SARS-CoV2 (COVID –19) Asociación Ecuatoriana de Medicos Expertos en Medicina Integrativa (A E M E M I) https://drive.google.com/file/d/1EXobhZo1-gQ_JE6C6g8ZGjSobTCs_it9/view

[11] Hay que tener en cuenta que en estos reportes la dosis de dióxido de cloro suele expresarse en ml diluidos de disolución concentrada a 3.000 mg/l (ppm), por lo que para calcular la equivalencia en mg/día, debe multiplicarse por 3 las dosis dadas en mililitro, para cada litro diario administrado. Por ejemplo, cada 10ml de dióxido diluidos en 1l contienen 30 mg de dióxido de cloro. Recíprocamente, cada 1 mg/día equivale a una dosis de 0.33 ml de solución concentrada a 3.000 mg/l.



Dosis de DIOXIDO DE CLORO/CLORITO empleadas en estudios de toxicidad subaguda (<28d), o crónica (>90d) (ASTDR, 2004)

Figura 2

Así por ejemplo, y tomando como referencia de dosis potencialmente terapéuticas las empleadas en el estudio de la *AEMEMI de Ecuador, la dosis diaria total administrada por via oral fue de entre 0,4-0,9 mg/kg/día, muy por debajo de los niveles de toxicidad mínima descritos en el presente informe.*

**En conclusión, no se dispone de evidencias experimentales que permitan afirmar que a dosis inferiores a 3 mg/kg/día exista riesgo de reacciones adversas ni variaciones en parámetros clínicos relevantes. Esta dosis equivale a 210 mg de dióxido de cloro o clorito al día para un adulto medio de 70kg. La toxicidad mínima observable sería esperable a partir de 5,7 mg/kg/dia, equivalente a 420 mg/dia para un ser humano adulto medio.**

*España, 22 de Octubre de 2020*

*Nota importante: Las estimaciones sobre toxicidad del dióxido de cloro efectuadas en este informe presuponen el empleo de un producto de alta pureza, debidamente estabilizado y/o conservado, así como con los debidos controles de concentración previos a su administración y analíticas de impurezas y posibles subproductos de degradación que pueden presentar toxicidad añadida. Las afirmaciones de este informe son responsabilidad del autor y no involucran postura oficial alguna de la Universidad de Almeria.*

964

# Anexo 7.

ESTADO PLURINACIONAL DE BOLIVIA

Asamblea Legislativa Departamental de Cochabamba

# LEY DEPARTAMENTAL DE 22 DE JULIO DE 2020
## LEGISLATURA 2019-2020

## N°

## "PRODUCCIÓN Y DISTRIBUCIÓN GRATUITA Y SUPERVISADA DE DIÓXIDO DE CLORO"

Por cuanto, la Asamblea Legislativa Departamental de Cochabamba, sanciona la siguiente Ley:

**LA ASAMBLEA LEGISLATIVA DEPARTAMENTAL DE COCHABAMBA**

**SANCIONA:**

**ARTÍCULO 1. (OBJETO)** La presente Ley tiene por objeto promover y regular la producción de dióxido de cloro y su distribución gratuita en Cochabamba, garantizando el acceso a este producto como alternativa para superar el coronavirus.

**ARTÍCULO 2. (ALCANCE)** La presente Ley tiene como alcance y aplicación toda la jurisdicción del departamento de Cochabamba.

**ARTÍCULO 3. (BASE LEGAL)** La presente ley tiene como base legal lo establecido en los artículos 9 numeral 5), 18, 35, 36, 37, 299 parágrafo II numeral 2) y 300 de la Constitución Política del Estado; el artículo 81 parágrafo III de la Ley N° 031 Marco de Autonomías y Descentralización "Andrés Ibáñez" y los artículos 5 numeral 1), 18 inciso d), 36 inciso e) de la Ley N° 602 de Gestión de Riesgos y Ley Departamental N° 964 "Declarar de interés y prioridad departamental las acciones y medidas necesarias para la prevención, contención de la propagación y atención del contagio del coronavirus (COVID-19)".

**ARTÍCULO 4. (DIÓXIDO DE CLORO)**

**I.** El Dióxido de Cloro es una sustancia que tiene un ión de cloro y dos iones de oxígeno, resultando un gas de oxigenación celular que según investigaciones recientes previene, combate y ayuda a la prevención, tratamiento y recuperación de enfermos contagiados por el coronavirus (COVID-19).

**II.** El Dióxido de Cloro, será aplicado de acuerdo a su protocolo de uso para la prevención, atención y tratamiento para el coronavirus (COVID-19) en el Departamento de Cochabamba, por vía oral o vía intravenosa de acuerdo a diagnóstico clínico del enfermo con coronavirus (COVID-19) y con pleno e informado consentimiento de éste o en su defecto por sus familiares.

**ARTÍCULO 5. (AUTORIZACIÓN DE SUSCRIPCIÓN DE CONVENIOS)**

1. Se autoriza al Órgano Ejecutivo Departamental de Cochabamba la suscripción de convenios interinstitucionales con la Universidad Mayor de San Simón y/u otras universidades privadas o públicas, así como laboratorios privados y organismos internacionales para la producción de dióxido de cloro, atendiendo a los estudios científicos sobre dicha sustancia.
2. Se autoriza al Órgano Ejecutivo Departamental de Cochabamba la suscripción de convenios intergubernativos con el Gobierno Central del

Estado y los Gobiernos Autónomos Municipales para la producción y distribución del Dióxido de Cloro.

**ARTÍCULO 6. (PRODUCCIÓN DE DIÓXIDO DE CLORO)** El Órgano Ejecutivo del Gobierno Autónomo Departamental de Cochabamba, a través de la Secretaría de Desarrollo Humano, realizará las modificaciones presupuestarias para garantizar el presupuesto necesario de la producción masiva y distribución gratuita del Dióxido de Cloro.

**ARTÍCULO 7. (PROTOCOLO DE USO DE DIÓXIDO DE CLORO)** El Servicio Departamental de Salud (SEDES) asumirá las siguientes responsabilidades:

1. Elaborará, aprobará y pondrá en vigencia, un protocolo para el uso del Dióxido de Cloro, en los diferentes hospitales de 1°, 2° y 3° nivel del sistema público, privado y de la seguridad social tomará en cuenta cantidades y tiempos de suministro del Dióxido de Cloro, en enfermos con coronavirus (COVID-19) y de manera preventiva cantidades y ritmo de suministro del Dióxido de Cloro para aquellas personas que hayan tenido contacto por riesgo de contagio.
2. Elaborará, aprobará y socializará el formulario, de consentimiento informado, en formato electrónico y físico para las personas infectadas con el coronavirus (COVID-19) y las que han tenido contacto y/o riesgo de contagio, con pleno e informado consentimiento del interesado o en su defecto, con autorización de sus familiares.
3. Elaborará un protocolo de seguimiento y control de la producción, distribución y de los resultados del uso del dióxido de cloro.

**ARTÍCULO 8. (CAPACITACIÓN PARA EL USO Y APLICACIÓN DEL DIÓXIDO DE CLORO)** El Servicio Departamental de Salud, promoverá e impulsará la capacitación del personal médico de los centros de salud de primer y segundo nivel y centros hospitalarios de tercer nivel, públicos y privados, para el uso y aplicación del Dióxido de Cloro - CDS, por vía oral y vía intravenosa en enfermos con el coronavirus (COVID-19), cumpliendo el protocolo de atención y tratamiento. La capacitación también será para aplicar el protocolo para la prevención en personas con contacto por riesgo de contagio.

**ARTÍCULO 9. (AMBIENTE PARA LABORATORIO DE PRODUCCIÓN DE DIÓXIDO DE CLORO)** El Órgano Ejecutivo Departamental de Cochabamba otorgará un laboratorio debidamente equipado para la elaboración y producción masiva del Dióxido de Cloro y todos los implementos y personal técnico necesario para la producción, mientras que dure la emergencia sanitaria departamental.

**ARTÍCULO 10. (MEDIDAS DE SEGURIDAD)** El Órgano Ejecutivo Departamental dotará de manera permanente equipos de protección de bioseguridad a todo personal que trabaje en la producción y distribución gratuita de Dióxido de Cloro del departamento de Cochabamba.

**ARTÍCULO 11. (CONTRATACIÓN DIRECTA POR EMERGENCIA)**

**I.** Se autoriza al Órgano Ejecutivo Departamental la modalidad de Contratación Directa según Decreto Supremo N° 0181, Decreto Supremo N° 4174 de 4 de marzo de 2020 y Decreto Supremo N° 4205 de 1 de abril de 2020, para la adquisición y provisión oportuna de bienes, infraestructura, mobiliario, medicamentos, insumos, reactivos, equipamiento, equipos de bioseguridad y otros, en tanto perdure el coronavirus COVID-19 a nivel departamental.

**II.** Asimismo se autoriza la contratación excepcional de recursos humanos para el laboratorio de producción de Dióxido de Cloro.

967

**ARTÍCULO 12. (GRATUIDAD DE LA DISTRIBUCIÓN DE DIOXIDO DE CLORO)**

**I.** Las dosis necesarias de dióxido de cloro para los pacientes infectados con coronavirus (COVID-19), se distribuirán de forma gratuita.

**II.** A las personas que han tenido contacto y/o riesgo de contagio del coronavirus (COVID-19), se distribuirá el dióxido de cloro de manera gratuita por una sola vez.

**ARTÍCULO 13. (COMUNICACIÓN E INFORMACIÓN)** El Órgano Ejecutivo Departamental realizará acciones de comunicación e información a través de medios de comunicación, portales web, redes sociales de carácter oficial, para informar sobre las ventajas y cuidados del uso del Dióxido de Cloro, el "Protocolo de uso del Dióxido de Cloro, para la prevención, atención y tratamiento del coronavirus (COVID-19)", así como el reglamento para su producción y distribución.

## DISPOSICIONES TRANSITORIAS

**DISPOSICIÓN TRANSITORIA PRIMERA.** El Órgano Ejecutivo Departamental en un plazo no mayor a 3 (Tres) días calendario a partir de la promulgación de la presente Ley Departamental, deberá reglamentar el uso, producción y distribución del Dióxido de Cloro.

**DISPOSICIÓN TRANSITORIA SEGUNDA.** El Servicio Departamental de Salud en coordinación con el Órgano Ejecutivo Departamental, en un plazo no mayor a 2 días calendario elaborará y aprobará el "Protocolo de uso del Dióxido de Cloro, para la prevención, atención y tratamiento del COVID-19" en enfermos con coronavirus (COVID-19) y pacientes con contacto por riesgo de contagio.

**DISPOSICIÓN TRANSITORIA TERCERA.** El Órgano Ejecutivo Departamental dentro del marco de la emergencia sanitaria departamental, en un plazo máximo a 10 (Diez) días calendario posteriores a la reglamentación, deberá poner en funcionamiento el laboratorio de elaboración y producción de dióxido de cloro de manera responsable.

Remítase a la Gobernación para fines legales de promulgación y publicación.

Es dada en la sala de Sesiones de la Asamblea Legislativa Departamental, en la ciudad de Cochabamba a los veintidós días del mes de julio del año dos mil veinte.

[illegible] Quispe Escalera
PRESIDENTE
[illegible] LEGISLATIVA DEPARTAMENTAL
DE COCHABAMBA

[illegible] Muñoz Molina
[illegible] SECRETARIA
[illegible] LEGISLATIVA DEPARTAMENTAL
DE COCHABAMBA

Gobierno Autónomo Departamental de La Paz

# LEY DEPARTAMENTAL No. 193
**Ley de 9 de septiembre de 2020**

**Félix Patzi Paco, Ph. D.**
**GOBERNADOR DEL DEPARTAMENTO DE LA PAZ**

**Por cuanto:**

**LA ASAMBLEA LEGISLATIVA DEPARTAMENTAL DE LA PAZ**

**HA SANCIONADO:**

## "LEY QUE AUTORIZA LA PRODUCCIÓN, DISTRIBUCIÓN Y USO DEL DIÓXIDO DE CLORO (CDS) PARA LA PREVENCIÓN, ATENCIÓN Y TRATAMIENTO DEL COVID -19 EN EL DEPARTAMENTO DE LA PAZ"

### DISPOSICIONES GENERALES

**Artículo 1. (OBJETO)** La presente ley tiene por objeto ejercer el control de calidad y distribución para el uso compasivo y consumo del Dióxido de Cloro (CDS) y autorizarlo como agua mineral de manera voluntaria y consentida, para el bienestar de la salud, conforme la Constitución Política del Estado, la Ley No. 031 Ley Marco de Autonomías y Descentralización "Andrés Ibáñez" y normativa vigente.

**Articulo 2. (ÁMBITO DE APLICACIÓN)** El Dióxido de Cloro (CDS) se aplicará en los centros de salud de Primer, Segundo Nivel y Centros Hospitalarios de Tercer Nivel de los ochenta y siete (87) municipios del departamento de La Paz, que estén bajo tuición del Servicio Departamental de Salud (SEDES), así como en los Centros de Salud de carácter privado o de convenio que así lo requieran, de manera voluntaria.

**Artículo 3. (DIÓXIDO DE CLORO)** El Dióxido de Cloro es un agua mineral que resulta de la combinación de Clorito de Sodio (NCLO2) al 28% más ácido clorhídrico (HCL) al 4% el cual será aplicado para la prevención y tratamiento del Covid-19 en el Departamento de La Paz con consentimiento, manifiesta voluntad e información previa al paciente .

**Artículo 4. (AUTORIZACIÓN Y CONTROL PARA LA PRODUCCIÓN, COMERCIALIZACIÓN Y DISTRIBUCIÓN DEL DIÓXIDO DE CLORO-CDS) I.-** Se autoriza al Gobierno Autónomo Departamental de La Paz, suscribir acuerdos con Universidades y Laboratorios particulares debidamente establecidos en territorio nacional, para la producción y elaboración del Dióxido de Cloro (CDS) para consumo humano, de acuerdo a las características descritas en el artículo 3 de la presente Ley.

**II.-** El Órgano Ejecutivo Departamental adquirirá los lotes necesarios de Dióxido de Cloro (CDS) para su distribución gratuita en los Centros Médicos bajo dependencia del SEDES en concordancia con el artículo 2 de la presente Ley.

**III.** Los Gobiernos Autónomos Municipales establecidos dentro el territorio departamental podrán adquirir el Dióxido de Cloro (CDS) directamente de los laboratorios que lo estén produciendo sean estos a nivel universitario o particulares, a fin de realizar la misma distribución gratuita en los centros médicos de sus dependencias.

**IV.-** Se prohíbe la venta y distribución del Dióxido de Cloro (CDS) que no estén autorizados debidamente. La venta al público se podrá realizar por intermedio de las Farmacias legalmente establecidas.

**Artículo 5. (PROTOCOLO DE USO COMPASIVO DEL DIÓXIDO DE CLORO (CDS) PARA LA PREVENCIÓN, ATENCIÓN Y TRATAMIENTO DEL COVID 19)** **I.** El Órgano Ejecutivo a través del Servicio Departamental de La Paz – SEDES La Paz y en coordinación con las instituciones académicas y/o científicas aplicará el Protocolo de Uso Compasivo del Dióxido de Cloro - CDS, como medida previa a los Estudios Clínicos.

**II.** El Protocolo de Uso Compasivo del Dióxido de Cloro – CDS para la prevención, atención y tratamiento de enfermos de COVID-19, será aplicado por el personal médico en los centros de salud de Primer y Segundo Nivel, Centros Hospitalarios de Tercer Nivel y en personas naturales que hayan tenido contacto y riesgo de contagio con pleno consentimiento del interesado de manera voluntaria.

**Artículo 6. (ESTUDIO CLÍNICO)** El Órgano Ejecutivo del Departamento de La Paz a través del SEDES La Paz, de manera simultánea a la aplicación del Protocolo de Uso Compasivo del Dióxido de Cloro - CDS, como medida previa a los estudios clínicos, en el lapso de 45 días hábiles, realizará un Estudio Clínico en base a la Norma de Estudios Clínicos, para tal efecto podrá suscribir acuerdos y/o convenios con instituciones de carácter académico y/o científico, así también deberá asignar un presupuesto destinado a cubrir el costo del Estudio Clínico.

**Artículo 7. (CAPACITACIÓN PARA EL USO Y APLICACIÓN DEL DIÓXIDO DE CLORO – CDS)** El Gobierno Autónomo Departamental de La Paz a través del SEDES La Paz, deberá capacitar al personal médico de los centros de salud de primer y segundo nivel y centros hospitalarios de tercer nivel, en base al Protocolo de Uso Compasivo del Dióxido de Cloro - CDS, como medida previa a los estudios clínicos.

**Artículo 8. (PRESUPUESTO) I.** Para el cumplimiento de la presente ley, el presupuesto departamental será garantizado, asignado y dispuesto por el Órgano Ejecutivo Departamental, en el marco del "Plan Departamental Estratégico Operativo para la disminución del riesgo de contagio a través de la prevención, mitigación, atención, tratamiento y control sanitario permanente" para la prevención, atención, mitigación de la emergencia sanitaria COVID 19.

**II.** El cumplimiento de la presente Ley, será garantizado con un porcentaje de los recursos reasignados del Fondo de Promoción a la Inversión en Exploración y Explotación Hidrocarburífera – FPIEEH por Ley Nacional No. 1307 a los Gobiernos Autónomos Municipales y Departamentales.

**Artículo 9. (COMUNICACIÓN E INFORMACIÓN)** El Órgano Ejecutivo Departamental realizará acciones de comunicación e información a través de medios de comunicación, portales web, redes sociales de carácter oficial, para informar sobre el uso del Dióxido de Cloro, el "Protocolo de uso del Dióxido de

Cloro - CDS, para la prevención, atención y tratamiento del COVID 19", así como el reglamento para su producción y comercialización.

## DISPOSICIONES FINALES

**Disposición Final Primera.** El Órgano Ejecutivo Departamental reglamentará la presente Ley, en un plazo de 48 horas para su aplicación y vigencia en el Departamento de La Paz, que se computarán a partir de la promulgación de la presente ley.

**Disposición Final Segunda**. Queda prohibida la venta, fabricación y comercialización del Dióxido de Cloro que no esté debidamente autorizada, el incumpliendo de ésta disposición será sancionado por Ley.

**Disposición Final Tercera.** El SEDES La Paz elaborará y aprobará en coordinación con el Órgano Ejecutivo Departamental, en un plazo de 48 horas el Protocolo de Uso Compasivo del Dióxido de Cloro - CDS, como medida previa a los estudios clínicos.

## DISPOSICIONES ABROGATORIAS

Quedan abrogadas y sin efecto todas las disposiciones contrarias a la presente Ley en el Departamento de La Paz.

Remítase al Ejecutivo del Gobierno Autónomo del Departamento de La Paz, para fines constitucionales.

Es dada en la Asamblea Legislativa Departamental de La Paz, a los días 25 del mes de agosto de dos mil veinte años.

Fdo. H. Edwin Zarate Mamani; Presidente, Saturnino Edgar Apaza Machaca; Vicepresidente, Sucy Vicky Chura Quiuchaca; Secretaria, José Pepe Flores Cuentas; Vocal I de la Asamblea Legislativa Departamental de La Paz.

**POR TANTO:** La promulgo para que se tenga y cumpla como Ley Departamental.

Es dado en la Gobernación de La Paz, a los nueve (9) días del mes de septiembre de dos mil veinte (2020) años.

*Felix Patzi Paco*
GOBERNADOR
DEPARTAMENTO DE LA PAZ

971

# LEY DE 14 DE OCTUBRE DE 2020 N°

*Estado Plurinacional de Bolivia*
*Asamblea Legislativa Plurinacional*

**MONICA EVA COPA MURGA**
**PRESIDENTA DE LA ASAMBLEA LEGISLATIVA PLURINACIONAL**

Por cuanto, la Asamblea Legislativa Plurinacional, ha sancionado la siguiente Ley:

**LA ASAMBLEA LEGISLATIVA PLURINACIONAL,**

**DECRETA:**

## LEY QUE REGULA LA ELABORACIÓN, COMERCIALIZACIÓN, SUMINISTRO Y USO CONSENTIDO DE LA SOLUCIÓN DE DIÓXIDO DE CLORO (SDC) COMO PREVENCIÓN Y TRATAMIENTO ANTE LA PANDEMIA DEL CORONAVIRUS (COVID-19)

**ARTÍCULO 1. (OBJETO).** La presente Ley tiene por objeto regular de forma excepcional la elaboración, comercialización, suministro, administración y uso consentido de la Solución de Dióxido de Cloro, de manera preventiva y como tratamiento para pacientes diagnosticados con Coronavirus (COVID-19).

**ARTÍCULO 2. (DEFINICIONES).** A efecto de la aplicación de la presente Ley, se entiende por:

a) **Solución de Dióxido de Cloro (SDC).** El Dióxido de Cloro ($ClO_2$), es un compuesto químico gaseoso como resultado de la mezcla de los precursores Clorito Sódico ($NaClO_2$) activado con Ácido Clorhídrico (HCl), Ácido Cítrico ($C_6H_8O_7$) o electrólisis.

b) **Precursor Químico.** Es una sustancia indispensable o necesaria para producir otra mediante los compuestos químicos que constituyen una primera etapa en un proceso químico y que actúan como sustrato en las etapas posteriores.

c) **Prospecto.** Documento que incluye las características principales de un compuesto, tales como composición, indicaciones, dosificación, precauciones y en general toda la información necesaria para hacer correcto uso del mismo.

d) **Dosis.** La cantidad efectiva de principio activo de un compuesto, expresado en unidades de volumen o peso por unidad de toma en función de la presentación, que se administra para producir una acción o efecto farmacológico.

**ARTÍCULO 3. (ELABORACIÓN).** Los laboratorios públicos o privados, acreditados y autorizados por el órgano rector competente, podrán elaborar la Solución de Dióxido de Cloro, debiendo estos cumplir con las condiciones de calidad e incluir al producto final prospectos que acrediten la composición, dosificación, precauciones y cuidados a la hora de consumir este compuesto.

**ARTÍCULO 4. (COMERCIALIZACIÓN DE LA SOLUCIÓN DE DIÓXIDO DE CLORO).** La comercialización de la Solución de Dióxido de Cloro, deberá realizarse con indicaciones de uso y detalle de dosificación de la misma, por:

a) Laboratorios y universidades, el gobierno del nivel central, gobiernos departamentales, gobiernos municipales, farmacias y clínicas legalmente establecidas.

b) Farmacias legalmente establecidas, sin necesidad de receta médica y con plena conformidad del comprador.

**ARTÍCULO 5. (SUMINISTRO).** Los gobiernos autónomos departamentales y municipales deberán garantizar el suministro en el subsector público de salud, de la Solución de Dióxido de Cloro, como medio alternativo consentido para el tratamiento del Coronavirus (COVID-19).

**ARTÍCULO 6. (ADMINISTRACIÓN).** Los profesionales médicos podrán administrar la Solución de Dióxido de Cloro, bajo consentimiento informado del paciente o un familiar, en conformidad a los protocolos estipulados.

**ARTÍCULO 7. (USO).** Las y los ciudadanos, estantes y habitantes del territorio boliviano, podrán utilizar la Solución de Dióxido de Cloro como medio alternativo para prevenir o tratar la infección y las consecuencias provocadas por el Coronavirus (COVID-19).

**ARTÍCULO 8. (COMUNICACIÓN Y DIFUSIÓN).** El Órgano Ejecutivo del nivel central de Estado, en coordinación con la Entidades Territoriales Autónomas, tienen la responsabilidad de efectuar las campañas de difusión sobre el uso consentido, responsable, adecuado e informado de la Solución de Dióxido de Cloro.

**ARTÍCULO 9. (SISTEMA EXCEPCIONAL DE ARANCELES).** Por el tiempo que dure la pandemia del Coronavirus (COVID-19), se libera el pago de los tributos aduaneros a la importación del Clorito de Sodio ($NaClO_2$), como precursor de la Solución de Dióxido de Cloro.

**ARTÍCULO 10. (RESPONSABILIDADES).** I. Se determinan las siguientes responsabilidades:

1. El nivel central del Estado, a través del Ministerio de Salud, será responsable de:
   a) Supervisar la elaboración y comercialización de la Solución de Dióxido de Cloro para uso preventivo o terapéutico alternativo para el tratamiento del Coronavirus (COVID-19).

   b) Realizar campañas de información, responsables y adecuadas, sobre el uso consentido y responsable de la Solución de Dióxido de Cloro.

2. Los gobiernos autónomos departamentales y municipales, en el marco de sus competencias, serán responsables de:
   a) Realizar campañas de información sobre el uso de la Solución de Dióxido de Cloro, responsable y adecuado.

   b) Adquirir la Solución de Dióxido de Cloro, de las universidades o laboratorios públicos o privados certificados y autorizados.

   c) Dotar gratuitamente a los establecimientos de salud, la Solución de Dióxido de Cloro como medio de prevención y tratamiento alternativo del Coronavirus (COVID-19).

II. Los gobiernos autónomos departamentales y municipales, podrán suscribir convenios con las universidades del Sistema Universitario Boliviano, para la adquisición de la Solución de Dióxido de Cloro, con el fin de promover, de esta manera, la investigación en las Instituciones de Educación Superior.

**ARTÍCULO 11. (FINANCIAMIENTO).** El Órgano Ejecutivo del nivel central del Estado y las entidades territoriales autónomas, de acuerdo a sus atribuciones y competencias, deberán considerar las siguientes fuentes de financiamiento para la distribución gratuita:

a) Recursos en el marco de la Ley N° 602 de 14 de noviembre de 2014, de Gestión de Riesgos.

b) Créditos y donaciones externas e internas, relacionadas con la pandemia del Coronavirus (COVID-19).

## DISPOSICIÓN TRANSITORIA

**ÚNICA.** La presente Ley será reglamentada por el Órgano Ejecutivo, mediante Decreto Supremo, en un plazo de cinco (5) días hábiles, computables a partir de su publicación en la Gaceta Oficial de Bolivia.

Remítase al Órgano Ejecutivo para fines constitucionales.

Es dada en la Sala de Sesiones de la Asamblea Legislativa Plurinacional, a los cinco días del mes de agosto del año dos mil veinte.

Sen. Leonidas Milton Barón Hidalgo
**PRESIDENTE EN EJERCICIO**
**CÁMARA DE SENADORES**

Dip. Eddy Henry Cabrera Cario
**PRESIDENTE EN EJERCICIO**
**CÁMARA DE DIPUTADOS**

**SENADORA SECRETARIA**
Sen. Adela Cussi Camala
TERCERA SECRETARIA
CÁMARA DE SENADORES
ASAMBLEA LEGISLATIVA PLURINACIONAL

**SENADORA SECRETARIA**
[illegible]
Primera Secretaria
CÁMARA DE SENADORES
ASAMBLEA LEGISLATIVA PLURINACIONAL

**DIPUTADA SECRETARIA**
Dip. [illegible]
PRIMERA SECRETARIA
CÁMARA DE DIPUTADOS
ASAMBLEA LEGISLATIVA PLURINACIONAL

**DIPUTADA SECRETARIA**
Dip. [illegible]
SEGUNDA SECRETARIA
CÁMARA DE DIPUTADOS
ASAMBLEA LEGISLATIVA PLURINACIONAL

974

# Anexo 8.

# Número de infectados diariamente en Francia, España, Estados Unidos de América, Alemania, México y Bolivia.



**Francia, 26 Octubre, 2020. Número de infectados por COVID-19, diariamente**
***Fuente:*** https://www.google.com/search?sxsrf=ALeKk01IUayy-hbedltU67pZssyh7y47jg%3A1603726133045&ei=NeuWX8SsAsK0sQXLuKilCg&q=estadisticas+covid+Francia&oq=estadisticas+covid+Francia&gs_lcp=CgZwc3ktYWIQAzIECCMQJzIGCAAQFhAeOgQIABBDOgIIAFDr-RhYyv8YYlaFGWgAcAB4AIABvgGIAa4JkgEDMC44mAEAoAEBqgEHZ3dzLXdpesABAQ&sclient=psy-ab&ved=0ahUKEwiEm-izydLsAhVCWqwKHUscCqEQ4dUDCA0&uact=5



**España, 26 Octubre, 2020. Número de infectados por COVID-19, diariamente**
**Fuente:**
https://www.google.com/search?sxsrf=ALeKk02WVypTw0mWFlSZ_FqQexW582kQ9g%3A1603727778823&ei=ovGWX6jkMc-GsAXP0LsI&q=estadisticas+covid+Espa%C3%B1a&oq=estadisticas+covid+Espa%C3%B1a&gs_lcp=CgZwc3ktYWIQAzIECCMQJzICCAAyAggAMgIIADICCAAyBggAEBYQHjIGCAAQFhAeOgQIABBDOgcIABAUEIcCUMXES1jIyktg9c9LaABwAHgAgAGRAogBxwmSAQUwLjUuMpgBAKABAaoBB2d3cy13aXrAAQE&sclient=psy-ab&ved=0ahUKEwiovcrEz9LsAhVPA6wKHU_oDgEQ4dUDCA0&uact=5



**Estados Unidos de América, 26 Octubre, 2020. Número de infectados por COVID-19, diariamente**
**Fuente:**
https://www.google.com/search?sxsrf=ALeKk01nuImZbGikiNJWZxD_ia_FFW67xQ%3A1603726545967&ei=0eyWX_S5OoK6sQXArproCA&q=estadisticas+covid+USA&oq=estadisticas+covid+USA&gs_lcp=CgZwc3ktYWIQAzIECCMQJzIFCAAQywE6BggAEBYQHjoCCABQmMUUWPLHFGCAzhRoAHAAeACAAbABiAHoBJIBAzAuNJgBAKABAaoBB2d3cy13aXrAAQE&sclient=psy-ab&ved=0ahUKEwi05tr4ytLsAhUCXawKHUCXBo0Q4dUDCA0&uact=5



**Alemania, 26 octubre, 2020. Número de infectados de COVID-19, diariamente.**
**Fuente:**
https://www.google.com/search?sxsrf=ALeKk02MN6QEbDriIR7i5I1NS4aS3sLQVA%3A1603726886080&ei=Ju6WX-yxBInaswXKw6u4BQ&q=estadisticas+covid+Alemania&oq=estadisticas+covid+Alemania&gs_lcp=CgZwc3ktYWIQAzIECCMQJzoCCAA6BQghEKABOgYIABAWEB5Q2LkNWIHSDWCI2A1oAnAAeACAAbgCiAGqEJIBBzAuNy4zLjGYAQCgAQGqAQdnd3Mtd2l6wAEB&sclient=psy-ab&ved=0ahUKEwjs3PGazNLsAhUJ7awKHcrhClcQ4dUDCA0&uact=5



**México 26 octubre, 2020. Número de infectados de COVID-19, diariamente.**
**Fuente:**
https://www.google.com/search?sxsrf=ALeKk01Z7LyqPVOzI_jSAnUqFWMpCin9Uw%3A1603729211351&ei=O_eWX4X-FMGGsQWA24jADA&q=estadisticas+covid+Mexico&oq=estadisticas+covid+Mexico&gs_lcp=CgZwc3ktYWIQAzIECCMQJzICCAAyBggAEBYQHjIGCAAQFhAeMgYIABAWEB4yBQgAEMsBMgUIABDLAToFCAAQsQNQj8UDWP3KA2CL0QNoAHAAeACAAcUBiAHBB5IBAzAuN5gBAKABAaoBB2d3cy13aXrAAQE&sclient=psy-ab&ved=0ahUKEwjFh9Xv1NLsAhVBQ6wKHYAtAsgQ4dUDCA0&uact=5



**Bolivia, 26 octubre, 2020. Número de infectados de COVID-19, diariamente.**
**Fuente:**
https://www.google.com/search?sxsrf=ALeKk01Jv3vY9EhLdjyb5FxtipLbGVGVKw%3A1603729273284&ei=efeWX7XTEIiMsQXRy73QDw&q=estadisticas+covid+bolivia&oq=estadisticas+covid+bolivia&gs_lcp=CgZwc3ktYWIQAzIECCMQJzoECAAQQzoCCAA6BggAEBYQHjoICCEQFhAdEB5QteFJWMD4SWCjgEpoAXAAeACAAdkDiAHRC5IBBzAuOC40LTGYAQCgAQGqAQdnd3Mtd2l6wAEB&sclient=psy-ab&ved=0ahUKEwj185iN1dLsAhUIRqwKHdFlD_oQ4dUDCA0&uact=5

## Infecciones por día de COVID-19, Oct 26, 2020

| País | Población Millones | Infectados/día* | Infectados /millón habitantes |
|---|---|---|---|
| Francia | 67 | 46,489 | 694 |
| España | 47 | 19,270 | 410 |
| EUA | 328 | 74,492 | 227 |
| Alemania | 83 | 12,377 | 149 |
| México | 130 | 5,663 | 44 |
| Bolivia | 11 | 136 | 12 |

*Promedio de los últimos 3 días (23 al 26 de octubre, 2020): Google.com/search?....